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Faster rates of age-related cognitive decline may result in early onset of cognitive impairment and 
dementia. Ethanol use is highly prevalent(~70%) in the US. The relationship between ethanol intake and 
cognitive decline has been extensively studied.  However, findings have inconsistent, which may be 
attributed to the use of single use of ethanol intake, short follow-up times (<5 years), and not taking 
genetic predisposition to ethanol drinking into account.  
There is substantial genetic variability in ethanol consumption, and in vitro studies report 
differences in ethanol metabolism kinetic properties associated with genetic variants of different 
prevalence in diverse populations. The objective of this study was to assess the association of long-term 
trajectories of ethanol intake in mid-life with 15-year cognitive change from mid-to-late life among 
African-American and European-American adults, and of effect modification by ethanol drinking-
associated genetic variants. We utilized data from a large biracial community cohort of men and women, 
who completed four assessments of ethanol intake and repeated assessments of cognitive function in three 
cognitive domains: processing speed, executive function, and language. Ethanol intake trajectories were 
defined using four measures during a 9-year interval (1987-1998) as i) stable never drinkers, ii) stable 
low-to-moderate drinkers, iii) stable heavy drinkers, iv) stable former drinkers, v) mostly low-to-moderate 
drinkers, vi) mostly heavy drinkers, and vii) mostly former drinkers. 
The results from this study suggest that stable low-to-moderate drinking and stable heavy 
drinking in mid-life are not associated with 15-year cognitive decline from mid-to late-life among 





unweighted genetic risk score  comprised of ethanol intake-associated genetic variants (20 SNPs, African-
Americans; 11 SNPs, European-Americans). Our findings of no association between stable low-to-
moderate drinking during mid-life and 15- year cognitive decline from mid-life to late-life are consistent 
with previous studies finding demonstrating that moderate ethanol intake may not be protective of 
cognitive decline and suggests that low-to-moderate drinking should not be recommended to influence 
cognitive aging. Furthermore, the lack of evidence for effect modification suggests that the genetic 
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ALDH2 Aldehyde Dehydrogenase 2 
APOB Apolipoprotein B  
APOE Apolipoprotein E 
APOE ɛ2 Apolipoprotein E ε2 allele 
APOE ε4 Apolipoprotein E ε4 allele 
Aβ Amyloid β 
CYP2E1 Cytochrome P450 
RALDH1 Retinaldehyde dehydrogenase 1 











CHAPTER I: INTRODUCTION 
Cognitive impairment is a growing public health problem in the U.S. due to a rapidly aging and 
increasingly diverse population [1]. To reduce associated disability and morbidity [2], caretakers’ burden 
[3-7], and high health care costs [8], it is important to identify and intervene upon modifiable factors that 
may prevent or reduce the risk of cognitive impairment. One such factor is ethanol use, which has a high 
prevalence of use (70%) and misuse (14%)  in the U.S. [9]. Studies of the association of ethanol intake 
with cognitive decline have yielded inconsistent findings, likely attributable to a reliance on a single 
measurement of ethanol intake, non-standardized definitions of cognitive decline, short follow-up times, 
and or lack of analytic adjustment of confounders and effect measure modifiers. Few studies investigated 
the effects of ethanol intake in African Americans despite the disproportionate burden of cognitive 
impairment in this population.  
Importantly, no study has investigated the effects of ethanol intake on cognition from mid-life to 
older adulthood. Further, ethanol-metabolizing gene variants alter the rate of ethanol oxidation, yet few 
studies have evaluated a possible effect measure modification of the ethanol intake-cognitive decline 
relationship by genetic variation in ancestrally diverse populations. Thus, studies based on diverse 
populations with repeated measurements of ethanol intake and cognitive function that have been 
genotyped for ethanol-metabolism SNPs are needed to better understand the relationship of ethanol intake 
with cognitive decline.  
This doctoral research assessed the role of ethanol intake in cognitive impairment, as modified by 
genetic susceptibility in the bi-racial, population-based ARIC cohort of African-American and European-





examinations over 22 years of follow-up. Multiple imputation by chained equations will be used to 



























CHAPTER II: SPECIFIC AIMS 
 
2.1. Rationale 
The proposed study seeks to estimate the relationship of ethanol intake and cognitive decline and 
evaluate possible modification of the ethanol intake-cognitive decline association by genetic susceptibility 
in a population-based sample of African-American and European-American participants aged 45-64 at 
baseline in the Atherosclerosis Risk in Communities (ARIC) study. This study will utilize data from 
ARIC visits 1-5. Manuscript 1 will address Specific Aim 1  and manuscript 2 will address Specific Aim 2.   
2.2. Specific Aims 
Specific Aim 1: Characterize 9-year trajectories of ethanol intake during mid-life in African-American 
and European-American adults and examine whether long-term trajectories of ethanol intake in mid-life 
are associated with 15-year rate of decline in cognition from mid-to-late life among African-American 
and European-American adults. 
Hypothesis: a) Stable heavy drinking, mostly heavy drinking, stable former drinking, and mostly former 
drinking in mid-life is associated with greater 15-year cognitive decline compared to stable never 
drinking. b) Stable low-to-moderate drinking and mostly low-to-moderate drinking in mid-life is 
associated with lesser 15-year cognitive decline compared to stable never drinking.  
Specific Aim 2: Assess effect modification of the ethanol intake-cognitive decline relationship by 
ethanol-intake associated SNPs in African-American and European-American men and women from mid-
to-late life. 
Hypothesis: Greater genetic ability to process ethanol (lower SNP set scores) is inversely related to 15-





2.3. Public Health Implications 
Ethanol intake in mid-life is hypothetically associated with rate of cognitive decline from mid-to-late 
life through cerebrovascular and cardiovascular pathways. However, findings of a relationship between 
ethanol intake and cognitive decline have been inconsistent and limited by their use of single 
measurements of ethanol intake, assessment of ethanol intake in late life, and by not taking potential 
confounders and effect modifiers into account. Given the high prevalence of ethanol intake among adults 
in the U.S. and the dramatic increase in the prevalence of cognitive decline due to the projected aging and 
diversification of the population, understanding the relationship between ethanol intake in mid-life and 
rate of cognitive decline from mid-to-late life is important in reducing the burdens associated with 
cognitive decline.  
This doctoral research work, by utilizing data from a large, racially-diverse population-based cohort 
with repeated measurements of ethanol intake and  well-characterized cognitive function, quality 
controlled genetic data, and rich covariate data, has overcome some of the limitations of previous studies 
and aims to provide clear antecedent-consequent estimates of the ethanol intake-cognitive decline 
association. By exploring possible effect modification of this association by ethanol intake-associated 
genetic, this study aimed to inform mechanisms by which ethanol affects cognition.  This study has added 
to the knowledge base by providing data on the effects of ethanol intake for future meta-analyses. In 
addition, study results may inform clinicians as they assess the risks and benefits of ethanol intake for 










CHAPTER III: BACKGROUND AND SIGNIFICANCE 
This chapter reviews the epidemiology of cognitive decline and how cognitive decline is related 
to cognitive impairments such as mild cognitive impairment (MCI) and dementia. In addition, we will 
review literature on the effects of ethanol intake on cognitive decline, evidence of and reasons for 
inconsistent studies finding, and proposed mechanisms that may underlie both the neurotoxic effects and 
neuroprotective effects of ethanol on cognition.  Furthermore, we acquired knowledge from in vitro and 
genetic association studies that polymorphisms within ethanol-metabolizing genes affects ethanol 
metabolism and may modify the ethanol intake-cognitive decline relationship.  
First, in Section 3.1, we will discuss the epidemiology and public health burden of cognitive 
decline, and risk factors of cognitive decline that were identified in observational studies. Second, in 
Section 3.2,we will discuss the most widely used questionnaire measures of ethanol intake in 
epidemiological studies. Third, in Section 3.3,we will discuss the six primary neurocognitive domains, 
and in Section 3.4, we will discuss the neuropsychological tests and test batteries commonly used to 
assess decline in single or multiple neurocognitive domains. Fourth, in Section 3.5, we will discuss the 
absorption and elimination of ethanol intake in the human body, the different pathways of ethanol 
metabolism and polymorphic enzymes affecting the rate of ethanol metabolism. Fifth, in Section 3.6,we 
will discuss the proposed mechanisms that underlie the ethanol intake – cognitive decline relationship . 
Sixth, in Section 3.7, we will review prospective studies of ethanol intake and cognitive decline. We will 
conclude this chapter with a review of genetic association studies of ADH and ALDH polymorphisms 
with ethanol dependence and ethanol consumption (Section 3.8) and of gene-environment studies of ADH 





3.1. Epidemiology of Cognitive Decline  
3.1.1. Cognitive Decline 
Cognitive decline refers to the decline in mental processes, such as attention, short-term and long-
term memory, reasoning, movement coordination, and planning of tasks, which are important for the 
conduct of daily living activities (Table 1) [10, 11]. Neurobiological and cognitive performance studies 
suggest that declines in cognitive function are gradual and develop from early adulthood, mid-20s or early 
30s. The extent of decline depends on the type of cognitive domain [12-14]. Crystallized cognitive 
abilities (i.e., language and visuospatial), which refers to the skills, ability, and knowledge that is 
overlearned, well-practiced and familiar, remain stable or gradually improve at a rate of 0.02 to 0.003 
standard deviations per year through the sixth and seventh decades of life [15, 16]. Fluid cognitive 
abilities (i.e., processing speed, attention, memory, language, visuospatial, and executive function), which 
refer to abilities to problem-solve and reason, independent of one’s past knowledge, peak in the third 
decade of life and then decline at an estimated rate of -0.02 standard deviations per year [15, 16]. By age 
70, most individuals have a significantly lower cognitive performance compared to their mid-life 
cognition levels [17, 18]. Although cognitive decline with age is normal, decline is not inevitable.  
Studies indicate that older adults retain exceptional cognitive function until their 70s and 80s and have 
performance that is comparable or better than younger adults [19-22].  
The rate of cognitive decline varies among individuals [23-27].  Studies have shown that rate of 
cognitive decline in older adults is associated with lifetime differences in experiences, health status, 
lifestyles, education, attitudinal and emotional factors, socioeconomic status, and genetics [11]. It is well 
documented that there exist racial and ethnic differences in cognitive function at older ages [28-30]. 
However, it is unclear whether racial and ethnic differences exist for rates of cognitive decline. Findings 
are inconsistent on the effect of race on cognitive decline, with some studies reporting African-Americans 
having higher rates of cognitive decline compared to European-Americans [31-33], while other studies 
report no difference in cognitive decline by race [34, 35], and others report that African-Americans have 





Faster rates of cognitive decline may lead to earlier onset of cognitive impairment and dementia, 
which may result in significant burden in those experiencing decline and their caregivers [39].  Age-
related cognitive decline occurs on a continuum, and there is not yet a consensus of a boundary that 
distinguishes physiological and pathological changes [40]. Consequently, there is no standardization in 
the methods of research to define age-related cognitive decline, making comparisons of study results 
difficult. As a result, reliable epidemiological evidence on risk of cognitive decline are difficult to collect, 
and are therefore lacking in literature [41].   
By 2050, it has been projected that the number of Americans over the age of 65 will double to 
83.7 million, from  43.1 million in 2010 [1]. In addition to an increase in the number of individuals aged 
65 years and older, it expected that the U.S. will become more racially and ethnically diverse [1].  
Consequently, the number of Americans at risk for cognitive impairment and dementia will increase 
dramatically as the population ages. Furthermore, studies indicate that African American and other racial 
minority groups are disproportionately burdened with Alzheimer’s disease (AD), the most common form 
of dementia, and other forms of cognitive impairment [37-40]. In an attempt to reduce the incidence of 
cognitive impairment and dementia, current research has focused on identifying modifiable risk factors 
that can prevent or delay the progression of cognitive decline in diverse populations.  
3.1.2. Mild Cognitive Impairment and Dementia  
3.1.2.1. Definition, Prevalence, and Incidence of MCI 
 MCI is a syndrome defined as cognitive decline greater than expected for an individual’s age and 
education level, but that does not interfere notably with activities of daily life [42]. The National Institute 
on Aging-Alzheimer’s Association (NIA-AA) core clinical criteria for MCI include 1) evidence of 
concern about a change in cognition, in comparison with the individual’s previous cognitive level,  2) 
impairment in one or more cognitive domains that is greater than would be expected for the patient’s age 
and educational background, 3) mild problems performing complex functional tasks which they used to 
perform previously (e.g.,  paying bills, preparing a meal, shopping, etc.) while able to  maintain 





impairment in social or occupational functioning, or 5) a score of 1 to 1.5 standard deviations below the 
mean for their age and education-matched peers on culturally appropriate normative data on cognitive  
tests [43, 44]. Cognitive and functional severity within the MCI definition varies widely, thereby the MCI 
syndrome is heterogenous. The heterogeneity of MCI explains the variability in prevalence rates, 
incidence rates, and rates of progression to dementia. 
 Subtypes of MCI are characterized clinically by the presence of memory impairment (amnestic 
MCI) or the absence of memory impairment with presence of impairment in one or more non-memory 
cognitive domain (non-amnestic) [45]. Classification of MCI subtypes relates to the underlying etiology, 
pathology, clinical presentation, and outcomes (Table 2). The etiology of MCI includes neurogenerative 
disease, apolipoprotein E ε4 allele (APOE ε4), spontaneous features of parkinsonism damage, and 
cerebrovascular disease. Pathology of MCI can include neurodegenerative, amyloid β (Aβ) plaques, 
neurofibrillary tangles, hippocampal atrophy, reduced brain volume, cerebrovascular, cortical infarctions, 
subcortical infarctions, and white matter hyperintensities. MCI may consist of impairment in a single or 
multiple cognitive domains [45]. The number of impaired domains determines disease severity and the 
likelihood of progression to dementia. Multiple-domain MCI represents greater disease severity compared 
to single domain MCI, which in turn implies a higher rate of progression from MCI to dementia.  Single 
or multiple domain amnesia MCI may progress to AD if there is an underlying degenerative or vascular 
pathology. Typically, single or multiple domain non-amnestic MCI as a manifestation of  degenerative 
etiology progresses to non-AD dementias (e.g., frontotemporal dementia) or dementia with Lew Bodies, 
[46]. 
Population based cohort studies of MCI estimated the prevalence of MCI in the US to be 16-20% 
in individuals aged 65 and older [45]. The few studies on MCI incidence rates observed estimates ranging 
from 5.1 to 168 per 1000 years [45, 47]. 
Relatively few studies examined the mortality of MCI cases. Study findings suggest increased 
mortality among MCI cases compared to cognitively normal individuals over a median follow-up time of 





An important MCI outcome is the increased risk of progression to dementia [51], with most 
studies reporting rates of progression from MCI to dementia from 10-15% per year [45, 51]. Risk factors 
for progression to dementia include the degree of functional impairment, severity of neuropsychological 
test scores [52], and presence of neuropsychiatric behavior [53] at the time of MCI diagnosis. 
MCI is an important public health concern due to the increased risk of progression to dementia 
and increased mortality.  
3.1.2.2. Definition, Prevalence, and Incidence of Dementia 
Dementia is a disorder characterized by a decline in cognition involving one or more cognitive 
domains that affects an individual’s ability to perform everyday activities [54], unlike MCI where the 
ability to function in daily life is preserved . The NIA-AA defines  dementia when there are cognitive or 
behavioral (neuropsychiatric) symptoms that 1) interfere with the function of usual daily activities, 2) 
represent a significant decline in from previous level of functioning, and 3) are not explained by delirium 
or major psychiatric disorder; 4) cognitive impairment detected and diagnosed through a combination of 
medical history and mental status examination or neuropsychological tests; cognitive or  behavioral 
impairment that involves a minimum of two of the following domains: recent memory, executive 
function, visuospatial abilities, and language [55].  AD is the most common form of dementia. Other, less 
common forms of dementia include Vascular (multi-infarct) dementia (VaD), Lewy bodies Dementia 
(LBD), Parkinson Disease Dementia (PDD), and Frontotemporal Dementia (FTD).  
AD is irreversible and progressive, it  slowly destroys memory and thinking skills and eventually 
the ability to carry out simple tasks. AD accounts for an estimated 60 to 80 percent of dementia cases. For 
a diagnosis of probable Alzheimer's, the criteria adapted from the NIA-AA include dementia established 
by examination and objective testing, progressive worsening of memory and other cognitive functions, 
and deficits in two or more cognitive areas (executive function, visuospatial abilities, and language). 
Absence of systemic disorders or other brain diseases, which could account for the deficits in memory 





VaD may arise as a sequel to any form of cerebrovascular disease. VaD accounts for about 20 
percent of dementia cases. A diagnosis of probable vascular dementia VaD is based on the following 
information: history of stroke, evidence of relevant cardiovascular disease (CVD) by brain imaging 
including multiple large-vessel infarcts or a single strategically placed infarct,  any combination of onset 
of dementia within three months following a recognized stroke; abrupt deterioration in cognitive 
functions; or fluctuating, stepwise progression of cognitive deficits [56]. 
LBD is caused by abnormal deposits of a protein called alpha-synuclein in the brain. These 
deposits, called Lewy bodies, can lead to impairment in thinking, movement, behavior, and mood. The 
LBD Consortium core clinical revised criteria for the diagnosis of probable LBD include at least two of 
the following features: fluctuating cognition with pronounced variations in attention and alertness, 
recurrent visual hallucinations that are typically well formed and detailed, and spontaneous features of 
parkinsonism [57]. 
PDD should be used to describe dementia that occurs in the context of well-established Parkinson 
disease. The diagnosis is PDD when an individual is originally diagnosed with Parkinson's based on 
movement symptoms and dementia symptoms don't appear until a year or more later [57]. 
FTD is caused by a family of brain diseases known as frontotemporal lobar degeneration (FTLD). 
These disorders are the result of damage to neurons in parts of the brain called the frontal and temporal 
lobes. The diagnosis of FTD requires a thorough history, verified by a caregiver, and a neurological 
examination [58].  
In 2015, the prevalence of AD in the US was estimated at 5.2 million among individuals aged 65 
years and older. In the US, an individual develops AD every 67 seconds. By 2050, a new case of AD is 
expected to develop every 33 seconds, resulting in approximately 1 million new cases per year, and the 
expected prevalence to triple to 16 million due to the aging population [59, 60].  
AD is the sixth-leading cause of death in the US and the fifth-leading cause of death in those aged 





deaths from heart disease, stroke, and prostate cancer decreased by 14%, 23%, and 23%, respectively 
[61]. In 2015, it was estimated that 700,000 individuals aged 65 years and older will die from AD.  
AD is also a leading cause of disability and morbidity. From 1990 to 2010, AD’s rank in 
disability-adjusted life-years (DALYs) rose from 25th to 12th, and from 32nd to 9th in life year lost (YLL), 
the largest increase for any disease [2].  
AD is burdensome on patients, care givers, and society. In 2014, an estimated 17.9 billion hours 
of unpaid care was provided by 15.7 million caregivers of individuals with AD [59]. The economic value 
of care provided by unpaid caregivers in 2014 was $217.7 billion [59]. Family members who care for AD 
patients experience distress including emotional stress and depression, deteriorated health, and depleted 
income and finance due to disruptions in employment [3-7].  AD is one of the most expensive chronic 
diseases.  In 2015, the cost of health care, long-term care and hospice for individuals with AD was $226 
billion [8].     
3.1.3. Risk Factors for Cognitive Decline 
Given the public health importance of preventing cognitive impairment in individuals and 
promoting cognitive health, achieving a better understanding of the various beneficial and deleterious risk 
factors that influence cognitive decline is important so that  prevention and remediation efforts can be 
developed [11]. Over the past several decades many modifiable risk and protective factors have been 
studied in relation to cognitive decline [10, 62, 63].  Presented in Table 3 is a summary of findings on 
potential risk factors for cognitive decline from observational studies. In this section, risk factors for 
cognitive decline will be discussed.  
Risk factors for cognitive decline include demographic factors (age, sex, race, educational 
attainment, and social support), genetic factors (APOE ε4 allele), lifestyle factors (smoking, physical 
activity, omega-3 fatty acids (ω-3 FAs)), and medical factors (diabetes, hypertension, hyperlipidemia, 







3.1.3.1. Demographic Factors 
 
 Demographic risk factors of cognitive decline include age, sex, race, educational attainment, and 
social support. 
A3.1.3.1. Age 
 As discussed in Section A.1., cognitive abilities tend to decline with age [64]. “Fluid abilities” are 
most affected by age, while “crystallized” abilities are more resistant. 
A.3.1.3.2. Sex 
 
Reports on sex differences in cognitive function have been inconsistent [36, 65-69]. Some studies 
reported lesser age-related cognitive decline in women [65-67], while others reported greater age-related 
cognitive decline in women [36], and no sex differences in age-related cognitive decline [68, 69]. Sex 
differences in age-related cognitive decline have been attributable to improved living conditions and less 
gender-restricted educational opportunities favoring women in some cognitive functions (episodic 
memory) and decreasing or eliminating differences in other cognitive abilities [70]. 
A.3.1.3.3. Race 
 
 As discussed in Section A.1., studies finding on the effect of race on cognitive decline are 
inconsistent, with some studies reporting African-Americans having higher rates of cognitive decline 
compared to European-Americans [31-33], while other studies report no difference in cognitive decline 
by race [34, 35], and others report that African-Americans have slower rates of cognitive decline than 
European-Americans [29, 36-38]. An explanation for racial differences in cognitive impairment is that 
elderly African-Americans have fewer years of education than European-Americans [31, 71, 72] and such 
differences may contribute to racial differences in cognitive decline [31]. 
A.3.1.3.4. Educational Attainment 
 
Low educational attainment has been associated with poor cognitive function and faster age-
related cognitive decline [73-75] . The concept of cognitive reserve has been proposed as an explanation 
for why less education is associated with greater cognitive decline. Education may directly modify brain 





“cognitive reserve capacity” hypothesis postulates that conditions in early-life affect the rate of cognitive 
decline in later-life [76]. Early-life education may have effects in late-life if individuals with more 
education continue to engage in mental stimulation, which may result in beneficial neurochemical or 
structural alterations in the brain [77].    
A.3.1.3.5. Social Support 
 
Some studies demonstrated that social activities, larger social networks, and a history of social 
contact are associated with cognitive function [78-90]. In the study by Yeh et al., marriage and perceived 
positive support from friends were significantly and positively associated with cognitive function, while 
loneliness and living alone were not significantly associated with cognitive function [88]. Because social 
activities provide the challenge of effective communication and participation in complex interpersonal 
exchanges, social support has been thought to inhibit cognitive decline in the elderly [89]. However, an 
independent coordinated analysis of four longitudinal studies found no effect social activity on cognitive 
function [91]. Most studies of social engagement and cognitive function are small, are combined with 
cognitive training and/or physical activities, and/or dissimilar in types of social engagement, making it 
difficult to draw any conclusions [63].   
A.3.1.3.2. Lifestyle Factors  
 
 Lifestyle risk factors of cognitive decline include smoking status, physical activity, and ω-3 FAs. 
A.3.1.3.2.1. Smoking  
Prospective studies of smoking exposure on age-related cognitive decline has been inconclusive 
[92-100], with some studies reporting null associations [92-94], and others reporting a positive 
association [96-101].  
The British 1946 birth cohort study considered the difficulty of finding an association between 
smoking and cognitive impairment provided the differential high morality of smokers especially among 
the elderly population [101]. This study, after controlling for socioeconomic and health status variables, 
found that smokers who survive into later life maybe at risk of clinically significant cognitive decline. 





or more). Early studies in middle-aged adults indicated that current smoking and number of pack-years of 
smoking are related with reduced performance on tests of psychomotor speed assessed 5 years later [99]. 
Similar results were observed for cognitive decline in a large cohort study (Rotterdam Study) conducted 
in multiple European countries [96] and in a recent study that was conducted in the US [102].   
The mechanisms by which smoking affects cognitive decline remain unclear. However, it has 
been shown that smoking exposure is associated with periventricular and subcortical white matter lesion 
progression, which themselves are associated with greater cognitive decline independent of known 
cardiovascular risk factors [95].  
A.3.1.3.2.2. Physical Activity 
Physical activity is postulated to have potential protective effects on cognitive function by 
reducing the risk of related comorbidities (coronary heart disease (CHD), stroke, and diabetes mellitus), 
sustaining cerebral blood flow [103], improving aerobic capacity and cerebral nutrient supply [104, 105] 
as well as growth factors ( i.e., brain-derived neurotropic factor) [106, 107].   In their system review, 
Beydoun et al. suggested that physical activity could represent an important and potent protective factor 
for cognitive decline in elderly persons, with 21 of 24 prospective studies reporting an association 
between physical activity and cognitive outcomes [10].  
Several randomized trials and a Cochrane review of such trials reported significant improvement 
in cognitive function among previously inactive, but healthy, seniors who started an exercise program 
[108, 109] . Studies consistently demonstrated that exercise must be regular and vigorous [110-113]. 
However, studies have been unable to determine the optimal duration, type and intensity of physical 
activity, and time period in an individual’s lifespan that physical activity should occur so that its 
protective effect on cognitive decline is maximized [63].  
A.3.1.3.2.3. ω-3 FAs 
Epidemiological studies suggest that ω-3 FAs are protective of cognitive decline [114].  In animal 
and in vitro studies, ω-3 FAs have been shown to have a wide variety of beneficial effects on neuronal 





A.3.1.3.3. Genetic Factor 
 
 A genetic risk factor for cognitive decline is the APOE ɛ4 allele. 
 
A.3.1.3.3.1. Apolipoprotein E ɛ4 genotype 
 
 The APOE ɛ4 allele is a well-established risk factor for AD [115], and has been implicated in an 
earlier age of onset of AD [116] compared to non-carriers.  APOE, a lipid transport protein that is 
encoded by the polymorphic APOE gene, has three functional main isoforms that are encoded by three 
common polymorphisms, ɛ2 (cys112, cys158), ɛ3 (cys112, arg158), and ɛ4 (arg112, arg158). Although 
these allelic forms differ from each other by only one or two amino acids at positions 112 and 158, these 
differences alter APOE structure and function. While the APOE ɛ2 allele may be protective of AD [117], 
the APOE ɛ4 allele has been associated with reduced neuronal survival and cognitive impairment [117, 
118]. Prospective studies indicate that carriers of the APOE ɛ4 allele are at increased risk of cognitive 
decline [119-125].  
A.3.1.3.4. Cardiovascular Disease Risk Factors  
 
 Cardiovascular disease risk factors of cognitive decline include diabetes, hypertension, 
hyperlipidemia, obesity, stroke, and depression. 
A.3.1.3.4.1. Diabetes 
 
Diabetes has been consistently associated with an increased risk of cognitive decline [126-132].  
The ARIC study of 13,351 African-American and European-American adults ages 48 to 67 at visit 2 
reported mid-life diabetes is associated with greater cognitive decline over 20-years compared to diabetes 
[62, 131]. The mechanisms that underlie the associations of diabetes with cognitive decline remain 
unclear, but glycemic control may play a crucial role in this association and could contribute to both 
neurodegenerative and vascular damage [133].  
A.3.1.3.4.2. Hypertension 
 
Longitudinal studies have provided strong evidence of a high blood pressure (hypertension) and 
cognitive decline relationship [134].  Mid-life hypertension is consistently reported as a risk factor for 





adults ages 48-67 at study baseline reported that hypertension in mid-life was independently associated 
with a steeper decline in cognitive performance over 20 years [135]. By contrast, studies indicate that 
late-life hypertension may not be a critical risk factor in cognitive aging [142].The effect of hypertension 
on cognitive function is likely mediated by several mechanisms, which includes small and large vessel 
disease, microinfarcts, leukoaraiosis, and changes in cerebral metabolism [143].  
A.3.1.3.4.3. Hyperlipidemia 
 
Hyperlipidemia, especially hypercholesterolemia, is associated with cognitive decline [144]. 
Lipid regulation plays a crucial role in neuroplasticity and survival [145]. Like hypertension, 
hyperlipidemia may be a stronger risk factor in mid-life cognitive decline than in late life [146, 147].  
A.3.1.3.4.4. Obesity 
Although additional longitudinal studies are needed [62], emerging evidence support the 
existence of obesity-related brain changes and dysfunction [148]. The mechanisms by which obesity 
contributes to cognitive decline remains unclear. The effects of obesity on cognition are likely mediated 
through pathways such as the effects of diabetes or metabolic syndrome (i.e., inflammation, insulin 
resistance, endothelial dysfunction, and microvascular disease). Obesity may also increase the risk of 
cognitive aging directly through the presence of excessive adipose tissue and the secretion of 
inflammatory proteins (i.e., leptin), which is associated with cognitive impairment and decline [149-151]. 
A meta-analysis conducted by Anstey et al. of 15 prospective studies with follow-up times ranging from 




Stroke is associated with cognitive decline [153, 154]. Stroke may cause long-term cognitive 
decline by inducing or exacerbating neurodegenerative disease [155, 156], or neurodegenerative disease 









Studies have found an association between depressive symptoms and rate of cognitive decline 
that is independent of the neuropathologic conditions most strongly linked to late-life cognitive decline 
[158-160].  However, it remains unknown if depression increases an individual’s risk of cognitive decline 
or serves as an early marker of brain changes [63].  
3.1.4. Summary 
In summary, the public health burden of cognitive decline is increasing due to an aging 
population. Therefore, it is of public health significance to identify and intervene upon modifiable factors 
that may prevent or reduce the risk cognitive decline. Few prospective studies have examined the 
relationship between modifiable factors and cognitive decline. These studies provide evidence from 
which we can conclude that regular physical activity, a healthy diet, smoking cessation, and reduction and 
management of obesity, diabetes, hypertension, and stroke may reduce the risk of cognitive decline [63].  
However, much remains to be known about the relationship between other modifiable factors such as 
ethanol intake and cognitive decline, and how this relationship maybe modified by single polymorphisms 
in ethanol-metabolizing genes.  As a result, the focus of this work will be on the association between 
ethanol intake and cognitive decline, and the possible modification of this relation by single nucleotide 
polymorphisms (SNPs) within ethanol-metabolizing genes.  
In Section 3.2, we will discuss the proposed mechanisms that underlie the ethanol intake-
cognitive decline relationship.  
3.2. Measurements of Ethanol Intake 
 
The most commonly used methods in epidemiological studies to measure self-reported ethanol 
intake include the food frequency questionnaire (FFQ), the quantity/frequency (QF), and the graduated 
frequency (GF). Epidemiological studies of ethanol intake largely use self-reports [161-163]. Self-reports 
of ethanol intake are mostly reliable [164-166].  Regarding validity, in the absence of a “gold standard”, 





measurements may be attributable to the construct validity of the assessment tool (questions and response 
categories) and the assessment mode (e.g., self-report, interviewer administered, observer rating, or 
computer assisted) [167, 168]. 
 The FFQ [169] is the most common method of dietary assessment that is used by large 
epidemiological studies of diet and health [170]. The FFQ asks participants to report the frequency and 
quantify of food items and food groups over a specified period. More specifically, in epidemiological 
studies of ethanol intake, participants are asked how often on average over a defined time (e.g., day, 
week, months and year), they consumed each type of alcoholic beverage (i.e., beer, wine, and spirits/hard 
liquor, separately). Advantages of the FFQ include a low burden on the respondent, a low administrative 
cost, and the ease at which the test can be administered compared to other methods of dietary assessments 
(~30 minutes) [170, 171].  Disadvantages of the FFQ include a heavy reliance on participant’s long-term 
memory, and with an FFQ the precision in quantifying intake is not possible [172, 173].   
The QF  [174] is among the earliest measures of ethanol intake. QF measures are known as 
estimation formulae because they query participants about their “average” ethanol intake patterns with 
two questions that inquire about: 1) the overall frequency of ethanol intake within a specified period of 
time (F) (“How often do you drink?”), and 2) the number of drinks consumed on days that the participant 
drank (Q) (“How many per occasion?”) [175]. Total volume of ethanol intake is derived by multiplying 
frequency (F) and quantity (Q).  QF measures generally provide reliable information on quantity and 
frequency of drinking day and are most useful when time is limited and information about atypical 
drinking is not required. One advantage of the QF is that it is simple and relatively easy to complete.  The 
QF has numerous disadvantages [176, 177]. Researchers have suggested that responses to QF tend to 1) 
describe ‘modal’ rather than ‘average’ behavior [162, 175, 178], 2) misclassify drinkers and under-report 
occasions of heaving drinking [179, 180], and 3) underestimate volume of ethanol intake [181-183] . 
The GF [176] measure was developed to overcome some of the limitations of QF and allows 
pattern information as well as generate volume of ethanol intake directly. GF comprises of a series of 





drinks, etc.) or thresholds [184]. Compared to QF, GF estimates for volume  consumer is higher [182].  
There is also evidence to suggest that GF overestimate ethanol intake [185]. Some of this overestimate 
may have been partly due to the algorithm for calculating total frequency which used the middle range for 
each frequency category [186]. Nonetheless, the GF measure is widely used in survey research involving 
ethanol intake.  
3.3. Neurocognitive Domains 
  Cognition is important for functional independence (i.e., an individual’s ability to perform 
activities of daily living) such as living independently, managing finances, adhering to medication, and 
driving safety. Intact cognition is critical for effective communication, which includes processing and 
integrating sensory information and appropriately responding to others. Cognitive abilities often decline 
with age. Because cognitive abilities generally decline with age, it is of public health significance to 
comprehend the types of cognition changes that occurs with normal aging [187].  
 In this section, we will describe the primary neurocognitive domains, as well as decline in each 
domain. 
3.3.1. Memory 
Memory is the capacity to process, maintain, and to immediately manipulate available 
information [188]. The two main types of memory are working memory (short-term memory) and long-
term memory (Table 4) [189]. Both types of memory are important to everyday functioning [11].   
3.3.1.1. Working Memory - Short-term Memory - Recent Memory  
Working memory is the ability to temporarily retain information while it is processed or being 
used. Working memory encompasses the active manipulation of information, the maintenance of some 
information, while concurrently processing incoming information [11].  Working memory plays an 
essential role in the execution of many activities, such as adherence to a medication schedule [11], and is 
a central component of other cognitive abilities such as language processing, problem solving, decision 





memory generally declines with age, largely for complex task [190-193]. In this work, the association 
between ethanol intake and decline in short-term (recent) memory will be assessed.  
3.3.1.2. Long-Term Memory  
Long-term memory is the system for storage of permanent knowledge and a repository of an 
individual’s knowledge [11]. Long-term memory is divided in 2 types: explicit (or declarative) memory 
and implicit (or procedural) memory (Table 4). Declarative memory (“knowing what”) is memory of facts 
and events and refers to those memories that can be consciously recalled (or "declared"). It is sometimes 
called explicit memory, since it consists of information that is explicitly stored and retrieved, although it 
is more properly a subset of explicit memory. Declarative memory can be further sub-divided 
into episodic memory and semantic memory [11]. Procedural memories also known as skill learning, 
refers to learning and remembering how to perform an activity such as driving a car, riding a bicycle, 
cooking a favorite recipe, or using a software program. These memories are typically acquired through 
repetition and practice [11]. Long-term memory was not assessed in the ARIC study. Therefore, we will 
not provide details on the different types of long-term memory and we will not describe decline in each 
long-term memory domain.  
3.3.2. Speed of Information Processing 
 Speed of information processing reflects the efficiency of cognitive operations [11].  Declines in 
processing speed may affect an individual’s ability to recall spoken instructions, address important 
information, or perform tasks that have pacing demands [11]. In this work, the association between 
ethanol intake and decline in processing speed will be assessed. 
3.3.3. Executive Function 
 Executive function refers to cognitive skills used to regulate behavior and modify responses 
based on environmental cues [11]. These cognitive skills include the ability to plan actions, organize 
information, think abstractly, allocate mental resources, reason, problem solve, adjust to new situations, 





individual’s ability to make decisions, to respond, and to concurrently process relevant and irrelevant 
information. Declines in executive function have been linked to declines in the ability to perform 
important daily life activities such as medication management [194]. In this work, the association between 
ethanol intake and decline in executive function will be assessed. 
3.3.4. Attention/Concentration 
Attention is the capacity for processing information [11]. Humans are limited by the quantity of 
information they can process with a specified timeframe. For most individuals, especially for older adults, 
performing tasks at full capacity for long durations can be tiresome [195, 196]. Cognitive performance in 
attention tends to decline and be susceptible to error, when capacity limits have been exceeded [195].  
Summarized in Table 5 are the different types of attention which includes selective attention, divided 
attention, and sustained attention. The attention neurocognitive domain was not assessed in the ARIC. 
Therefore, declines in attention will not be evaluated in this work.  
3.3.5. Language  
 Language function  refers to the ability to comprehend and formulate speech, read, write, and 
promptly name words by category or sound [11]. Language function is an important component of human 
behavior and a main mechanism for communication [11]. Language processing is essential for completing 
cognitive tasks and includes comprehending written and spoken instructions and social interactions. 
Individuals whose spoken language is impeded, for example, by hearing loss may withdraw from social 
interaction [197]. Reduced social interaction not only negatively impacts an individual’s quality of life 
but may contribute to cognitive decline. In this work, we will assess decline in the language 
neurocognitive domain. 
3.3.6. Sensory and Motor Function - Visuospatial Skills 
 Visuospatial skills refer to an individual’s ability to identify visual and spatial relationships 
between objects [11]. Visuospatial skill is measured in terms of the ability to imagine objects, produce 





pertinent for tasks such as learning environmental layouts and routes, map reading, and translating 
directions [11]. The visuospatial skills domain was not assessed in the ARIC. Therefore, decline in 
visuospatial skills will not be evaluated in this work. 
3.4. Measurements of Cognitive Function  
 In the previous section, we discussed the different neurocognitive domains and described decline 
in each cognitive domain. In this section, we will discuss neuropsychological tests that are used in clinical 
settings and epidemiological studies to screen for dementia and measure cognitive changes over time.  
Neuropsychological tests are specifically designed tasks used to measure a psychological function 
known to be linked to a brain structure or pathway. Neuropsychological tests are utilized in research of 
brain function and in clinical settings to diagnose cognitive deficits. Since neuropsychological tests are 
usually administered to an individual by a trained individual in a quiet room, these tests provide an 
estimate of an individual’s  peak level of cognitive performance [198].  
Most neuropsychological tests that are in current use are based on psychometric theory. In this 
psychological model, an individual’s raw score on a test is compared to a large general population 
(“normative sample”) that is similar to the individual in one or more characteristics such as age, gender, 
level of education, and race. Research findings have found that these characteristics are associated with 
cognitive performance in cognitively healthy people. The comparison of an  individual’s raw score to a 
normative sample, therefore provide a fair assessment of their cognitive function [11].   
Most forms of cognition involve multiple cognitive functions working in unison, however tests 
can be organized into broad categories based on the cognitive function which they predominantly assess 
[15].  Some tests appear under multiple headings as different versions and aspects of tests can be used to 
assess different functions [15].   
In this work, we narrowed our discussion of psychological tests to the digit symbol substitution 
test (DSST), delayed word recall test (DWRT), word fluency test (WFT) that were employed in the ARIC 
Study to assess cognitive deficits in the attention and psychomotor speed, verbal learning and short-term 





combine multiple tests to provide an overview of cognitive abilities. Test batteries are commonly used in 
prospective studies to assess the relationship between ethanol intake and cognitive decline. If 
implemented early, these tests may be used to rule out problems in certain cognitive functions and 
provide an indication of functions which may be tested specifically. Tests of mental status include the 
MMSE, the modified Mini-Mental State Examination (3MS), the Telephone Interview for Cognitive 
Status (TIC-S), and the Cognitive Abilities Screening Instrument (CASI). 
3.4.1. Neuropsychological Tests 
The DSST is a subset of the Revised Wechsler Adult Intelligence Scale. The DSST assesses the 
attention and psychomotor speed cognitive domains. DSST requires use of motor speed, sustained 
attention, and visual spatial skills. Participants are given 90 seconds to  fill in blank squares with symbols 
corresponding to digits from 1 to 9 using a key that matches digits to symbols [199]. The DSST test 
scores ranges from 0 to 93 and has high reliability (0.82-0.88) in older adults [199]. The DSST test is 
more sensitive to brain damage, cognitive decline, and dementia than other Wechsler Adult Intelligence 
tests [199]. Unlike the MMSE, the DSST does not suffer from a ceiling effect and can identify changes at 
the highest levels of cognition [200]. 
The DWRT assesses verbal learning and short-term memory. Participants are asked to learn 10 
items, and after a five-minute delay are given 60 seconds to recall the word. The DWRT score ranges 
from 0 to 10 and has a high test-retest reliability of 0.75 in older adults [201]. Of all the cognitive tests, 
the DWRT is the most discriminating test in identifying individuals with early AD. DWRT appears to be 
affected by age and sex, and there is evidence of practice effects  [202]. 
The WFT , also known as the Controlled Oral Word Association Test (COWA) is a part of the 
Multilingual Aphasia Examination (MAE) [203]. The WFT assesses executive function and language 
[203, 204]. Participants are given 60 seconds to generate as many words as possible for the letters F, A 
and S, avoiding proper nouns. The WFT score is the total number of acceptable words generated for the 





detecting frontal lobe damage and early mental decline in older persons [207]. Factors that may influence 
WFT include education, sex, and age [207].  
3.4.2. Batteries Assessing Multiple Neuropsychological Functions 
The MMSE is used extensively in clinical and research settings to measure global cognitive 
impairment in older adults [208, 209]. The MMSE is commonly used in medicine to screen for dementia, 
and in longitudinal studies to measure cognitive chance over time [210].  The MMSE is a quick (~5 to 10 
minutes to administer) and short exam (consists of 11 questions, maximum total score of 30) that assesses 
seven areas of cognitive functioning (i.e., orientation to time, orientation to place, registration of three 
words, attention and calculation, recall of three words, language, and visual construction), and has a cut-
off of 23/24 out of 30 to show significant cognitive impairment. The MMSE has been shown to have both 
good test-retest reliability (0.80–0.95) [208-211] and acceptable sensitivity and specificity to detect mild 
to moderate stages of dementia [208-212]. However, the MMSE is less sensitive in detecting MCI and 
fails to discriminate patients with early stages of AD from normal patients. It is also insensitive to 
impairments in executive functioning, abstract reasoning, and visual perception/construction [213-215]. 
Moreover, the MMSE is affected by demographic factors such as age, education and race/ethnicity, with 
age exerting the greatest effect [216]. This has limited its use for detecting change in clinical work and in 
research studies. MMSE has a “floor” effect in terms of its inability to detect changes in established 
advanced dementia in those with little formal education and those with severe language problems, and a 
‘ceiling’ effect in that it may fail to detect very mild illness, and mild/moderate cognitive impairment in 
people at high educational level or premorbid intelligence [217]. 
Because of the shortcomings of the MMSE can be attributable to the narrow range of possible 
scores and ceiling effect, an expanded version of the MMSE, 3MS was developed to include four 
additional questions (date and place of birth, word fluency, similarities, and delayed recall of words), and 
to increase the maximum total score to 100 points [218]. Several studies have consistently shown the 





detecting dementia in comparison to the MMSE [220, 222, 224]. Additionally, a reduced rate of false-
negative classifications and an increased sensitivity of the 3MS over the MMSE [223]. 
The TICS [225], is a global mental status test that can be administered over the phone or face-to-
face. The TICS are used in epidemiological studies and clinical trials to monitor changes in cognitive 
functioning over time,  and is known to have high reliability and validity [225, 226]. The TICS is a quick 
(~10 minutes to administer) and easy measure (consists of 11 questions, maximum total score of 41) that 
assesses six cognitive domains (i.e., orientation, concentration, short-term memory, language, praxis, and 
mathematical skills), and has a cut-off of 24 out of 41 to show significant cognitive impairment. The 
TICS demonstrates a high correlation with the MMSE and has been found to have excellent sensitivity 
(94%) and specificity (100%) in differentiating participants with AD from those who have normal 
cognitive functioning [225]. Although the TICS was modeled after the MMSE, it has less ceiling effects 
than the MMSE, and can be reliably used even for persons with visual or physical deficits [226, 227]. A 
modified version of the TICS, the TICS-m [226, 228] was developed to include the delayed recall item, 
known as the most sensitive cognitive measure for MCI and AD detection. The addition of the delayed 
recall item of the TICS-m has resulted in enhanced sensitivity of the measure for detecting cognitive 
impairment and reduced ceiling effects  relative to the MMSE [229, 230].The TICS-m has been found to 
have excellent sensitivity (>99%) and specificity (86%) in the screening and detection of AD [231, 232]. 
The CASI is an instrument designed for identifying cognitive changes in the elderly. The CASI 
has been used to screen for dementia in epidemiological studies  [233-237]. The CASI consists of items 
either  identical or similar  to the ones used in  the Hasegawa Dementia Rating Scale (Hasegawa 
DRS[238]), the MMSE [208], and the 3MS [218]. The CASI can be administered in approximately 15-20 
minutes and consists of 25 questions that assesses nine cognitive domains of attention, concentration, 
orientation, short-term memory, long-term memory, language abilities, visual construction, category 
fluency and abstraction and judgment, which adds up to a total score of 100. The CASI has a maximum 





3.5. Ethanol Intake Metabolism 
3.5.1. Ethanol Absorption and Elimination  
Ethanol intake is probably the most extensively investigated drug due to its widespread use and 
distinct pharmaceutical properties [240]. After oral intake, ethanol is transported from the stomach to the 
small intestine, where it is rapidly absorbed into the blood and distributed throughout the body (Figure 3) 
[241, 242]. Approximately 20% of ethanol is absorbed from the stomach while 80% is absorbed from the 
small intestine [240]. The rate of absorption of ethanol depends on a variety of factors that include ethanol 
volume and concentration [241, 243, 244], and fed or fasting state [245]. Ethanol is highly miscible to 
water and can also be found in body fluids and tissues [242]. Ethanol is primarily metabolized in the liver 
(~95% of ingested ethanol), but other metabolic pathways include breath (0.7%), sweat (0.1%) and urine 
(0.3%) [242].   
Ethanol metabolism involves several enzymes. The primary enzymes involve in ethanol 
metabolism in the liver are ADH and ALDH (Figure 4). These enzymes help break apart the ethanol 
molecule, making it possible to eliminate it from the body. Upon ingestion and absorption into the blood 
stream, ADH metabolizes ethanol to acetaldehyde, a highly toxic substance and known carcinogen [246]. 
Then, in a second step, acetaldehyde is further metabolized to a less active byproduct, 
namely acetate [246], which then is broken down into water and carbon dioxide allowing for easy 
elimination [247]. This reaction is mediated by the mitochondrial enzyme ALDH (Figure 4). In this 
metabolic chain of events, two basic mechanisms result in the accumulation of acetaldehyde in the body: 
1) faster metabolism of ethanol to acetaldehyde, which is related to increased ADH activity, and/or 2) 
slower metabolism of acetaldehyde to acetate, which is caused by decreased ALDH activity. The 
excessive production or accumulation of acetaldehyde results in the flushing response, which may be 
accompanied by lightheadedness, nausea, accelerated heart rate, and headaches [248]. Individuals 
experiencing flushing typically drink little or no ethanol due to the unpleasantness of this reaction [248].   
The enzymes cytochrome CYP2E1  and catalase also break down ethanol to acetaldehyde thus 





has consumed large amounts of ethanol, and catalase metabolizes only a small fraction of ethanol in the 
body [246].  
There exists a substantial degree of inter-individual and ethnic variability in metabolic rates of 
ethanol, which may vary as much as three- to four-fold from individual to individual [250]. Such inter-
individual variability may in part due to genetic variations in the ADH and ALDH genes, which 
determines the metabolic rate of ethanol, and therefore impacts individual susceptibilities to the toxic 
effects of ethanol [251]. Factors that influences ethanol metabolism include age [252, 253], gender [254, 
255], ethnicity and genetics [254, 256-259], body mass index (BMI) and liver size [255], and food intake 
[260].  
3.5.2. Pathways of Ethanol Metabolism 
3.5.2.1. ADH Pathway 
ADH, an enzyme that facilitates the conversion of ethanol to acetaldehyde using nicotinamide 
adenine dinucleotide (NAD+), is the first step of ethanol metabolism in the liver (Figure 4)  [246, 249]. In 
humans, AHD genes cluster in a region of chromosome 4q21 covering  approximately 370 KB [261]. 
Humans have seven ADH genes (i.e., ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH6, and ADH7) that 
have categorized into five classes based on their structural and kinetic properties (Table 6) [262].  
Class I ADH genes (i.e., ADH1A, ADH1B, and ADH1C) are closely related.  Class I ADH encodes 
α, β, Ƴ subunits, which may form homodimers or heterodimers comprised of the three subunits (i.e., αα, 
αβ, ββ, β Ƴ, ƳƳ, etc.) [263]. Class I genes are ubiquitous in the body, but 90% can be found in the liver. 
Class I genes metabolize most of the ethanol in the liver (almost 70% of total ethanol metabolizing 
capacity) [264, 265].  
In humans, ADH genes are expressed differently in various tissues [266]. ADH4 encodes π-ADH, 
is solely expressed in the liver, and contributes significantly to the oxidation of ethanol at higher 
concentrations. This gene plays a key role in ethanol metabolism by the liver, especially at high blood 





expressed in human tissues (e.g., gastrointestinal tissues), and have very low affinity for ethanol. ADH6 
mRNA is expressed in fetal and adult liver, but its role in ethanol metabolism remains unknown. ADH7 
encodes σ-ADH, is not highly expressed in the liver, but contributes to ethanol oxidation [246].   
3.5.2.2. ALDH Pathway 
 
 ALDH, an enzyme that catalyzes the conversion of acetaldehyde to acetate acetaldehyde using 
nicotinamide adenine dinucleotide (NAD+) is the second step of ethanol metabolism in the liver (Figure 4) 
[267]. In humans, several isoforms of ALDH with different structural and kinetic properties have been 
identified in different organs and tissues (Table 7) [251]. However, the two main ALDH enzymes that are 
involved in the oxidation of acetaldehyde to acetate are: ALDH1 and ALDH2 [264, 268].  ALDH1 which 
is found in the cytosol is encoded by the Aldehyde Dehydrogenase 1 Family Member A1 (ALDH1A1) 
gene. The ALDH1A1 gene covers approximately 52 kb on chromosome 9, displays relatively low catalytic 
activity (Km ~30 μM) for acetaldehyde oxidation. The mitochondrial ALDH2 enzyme, although largely 
found in the liver and stomach, is extensively distributed in other bodily tissue including the brain.  
ALDH2, which covers approximately 43 kb on chromosome 9, plays a major in acetaldehyde oxidation 
largely due to its high catalytic activity (Km ~3 μM) for acetaldehyde oxidation [246, 269]. 
3.5.2.3. CYP2E1 Pathway 
 
Although most ethanol metabolism is accounted for by ADH, a small portion of ingested ethanol 
is metabolized by non-ADH enzymes [270, 271].  The microsomal ethanol oxidizing system (MEOS) 
which consists primarily of the cytochrome P450 isoform, P4502E1 (i.e., CYP2E1), accounts for the 
major non-ADH ethanol oxidation in the liver. CYP2E1 primary role in ethanol metabolism is the 
oxidization ethanol to acetaldehyde.  Compared to ADH, CYP2E1 plays a small role in ethanol 
metabolism in the liver when a normal amount of ethanol in consumed due to its low catalytic activity. 
However, with chronic or prolonged ethanol intake, CYP2E1 can play a significant role in ethanol 
metabolism. Following chronic ethanol intake, CYP2E1 increases the rate of ethanol clearance 





Because CYP2E1 plays a less important role in ethanol oxidation in the liver, it is not a focus in this 
work. 
3.5.2.4. Catalase  
 
Catalase is another enzyme that metabolizes ethanol to acetaldehyde. Catalase can be found in 
cell bodies called peroxisomes. In the presence of a hydrogen peroxide (H2O2) – generating system, 
catalase is capable of oxidizing ethanol intake in vitro producing acetaldehyde and water. The 
contribution of catalase to the elimination of ethanol in vitro is unclear. Most studies concluded that 
catalase is a minor pathway of ethanol oxidation because quantitatively it lacks the hydrogen peroxide 
that is needed to oxidize ethanol  [272, 273]. As a result, catalase will not be of focus in this work. 
3.5.3. Polymorphic Variants Affecting the Rate of Ethanol Metabolism 
 
As mentioned, genetic variants exist in several classes of the ADH and ALDH enzymes that alter 
the rate of ethanol oxidation and have been associated with susceptibility to several morbidities which 
include cardiovascular disease, alcohol liver disease, alcoholism, and cognitive impairments. 
3.5.3.1. ADH Variants 
The ADH gene cluster includes many single-nucleotide polymorphisms (SNPs). Some of these 
genetic variants result in an altered amino acid sequence of the encoded enzyme and are therefore 
considered functional or coding SNPs (cSNP). Detailed functional studies are lacking for all these cSNPs 
except for those that produce the ADH1B and ADH1C alleles (Table 8) [274]. 
3.5.3.1.1. The ADH1B Alleles  
The three most studied alleles of ADH1B usually are referred to as ADH1B*1 (the reference 
allele, which encodes the β1 form of the enzyme and carries the amino acid arginine [Arg] at positions 48 
and 370 in the amino acid chain ), ADH1B*2 (encoding β2 and carrying histidine [His] at position 48: 
His48Arg370 (rs1229984)), and ADH1B*3 (encoding β3 and carrying cysteine [Cys] at position 370: 
Arg48Cys370 (rs2066702)) [274]. In both the β2 and β3 subunits, amino acid substitutions occur at an 





higher turnover rate (i.e., how many molecules of ethanol the enzyme will convert to acetaldehyde in 1 
minute at saturating ethanol concentrations) for β2 and β3  subunits, respectively, than in β1 because the 
coenzyme is released more rapidly at the end of the reaction (Table 8) [264] .   Therefore, individuals who 
carry at least one ADH1B*2  allele or at least one ADH1B*3 allele experience rapid oxidation of ethanol 
and acetaldehyde accumulation levels in the body. Because acetaldehyde has harmful effects on the body, 
individuals carrying these alleles are less likely to drink and have a lower risk of ethanol dependence 
[274].  
3.5.3.1.2. The ADH1C Alleles  
ADH1C also has cSNPs, of which alleles ADH1C*1 and ADH1C*2 are the most studied. These 
two alleles differ at two sites, resulting in two amino acid changes: the enzyme encoded by ADH1C*1 
(γ1-ADH) has Arg at position 272 and isoleucine (Ile) at position 350, whereas that encoded by 
ADH1C*2 (γ2-ADH) has glutamine (Gln) at position 272 and valine (Val) at position 350 [275]. 
Compared to the ADH1B isozymes, the kinetic differences between γ1-ADH and γ2-ADH are smaller 
(Table 8) [274]. In most instances, the ADH1C*1 and ADH1C*2 alleles are in very high linkage 
disequilibrium (occur together). ADH that consists of two γ1 (i.e., γ1 γ1) has a turnover rate that is ~70 
percent higher than that of the  γ2γ2 enzyme  [276].  Therefore, individuals who carry the ADH1C*1 
allele are less likely to drink and have a lower risk of ethanol dependence [274].   
ADH1B and ADH1C alleles differ in their rates of ethanol metabolism in the liver due to the 
differences in the amino acid that they encode. Presence of the ADH1C*2 allele have been linked to 
lessen oxidizing capability (i.e., slow ethanol oxidation to acetaldehyde), while presence of the ADH1B*2 
and ADH1B*3 alleles are related to significantly higher oxidative capability (i.e., rapid ethanol oxidation 
to acetaldehyde) [277] .  
3.5.3.1.3. ADH Population Genetics 
The frequency distribution of ADH1B coding variants differs by race/ethnic population, with the 





allele highly prevalent in East Asians (60%-80%)  (e.g., Chinese and Japanese), but uncommon in 
Caucasian (0%-10%) and African (<5%) populations; and the ADH1B*3 allele having a prevalence of 
25% of individuals of African ancestry, and not present in European populations [278].  With regards to 
the ADH1C gene, the ADH1C*1 and ADH1C*2 have an approximately equal frequency in Caucasians 
(40%-50%), but ADH1C*1 predominates in African (~85%), and East Asian (~95%) populations, higher 
prevalence are found in the latter two populations [276, 279-281].  
3.5.3.1.4. Noncoding ADH Variants 
 In vitro studies have shown that some non-coding SNPs affect the level of gene expression of the 
ADH gene (Table 9) [282-284].  It is possible that many different variations in the region that contains the 
ADH genes also affect the level of expression of the different ADH enzymes in the intact organism (i.e., in 
vivo), thereby influencing ethanol metabolism, its physiological effects, and ultimately; drinking behavior 
and risk for alcoholism. However, detailed analyses of which SNPs are functional are difficult because 
many of the ADH variations are inherited together with nearby SNPs as haplotypes [274].  
3.5.3.2. ALDH Variants 
The acetaldehyde produced by the action of one or more ADH enzymes must be oxidized by 
efficiently by one or more ALDH in order for the cell/tissue to maintain non-toxic level of acetaldehyde 
[274]. Even short-termed elevation of acetaldehyde can trigger an adverse reaction in individuals whose 
ALDH activity is reduced either genetically or pharmacologically [274]. Eighteen genes that encode 
members of the ALDH enzyme superfamily have been identified in humans. Three of these genes are 
most relevant to the acetaldehyde oxidation: ALDH1A, ALDH1B1, and ALDH2 (Table 10). The 
ALDH1A1 gene is located in the cytosol, whereas ALDH1B and ALDH2 are produced in the nucleus. 
However, ALDH1B and ALDH2 have leader sequences that direct them to mitochondria,  where they 





3.5.3.2.1. The ALDH Alleles 
The best-known genetic polymorphism in the ALDH gene is ALDH2. ALDH2 has the highest 
affinity for acetaldehyde and is the enzyme most responsible for acetaldehyde oxidation. The ALDH2 
genetic variant rs671(Glu504Lys) has two allelic variants, ALDH2*1 (Glu504) and ALDH2*2 (Lys504), 
encoding for the active and inactive subunits, respectively. The inactive ALDH2*2 allele results from a 
single amino acid exchange, the substitution of lysine for glutamate at position 504 of the precursor 
protein (487 of the mature protein) [286, 287]. Studies of liver extracts suggest that the inactive ALDH2*2 
allele is dominant over the active ALDH2*1; individuals who are both homozygous and heterozygous for 
ALDH2*2 lack detectable ALDH2 activity in the liver [288, 289]. As a result, individuals who are 
homozygous or heterozygous for the ALDH2*2 are likely to experience the accumulation of acetaldehyde 
levels in their blood causing toxic reactions that include severe facial flushing, nausea, increase skin 
temperature and heart rate [259, 261, 290, 291]. 
3.5.3.2.2. ALDH Population Genetics 
  
The distribution of the ADH2 and ALDH2 genotypes and the frequencies for the respective alleles 
in various populations, grouped according to their racial origin, is shown in Table 11 [278]. The inactive 
ALDH2*2 allele is not observed in Caucasian and African-American populations as these two ethnic 
groups predominately expresses the homozygote normal (ALDH2*1/*1). In contrast, the inactive allele is 
prevalent in East Asian populations (Chinese, Japanese, and Koreans), with ~30% are heterozygote 
(ALDH2*1/*2) and ~2% are homozygote atypical (ALDH2*2/*2) [278]. 
3.5.4. The Influence of ADH and ALDH Polymorphisms on Ethanol Metabolism 
 Functional polymorphisms of genes for the ethanol-metabolizing enzymes ADH and ALDH2, 
and differences in the prevalence of the polymorphic alleles in different ethnic populations, have resulted 
in several studies examining race-ethnic differences in ethanol metabolism and the influence of the 
ADH1B, ADH1C, and ALDH2 genotypes. In vitro, the isozymes encoded by the polymorphic alleles have 





A study of 68 Japanese subjects genotyped for both the ADH1B and ALDH2 polymorphisms 
compared the ethanol disappearance rates (mg/ml/h) and elimination rates (mg/kg/h) among groups based 
on both ADH1B (ADH1B*1/*1, ADH1B*1/*2, and ADH1B*2/*2) and ALDH2 (ALDH2*1/*1, 
ALDH2*1/*2, ALDH2*2/*2) genotypes. This study found no differences in ethanol metabolism among 
ADH genotypes. However, significant differences in ethanol metabolism were observed among the 
ALDH2 genotypes. Study findings indicated that subjects homozygous for ALDH2*1/*1 displayed no 
increase in acetaldehyde levels regardless of their ADH1B genotype. Also observed was a progressive 
increase in peak acetaldehyde levels in subjects with the ALDH2*1/*2 and ALDH2*2/*2 genotypes. 
Furthermore, disappearance rates and elimination were significantly different among the ALDH2 
genotypes, and in decreasing order the values were ALDH2*1/*1, ALDH2*1/*2, ALDH2*2/*2 [256]. 
Similar findings were observed in other studies of Asians that reported no effect of the ADH1B*1/*2 
allele on ethanol metabolism once adjustment has been for the ALDH2*2 allele.  
A study of 109 young healthy Jewish men that assessed the effect of the ADH1B polymorphism 
on ethanol elimination rate (measured by an ethanol clamp) found significantly higher ethanol elimination 
rates among carriers of the ADH1B*2 allele (heterozygotes - ADH1B*1/*2 and homozygotes -  
ADH1B*2/*2) compared with the ADH1B*1/*1 homozygotes. This effect of ADH1B genotypes on 
ethanol metabolism is considered to be direct since the ALDH2 gene has not been observed in Jewish 
populations [292].  
A study of 112 African- American men and women, selected by genotype, examined the 
influence of ADH1B*3 polymorphism on ethanol metabolism. After receiving an oral dose of ethanol, 
participants’ ethanol disappearance rates (mg% per h) were determined from the slope of the pseudo-
linear portion of the blood ethanol concentration vs. time curves. Study findings indicate that carriers of 
the ADH1B*3 allele (heterozygotes and homozygotes) had a higher ethanol disappearance rate than 
ADH1B*1 homozygotes [254].  A more recent study of 91 African-Americans reported that the 
ADH1B*3  polymorphism had no effect on breath ethanol concentrations following a moderate oral dose 





faster ethanol elimination rates than those with the ADH1B*1 alleles.  However, this result was not 
significant which may be attributed to the study’s number of subjects with the ADH1B*3  alleles and the 
low frequency of the genotype in the Native American population [294].   
The influence of ALDH2 polymorphism on ethanol metabolism has been studied more 
extensively in Asian populations largely because of the high frequency of the polymorphisms in this 
population. Most studies compared peak concentrations of ethanol and acetaldehyde, peak responses on 
subjective and cardiovascular measures, and flushing across AHD1B and ALDH2 genotypes. Study result 
are generally consistent with reporting that individuals who are heterozygous or homozygous for ALDH2 
showed increased acetaldehyde levels following ethanol intake [256, 258, 261, 291, 295, 296]. Some 
studies demonstrated the accumulation of acetaldehyde in carriers of the ALDH2*2 allele without any 
difference in ethanol concentrations or elimination rates [258, 259]. A study of 100 Chinese men 
observed that the presence of the ALDH2*2 allele was associated with slower ethanol metabolism. In 
individuals homozygous for ALDH2*1, the presence of two ADH2*2 alleles correlated with slightly faster 
alcohol metabolism and more intense flushing [297].  Studies conducted by Peng et al demonstrated the 
effect of the ALDH2 polymorphism on ethanol and acetaldehyde metabolism and the lack of effect of 
ADH1B polymorphism on acetaldehyde metabolism [259, 290, 295].  
Recent efforts to understand the influence of genetic variations in ethanol-metabolizing enzymes 
on ethanol metabolism include the use of large-scale genetic association studies. Genome wide 
association studies (GWAS) or pathway-based candidate gene studies for many complex traits, like 
ethanol metabolism, have demonstrated an important role of intronic, intergenic, and non-coding variants 
in susceptibility to disease/phenotype. Where, in many cases, the underlying functional variant is not 
identified but a tag SNP marks a region of the genome as influential. Despite the discovery of the actual 
functional variant, the data in most of these studies are generally supportive or shown an important role of 
regulatory genetic variants influencing of phenotypic variation. One such candidate pathway study has 
been conducted for ethanol intake. In a large cohort of twin pairs of Caucasian ancestry103 single 





associations with variation in blood and breath ethanol concentrations after an alcohol challenge. Study 
findings indicated significant associations between rate of elimination and SNPs in the ADH1B, ADH1C, 
and ADH7 genes [298, 299].  
3.5.5. Summary 
In summary, genetic polymorphism in ADH and ALDH genes alters the metabolism of ethanol 
and/or acetaldehyde. Polymorphisms in ADH1B gene results in variants that code for isozymes that 
demonstrate faster rates of ethanol metabolism, whereas the ALDH2*2 polymorphism results in a 
“deficient” form of ALDH2 that demonstrates an accumulation of acetaldehyde and its associated 
physiological effects which include facial flushing. 
3.6. Mechanisms Underlying the Ethanol Intake and Cognitive Decline Relationship 
3.6.1. Mechanisms for Neurotoxic Effect of Ethanol  
 The brain is highly susceptible to the neurotoxic effects of ethanol. Chronic cerebral dysfunction 
may result from brain damage caused by long-term ethanol intake [300].  The neurotoxic effects of 
ethanol that cause cognitive deficits may be mediated directly through damage to brain structures or 
indirectly through malnutrition, ethanol metabolite toxicity, electrolyte imbalance, or accompanying 
physical illnesses including liver disease and infection [301].  
Ethanol’s direct neurotoxic effect on the brain is mediated through ethanol’s effect on the N-
methyl-D-aspartate receptors (NMDARs) of glutamatergic neurons. Glutamate (Figure 1) (green circles) 
exerts its effects by acting on various types of receptors, including the NMDARs and α-amino-3-hydroxy-
5-methylisoxazole-4-proprionic acid receptors (AMPARs), both of which are ion channels, and 
metabotropic glutamate receptors (mGluRs), which are coupled to G-proteins. G-proteins, in turn, 
indirectly activate protein kinase C (PKC) and activate or inhibit adenyl cyclase (AC), depending on the 
mGluR and G-protein involved. In the absence of ethanol, glutamate leads to the activation of the 
postsynaptic neuron and the generation of a new nerve signal [302]. In the presence of ethanol (Figure 2) 





into the cell. As a result, the activity of the neuron is reduced and no or fewer nerve signals are generated 
[302].  Because many glutamatergic cells are densely concentrated in the frontal lobes and subcortical 
cells such as the hippocampus, these brain structures are vulnerable to excitotoxicity of ethanol intake 
[300, 303]. An example of an indirect neurotoxicity is Korsakoff syndrome. Korsakoff syndrome is a 
neurological disorder caused by thiamine (Vitamin B1) deficiency in the brain. Thiamine deficiency 
causes an excessive release of glutamate which may exert a neurotoxic effect that is similarly to ethanol. 
Chronic ethanol abuse and thiamine deficiency may have an additive or synergistic neurotoxic effect 
[304]. Studies of amnesia involving Korsakoff patients demonstrated that Korsakoff syndrome has an 
anterograde component (inability to learn information due to data not successfully transferred from short-
term memory to long-term memory) and retrograde component (inability to recall pre-existing memories) 
[305] .  
Genetic susceptibility to the neurotoxic effects of ethanol has been linked to the APOE ɛ4 allele. 
Reports indicate that individuals with the APOE ɛ4 allele have a neural repair mechanism that is less 
effective than individuals without the allele, and, therefore, are more vulnerable to the deleterious effects 
of ethanol [306, 307]. Homocysteine (Hcγ) is also implicated in ethanol neurotoxicity. Elevated serum 
levels of homocysteine overstimulate glutamate NMDARs, increasing NMDAR transmission and the 
potential for excitotoxity [308-311]. Ethanol neurotoxicity is also influenced by the immune system. 
Long-term ethanol use induces systemic cytokines such as tumor necrosis factor alpha (TNFα), which is 
involved in potentiating glutamate excitotoxicity and activating resident microglia, thereby inducing 
neuroinflammation [312]. Other mechanisms that may influence ethanol induced neurotoxicity include 
free radical toxicity, acetaldehyde toxicity, modulation of the nicotinic acetylcholine, however addition 
research is needed to confirm these findings [303, 313-315]. 
3.6.1.1.  Acute Effect of Heavy Ethanol Intake on Cognition  
Cognitive impairment, blackout, and hangover are common symptoms of acute ethanol 
neurotoxicity. Heavy ethanol intake causes acute intoxication, and blackouts that may not involve loss of 





usually experiences hangover symptoms that may include headache, drowsiness, concentration problems, 
fatigue, nausea, vomiting, diarrhea, loss of appetite, depression, hyper-excitability and anxiety, which 
may persists for a considerable amount of time [316]. Blackouts and hangovers precede ethanol-related 
cognitive dysfunction and risk factors for brain damage that may cause transient or permanent cognitive 
dysfunction.[317, 318]  
 Ethanol intoxication during or following heavy ethanol intake causes clinical behavioral changes 
and physiological changes that may result in impairments in cognitive functions (memory, attention, 
executive function, and visuospatial). Most of these impairments are reversible after the withdrawal of 
ethanol [319-321].  
 A blackout is associated with impaired episodic memory [322]. Blackouts are consistently 
associated with accelerated increase in blood ethanol concentration. However, blackouts may not occur in 
all individuals who consume ethanol rapidly or excessively, thereby suggesting that genetics may modify 
the effects of ethanol on the brain. Ethanol-related blackouts may interfere with the various stages of 
memory (encoding, storage, and retrieval), and cause partial or complete deficits in retrieval. Blackouts 
may be caused by damage to the hippocampus which plays a role in memory encoding at the cellular 
level, and antagonization of the NMDARs, which are required for the induction of long-term potentiation 
in the hippocampus at the molecular level [323]. 
3.6.2. Mechanisms for Neuroprotective Effect of Ethanol 
The neuroprotective effect of low-to-moderate ethanol intake (LMEI) is exemplified by its 
complex effect on coronary artery disease (CAD) and ischemic stroke. Several epidemiological studies 
have reported a J-shaped relationship between ethanol intake and CAD, with LMEI lowering risk of CAD 
compared to non-drinking, but increased risk for heavy ethanol intake [324-326]. A similar J-shaped 
curve reportedly describes the association of ethanol intake and ischemic stroke [327]. 
Several mechanisms appear to explain the protective effect of ethanol. Ethanol increases insulin 
sensitivity [328], prevents platelet aggregation [329], increases fibrinolysis [330], opposes thrombin 





Moreover, animal studies have linked the neuroprotective effects of ethanol to ethanol’s 
interactions with protein kinase C (PKC), adenosine receptor, and cardio protection proteins that include 
superoxide dismutase, nitric oxide synthase, and heat shock proteins [324]. Furthermore, findings suggest 
that neuroprotection is correlated with down-regulation of inducible nitric oxide synthase and up-
regulation of endothelial nitric oxide synthase [332]. The neuroprotective effect of ethanol also has been 
attributed to antioxidant polyphenols such as resveratrol, which is abundant in red wine [333-335].  
3.7. Prospective Cohort Studies of Ethanol Intake and Cognitive Decline  
3.7.1. Review of Prospective Cohort Studies of Ethanol Intake and Cognitive Decline 
Fifteen prospective studies examined the association between ethanol intake and cognitive 
decline [32, 93, 336-348] (Tables 12 and 13). However, the relationship of ethanol intake with cognitive 
decline remains poorly understood due to inconsistent study findings. While heavy ethanol intake has 
been identified as a risk factor for cognitive decline [348], low-to-moderate ethanol intake has been 
associated with lesser cognitive decline [336, 339, 340, 342-344, 346, 347] and no cognitive decline [93, 
341, 345, 348].  
Of the fifteen studies, twelve studies studied the relationship between ethanol intake and 
cognitive decline [93, 336, 339-348]. Of the twelve studies that examined the low-to-moderate ethanol 
intake - cognitive decline relationship, eight reported that low-to-moderate ethanol intake is associated 
with lesser cognitive decline [336, 339, 340, 342-344, 346, 347]. The Epidemiology  of Vascular Aging 
(EVA) study of 1,389 men and women ages 59-71 years in Western France reported that low ( <2 glasses) 
or moderate (2-5 glasses) ethanol intake was associated with decreased risk of decline in MMSE (global 
cognitive function) in participants without the APOE ε4 allele, whereas moderate ethanol intake increased 
the risk of cognitive decline in those without the APOE ε4 allele [336]. The Women’s Health Initiative 
Memory Study (WHIMS) of 4,461 postmenopausal women ages 65-79 years reported that moderate 
ethanol intake (<1 drink per day, and ≥1 drink per day) was associated with lesser decline in 3MSE 





Independent Elders Survey (MoVIES project) study of 1,681 men and women ages 65 years and older 
reported that both minimal (ethanol intake once per month or less) and moderate ethanol intake (ethanol 
intake more than once per month) was associated with lesser decline on the MMSE (general mental 
status) and Trail making tests (executive function and psychomotor speed) over 7.3 when compared to 
those with no ethanol intake [340]. The Nurses' Health Study (NHS) of 12,480 female nurses aged 70 to 
81 years old reported lower relative risk of substantial decline on the MMSE (general cognition) over 2 
years among moderate (1.0-14.9g) drinkers than nondrinkers [342]. The Northern Manhattan Study 
(NOMAS) of 2,631 men and women ages 40 years and older reported that less than one drink per week, 
between one drink weekly up to two drinks daily, and more than two drinks daily were associated with a 
lesser decline in TICS-m scores over 2.2 years compared to never drinkers [343]. The Pravastatin in the 
Elderly at Risk (PROSPER) study of 5,804 men and women ages 70 to 82 years reported that in women, 
low (1 to 3 U per week) or moderate (> 3 U per week) intake was associated with lesser MMSE (general 
cognitive function) over 3.2 years than no ethanol intake [344]. The Baltimore Longitudinal Study of 
Aging (BLSA) of men and women aged 17-97 years of 628–1305 individuals (depending on the cognitive 
outcome) reported among participants less than age 70, ethanol intake was associated with faster decline 
or slower improvement on the MMSE (global cognition) and on the verbal fluency test - letter (VFT-L) 
[347]. Finally, the Seattle Longitudinal Study (SLS) of men and women ages 45 years and older reported 
that moderate ethanol intake (no more than 7 drinks per week) was associated with lesser decline in 
Thurstone Primary Mental Abilities (verbal memory) over 7 years [346]. 
In contrast to the previous studies, the remaining four studies reported that there is no association 
between levels of ethanol intake and cognitive decline (Tables 12 and 13). The Established Populations 
for Epidemiologic Studies of the Elderly (EPESE) of 3,809 men and women ages 65 years and older 
reported that moderate intake (>= 1 ounce) was not associated with lesser decline in memory over 3 years 
[93]. The Medical Research Council  (MRC) National Survey of Health and Development (the British 
1946 Cohort) of 1,764 men and women age 43 at study baseline and 53 at follow-up reported that 





smaller decline in memory in men and greater decline in psychomotor speed in women over a follow-up 
period of 10 years [341]. The ZARADEMP Project study of 4,803 men and women ages 55 and older in 
Spain reported that low (< 12 grams per day) or moderate ethanol intake (12-24 grams per day) was not 
associated with reduced risk of decline in MMSE (global cognition) over 4.5 years[345]. Finally, the 
Whitehall ll Cohort Study of 10,308 British civilian workers ages 44-69 reported no association between 
moderate ethanol intake (< 20 g/d) and lesser decline in global cognition z-scores [348]. 
Few studies (N=2) examined the relationship between heavy drinking and cognitive decline due 
to small size [93, 342, 343, 345] or due to the underrepresentation of heavy drinkers in the study 
population [339, 340, 344]. While the Whitehall ll Cohort Study [348] reported that heavy ethanol intake 
was associated with greater decline in global z-scores, the NHS found no association [342]. 
3.7.2. Limitations of Prospective Cohort Studies of Ethanol Intake and Cognitive 
Overall, the reported relationship between ethanol intake and cognitive decline is inconsistent. 
Inconsistent study findings may be attributable to methodological issues as they often include single 
measurements of ethanol intake [93, 336, 339-341, 344-347],  non-standardized definitions of cognitive 
decline, short follow-up times (<5 years)  [93, 336, 339, 342-345], and an analytic approach that does not 
appropriately consider confounders and effect modifiers  [93, 336, 337, 339-348]. 
A short follow-up time (<5 years) may not capture changes in ethanol intake patterns that may 
occur, or in association with cognitive decline. Therefore, long-term studies are needed to study the 
relationship between ethanol intake and cognitive decline.  
Most studies did not have data available on APOE ε4 allele status, which is an established strong 
risk factor for cognitive impairment.  
Studies were also limited by an inconsistent use of outcome measures. Some studies use 
multidimensional measures of cognition (e.g., MMSE  [336, 340, 344, 345, 347], 3MSE [339], TICS 
[342], TICS-m [343], and CASI [338]), whereas others examined only specific tasks (e.g., the DSST) [93, 
341, 344, 346, 348].  As a result, the clinical meaning of changes in cognition associated with ethanol 





cognitive function) [336, 340, 344, 345, 347], which have known “ceiling effects”, thereby failing to 
capture differences in cognitive function among those with higher level of cognitive performance [349]. 
Few studies assessed decline in specific domains cognitive decline [342, 344, 347, 348], which is 
important since cognitive decline affects different domains differently [11].  Most studies evaluated 
change in cognitive performance at two points [93, 336, 339, 341, 342, 345-347], when  multiple 
measurements of cognitive function performed at various points across the life span are needed to make 
more to firm conclusions on the effect of ethanol intake on cognition [11, 350]. 
Existing studies were conducted primarily in older populations (≥65 years at study baseline) [93, 
336, 339, 340, 342-347], failing to capture the effect of ethanol intake on cognitive decline earlier in life. 
Only one study adjusted for attrition/missing data (differential), which may have produced less biased 
estimate of the effect of ethanol intake on cognitive function [346]. A limited number of studies 
investigated the effects of ethanol in African-Americans populations although the prevalence, incidence, 
and cumulative risk of AD, the most common form of dementia, appears to be much higher in African-
Americans than in European-Americans [343, 347]. Furthermore, few studies investigated the effects of 
mid-life ethanol intake with late-life cognition [341, 348].  
3.7.3. Summary of Prospective Studies of Ethanol Intake and Cognitive Decline 
Although the relationship between ethanol intake and cognitive decline has been studied 
extensively, it remains poorly understood due to inconsistent study results. Methodological issues may 
account for inconsistent studies finding. Therefore, additional analyses of large, diverse populations with 
repeated measurements of ethanol intake and cognitive function are needed to better understand the 
relationship of ethanol intake with cognitive decline.  
3.8. Genetic Association Studies of ADH and ALDH Polymorphisms with Ethanol Dependence and 
Ethanol Intake 
 
Genetic polymorphisms that affects functional ADH and ALDH activities may be relevant for the 
biological actions of ethanol [259, 351]. Ethanol dependence syndrome is a complex behavioral disorder 





353]. Twin, adoption, and family studies demonstrated that genetic factors play a role in the determining 
drinking behavior and risk of ethanol use disorders [354, 355]. Ethanol dependence is moderately 
heritable, with heritability in most studies estimated to be 0.50-0.60 [355-360]. As previously mentioned, 
ethanol is metabolized in the liver to acetaldehyde and acetate primarily through the ADH and ALDH 
enzymes. Genetic polymorphisms in the genes encoding ADH and ALDH are associated with alteration 
enzyme kinetics  [274, 361]. As a result, the roles of SNPs within ethanol-metabolizing genes, ADH (i.e., 
the Class I, low Km ADHs ADH1A, ADH1B and ALDH1C) and ALDH (i.e., ALDH2), in ethanol 
dependence has been extensively examined, as well as quantitative ethanol intake measures.  SNPs within 
ethanol-metabolizing genes have been associated with the risk of developing ethanol dependence and 
ethanol intake (Table 14). The significant association between ALDH2 and ADH1B variants and ethanol 
dependence risks have been explained by the hypothesis that any increase in acetaldehyde production, or 
reduction in its subsequent elimination, will reduce and individual’s vulnerability to ethanol abuse and 
ethanol dependency disorders due to the adverse effects associated with elevated blood and tissue 
acetaldehyde [352].  
In this work, we focus on functional (e.g., intronic, exonic, intergenic, etc.) coding genetic 
variants within ADH and ALDH genes that have been identified by GWAS or pathway-based candidate 
gene studies to play an important role in ethanol metabolism and susceptibility to ethanol dependence 
(Table 14). For the ADH gene, the focus is placed on SNPs that produce the ADH1B and ADH1C alleles 
because studies on the functionality of other ADH coding SNPs are lacking. The ALDH missense SNP 
rs671 is not considered in this work because it is monomorphic in the ARIC study population. Although 
in vitro studies have shown that non-coding SNPS affect the levels of gene expression, they are not be 
considered in this work. Detailed analysis of which ADH non-coding SNPS are functional are difficult 





3.8.1. ALDH Polymorphisms and Ethanol Intake Phenotypes 
The importance of ALDH genetic variation in risk for AD has been well established among Asian 
populations. The loss of function SNP rs671 (Glu504Lys) in the ALDH2 gene results in an amino acid 
change from glutamic acid to lysine at position 504 in the ALDH enzyme. The ALDH2*2 allele that 
contains the rs671 polymorphism is associated with reduced ALDH activity, which results in the 
accumulation of acetaldehyde following ethanol intake and a flushing response, thereby reducing the 
likelihood of ethanol abuse [362]. A meta-analysis of 53 studies, which included a total of 9,678 cases 
and 7,331 controls of East-Asian ancestry found that the risk allele ALDH2 (rs671) *1 (Glu504) is 
significantly more prevalent individuals who are ethanol dependent. In contrast, the less active ALDH2 
(rs671) *2 (Lys504) allele was found to be protective of ethanol abuse [363].   
3.8.2. ADH Polymorphisms and Ethanol Intake Phenotypes 
3.8.2.1. ADH1A 
 A study conducted by Zuccolo et al 2009 of 7,410 women of European ancestry, participants of 
the Avon Longitudinal Study of Parents and Children (ALSPAC), found evidence of an association 
between ADH1A intronic SNP rs2866151 and weekly drinking before pregnancy [364]. A genome-wide 
association study (GWAS) of ethanol dependence conducted in 2,379 European-American and 3,318 
African-American subjects conducted by Gelernter et al in 2014 found that the intronic ADH1A SNP 
rs904092 is associated with ethanol dependence in European-American and African-American 
populations, with replication in an independent sample of Germans [365].  
3.8.2.2. ADH1B 
 In the ADH1B gene, a SNP called rs1229984 (Arg48His), results in an amino change at position 
48 in the β subunit of ethanol dehydrogenase from arginine to histidine [246]. In vitro studies have shown 
that rs1229984 increases the maximal velocity (Vmax) at which ethanol is oxidize to acetaldehyde by over 
100-fold [366, 367] .The ADH1B rs1229984 is common in East-Asian populations, with  frequency 





intake and a reduced risk of ethanol abuse in East-Asian populations [360, 362, 368]. Although the 
frequency (range: 0-10%) of rs1229984 variant is  low in populations of European and African descent 
[278, 369]  (0-10%), there is consistent evidence that this variant has a strong protective effect for ethanol 
abuse in Europeans [364, 365, 370-373] and African-Americans  [365]. In European populations, 
rs1229984 variant is associated with  lower ethanol intake (defined maximum number consumed in a 24-
hour period) [371, 374], total number of drinks taken in the past year [374], and average ethanol intake 
and binge drinking during pregnancy [364]. Although, rs1229984 is rare among European and African 
populations, at an individual level the effect of this ADH1B variant on the level of ethanol consumed and 
the risk of developing ethanol dependence is the same irrespective of ethnicity [248].  
  A GWAS of 2,379 European-American and 3,318 African-American subjects conducted by 
Gelernter et al 2013 that was previously mentioned, found that the ADH1B SNP rs1789882 (Arg369Cys), 
is associated with ethanol dependence in African-Americans; the first Genome Wide Significant (GWS) 
finding for ethanol dependence in African-Americans, although the risk locus was previously known 
[375]. Associations with ethanol dependence were also found for the ADH1B SNPs rs2066702 
(Arg370Cys) and rs1693457 in European and African-American populations with replication in an 
independent sample of Germans [365].  
 An association analysis conducted by Macgregor et al 2009 that included 4,597 Australian twins, 
participants of the Twin study conducted at the Queensland Institute of Medical Research (QIMR) study, 
observed an independent association between ADH1B SNP rs1042026 and alcohol intake, after 
controlling for rs1229984 [374].  
3.8.2.3. ADH1B/ADH1C 
 A recent association analysis conducted by Way et al 2015 in a sample of 1,076 individuals of 
European ancestry (i.e., British and Irish) found significant associations between risk of ethanol 
dependency and the ADH1B/1C intergenic variant, rs1789891. This observed association was largely 






 Polymorphisms in the gene encoding ADH1C have been implicated in 
the risk for developing ethanol dependency syndrome. Three non-synonymous ADH1C 
SNPs rs698 (IIe50Val) [248, 372, 376, 377], rs1693482 (Arg272Gln) [248, 372, 374, 376], and rs283413 
(G78stop) [372, 378, 379] have been associated with ethanol dependence risk. However, these 
associations are not completely independent [368, 372] .  GWASs observed an association between 
ADH1C SNPs rs2241894 [365] and rs1614972 [248, 365] and ethanol dependence.  
3.8.2.5. ADH4 and ADH5 
 Variants in ADH4 and ADH5 sporadically have been linked to ethanol dependence. Macgregor et 
al 2009 reported associations between ADH4 SNPs rs3762894 and rs1126671 and ethanol dependence 
symptoms as well quantity, frequency, and maximum drinks [374]. A study of 715 European-Americans 
and 210 African Americans reported associations between ADH4 SNPs and ethanol dependence [380] 
3.8.3. Summary 
In summary, genetic variations in ADH1A , ADH1B, ADH1C, ADH4, ADH5, and ALDH2 





3.9. Gene-Environment Studies of ADH and ALDH Polymorphisms and Ethanol Intake on 
Cognitive Decline 
 
 Reports of the relationship between low-to-moderate ethanol intake and cognitive decline have 
been inconsistent. While some studies reported lower cognitive decline for low-to-moderate ethanol 
intake compared to no ethanol intake, others reported no association. Several mechanisms have been 
suggested to underlie the protective effect of low-to-moderate ethanol intake on cognition which include 
possible anti-inflammatory properties of ethanol [324]. The lack of consistent results has been attributed 
to methodological issues such as uncontrolled confounding. In vitro studies found that SNPs within 
ethanol-metabolizing genes (ADH, ALDH, CYP2E1)  with different kinetic properties and ethnic 
distribution alters the rate of ethanol oxidation and therefore impacts individual susceptibilities to the 
toxic effects of ethanol [251].The direction of effect of ethanol intake on cognitive change may thus 
depend on genetic differences in the ability to metabolize ethanol. 
To our knowledge, only one  study has investigated an effect modification of the ethanol intake-
cognitive decline relationship by SNPs within ethanol-metabolizing genes[381].  This study used a 
Mendelian randomization (MR) design, a method that allows testing for, or in certain cases to estimate, a 
potential causal effect from observational data in the presence of confounding factors. MR designs use 
common genetic polymorphisms with well-understood effects on exposure patterns (e.g., ethanol intake) 
or effects that mimic those produced by modifiable exposures. Importantly, the genotype must only affect 
the disease status indirectly via its effect on the exposure of interest. Because genotypes are assigned 
randomly when passed from parents to offspring during meiosis, the population genotype distribution 
should be unrelated to the confounders that typically plague observational epidemiology studies if one 
assumes that choice of mate is not associated with genotype. In this regard, MR has been described as a 
“natural” randomized controlled trial [382]. 
The study, conducted in 1,079 participants in the Lothian Birth Cohort 1936 observed a 
statistically significant interaction of a four-SNP score  indexing alcohol dehydrogenase activity (ADH7 





cognitive change (interaction beta parameter estimate= -1.13, p=0.007) [381]. This study used a 
population homogenous for age and culture, which may reduce potential confounding. Limitations of this 
study include the use of a single measurement of ethanol intake measured at ~age 70, the measurement of 
cognitive function at ages ~11 and ~70 years, and a marked attrition over the prolonged period of follow-
up which was not accounted for in the analyses. 
Therefore, there is need to study the effect modification of ethanol intake-associated SNPS on the 
ethanol intake-cognitive decline relationship using large prospective studies with repeated measurements 
of ethanol intake and standardized measures of cognitive function to determine whether effect 
modification exists. Little is known about the effect of ethanol intake-associated genetic variants in other 
populations such as African-Americans; therefore, it is important that the role of these SNPs be assessed 
in ancestrally diverse populations. The rich data source of the ARIC study which includes repeated 
measurements of ethanol intake of cognitive function collected on African-American and European-
American men and women from mid- to-late life that were genotyped for ethanol intake-associated SNPS 
is well-suited to address this current research need.  Evidence of effect modification of the ethanol intake-
cognitive decline relationship by SNPs within ethanol-metabolizing genes would inform the mechanisms 
by which ethanol affects cognition and be relevant to understanding the potential public health risk and 














3.10. Supporting Figures and Tables 
 
Table 1. Cognitive domains [11] 
Concepts Definition 
Language 
Consists of an array of abilities, including understanding 
and producing speech, reading, writing, and naming 
Visuospatial Skills 
Abilities to make sense of the visual world—shapes, angles, larger gestalts 
vs details, the meaning of forms—and to reproduce what one sees. 
Executive function 
A variety of higher-order functions—planning, conceptualizing, organizing, 
and evaluating 
Learning and memory 
Process that allows to maintain and to 
immediately manipulate available information 
Attention/Concentration 
The ability to focus awareness on a given stimulus or task, to concentrate on 
that stimulus or task long enough to accomplish a goal, and to shift 
awareness if appropriate. 
Social cognition 






















Table 2. MCI subtypes by etiology, pathology, presentation and outcomes [45] 
Variable Amnestic Non-amnestic 
Etiology Neurodegenerative disease Vascular damage 
  APOE ε4 genotype Cerebrovascular disease 
Pathology Neurodegenerative Cerebrovascular 
 Amyloid β plaques Cortical infarctions 
 Neurofibrillary tangles Subcortical infarctions 
 Hippocampal atrophy White matter hyperintensities 
 Reduced brain volume  
Presentation Memory impairment present 
Impairment in non-memory 
domains 
Long term outcomes Alzheimer’s dementia Non-Alzheimer dementias: 
   Vascular dementia 
   Lewy body, Frontotemporal 



















Table 3. Summary of findings on potential risk factors for cognitive decline from observational studies 
and randomized controlled trials [62] 
Factors Direction of Association  Strength of Evidence 
Demographic   
Age (Older) Increased risk Strong 
Sex (Male) Increased risk Unclear 
Race (African-American) Increased risk Unclear 
Educational Attainment (Low) Increased risk Strong 
Social Support Decreased risk Unclear 
Lifestyle   
Smoking Increased risk Strong 
Physical Activity Decreased risk Strong 
ω-3 Fatty acids Decreased risk Moderate 
Genetic   
APOE ɛ4 genotype Increased risk Low 
Medical   
Diabetes Increased risk Strong 
Hypertension Increased risk Strong 
Dyslipidemia Increased risk Unclear  
Obesity Increased risk Strong 
Stroke Increased risk Strong 
History of Depression Increased risk Lower 
















Table 4. Types of memory [189] 
Type of 
Memory Type of Knowledge Example 
Episodic Personal Experience 
Imagery (sounds, smells, pictures) (space and 
time) 
Semantic General Knowledge 
Meanings and Propositions (facts and general 
knowledge) 
Declarative How things are or were "Knowledge knowing." How things are. 
Procedural How to do things "Knowledge knowing." How to do things. 
Explicit Knowledge easily explained Consciously recalled (How to add and subtract) 

























Table 5. Types of attention 
Selective attention Focus on specific aspects of experience that is relevant while ignoring others 
Divided attention Concentrating on more than one activity at a time 
Sustained attention Maintain focus on selected stimulus over prolonged period; called vigilance 
Executive attention 
Focus on attention planning, goals, errors, and compensation, monitoring, 
and unknown  













Table 6. Alcohol dehydrogenase (ADH) genes and proteins [246, 274] 
Official 
Gene Name* Old Name† 
Nonstandard 
Name‡ Sequence§ Protein Class¶ 
ADH1A ADH1 ADH1A NM_000667 α I 
ADH1B ADH2 ADH1B NM_000668 β I 
ADH1C ADH3 ADH1C NM_000669 γ I 
ADH4 ADH4 ADH2 NM_000670 π II 
ADH5 ADH5 ADH3 NM_000671 χ III 
ADH6 ADH6 ADH5 NM_000672 ADH6 V 
ADH7 ADH7 ADH4 NM_000673 σ IV 
Abbreviations: ADH1A, alcohol dehydrogenases class 1A; ADH1B, alcohol dehydrogenases class 1B; ADH1C, 
alcohol dehydrogenases class 1C; ADH4, alcohol dehydrogenases class 4; ADH5, alcohol dehydrogenases class 5; 

































Table 7. Aldehyde dehydrogenase (ALDH) genes and proteins [246] 
Official Gene 
Name Older Names 
Chromosomal 
Location Protein Sequence 











Abbreviations: ALDH1, aldehyde dehydrogenase 1, ALDH1A, aldehyde dehydrogenase 1 family member A1; 
ALDH2, aldehyde dehydrogenase 2; RALDH1, retinaldehyde dehydrogenase 1, and NM, nucleotide M. 























Table 8. Alcohol dehydrogenase (ADH) genetic variants [246, 274] 
ADH 
Class Official Gene Name* 
Amino Acid 
Difference   





I ADH1A  α 4 30 
I ADH1B*1 Arg48, Arg370 β1 0.05 4 
I ADH1B*2 His48, Arg370 β2 0.9 350 
I ADH1B*3 Arg48, Cys370 β3 40 300 
I ADH1C*1 Arg272, lle350 γ1 1 90 
I ADH1C*2 Gln272, Val350 γ2 0.6 40 
II ADH4  π 30 20 
III ADH5  χ >1,000 100 
IV ADH7  σ 30 1800 
V ADH6  ADH6 ? ? 
Abbreviations: ADH, aldehyde dehydrogenase; ADH1A, aldehyde dehydrogenase 1 family member A1; ADH1B, 
aldehyde dehydrogenase  class 1B; ADH1C, aldehyde dehydrogenase  class 1C; ADH4, alcohol dehydrogenases 
class 4; ADH5, alcohol dehydrogenases class 5; ADH6, alcohol dehydrogenases class 6; ADH7, alcohol 
dehydrogenases class 7; Arg48, arginine 48; Arg272, arginine 272; Arg370, arginine 370; His48, histidine 48; 
Cys370, Cysteine 370; lle350, isoleucine 350; Gln272, glutamine 272; Val350, valine 350, Km,  Michaelis Constant; 



















Table 9. Non-coding SNPs that affect the level of gene expression of the ADH gene 






A2 Reference Region 
ADH4 rs7678936 intron G T [284] 
Distal upstream 
enhancer (4E4) 
  rs7678890 intron T G   
ADH1B  rs1159918 upstream T G [283] Proximal promoter  
 rs1229982 upstream A C   
ADH1C rs11499823 upstream T C [282] Regulatory 
 rs1629838 upstream C T   
 rs11499824 upstream G A   
 rs11499825 upstream T C   
 rs11499826  C T   
 rs4093924  A G   
 rs11499830 intron in del   
 rs283408  A C   
 rs10006545  A G   
 rs2453980  G A   
 rs11499828  A G   
 rs1662036  T G   
Abbreviation: rs, reference SNP; ADH4, aldehyde dehydrogenase 4; ADH1B, aldehyde dehydrogenase class 1B; 


















Table 10. Kinetic constants for acetaldehyde oxidation by human aldehyde dehydrogenases [274] 
Enzyme KM (μM) Vmax (min−1) Vmax (min−1 μM−1) 
ALDH1A1 180 380 2.1 
ALDH1B1 55 40 0.7 
ALDH2*1 0.2 280 1400 
ALDH2*2 1.4 20 14 
Abbreviations: Vmax, maximal velocity; Km, Michaelis Constant; ALDH1A, aldehyde dehydrogenase 1 family 
member A1; ALDHB1, aldehyde dehydrogenase 1 family member B1; ALDH2, aldehyde dehydrogenase 2; μM, 

























Table 11. Distribution of the ADH2 and ALDH2 genotypes, by alleles and racial groups [278] 
 
Population 
ADH2      ALDH2 
n Genotype   Gene 
f  
 n Genotype   Gene frequency 
 1-1 1-2 2-2      1-1 1-2 2-2    
Caucasoids                
Germans 233 214 19 0  0.959 0.041  193 193 0 0  1  
Swedes 90 89 1 0  0.994 0.006  99 99 0 0  1  
Finns 85 83 2 0  0.988 0.012  100 100 0 0  1  
Hungarians 115 103 12 0  0.948 0.052  117 114 3 0  0.987 0.013 
Turks 44 34 9 1  0.875 0.125  57 57 0 0  1  
Indians 167 142 17 8  0.901 0.099  179 173 5 1  0.980 0.020 
Mongoloids                
Chinese 86 7 41 38  0.320 0.680  132 92 38 2  0.841 0.159 
Japanese 32 5 16 11  0.406 0.594  53 29 23 1  0.764 0.236 
Koreans 177 7 55 115  0.195 0.805  218 156 58 4  0.849 0.151 
Thais 111 51 46 14  0.667 0.333  111 100 11 0  0.950 0.05 
Filipinos 57 11 23 23  0.395 0.605  86 85 1 0  0.994 0.006 
Malays 65 11 31 23  0.408 0.592  73 68 5 0  0.966 0.034 
Negroids                
Africans 37 37 0 0  1   49 49 0 0  1  
Other populations                
Caboclos (Brazil) 20 18 0 2  0.900 0.100  23 15 8 0  0.826 0.174 
Auracanians (South Chile) 27 27 0 0  1   7 7 0 0  1  
Mestizos (Mexico) 57 51 6 0  0.947 0.053  61 61 0 0  1  
Papua New Guineans 204 179 22 3  0.931 0.069  242 240 2 0  0.996 0.004 
Australian Aborigines 22 10 9 3  0.659 0.341  37 37 0 0  1  
Swedish Lapps 100 99 1 0  0.995 0.005  100 100 0 0  1  
Eskimos (Alaska) 27 27 0 0  1   27 27 0 0  1  







Table 12. Review of prospective studies of the ethanol intake and cognitive decline relationship 
















The Established Populations for 
Epidemiologic Studies of the 
Elderly ((EPESE) of men and 
women aged 65 years or over 3,809 3 
Interview-administered 
questionnaire assessing 
ethanol intake in 
previous year (yes/no), 
and amount consumed in 




digit span test, 












The Epidemiology of Vascular 
Aging (EVA) study prospective 
study of men and women ages 
59-71 years in western France 1,389 4 
Self-reported, beverage-
specific number of 
glasses of ethanol 
consumed at 6 different 






Institute of Mental Health 
Epidemiologic Catchment Area 
of men and women ≥18 years 3,481 12.5 
Self-reported alcohol use 
assessed at 3 waves MMSE MMSE score 
Bond (2004) 
[338] 
Pooled prospective cohort ofthe 
Kame Project -a population-
based study of Japanese 
American adults aged persons 
aged 65 or older, and theAdult 
Changes in Thought (ACT) 
study of non-Hispanic Whites 
aged 65 and older 4,191 4 
Kame Project- 
Structured interview 
asking about ethanol 
intake frequency and 
duration, and type 
consumed. ACT Study- 
Structured interview that 
assessed current and past 
drinking behaviors and 




The Women's Health Initiative 
Memory Study (WHIMS). 
Randomized Clinical Trial (39 
US academic medical centers) 
of post-menopausal combination 
estrogen and progestin therapy   
of community-dwelling women 
aged 65-79 years  4,461 4.2 
Food frequency 
questionnaire                       
(FFQ) - assessed intake 
(beer, wine, and liquor 
separately) over the past 
3 months. 3MS 
Global 
cognitive 









The Monongahela Valley 
Independent Elders Survey 
(MoVIES project), a prospective 
epidemiologic study of dementia 
in a largely rural, blue-collar 
community of men and women 
aged ≥65 years 1,681 7.3 
Baseline 
Quantity/Frequency 
(QF) - lifetime history of 
alcohol use, alcohol 
use in the past year 
(yes/no), frequency of 
alcohol use during the 
past year, and number of 




Learning test and 
Story Immediate 













Trail Making A 





mental status      
Learning   
Memory     
Visuospatial    
Fluency 




The MRC NationalSurvey of 
Health and Development (the 
British 1946 birth cohort) 1,764 10 
QF at aged 43 - 
frequency of type of 
alcohol drank per day 















Nurses' Health Study of men of 
female nurses aged 70 to 81 
years old  12,480 2 
FFQ completed in 1984, 
1986. 1990, 1994, and 






















The Northern Manhattan Study 
(NOMAS). Community sample 
of men and women (Hispanic, 
black, white, and other groups) 
aged ≥40 years stroke free at 
study baseline 2,631 2.2 
Structured interviews 
adapted from FFQ 
(Baseline -  average 
amount consumed in the 
past year, Follow-up: 












delayed recall of 
ten-word list 
resulting in a 









Prospective Study of Pravastatin 
in the Elderly at Risk 
(PROSPER). Randomized 
placebo-controlled trial of 
pravastatin in men and women 
aged 70 to 82 with vascular risk 
factors or known vascular 
disease 5,804 3.2 
Self-reported on usual 
ethanol intake in units 
























Health, Aging and Body 
Composition (Health ABC) 
study, 
a prospective cohort study of 
3,075 community-dwelling 
black 





ethanol intake in 
previous year (yes/no), 
and amount consumed in 
previous month (number 
of drinks) 3MS   
Lobo (2010) 
[345] 
The ZARADEMP Project, a 
prospective community-based 
study of men and women aged 
55 years and older in Spain 4,803 4.5 
 Risk Factors 
Questionnaire - assessed 
Usual daily alcohol 
intake, present and past 
consumption, type, and 












The Seattle Longitudinal Study 
(SLS) of men and women age 
≥45 years 571 7 
Questionnaire - assessed 




























Evaluate the independent 
association of alcohol intake and 
longitudinal cognitive 








 7-d dietary records - 












(NAS); Trails A, 
Trail Making 
Test, part A; 
Trails B, 
TrailMaking 






































Whitehall II cohort Study aged 
of British civilian workers aged 
44-69 years at study baseline 10,308 10 
QF for previous year and 











averaging the z 










averaging the z 























Studies of the 
Elderly 
((EPESE) of 
men and women 
aged 65 years or 
over 
2; Baseline 
and 3 years 
follow-up 
visit 
None in the 
previous year;< 0.5 
ounce (15 ml) per 
day; 0.5 ounce to < 
1 ounce (15 ml to 
< 30 ml) per 
day; and ≥ 1 
ounces (30 ml or 
more) per day 
Age, sex, education, 
and income.  
No clear or consistent relation 
between moderate alcohol use 
and change in cognitive 
function. Individuals who 
consumed a very small amount 
of alcohol (< 0.5 ounce (15 ml) 
per day) had a normal change 
score that was 0.088 (95% CI: 
0.015,0.160) better for digit span 









study of men 
and women ages 
59-71 years in 
western France 
2; Baseline 
and 3 years 
follow-up 
visit 
Never, fewer than 
two drinks, two to 
five drinks, or five 
drinks or more 




depressive symptoms at 
study entry. 
Alcohol consumption was 
associated with a decreased risk 
of cognitive deterioration in 
individuals without the ApoE ɛ4 
allele (<2 glasses (RR=0.7, 95% 
CI=(0.5,1.1)), 2-5 glasses 
(RR=0.6,95% CI=(0.4,1.1)),≥5 
glasses (RR=0.3,95% 
CI=(0.1,1.3))) whereas moderate 
drinking increased the risk of 
deterioration in ApoE ɛ4 allele  
(<2 glasses (RR=1.9, 95% 































and 11 years 
Nonusers, social 
users, habitual 
users, binge users, 
heavy/frequent Age, race, and education. 
Alcohol use was associated 
with significantly less 
cognitive decline in alcohol 
drinkers (Mean change in 
MMSE (β)=–1.25, 95% CI: –
1.37, –1.13) when compared 
with nondrinkers (β=–1.99, 
95% CI: –2.31, –1.67) for both 
sexes. When adjusted, a trend 
toward significantly less 
cognitive decline was seen in 
women drinkers (p<0.0001), 


























past drinkers, and 
abstainers 
Age, BMI, education and 
income, smoking, history 
of diagnosed stroke, 
hyper-tension, coronary 
heart disease, depression, 
and diabetes. 
Drinkers had higher scores on 
cognition, measured by the 
CASI over the 4-yearfollow-up 
period than abstainers or past 
































therapy   of 
community-
dwelling women 
aged 65-79 years  
7; Baseline 
and annually 
up to 6 years 
none, <1 drink per 
day, and ≥1 drink 
per day. 
Age, years since 
menopause, education, 
ethnicity, family income, 
use of tobacco, body 
mass index (BMI), 
Hypertension (HTN), 
Cardiovascular Disease 
(CVD), diabetes (DM), 
statin therapy, aspirin; 
prior use of hormone 
therapy (HRT), and 
intervention assignment 
Compared with no intake, 
intake of ≥1 drink per day was 
associated with higher baseline 
Modified Mini-Mental State 
Examination scores (p < 0.001) 
and a covariate-adjusted odds 
ratio of 0.40 (95% confidence 
interval: 0.28, 0.99) for 



















men and women 





Age, sex, educational 
level, and                    
recruitment status, 






Compared to no drinking, both 
minimal  and moderate 
drinking were associated with 
lesser decline on the MMSE 
(minimal, Odds Ratio 
(OR)=0.30, 95% CI: 
0.14,0.65); moderate,  
(OR=0.08, 95% CI: 0.02,0.28) 
and  Trailmaking tests 
(minimal, OR=0.20,95% CI: 
0.05,0.85; moderate, 
OR=0.05,95% CI: 0.01–0.45). 
Minimal drinking was also 
associated with lesser decline 
























of Health and 
Development 
(the British 1946 
birth cohort) 
2; Aged 43 
and 53 







occupational social class, 
general cognitive 
abilityand a range of 
health indicators. 
Alcohol consumption was 
associated with a slower 
memory decline from 43 to 53 
years in men (F for equality of 
means = 2.35, P = 0.05), but a 
more rapid decline in visual 
search speed for the same 
interval in women (F = 2.94, P 
= 0.03), and a faster decline 
with increasing alcohol 






Study of men of 
female nurses 
aged 70 to 81 
years old  
2; Baseline 
and two years 
follow-up 
visit 




high cholesterol levels, 
and heart disease; 
physical activity; age at 
menopause; HRT use, 
aspirin and ibuprofen, 
and vitamin E; BMI; 
smoking status; scores 
for the mental health and 
energy; and 
Social Network. 
Lower relative risk of 
substantial decline in general 
cognition over two years 
among moderate (1.0-14.9g) 
drinkers compared to 
nondrinkers (β (95% CI): 0.85 
(0.74,0.98). No significant 
association between higher 
levels of drinking (15.0 to 
30.0g) risk of decline. No 
significance differences in 
























sample of men 
and women 
(Hispanic, black, 
white, and other 
groups) aged 
≥40 years stroke 




never, past, less 
than one drink 
weekly, one drink 
weekly up to two 
daily, and more 
than two drinks 
daily. 
Age, education, gender, 
race-ethnicity, insurance 
status, hypertension, 
diabetes, cardiac disease, 
physical inactivity, 
depression, current 
smoking, HDL-C level, 
and BMI.  
Drinking less than one drink a 
week (β (95% CI): 0.9 (-
1.2,1.9), P=0.09), between one 
drink weekly up to two drinks 
daily (1.5 (0.6,2.4), P=0.001), 
and more than two drinks 
daily (2.4 (0.8,4.0), P=0.003) 
were associated with less 
cognitive decline on the 
modified Telephone Interview 
for 
Cognitive Status (TICS-m) 













of pravastatin in 
men and women 
aged 70 to 82 
with vascular 










alcohol intake (1 to 
3 U per week) and 
moderate intake 
(>3 U per week). 
Men: Nondrinker, 
Low alcohol intake 
(1 to 7 U per 
week), and 
moderate intake 
(>7 U per week). 
Age, country, smoking 
status, body mass index, 
body weight, years of 
education, incident 
stroke, history of 
vascular disease, and 
version of test (if 
applicable).           
Women: Mean difference were 
for female drinkers than 
nondrinkers across all 
cognitive domains, with the 
exception of PWLT.                                                         
Decline similar across 
cognitive domains                                                     
Less decline in MMSE in low 
or moderate female drinkers 
than nondrinkers (0.05 MMSE 
units per annum, P=0.001                                                      






























and white men 
and women 
4; Baseline, 




>1 drink/day vs. ≤ 
1 drink/day) 






and history of 
myocardial infarction, 
stroke or TIA.   
The odds of individuals who 
drinks >1 alcoholic drink/day 
being a cognitive maintainer is 
1.33 (95% CI: 0.91,1.93) times 
than of individuals who drinks 
≤ 1 alcoholic drink/day.  The 
odds of individuals who drinks 
>1 alcoholic drink/day being a 
major cognitive decliner is 
0.67 (95% CI: 0.36,1.27) times 
than of individuals who drinks 









based study of 
men and women 
aged 55 years 












Age, years of education, 
Mini-Mental State 
Examination (MMSE) 
score at baseline, marital 
status, smoking status, 
hypertension, 
depression, psychotropic 
medication use, and 
disability.  
Men: Consumption of 
<40g/day was not associated 
with decreased risk of 
cognitive decline (<12 
alcohol/day (OR=0.61, 95% 
CI: 0.31,1,20), < 24 alcohol 
g/day (OR=1.19, 95% CI: 
0.61,2.32), and former drinkers 
(OR=1.03, 95% CI: 
0.59,1.82)).                                                                        
Women:  Consumption of <24 
g/day was not associated with 
decreased risk of cognitive 
decline (<12 alcohol/day 
(OR=0.88, 95% CI: 0.45,1.72), 
<24 alcohol g/day (OR=2.38, 
95% CI: 0.98,5.77), and former 






















Study (SLS) of 
men and women 














Age, gender, income, 
education, baseline 
drinking level (beer, 
wine, liquor) and 
smoking status 
Decline in verbal ability was 
seen among alcohol abstainers 
(Differences of Least Squares 
Means estimate (est.=1.54, 
P<0.0001) and moderate 
alcohol consumers (est.=1.18, 













US older adults 
2; Baseline to 
follow-up 
visit 
lower: <14 g/d, 
moderate alcohol 
consumption: 14 to 
28 g/d, and higher: 
>28 g/d. 
Age, gender, race, 
education, smoking, and 
BMI 
 Age <70 years: Alcohol intake 
was associated with faster 
decline or slower improvement 
on the MMSE (Global 
Cognition, P=0.008) and on the 
VFT-L test (Letter Fluency, 
P=0.001).  Overall, among 
men, and for 
Agebase ≥70 y, lower alcohol 
intake compared with 
moderate consumption was 
associated with poorer 
performance on the DS-B 
(overall, Ƴ031 = 20.76 6 0.28, 





















aged of British 
civilian workers 
aged 44-69 years 












g/d, and drinkers: 
≥ 36 g/d 
Age, sex, ethnicity, 
marital status, 
occupational position, 
and education.  
Men consuming 36 g/d or 
more of alcohol in midlife 
were more likely to experience 
faster 10-year cognitive 
decline compared with 
consumption between 0.1 and 
19.9 g/d (mean difference 
(95% CI) in 10-year decline in 
global cognition =-0.10 (-0.16, 
-0.04), executive function= -
0.06 (-0.12,0.00), and 
memory=-0.16 (-0.26, -0.05). 
No differences in cognitive 
decline were observed for 
alcohol abstainers, quitters, 
and light or moderate alcohol 
drinkers (<20g/d). Weaker 
evidence of an association in 
women. In women, compared 
to those drinking 0.1 to 9.9 g/d 
of alcohol, 10-year abstainers 
shower fast decline in the 
global cognitive score (-0.21 (-
0.37, -0.04) and executive 







Table 14. Ethanol metabolizing SNPs associated with ethanol dependence and intake [383] 







of  A1† 
References  Available in ARIC 
Final 
instruments 
4 ADH1A rs904092 upstream A G 0.246 0.147 NA Gelernter et al, 2014 No   
4 ADH1A rs2866151 intronic T A 0.254 0.520 + Zuccolo et al, 2009 No   
4 ADH1B rs1042026 downstream G A 0.066 0.278 - Macgregor et al, 2009 Yes No, high missing rate 
4 ADH1B rs1229984 exonic A G 0.000 0.015 - 
Gelernter et al, 2014; 
Zuccolo et al, 2009; 
Agrawal et al, 2012; 
Ferrari et al, 2012; Li et 
al, 2011; Bierut et al, 
2012; Way et al, 2015; 
Jorgensen et al, 2017 
Yes 
No, did not 
pass quality 
control‡ 
4 ADH1B rs2066702 exonic A G 0.205 0.000 - Gelernter et al, 2014 Yes  Yes 
4 ADH1B rs1789882 exonic A G 0.246 0.141 - Gelernter et al, 2014 No   
4 ADH1B rs1693457 intronic C T 0.246 0.147 - Gelernter et al, 2014 Yes  Yes 
4 ADH1B/1C  rs1789891 intergenic A C 0.025 0.167 + Way et al, 2015; Agrawal et al, 2012 Yes  Yes 
4 ADH1C rs1693482 exonic A G 0.139 0.475 + 
Macgregor et al, 2009; 
Agrawal et al, 2012; 
Way et al, 2015; Toth 
et al, 2011 
Yes 
No, in high 
LD with 
rs698 and has 
lower sample 
size 
4 ADH1C rs698 exonic C T 0.139 0.475 + 
Agrawal et al, 2012; 
Way et al, 2015; Toth 
et al, 2011; Li et al, 
2012 
Yes  Yes 
4 ADH1C rs283413 exonic T G 0.000 0.005 - 
Way et al, 2015; 
Biernacka et al, 2013; 
Norden-Krichmar et al, 
2014 
No   






Table 14. Ethanol metabolizing SNPs associated with ethanol dependence and intake [383] 







of  A1† 
References  Available in ARIC 
Final 
instruments 




4 ADH4 rs3762894 upstream G A 0.205 0.131 NA Macgregor et al, 2009 No   
4 ADH4 rs1042363 exonic T C NA NA - Luo et al, 2005 No   
4 ADH4 rs1126671 exonic A G 0.189 0.273 + Luo et al, 2005 Yes  Yes 
4 ADH5 rs1230165 downstream C T 0.082 0.152 NA Macgregor et al, 2009 No   
12 ALDH2 rs671 exonic A G 0.000 0.000 - 
Agrawal et al, 2012; 
Rietschel et al, 2013; 
Jorgensen et al, 2017 
Yes No, monomorphic 
Abbreviations: Chr, chromosome; rs, reference SNP; A1, minor allele; A2, major allele; *, obtained from 1000 Genome; AA, African-Americans; EU, 








Figure 1. Actions of the brain’s glutamate system in the absence of ethanol [302] 
 
 
































CHAPTER IV: METHODS 
4.1. Overview 
This study benefited from the long follow-up of the ARIC cohort of African-Americans and 
European-Americans from mid-to-late life to examine the association of ethanol intake in mid-life and 
cognitive decline from mid-to-late life. The availability of repeated measures of ethanol intake and well-
characterized cognitive function allowed for the characterization of long-term patterns of ethanol intake 
over nine-years in mid-life and the assessment of change in cognitive function over a 15-year period from 
mid-to-late life. The availability of genetic data for a majority of study population allowed for the 
exploration of possible mechanisms by which ethanol intake affects cognitive function by evaluating for 
possible effect modification of the ethanol intake-cognitive decline relation by ethanol intake-associated 
genetic variants. Fine-mapping and conditional analyses were used to identify genetic variants that are 
mostly strongly associated with ethanol intake among African-American participants. The potential for 
confounding was reduced by adjusting for of lifestyle, genetic, and clinical risk factors in all analyses. 
The potential of population stratification by controlling for principal components.  Multiple imputations 
by chained equations (MICE) was used to account for attrition of the cohort during the course of follow-
up.  
4.2. Study Population 
4.2.1. Description of the ARIC Study Cohort 
The Atherosclerosis Risk in Communities (ARIC) study is a community-based, prospective 
cohort study established in 1987, designed to investigate the etiology of atherosclerosis and its clinical 
sequelae. From 1987 through 1989, 15,792 adults aged 45 to 64 years were recruited through probability 
sampling from 4 U.S. communities: Washington County, Maryland; Forsyth County, North Carolina; 





approximately 3 years apart from 1987-1989 through 1996-1998, and a fifth examination visit was 
conducted in 2011-2013 (Figure 5).  
4.2.2. Inclusion Criteria 
For Aim 1 analyses, we included participants with at least one measurement of ethanol intake 
from visits 1-4 and at least one measurement of cognitive function at visits 4 and 5. 
For Aims 2 analyses, we included participants with ethanol intake measured at study baseline 
(visit 4) and those with genetic data that are associated with ethanol intake across ARIC visits 1-4. 
4.2.3. Exclusion Criteria 
 
Excluded from the proposed analyses were participants who prohibited use of their 
deoxyribonucleic acid (DNA) for research purposes, who did not self-identify as African-American or 
European-American, African-Americans residing in Washington County or Minneapolis (due to small 
numbers), participants missing one or more cognitive function tests at study baseline, and those with 
missing covariates at study baseline. 
4.3. Exposures Assessment 
         
4.3.1. Ethanol Intake 
 
Ethanol intake was assessed at all visits by means of an interviewer-administered questionnaire  
[169]. During the exam, participants were asked the following questions: Do you presently drink 
alcoholic beverages?”, and “Have you ever consumed alcoholic beverages?”. Individuals replying no to 
both questions were classified as never drinkers. Those who replied “no” to the first question and “yes” to 
the second question were classified as former drinkers.   
Current drinkers were asked how often they usually drank wine, beer, or hard liquor. The amount 
of ethanol consumed (in grams per week) was calculated assuming the following ethanol content: 4oz of 
wine = 10.8 grams; 12 oz. of beer = 13.2 grams; and 1.5 oz. of distilled spirits = 15.1 grams. For a drinker 
who reported less than one drink per week, the ethanol intake was recorded as 0 g per week. History of 





“Was there ever a time in your life when you consumed 5 or more drinks of any kind of alcoholic 
beverage almost every day?”. We used this variable only for further description of the study sample. 
Categories of ethanol intake at each visit were created based on the U.S. Department of Agriculture and 
U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2015-2020 guideline 
for low-to-moderate drinking (≤210 grams/week for men and ≤105 grams/week for women) and heavy 
drinking (> 210 grams/week for men and > 105 grams/week for women) [384]. 
4.4. Outcome Assessment 
4.4.1. Assessment of Cognitive Status in ARIC 
Cognitive function was assessed at visit 2 (1990-1992; ages 48-67), visit 4 (1996-1998; ages 54-
73), and visit 5 (as part of the ARIC-NCS) (2011-2013; ages 70-89 years) using 3 standardized cognitive 
tests to assess different domains of cognition: verbal learning and short-term memory, executive function 
and processing speed, and executive function and expressive language. 
4.4.2. Cognitive Function Tests 
Verbal learning and recent memory were assessed by the delayed word recall test (DWRT). 
Participants were asked to learn 10 nouns, and after a five-minute delay were given 60 seconds to recall 
the words. The  DWRT score is the number of words recalled  (0-10) [201]. DWRT has a  high test-retest 
reliability of 0.75 in older adults [201].  
Executive function and processing speed were assessed by the digit symbol substitution test 
(DSST). Participants were given 90 seconds to  fill in blank squares with symbols corresponding to digits 
from 1 to 9 using a key that matches digits to symbols [209]. DSST has high reliability (0.82-0.88) in 
older adults [209]. 
Executive function and expressive language were assessed by the word fluency test (WFT) , 
during which participants generate as many words starting with the letters F, A, and S as possible within 
60 seconds, with one trial per letter [385]. The WFT score is the total number of acceptable words 





three tests were administered by trained examiners using standardized protocols in a quiet room. 
Recordings were reviewed for quality control. 
To facilitate comparison across cognitive tests, Z scores standardized to visit 2 were calculated 
for each test by subtracting the participant’s overall mean test score at visit 2 from their test score at each 
visit and then dividing by the standard deviation of the visit 2 scores. 
A factor score for general cognitive performance was previously derived using factor analysis 
[386, 387], and was scaled to have a mean of 50 and standard deviation of 10 at the 1990–92 visit [387].  
4.5. Covariates Selection and Assessment 
4.5.1. Selection of Covariates 
Potential confounders were identified based on substantive knowledge of factors associated with 
ethanol [388] and risk of cognitive decline [10, 62, 63], and from existing literature on the association 
between ethanol and cognitive decline. Selection of confounders to include in primary analyses was based 
on directed acyclic graph analysis (DAG) (Figure 6) that included all potential confounders identified 
from the literature: demographic characteristics (age, sex, race, educational attainment, and social 
support), lifestyle factors (smoking status, physical activity, and omega-3 fatty acids), genetic risk factor 
(APOE ε4 allele) and medical history (diabetes, stroke, and depression) (Table 15).  
Figure 6 presents the results of an assessment of potential confounding which may be present in 
the examination of the association of ethanol intake with change in cognitive function.  The figure was 
created using the “DAGgity” software [389], which allows examining relationships between the exposure 
and outcome of interest, while accounting for all known associated factors and determining the minimal 
adjustment set needed to minimize confounding. Covariates in Figure 6 represented by pink circles were 
determined to be potential confounders, due to their direct or indirect association with the exposure and 
the outcome. Covariates represented by blue circles are those covariates that are associated with the 
outcome but are not on an “open path” (not causally associated) with the exposure. For the association of 





confounders: age, sex, SES (i.e., education attainment), social support, history of stroke, diabetes, and 
depression (Figure 7). By adjusting for those nine variables all the confounding paths are blocked. 
Additional adjustment could result in over adjusting and biasing the results. 
4.5.2. Assessment of Covariates  
4.5.2.1. Demographic Factors 
Demographic factors associated with ethanol intake and cognitive decline that were treated as 
confounders in this work include age, sex, race, and educational attainment. Described below are the 
specific characteristics of each of these variables in the ARIC study. 
4.5.2.1.1. Age, Sex, and Educational Attainment 
Age, sex, and educational attainment (< high school, high school, >high school), and smoking 
status (current, former, never) were assessed at visit 4 via self-report from the home interviews. 
4.5.2.2. Lifestyle Factors 
Lifestyle factors associated with ethanol intake and cognitive decline that were treated as 
confounders in this work include smoking status, physical activity, and diet. Described below are the 
specific characteristics of each of these variables in the ARIC study. 
4.5.2.2.1. Smoking Status 
Cigarette smoking status was measured at visit 4 by self-report.  Cigarette smoking status was 
categorized as current, former, and never.  
4.5.2.2.2. Physical Activity 
Physical activity in ARIC participants was measured at  visits 1 and 3 using the modified Baecke 
questionnaire [390], which asks about three levels of physical activity (low, medium, and high intensity) 
in sports, during leisure time, and at work. The answers then were converted to minutes per week of 






Factor analysis were used to derive diet patterns and adjust for overall diet quality. The Healthy 
Food Score, adapted from Steffen et al. [391, 392] was created by summing the scores of food groups. 
Food groups included: dairy (low-fat and whole milk, cheese, yogurt, ice cream), vegetables, fruit 
(without juice), fruit juice, legumes, refined grain, whole grain, nuts, fish, meat (combined poultry, 
processed meat, beef, pork, and lamb), diet beverages, sugar-sweetened beverages, and coffee and tea. 
Daily intake of food groups was categorized into quintiles, except alcohol intake, legume, and beverages. 
Each quintile of food group intake was assigned a score: 0–4. For dairy, vegetables, fruit (without juice), 
fruit juice, refined grain, whole grain, nuts, and fish, scores were assigned in order (Quintile 1 = 0, 
Quintile 2 = 1, Quintile 3 = 2, Quintile 4 = 3, Quintile 5 = 4); for meat, the score was the reverse. Due to 
the limited range of intake, scoring for intake of legumes was 0, 1, and 2, if daily intake was 0, <1, and ≥1 
serving, respectively. The score was reversed for diet beverages and sugar-sweetened beverages: 2, 1, and 
0 for 0, >0 to <1, and one or more servings usually consumed per day, respectively. Daily coffee and tea 
intake were scored in five categories from 0 to 4, for 0, >0 to ≤2, >2 to ≤4, >4 to ≤6, and >6 cups per day, 
respectively. For alcohol intake, a score of 4 was assigned to the men who consumed between 10 and 50 g 
per day and to women who consumed between 5 and 30 g per day; otherwise a score of 0 was assigned 
[391]. 
4.5.2.3. Genetic Factor 
4.5.2.3.1. Apolipoprotein E ε4 Polymorphism 
Genotyping of the APOE polymorphisms at codons 112 and 158 in exon 4 was performed by 
using the TaqMan assay (Applied Biosystems, Foster City, California) [393, 394]. Allele detection and 
genotype calling were performed by using ABI 7900 and Sequence Detection System software (Applied 
Biosystems) [393]. The ARIC Study has extensive quality control measures for all genotyping assays, 
including but not limited to robotic liquid handling, separate pre– and post–polymerase chain reaction 





controls, computerized sample tracking, and data validity checks [394]. The APOE ε4 polymorphism will 
be categorized as presence of 0,1, or 2 alleles.  
4.5.2.4. Cardiovascular Disease Risk Factors 
Medical risk factors associated with ethanol intake and cognitive decline that were treated as 
confounders in this work include diabetes, depression, and stroke. Described below are the specific 
characteristics of each of these variables in the ARIC study. 
4.5.2.4.1. Diabetes 
Diabetes (yes, no) at visit 4 was defined as self-reported history of a physician’s diagnosis of 
diabetes, fasting blood glucose level of ≥126 mg/dL, or non-fasting blood glucose level of ≥200 mg/dL, 
or diabetes medication use in the past 2 weeks [395].  
4.5.2.4.2. Stroke 
Stroke was defined by a self-reported history at visit one or an adjudicated event between visits 1 
and 4 [396]. 
4.6. Genotyping and SNP Selection 
Consenting ARIC study participants were imputed separately by race using IMPUTE2 [397] with 
the 1000 Genomes Project phase 1 (March 2012) reference panel. Quality control excluded individuals 
based on single nucleotide polymorphism (SNP) mismatch, high discordance with previous TaqMan 
assay genotypes, genetic outlier status, and relatedness. SNPs with IMPUTE info score < 0.8 or minor 
allele frequency (MAF) < 0.05 were excluded. Only autosomal variants (on chromosomes 1–22) were 
considered [398]. Principal components analysis was used to estimate population substructure with 
EIGENSTRAT [399].    
The GWAS & Sequencing Consortium of Alcohol and Nicotine Use (GSCAN) meta-analyses of  
941,280 participants of European ancestry from 34 studies, including the ARIC study, identified 100 
single nucleotide polymorphisms (SNPS) in 82 genetic loci to be independently associated with number 





SNPs were available for ARIC European-American participants (Appendix Table 1), and 74 SNPs were 
available for ARIC African-American participants (Appendix Table 1).  
To determine if the GSCAN index SNPs replicate in the ARIC study population, we assessed 
association between the index SNPs and weekly ethanol intake across ARIC visits 1-4, separately, among 
European (99 SNPs) (Appendix Table 2) and African-American participants (74 SNPs) (Appendix Table 
3). Among European-American participants, 11 SNPs direction of effect were consistent with the effect 
reported by GSCAN and were nominally significantly associated (P-value <0.05) with at least one 
measurement of weekly ethanol intake assessed across ARIC 1-4 (Appendix Table 4). These 11 SNPs 
were used to address Specific Aim 2 among ARIC European-American participants. Among ARIC 
African-American participants, one SNP ((rs12795042 ) was associated with weekly ethanol intake at 
study baseline (visit 4). However, this SNP’s direction of effect was not consistent with the GSCAN SNP, 
and hence was not considered for this study (Appendix Table 3). 
To characterize the best tag SNP in ARIC African-American participants, we conducted fine-
mapping in the 1 MB region (± 500 kb windows surrounding each of the 99 GSCAN SNPs (index SNPs). 
Within each region, we identified the most strongly associated SNP with weekly ethanol intake at study 
baseline and in linkage disequilibrium (LD) (r2>0.2) with the index SNP. We identified a total of 92 
mostly strongly associated SNPs (Appendix Table 5). Of the 92 SNPs, 20 SNPs direction of effect were 
consistent with their index SNPs and were nominally significantly associated with at least one 
measurement of  weekly ethanol intake assessed across ARIC 1-4 (Appendix Table 6). Conditional 
analyses were performed and determined that 20 SNPs are independent of their GSCAN index SNPs 
(Appendix Table 7). These 20 SNPs were used to address Specific Aim 2 among ARIC African-American 
participants (Appendix Table 6). 
4.7. Statistical Approach 
4.7.1. Specific Aim 1 
Specific Aim 1: Characterize temporal trajectories of ethanol intake during mid-life in African-American 





are associated with 15-year rate of decline in cognition from mid-to-late life among African-American 
and European-American adults. 
 We characterized temporal trajectories of ethanol intake during mid-life, separately in African-
American and European-American adults, by first, categorizing study participants ethanol intake status at 
ARIC visits 1-4 as low-to-moderate drinkers ((≤210 grams/week for men and ≤105 grams/week for 
women), heavy drinkers (> 210 grams/week for men and > 105 grams/week for women), former drinkers 
and never drinkers. Second, we cross tabulated ethanol intake status variables from visits 1-4. Finally, 
from the cross tabulation of ethanol intake results, trajectories of ethanol intake were identified as 1) 
stable never drinkers, 2) stable low-to-moderate drinkers, 3) stable heavy drinkers, 4) stable former 
drinkers, 5) mostly low-to-moderate drinkers, 6) mostly heavy drinkers, and 7) mostly former drinkers. In 
creating the ‘mostly’ ethanol intake trajectories, ethanol intake status at study baseline (visit 4) was taken 
in account. Participants with non-current drinking status (i.e., never or former) across visits 1-3, but 
reported current drinking at visit 4 (i.e., low-to-moderate or heavy) were assigned to the “mostly” ethanol 
intake category at visit 4 (i.e., low-to-moderate or heavy). Participants with current drinking status (i.e., 
low-to-moderate or heavy) across visits 1-3 but reported former drinking at visit 4 were assigned to the 
“mostly” former long-term pattern of ethanol intake. Participants who reported 2 visits of current drinking 
(i.e., low-to-moderate or heavy) and 2 periods of former drinking were assigned to the “mostly” ethanol 
intake category at visit 4 (i.e., former, low-to-moderate or heavy). 
 To evaluate change in general cognitive performance, DSST, DWRT, and WFT tests between 
visits 4 and 5, multivariable linear regression models were used with the outcome being visit 5 z-score 
minus visit 4 z-score. All models were race-stratified and were adjusted for age, age squared, sex race-
center, education attainment, smoking status, body mass index (BMI), diabetes, history of stroke, diet 
score, physical activity, and the Apo lipoprotein E ε4 (APOE ε4) allele. 
Temporal trajectories of ethanol intake were evaluated as a categorical variable in the analysis 
models, with stable never drinking as referent. Z-scores of DWRT, DSST, WFT, and global cognition 





4.7.1.1. Multivariate Imputation by Chained Equations (MICE) Models to Account for Attrition in 
ARIC 
 
The long follow-up of the ARIC study resulted in some loss to follow-up due to refusal to 
participate or death. At Visit 2 13,351 participants underwent cognitive assessment, while at Visit 4 the 
number of participants dropped to 10,720 (80.3% of baseline number of participants) and to 5,987 (45.8% 
of baseline number of participants) at Visit 5. The number of participants who died was 1,350 (10.1% of 
baseline number of participants) between Visit 2 and Visit 4 and 2,037 (15.3% of baseline number of 
participants) between Visit 4 and Visit 5. The number of those who refused to participate was 1,281 
(9.5% of baseline number of participants) at Visit 4 and 2,696 (20.2% of baseline number of participants) 
at Visit 5.  
Missing data due to attrition were imputed by multiple imputation using chained equations 
(MICE)[401]. Missing ethanol intake and cognitive data across ARIC visits were imputed based on the 
observed values of key covariates for a given individual, as well as the relations observed in the data for 
other participants. To account for the uncertainty of the imputation and ensure correct standard error 
estimation [402], 25  datasets were imputed. Validation of the MICE approach for cognitive outcome in 
ARIC has been previously reported and it has been determined that MICE produced unbiased imputed 
values [403]. For this study, validation using observed data demonstrated MICE produces unbiased 
imputation of global cognition factor z-scores (Figure 8). 
4.7.1.2. Statistical Power to Examine Association Hypothesized in Specific Aim 1 
In Specific Aim 1, we estimated the relationship between ethanol intake and change in cognition 
function over a 15-year follow-up from Visit 4 to Visit 5. The R package ‘longpower’[404] was utilized 
to estimate the power to detect the mean difference in the 15-year rate of change in global z-score 
between heavy drinking compared to never drinking and LM drinking compared to never drinking. 
Presented in Table 16 are parameter (i.e., sample size, parameter estimates, residual variance and working 





power of the proposed analyses. Also assumed in the power size calculation were a significant level of 
α=0.05 and a ‘one-sided’ test. 
Power calculation results, assuming a significance level of α-0.05 and a ‘one-sided” test, suggest 
this study had 1) excellent power (≥95%)  to detect a mean difference of ≥0.02 in the 15-year rate of 
change in global cognition factor z-score between stable low-to-moderate drinking and never drinking 
among African-Americans and European-Americans participants, separately; 2) excellent power (≥94%)  
to detect a mean difference of ≥0.03 in the 15-year rate of change in global cognition factor z-score 
between stable heavy drinking and never drinking among African-Americans and European-Americans 
participants, separately;  3) excellent power (≥90%) to detect a mean difference of ≥0.02 in the 15-year 
rate of change in global cognition factor z-score between stable former drinking and never drinking 
among African-Americans and European-Americans participants, separately; 4) excellent power (≥97%) 
to detect a mean difference of ≥0.02 in the 15-year rate of change in global cognition factor z-score 
between mostly low-to-moderate drinking and never drinking among African-Americans and European-
Americans participants, separately; 5) excellent power (≥95%) to detect a mean difference of ≥0.05 in the 
15-year rate of change in global cognition factor z-score between mostly heavy drinking and never 
drinking among African-Americans and European-Americans participants, separately; and 6) excellent 
power (≥97%) to detect a mean difference of ≥0.03 in the 15-year rate of change in global cognition 
factor z-score between mostly former drinking and never drinking among African-Americans and 
European-Americans participants, separately (Table 16). 
4.7.2. Specific Aim 2 
Specific Aim 2: Evaluate for the effect modification of the ethanol intake-cognitive decline relationship 
by ethanol intake associated SNPs in African-American and European-American men and women from 
mid-to-late life. 
4.7.2.1. Population Stratification Confounding 
Although environmental exposures are not thought to influence genotype, confounding can still 





many loci, distinct populations have different allele frequencies, and in an ethnically diverse population, 
ethnically-related differences in genotype may appear to be associated with a trait because genotype at an 
entirely different locus, also correlated with ethnicity, influences the trait.   Different ethnic groups often 
share distinct lifestyle characteristics, and these differences may cause the trait to be associated with 
ethnic group. When this occurs, any genotype that is more prevalent in an ethnic group with higher or 
lower levels of the trait will appear to be associated with the trait in an ethnically diverse population. This 
population structure is referred to as “population stratification”, meaning the population under study is 
comprised of strata formed by ethnic groups that have different trait distributions and different genotype 
distributions [405]. 
A consequence of population stratification is the potential for increased allelic associations and 
deviations from Hard-Weinberg equilibrium [406]. Another consequence of population stratification is 
bias in the estimate of genetic associations, which may lead to incorrect inferences and inconsistent study 
findings [407]. Studies have shown that the bias due to population stratification is small in magnitude 
[408, 409] and is bounded by the magnitude of the difference in background disease rates across the 
populations being compared [410]. Simulation studies have shown that the adverse effect of population 
stratification increases with increasing sample size [411, 412].   
Several approaches exist to correct for the effects of population stratification, which includes 
adjustment for principal components methods [413-415]. In this method, the first principal component of 
the GWAS SNPs is computed and included as independent variable in regression models relating SNP 
genotype to trait.  The first principal component is designed to summarize most of the variation in a large 
number of variables with many fewer variables. In general, for n variables X1, …, Xn, the first principal 
component is the linear combination a1X1+…. + anXn. with the largest observed variance [414]. The 
second principal component is the linear combination a1΄X1+…. + an΄Xn, with largest observed variance 
among linear combinations uncorrelated with the first principal component, and so on. Price et al 2006 





To minimize population stratification bias, we adjusted for principal components in the regression 
models that will be used to address Specific Aim 2.   
4.7.2.2. Single Ethanol Intake-Associated SNPs  
We used linear regression models to estimate the relationship of ethanol intake associated SNPs 
within with ethanol intake. In all models, genotypic effects will be modeled additively as the number of 
minor alleles increases. Ethanol intake was assessed as a continuous variable.  All models were adjusted 
for age, sex, gender, education, center, and principal components. Regression coefficients and 95% 
confidence intervals (CIs) will be estimated. A Bonferroni correction (α/n) for  number of  independent 
tests (African-Americans, n=20; European-Americans, n=11) were used to adjust P values and control for 
type 1 error introduced by multiple testing. 
4.7.2.3. Genetic Risk Scores of Ethanol Intake-Associated SNPs  
Allele sores or genetic risk sores are a convenient way of summarizing multiple genetic variants 
that are associated with a risk factor [416]. The most common method sums the number of risk-conferring 
alleles that an individual has (0, 1, or 2) across all loci [417]. A genetic risk score (GRS) can be 
unweighted or weighted. An unweighted GRS is created as the total number of risk factor-increasing 
alleles present in the phenotype of an individual. The unweighted GRS and its construction is based on 
the assumption that each risk allele confers identical risk; thereby assigning equal weights to genetic 
variant [416]. However, for most complex traits, effect sizes across identified SNPs vary [418]. 
Therefore, GRSs are often weighted. A weighted GRS takes into consideration that each allele contributes 
a weight reflecting an estimate of the effect of the corresponding genetic variant on the risk factor. These 
can be derived internally from the data under-analysis or externally derived from prior knowledge or an 
independent data source, such as GWAS meta-analysis effect sizes, therefore giving more weight to 
variants with stronger effects [416, 417] . Weighted scores may increase statistical power compared to 





The weighting approach is utilized when the target population (the population in which GRS will 
be evaluated)  is similar in demographic and ethnic composition as the meta-analysis population, from 
which the effect sizes were derived [417].  An unweighted GRS is the best option if stable effect size 
estimates are unavailable due to (1) no GWAS meta-analyses have been conducted on the trait of interest, 
and thus genetic variants are chosen from candidate gene studies or GWAS that are small and un-
replicated, 2) the target population in which the GRS will be evaluated differs from the ethnicities in 
existing meta-analyses, and 3) genetic variants identified using multiple traits on different measurement 
scales are to be combined into a single GRS  [417].  
GRS are essential for the modelling of multifactorial polygenic traits, specifically when the GRS 
comprises of either may common genetic variants with small effects, or of rare variant [416]. The GRS 
may explain a substantial proportion of variation in the risk factor, even if none of the genetic variants 
individually does [416]. GRS  have been constructed for various traits, which includes fasting [419], 
blood pressure [420], and high-density lipoprotein cholesterol [383, 421]. 
We will use linear regression models to estimate the association between unweighted genetic risk 
score of SNPs within ethanol-metabolizing genes and ethanol intake in race-stratified analyses. The five 
SNPs will be coded to ensure consistent effect direction of increasing ethanol intake, which will be 
combined to create the unweighted genetic risk score [422]. All models will be adjusted for age and sex. 
Regression coefficients and 95% confidence intervals (CIs) will be estimated. We will also adjust for 
principal components to account for population stratification within each race/ancestry group.  
4.7.2.4. Gene-Environment Interaction  
Our study outcome, fifteen-year cognitive performance change was calculated by subtracting visit 
4 cognitive performance z-score from visit 5 neurocognitive exam z-score. 
To evaluate if the relationship between ethanol intake and decline in general cognitive 
performance is modified by ethanol intake-associated SNPs, multivariable linear regression models were 
used and included the unweighted GRS, log-ethanol measured at study baseline, an interaction term 





education attainment, smoking status, body mass index (BMI), diabetes, history of stroke, diet score, 
physical activity and APOE ε4 status. All models were race-stratified and further adjustments were made 
for principal components to account for population stratification.  
Statistical tests were 2-sided, and the test for statistically significant interaction was set a priori at 
P<0.10. However, adjustment for multiple testing using the Bonferroni method was performed for the 
interaction analyses based on single SNPs (African-Americans: P<0.005, European-Americans, P<0.009). 
Multiple Imputation were performed with  Stata15 (StataCorp, College Station, TX, USA) [423], 
and statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, USA) .The 
results from each imputed data set were summarized using Rubin’s rule [424] into an overall estimate 
accounting for both within and between imputation variances. 
4.7.2.5. Statistical Power to Examine Association Hypothesized in Specific Aim 2 
4.7.2.4.1. Association between Single Genetic Variants and Ethanol Intake 
In Specific Aim 2, we estimated the association between individual SNPs and weekly ethanol 
intake at ARIC visit 1-4. To estimate statistical power, preliminary estimates of effect allele frequency, 
beta estimate for the main effect of the SNPs, and mean (SD) for log-intake at each visit were inputted in 
the Quanto 1.2.4 [425] sample size software for gene association studies. Assuming an additive genetic 
model, a two-sided test, and a significance level of α=0.01/number of tested SNPs (African-Americans, 
20;  European-Americans, 11), this study has power ranging from 35%-94% to detect -0.12≤main genetic 
effect sizes≤0.17 log grams per week in African-American participants (Table 17). Among European-
American participants, this study has power ranging from 50%-94% to detect -0.07≤main genetic effect 
sizes≤0.34 (Table 18). 
4.7.2.4.2. Association between Unweighted Genetic Risk Score and Ethanol Intake 
In Specific Aim 2, we also estimated the association between the unweighted GRS and weekly 
ethanol intake at ARIC visit 1-4 among ARIC African-American and European-American participants. 





percentage of variation in weekly ethanol intake explained by the unweighted GRS at each visit, and a 
significance level of α=0.05 were inputted in the ‘AVENGEME’ (Additive Variance Explained and 
Number of Genetic Effects) R software [426] (Tables 19 and 20). It was determined that this study has 
99% power to detect an association between the unweighted genetic risk score and ethanol intake in 
African-Americans  and European-Americans, separately. 
4.7.2.4.3. Effect Modification of the Ethanol Intake-Cognitive Decline Association by GRS 
In Specific Aim 2, we evaluated the effect modification of the ethanol intake-cognitive decline 
relationship by ethanol-associated SNPs. The MLPowSim Software Package [427] was used to generate 
R code that created simulations to estimate power to detect effect measure modification of the ethanol-
intake cognitive decline by the GRS. We used the following assumptions from preliminary data analysis 
in estimating the power of the proposed analyses: sample size (African-Americans: N=1,733 and 
European-Americans: N=7,450); beta estimates for the model intercept, ethanol intake, GRS, and the 
GRS x ethanol intake interaction term (African-Americans: βintercept=-0.829, βEthanol=0.008, βGRS=-0.007, 
and βEthanol X GRS=-0.001, respectively; European-Americans:βintercept=-0.728, βEthanol=-0.010, βGRS=-0.001, 
and βEthanol X GRS=-0.0004, respectively), and mean (SD) estimates for ethanol intake, GRS, GRS x ethanol 
intake interaction term, and the mean square error (Table 21).   
Assuming an additive genetic model, a two-sided test, and a significance level of α=0.05, it was 
determined that this study has 97% power to detect effect measure modification of the ethanol intake-
cognitive decline relationship by a GRS of 11 ethanol intake-associated SNPs in European-Americans, 
and 83% power to detect effect measure modification by a GRS of 20 ethanol intake-associated SNPs 










4.8. Supporting Tables and Figures 
 
                         Table 15. Summary of the covariates used in the analysis 
Demographic factors Age, sex, race, educational attainment 
Lifestyle factors Smoking status, physical activity, and diet  
Genetic factors APOEε4 genotype 
Medical History Diabetes and stroke 










Table 16. Parameters for power size calculation to estimate ethanol intake-cognitive decline 
association 
Race Ethnicity/Drinking Contrast+ N 
Difference in the 15-
year rate of change in 
global z-score 
Power 
African-American       
  Stable never drinking 529 Reference   
  Stable low-to moderate drinking  197 0.03 99 
  Stable heavy drinking  19 0.08 94 
  Stable former drinking  225 -0.02 90 
  Mostly low-to moderate drinking  335 0.02 97 
  Mostly heavy drinking  60 0.15 95 
  Mostly former drinking  673 0.05 97 
European-American       
  Stable never drinking 1046 Reference   
  Stable low-to moderate drinking  3136 0.02 95 
  Stable heavy drinking  185 -0.03 99 
  Stable former drinking  686 0.07 99 
  Mostly low-to moderate drinking  1068 0.02 99 
  Mostly heavy drinking  493 -0.05 99 
  Mostly former drinking  1602 0.03 99 
+Referent group is stable never drinking; residual variance (African-Americans, 0.71; European-
Americans, 0.50); and working correlation (African-Americans, 0.50; European-Americans, 0.12) 







Table 17. Power estimate for main genetic effect of ethanol intake-associated SNPs on 
weekly ethanol-intake at ARIC visits 1-4 for ARIC African-American participants 
rsID 
Effect Allele 
Frequency Beta Weekly Ethanol Intake Power 
rs6673687 0.359 -0.14 At visit 1 55 
  -0.13 At visit 2 55 
  -0.15 At visit 3 60 
    -0.12 At visit 4 58 
rs35608804 0.482 -0.14 At visit 2 65 
rs7355953 0.058 -0.38 At visit 1 79 
  -0.21 At visit 4 45 
rs11940694 0.424 -0.12 At visit 1 45 
  -0.14 At visit 3 56 
rs10008281 0.293 0.16 At visit 1 62 
  0.13 At visit 4 60 
rs58440244 0.270 -0.14 At visit 1 49 
  -0.11 At visit 4 44 
rs78757076 0.242 -0.16 At visit 1 57 
rs271085 0.304 0.17 At visit 1 68 
  0.11 At visit 4 47 
rs11768390 0.457 -0.14 At visit 2 65 
  -0.12 At visit 4 61 
rs10283354 0.096 -0.29 At visit 1 76 
  -0.25 At visit 2 69 
  -0.22 At visit 4 68 
rs10840100 0.472 0.14 At visit 2 65 
  0.15 At visit 3 63 
rs1685404 0.245 -0.18 At visit 1 67 
  -0.16 At visit 2 63 
  -0.12 At visit 3 35 
rs2514218 0.158 -0.26 At visit 1 84 
  -0.18 At visit 4 69 
rs1022084 0.496 0.12 At visit 2 52 
  0.10 At visit 4 61 
rs7940127 0.289 -0.14 At visit 1 51 
  -0.11 At visit 4 46 
rs12910841 0.096 0.32 At visit 2 88 
  0.17 At visit 4 94 
rs6496321 0.154 0.20 At visit 1 61 
  0.22 At visit 4 85 
rs4780836 0.355 0.14 At visit 2 61 
rs62040427 0.306 -0.14 At visit 1 52 
  -0.13 At visit 4 61 
rs9929584 0.462 -0.15 At visit 2 71 
Abbreviations: SNP, Single Nucleotide Polymorphisms; ARIC, Atherosclerosis Risk in 
Communities (ARIC) Study 
Log-ethanol intake, mean (SD): visit 1,1.06 (1.89); visit 2, 0.086 (1.76); visit 3, 0.99 (1.92); 






Table 18. Power estimate for main genetic effect of ethanol intake-associated SNPs on 
weekly ethanol-intake at ARIC visits 1-4 for ARIC European-American participants 
rsID 
Effect Allele 
Frequency Beta Weekly Ethanol Intake Power 
rs1123285 0.338 -0.090 At visit 2 70 
    -0.070 At visit 3 50 
rs1229984 0.965 0.340 At visit 1 94 
  0.240 At visit 2 72 
  0.220 At visit 3 63 
    0.260 At visit 4 79 
rs12651313 0.441 -0.080 At visit 2 61 
    -0.080 At visit 3 62 
rs1713676 0.529 -0.070 At visit 1 50 
  -0.080 At visit 2 63 
    -0.080 At visit 4 64 
rs2165670 0.104 0.120 At visit 3 55 
rs55872084 0.232 0.110 At visit 1 74 
    0.110 At visit 4 77 
rs62250685 0.625 -0.080 At visit 2 60 
    -0.110 At visit 3 86 
rs7185555 0.141 -0.110 At visit 1 58 
rs72859280 0.033 0.190 At visit 1 48 
rs74664784 0.613 -0.070 At visit 2 50 
    -0.100 At visit 3 79 
rs7950166 0.635 -0.080 At visit 3 59 
Abbreviations: SNP, Single Nucleotide Polymorphisms; ARIC, Atherosclerosis Risk in 
Communities (ARIC) Study 








Table 19. Power estimate for the association between unweighted genetic risk score (uGRS11) 
and weekly ethanol intake at ARIC visits 1-4 among ARIC African-American participants 
Weekly Ethanol Intake Beta SE P-value 
Percent of 
variance 
explained (%) Power 
At visit 1 -0.045 0.016 0.006 0.41 99 
At visit 2 -0.047 0.015 0.002 0.52 99 
At visit 3 -0.037 0.017 0.029 0.28 99 
At visit 4 -0.032 0.013 0.019 0.30 99 







Table 20. Power estimate for the association between unweighted genetic risk score (uGRS11) 
and weekly ethanol intake at ARIC visits 1-4 among ARIC European-American participants 
Weekly Ethanol Intake Beta SE P-value 
Percent of 
variance 
explained (%) Power 
At visit 1 0.014 0.012 0.246 0.02 99 
At visit 2 0.019 0.011 0.092 0.04 99 
At visit 3 0.024 0.012 0.036 0.06 99 
At visit 4 0.023 0.011 0.041 0.06 99 








Table 21. Power estimate for the GRS x ethanol intake effect on 15-year cognitive 
change 
  African-American European-American 
Ethanol 4.16 (0.06) 4.17(0.02) 
GRS 11.73 (0.15) 5.91 (0.04) 
GRS x Ethanol 48.68 (0.89) 24.66 (0.21) 
Mean Square Error 0.71 0.49 
























Figure 7. Direct acyclic graph (DAG) for the minimal sufficient adjustment set of confounders of the 









Figure 8.Validation of multiply imputed global Z score using existing data of multiply imputed global Z 
score using existing data 
Note: Multiple imputation was done using chained equations, and 25 imputations were obtained and 
averaged for display in plot. 20% validation sample (N=1,247) to simulate missing completely at random 
(MCAR) data. All participants had a 0.2 probability of being selected. If selected, participants’ Z scores at 


















































CHAPTER V: RESULTS 
Manuscript A: Nine-year ethanol intake trajectories and their association with 15-year 
cognitive decline among African-American and European-American adults: The 
Atherosclerosis Risk in Communities Neurocognitive Study 
 
1. Overview 
Background: Faster rates of age-related cognitive decline may result in early onset of cognitive 
impairment and dementia. Ethanol use is highly prevalent (~70%) in the U.S., and although its 
relationship with cognitive decline has been extensively studied, it remains poorly understood. Previous 
studies used single measures of exposure to ethanol and few studies were conducted in diverse 
populations despite their disproportionate burden of Alzheimer’s disease and other forms of cognitive 
impairment.  
Objective: To assess the association of long-term trajectories of ethanol intake with 15-year rate 
of decline in cognitive function from mid-to-late life among African-American and European-American 
adults.  
Methods: A total of 10,876 (n=2,169 African-Americans, n=8,707 European-Americans) 
participants of the Atherosclerosis Risk in Communities (ARIC) study completed repeated assessments of 
ethanol intake using an interviewer-administered questionnaire across a 9-year interval (1987-1998) and 
two neurocognitive examinations at 1996 and 2013. Multivariable linear regression was used to assess the 
association between long-term trajectories of ethanol intake and decline in z-score for general cognitive 
function. Multiple imputations by chained equations were used to account for attrition.   
Results: Stable low-to-moderate drinking (African-Americans: (adjusted mean difference=0.03 
(95% CI: -0.13, 0.19)), European-Americans: 0.02 (-0.05,0.08)), stable heavy drinking (African-





Americans: -0.02 (-0.18, 0.14), European-Americans: 0.07 (-0.02, 0.16)), mostly low-to-moderate 
drinking (African-Americans: 0.02 (-0.11, 0.16), European-Americans: 0.02 (-0.06, 0.10)), mostly heavy 
drinking (African-Americans: 0.15 (-0.10, 0.41), European-Americans: -0.05 (-0.15, 0.05)), and mostly 
former drinking (African-Americans: 0.05 (-0.07, 0.16), European-Americans: 0.03 (-0.04, 0.10)) in mid-
life compared to stable never drinking were not associated with 15-year decline in general cognitive 
performance from mid-to-late life, after adjustment for attrition. Declines in cognitive performance were 
similar for long-term trajectories of ethanol intake and ethanol intake at study baseline.  
Conclusions: Stable low-to-moderate and stable heavy drinking in mid-life are not associated 
with lesser and greater cognitive decline, respectively, from mid-to-late life among African-American and 
European-American adults.  
2. Introduction 
Cognitive decline refers to the decrease in mental processes, such as attention, short-term and 
long-term memory, reasoning, movement coordination, and planning of tasks, which are important for the 
conduct of daily living activities [10, 11]. Neurobiological and cognitive performance studies suggest that 
declines in cognitive function are gradual and begin in early adulthood [12-14]. Faster rates of cognitive 
decline may lead to earlier onset of cognitive impairment and dementia, which may result in significant 
burden for those experiencing decline and their caregivers [39]. By 2050, it is projected that the number 
of Americans aged 65 years and older will triple,  and the U.S. will become more racially and ethnically 
diverse [1]. Racial ethnic disparities in dementia prevalence and incidence have been documented. 
Studies indicate that African-Americans and other racial minority groups are disproportionately burdened 
with Alzheimer’s disease (AD), the most common form of dementia, and other forms of cognitive 
impairment compared to European-Americans [428-431]. To reduce the incidence of cognitive 
impairment and dementia, current research has focused on identifying modifiable lifestyle risk factors that 
can prevent or delay the progression of cognitive decline. 
 The relationship between ethanol intake and cognitive decline [32, 93, 336-348] has been 





intake is associated with greater cognitive decline [348], low-to-moderate ethanol intake has been found 
associated with less cognitive decline [336, 339, 340, 342-344, 346, 347] or  no cognitive decline [93, 
345, 348]. Inconsistent findings may be attributable to the use of a single measurement of ethanol intake 
[93, 336, 339-341, 344-347] and short follow-up times (<5 years). A limited number of studies have 
investigated the effects of ethanol in African-Americans populations even though the prevalence, 
incidence, and cumulative risk of Alzheimer’s Dementia (AD) is documented to be higher in African-
Americans than in European-Americans [343, 347]. Furthermore, few studies investigated the effects of 
mid-life ethanol intake with late-life cognition [341, 348].  
Studies that used a single measure of ethanol intake at study baseline to define the drinking 
behavior of participants assume that drinking behavior is static thereafter. However, individuals’ drinking 
habits change over time [432, 433], which can affect their risk of developing disease [434, 435]. 
Therefore, not accounting for long-term drinking pattern or changes in ethanol intake can introduce bias 
in the study [436-438].  
Using a repeat assessment of ethanol intake over 9 years and repeat measurements of global and 
multidimensional cognitive function over 15 years, our aims were 1) characterize temporal trajectories of 
ethanol intake during mid-life in African-American and European-American adults, 2) examine whether 
long-term trajectories of ethanol intake in mid-life are associated with 15-year rate of decline in cognition 
from mid-to-late life among African-American and European-American adults, and 3) examine if short-
term ethanol intake measured in mid-life show comparable associations with 15-year cognitive decline.  
3.Methods 
Study Population 
The Atherosclerosis Risk in Communities (ARIC) study is a community-based, prospective 
cohort study established in 1987, designed to investigate the etiology of atherosclerosis and its clinical 
sequelae. From 1987 through 1989, 15,792 adults aged 45 to 64 years were recruited through probability 
sampling from 4 U.S. communities: Washington County, Maryland; Forsyth County, North Carolina; 





approximately 3 years apart from 1987-1989 through 1996-1998, and a fifth examination visit was 
conducted in 2011-2013 (Figure 9).  
The baseline for the present analysis was visit 4, which allows for the investigation of the 
association of trajectories of ethanol intake across 9 years in mid-life and subsequent 15-year cognitive 
decline from mid-to-late life (Figure 9). Of the 11,625 African-American and European-American 
participants who attended visit 4, we excluded African-Americans from Minnesota and Washington 
County due to small sample size (n=38), those who were missing one or more cognitive function tests at 
study baseline (n=625), and those with missing covariates (n=86), giving a final sample size of 10,876 
participants at study baseline.  
Assessment of Ethanol Intake 
Ethanol intake was assessed at all visits  by means of an interviewer-administered questionnaire  
[169]. During the exam, participants were asked the following questions: Do you presently drink 
alcoholic beverages?”, and “Have you ever consumed alcoholic beverages?”. Individuals replying no to 
both questions were classified as never drinkers. Those who replied “no” to the first question and “yes” to 
the second question were classified as former drinkers.   
Current drinkers were asked how often they usually drank wine, beer, or hard liquor. The amount 
of ethanol consumed (in grams per week) was calculated assuming the following ethanol content: 4oz of 
wine = 10.8 grams; 12 oz. of beer = 13.2 grams; and 1.5 oz. of distilled spirits = 15.1 grams. For a drinker 
who reported less than one drink per week, the ethanol intake was recorded as 0 g per week. History of 
excessive ethanol intake (yes/no) was only assessed during ARIC visit 3 using the following question: 
“Was there ever a time in your life when you consumed 5 or more drinks of any kind of alcoholic 
beverage almost every day?”. We used this variable only for further description of the study sample. 
Categories of ethanol intake at each visit were created based on the U.S. Department of Agriculture and 
U.S. Department of Health and Human Services. Dietary Guidelines for Americans, 2015-2020 guideline 
for low-to-moderate drinking (≤210 grams/week for men and ≤105 grams/week for women) and heavy 





categories across visits 1-4, trajectories of ethanol intake were then classified as 1) stable never drinkers, 
2) stable low-to-moderate drinkers, 3) stable heavy drinkers, 4) stable former drinkers, 5) mostly low-to-
moderate drinkers, 6) mostly heavy drinkers, and 7) mostly former drinkers. In creating the ‘mostly’ 
ethanol intake trajectories, ethanol intake status at study baseline (visit 4) was taken in account. 
Participants with non-current drinking status (i.e., never or former) across visits 1-3, but reported current 
drinking at visit 4 (i.e., low-to-moderate or heavy) were assigned to the “mostly” ethanol intake category 
at visit 4 (i.e., low-to-moderate or heavy). Participants with current drinking status (i.e., low-to-moderate 
or heavy) across visits 1-3 but reported former drinking at visit 4 were assigned to the “mostly” former 
long-term pattern of ethanol intake. Participants who reported 2 visits of current drinking (i.e., low-to-
moderate or heavy) and 2 periods of former drinking were assigned to the “mostly” ethanol intake 
category at visit 4 (i.e., former, low-to-moderate or heavy). 
Definition and counts for this long-term categorization are presented in Table 1. Average ethanol 
intake across 9-years in mid-life was calculated for each participant by averaging weekly ethanol intake 
reported in ARIC visits 1-4. 
Assessment of Cognitive Function 
Cognitive function was assessed at visit 2 (1990-1992; ages 48-67), visit 4 (1996-1998; ages 54-
73), and visit 5 (as part of the ARIC-NCS) (2011-2013; ages 70-89 years) using 3 standardized cognitive 
tests to assess different domains of cognition: verbal learning and short-term memory, executive function 
and processing speed, and executive function and expressive language. 
Verbal learning and recent memory were assessed by the delayed word recall test (DWRT). 
Participants were asked to learn 10 nouns, and after a five-minute delay were given 60 seconds to recall 
the words. The  DWRT score is the number of words recalled  (0-10) [201]. DWRT has a  high test-retest 
reliability of 0.75 in older adults [201].  
Executive function and processing speed were assessed by the digit symbol substitution test 





from 1 to 9 using a key that matches digits to symbols [209]. DSST has high reliability (0.82-0.88) in 
older adults [209]. 
Executive function and expressive language were assessed by the word fluency test (WFT) , 
during which participants generate as many words starting with the letters F, A, and S as possible within 
60 seconds, with one trial per letter [385]. The WFT score is the total number of acceptable words 
generated for the three letters [205]. WFT has a  test-retest reliability of 0.88 in older adults [206]. All 
three tests were administered by trained examiners using standardized protocols in a quiet room. 
Recordings were reviewed for quality control. 
To facilitate comparison across cognitive tests, Z scores standardized to visit 2 were calculated 
for each test by subtracting the participant’s overall mean test score at visit 2 from their test score at each 
visit and then dividing by the standard deviation of the visit 2 scores. 
A factor score for general cognitive performance was previously derived using factor analysis 
[386, 387], and was scaled to have a mean of 50 and standard deviation of 10 at the 1990–92 visit [387].  
Covariates 
Potential confounders were identified from the existing literature and the use of directed acyclic 
graphs (DAGs). Potential confounders included: demographic characteristics (age, sex, race-center, and 
educational attainment), lifestyle factors (smoking status, physical activity, and diet score), genetic risk 
factor (APOE ε4 genotype) and medical history (obesity, diabetes and history of stroke).  
Age, sex, and educational attainment (< high school, high school, >high school), and smoking status 
(current, former, never) were assessed at visit 4 via self-report from the home interviews. Time spent in 
moderate to vigorous physical activity in MET-minutes/week was measured at  visits 1 and 3 using the 
modified Baecke questionnaire [390].  APOE ε4 (0,1,2) was genotyped by TaqMan assay (Applied 
Biosystems, Foster City, California) [393, 394]. Body mass index (BMI) was calculated as weight (kg) 
divided by height squared (m2). Diabetes (yes, no) was defined as self-reported history of a physician’s 





≥200 mg/dL, or diabetes medication use in the past 2 weeks.  Stroke was defined by a self-reported 
history at visit one or an adjudicated event between visits 1 and 4 [396]. Dietary factors were assessed 
using an interviewer-administered 66-item FFQ measuring usual intake of foods over the past year at 
visits 1 (1987–1989) and visit 3 (1993–1995). We calculated the Healthy Food Score, adapted from 
Steffen et al. described elsewhere [391, 392].  
Statistical Analysis 
Multiple Imputation 
Missing data due to attrition were imputed by multiple imputation using chained equations 
(MICE)[401]. Missing ethanol intake and cognitive data across ARIC visits were imputed based on the 
observed values of key covariates for a given individual, as well as the relations observed in the data for 
other participants. To account for the uncertainty of the imputation and ensure correct standard error 
estimation [402], 25  datasets were imputed. Validation of the MICE approach for cognitive outcome in 
ARIC has been previously reported and it has been determined that MICE produced unbiased imputed 
values [403]. For this study, validation using observed data demonstrated MICE produces unbiased 
imputation of global cognition factor z-scores (Appendix Figure 1). 
Statistical Modeling 
To evaluate change in general cognitive performance, DSST, DWRT, and WFT tests between 
visits 4 and 5, multivariable linear regression models were used with the outcome being visit 5 z-score 
minus visit 4 z-score. All models were race-stratified and were adjusted for age, age squared, sex race-
center, education attainment, smoking status, body mass index (BMI), diabetes, history of stroke, diet 
score, physical activity, and the Apo lipoprotein E ε4 (APOE ε4) allele.   
Statistical analyses (including multiple imputation) were performed with  Stata15 (StataCorp, 
College Station, TX, USA) [423] and SAS version 9.4 (SAS Institute, Cary, NC, USA) . The results from 
each imputed dataset were summarized using Rubin’s rule [424] into an overall estimate accounting for 





Sensitivity analyses were undertaken to examine whether complete case analyses produced 
comparable results. 
4. Results 
Temporal trajectories of ethanol intake in study population  
The trajectories of ethanol during mid-life observed in our study sample were stable never 
drinking (13.8%), stable low-to-moderate drinking (30.1%), stable heavy drinking (1.8%), stable former 
drinking (7.9%), mostly low-to-moderate drinking (12.9%), mostly heavy drinking (5.2%), and mostly 
former drinking (20.7%) (Table 22).  
African-American participants had a higher proportion of never drinkers (stable never drinking, 
21.8%), stable former drinking (8.8%), mostly low-to-moderate drinking (14.5%), and mostly former 
drinking (25.9%) than European-American participants (stable never drinking, 11.9%; stable former 
drinking, 7.6%; mostly low-to-moderate drinking, 12.5%; and mostly former drinking, 19.4%). European-
American participants had a higher prevalence of stable low-to-moderate (35.5%), stable heavy drinking 
(2.0%), and mostly heavy drinking (5.9%) than African-American participants (stable low-to-moderate 
drinking, 8.2%; stable heavy drinking, 0.7%; and mostly heavy drinking, 2.4%). Overall, 7.7% of our 
study population long term ethanol intake could not be classified as stable never drinking, stable low-to-
moderate drinking, stable heavy drinking, stable former drinking, mostly low-to-moderate drinking, 
mostly heavy drinking, and mostly former drinking, or any other ethanol intake category used in ethanol 
research literature. 
Description of Baseline Characteristics 
The socio-demographic and clinical characteristics of the 10,876 African-American and 
European-American participants at study baseline are presented in Tables 23 and 24, respectively, by 
ethanol intake trajectories. The mean age of participants at study baseline was 63 years (range:52-75 
years), 56% were female, and 20% were African-Americans. Compared to European-Americans, African-
Americans were less educated, had a higher proportion of currents smokers (16.6% vs 13.9%), higher 





scores. History of excessive drinking was more prevalent among stable former drinkers (African-
Americans, 17.8%; European-Americans, 24.7%) ,stable heavy drinkers (African-Americans, 46.7%; 
European-Americans, 32.4%), and mostly heavy drinkers (African-Americans, 24.5%; European-
Americans, 15.1%) than stable low-to-moderate drinkers (African-Americans, 7.3%; European-
Americans, 3.1%), mostly low-to-moderate drinkers (African-Americans, 9.6%; European-
Americans,10.3%), and mostly former drinkers (African-Americans, 8.0%; European-Americans, 6.0%). 
Stable never drinkers, regardless of race, were most likely to be never smokers (African-
Americans, 80.3%; European-Americans, 80.1%), had slightly higher prevalence of hypertension in 
European-Americans only (36.5%), and had lower mean levels of weekly physical activity (African-
Americans, 7.1 (10.9); European-Americans, 8.9 (10.6)).  Stable heavy drinkers (African-Americans, 
66.7%; European-Americans, 30.1%) and mostly heavy drinkers (African-Americans, 58.5%; European-
Americans, 26.8%) had the highest proportion of current smokers.  Stable heavy drinkers had a higher 
prevalence of hypertension (66.7%) and stroke (6.7%) in African-Americans only. Whereas, stable former 
drinkers overall had the highest prevalence of diabetes (African-Americans, 22.6%; European-Americans 
21.4%), and mostly former drinkers had a higher prevalence of stroke in European-Americans only 
(3.6%). 
Higher baseline general cognitive performance, DSST, and WFT scores were observed for stable 
low-to-moderate drinkers, mostly low-to-moderate drinkers, stable heavy drinkers, and mostly never 
drinkers compared to stable never drinkers. Baseline scores for DWRT did not differ across categories of 
long-term ethanol intake.  
Nine-year ethanol drinking trajectories and 15-year cognitive decline  
Results from the multivariable linear regression models suggest no overall association between 9-
year trajectories of ethanol intake in mid-life and 15-year change in general cognitive performance, 
DWRT, WFT and DSST z-scores (Tables 25 and 26, and Figure 10).   
Among African-American participants, stable low-to-moderate drinkers (Adjusted 15-year 





moderate drinkers (-0.62 (-1.03, -0.21)), mostly heavy drinkers (-0.49 (-0.95, -0.03)), and mostly former 
drinkers (-0.60 (-1.00, -0.19)) had nominally lower 15-year decline in general cognitive performance           
z-scores than stable never drinkers (-0.64 (-1.05, -0.24)), equivalent to 5%, 12%, 4%,  24%, and 7% lesser 
decline, respectively. However, slightly greater 15-year decline in general cognitive performance were 
observed for stable former drinkers (-0.67 (-1.08, -0.25)) than stable never drinkers (-0.64 (-1.05, -0.24)), 
equivalent to 3% greater decline (Table 25).  
Among European-American participants, 15-year decline in general cognitive performance for 
stable low-to-moderate drinkers (-0.84 (-1.08, -0.60)), stable former drinkers (-0.78 (-1.03, -0.54)), mostly 
low-to-moderate drinkers (-0.84 (-1.08, -0.59 )), and mostly former drinkers (-0.83 (-1.07, -0.58)) had 
nominally lower 15-year decline in general cognitive performance than stable never drinkers                        
(-0.86 (-1.10, -0.62)) , equivalent to 2%, 8%, 2%,  and 4% lesser  decline, respectively. However, among 
European-American participants, slightly greater 15-year decline in general cognitive performance were 
observed for stable heavy drinkers (-0.89 (-1.18, -0.60)) and mostly heavy drinkers (-0.90 (-1.15, -0.66)) 
than stable never drinkers (-0.86 (-1.10, -0.62)), equivalent to 4% and 5% greater decline, respectively. In 
addition, European-American participants who were mostly heavy drinkers (-0.89 (-1.18, -0.61)) had a 
greater 15-year decline in DSST z-scores than European-American who were stable never drinkers          
(-0.78 (-1.06, -0.51)), equivalent to 14% greater decline (Table 26). 
Average ethanol intake across nine-years and 15-year cognitive decline 
 We observed no overall association between average ethanol intake across 9 years in mid-life and 
15-year change in general cognitive performance, DWRT, DSST, and WFT z-scores from mid-to-late life 
among African-American (Table 27) and European-American (Table 28) participants.  There was no 
evidence of trends of increased 15-year change in general cognitive performance, DWRT, WFT and 
DSST across quartiles of average ethanol intake across nine-years, among African-American and 







Ethanol intake measured at study baseline and 15-year cognitive change 
We also determined whether ethanol intake levels measured at study baseline (visit 4) showed 
similar trajectories of associations with 15-year change in general cognitive performance, DWRT, WFT, 
and DSST z-scores. Findings based on ethanol intake levels at study baseline were similar to those 
observed using 9-year ethanol drinking trajectories for African-American and European-American 
participants (Tables 29 and 30) (Appendix Figure 3).  
Among African-American participants, we observed no overall association between ethanol 
intake measured at study baseline and 15-year change in general cognitive performance (P= 0.697), 
DWRT (P=0.814), WFT (P= 0.609), and DSST z-scores (P= 0.614) (Table 29).  
Among European-American participants, we observed no overall association between ethanol 
intake and 15-year change in general cognitive performance (P=0.072), DWRT (P=0.177), and WFT      
z-scores (P=0.323) (Table 30). However, an association was observed between ethanol intake measured at 
study baseline and 15-year change in DSST z-scores (P=0.026).  The difference in 15-year change in 
DSST z-scores among heavy drinkers than never drinkers at study baseline was -0.10 (-0.19, -0.02), 
equivalent to 13% greater decline. Declines in cognitive performance were slighter higher for long-term 
trajectories of ethanol intake than ethanol intake at study baseline. 
Sensitivity analysis    
 In sensitivity analysis, we conducted a complete case analyses of the long-term trajectories of 
ethanol intake and ethanol intake status at study baseline (Appendix Tables 10-15). 
Nine-year ethanol drinking trajectories and 15-year cognitive decline  
 Among African-America participants, we observed no association between 9-year ethanol 
drinking trajectories and 15-year change in general cognitive performance z-score (P=0.314), DWRT z-
score (P=0.132), WFT z-score (P=0.063), and DSST z-score (P=0.847) (Appendix Table 10). However, 
differences in 15-year change in general cognitive performance (0.46 (0.04, 0.88)) and DWRT z-score 
(1.14 (0.19, 2.08)) were observed for stable heavy drinkers and stable never drinkers, equivalent to 





observed between stable former drinkers compared stable never drinkers (0.23 (0.05, 0.42)) and between 
mostly low-to-moderate drinkers and stable never drinkers (0.20 (0.05, 0.35), equivalent to 42% and 36% 
lesser decline, respectively (Appendix Table 10). 
 Among European-American participants, we observed an association between 9-year ethanol 
drinking and 15-year change in DWRT z-score (P=0.032) (Appendix Table 11). Differences in 15-year 
change in DSST z-score were observed for mostly low-to-moderate drinking and stable never drinking (-
0.07 (-0.14, -0.01)) and mostly heavy drinking and stable never drinking (-0.10 (-0.18, -0.02)), equivalent 
to 7% and 10% greater decline, respectively (Appendix Table 11). 
Average ethanol intake across nine-years and 15-year cognitive decline 
 Among African-Americans and European-Americans participants, we observed no association 
between average ethanol intake across 9-years in mid-life and general cognitive performance z-score 
(African-Americans: P=0.812, European-Americans: P=0.089), DWRT z-score (African-Americans: 
P=0.644, European-Americans: P=0.292), WFT z-score (African-Americans: P=0.904, European-
Americans: P=0.406), and DSST z-score (African-Americans: P=0.567, European-Americans: P=0.384) 
(Appendix Tables 12 and 13).  However, among European-American participants, we observed that 
participants in the highest quartile of cumulative average ethanol intake (-1.25 (-1.54, -0.96)) had greater 
15-year change in general cognitive performance than participants in the lowest quartile of cumulative 
average ethanol intake (-1.18 (-1,47, -0.89)) (Appendix Table 13). 
 Ethanol intake measured at study baseline and 15-year cognitive decline 
 Among African-American participants, we observed no association between ethanol intake 
reported at baseline and 15-year cognitive performance change z-score (P=0.052), DWRT z-score 
(P=0.478) z-score, WFT z-score (P=0.084), and DSST z-score (P=0.529) (Appendix Table 14). However, 
differences in 15-year change in general cognitive performance were observed between low-to-moderate 
drinkers and never drinkers (0.12 (0.02, 0.22)) and between former drinkers and never drinkers (0.10 
(0.01, 0.19)), equivalent to 10% and 8% lesser decline, respectively. Similarly, differences in 15-year 





0.26)) and between former drinkers and never drinkers (0.13 (0.02, 0.24)), equivalent to 22% and 21% 
lesser decline, respectively (Appendix Table 14).  
 Among European-American participants, we observed associations between ethanol intake 
reported at study baseline and 15-year change in DWRT z-score (P=0.007) and DSST z-score (P=0.016) 
(Appendix Table 15). The difference in 15-year change in DWRT z-score for heavy drinkers and never 
drinkers was -0.19 (-0.36, -0.02)), equivalent to 11% greater decline. The difference in the 15-year change 
in DSST z-score for low-to-moderate drinks and never drinkers was -0.06 (-0.11, -0.01), equivalent to 6% 
greater decline (Appendix Table 15). The difference in the 15-year change in DSST z-score for heavy 
drinkers and former drinkers was -0.11 (-0.18, -0.04), equivalent to 11% greater decline (Appendix Table 
15). Imputation produced smaller estimates of 15-year change in cognitive performance compared to 
complete case analyses, although confidence intervals overlapped. 
5. Discussion 
 This study, conducted in a community cohort, found no evidence that stable low-to-moderate 
drinking and mostly low-to-moderate drinking in mid-life are associated with lesser 15-year cognitive 
decline from mid-to-late life compared to stable never drinking, after adjustment for attrition. There was 
no evidence that stable heavy drinking, mostly heavy drinking, stable former drinking, and mostly former 
drinking are associated with greater 15-year cognitive decline from mid-to-late life, after adjustment for 
attrition. However, the 15-year change in digit symbol substitution test (a test of executive function and 
processing speed) for mostly heavy drinkers was slightly higher that stable never drinkers, equivalent to a 
14% greater decline.  No association was found for ethanol intake averaged across 9 years during mid-life 
and 15-year cognitive decline from mid-to-late life. Further, we did not observe an association with 
ethanol intake at baseline and 15-year cognitive decline, except for digit symbol substitution test in 
European-American participants, after adjustment for attrition. The 15-year rate of change for heavy 
drinkers was slightly higher than never drinkers at study baseline, equivalent to a 13% greater decline. In 





stable drinking categories and drinking categories measured at study baseline. Overall, a slightly lesser 
rate of decline was observed among African-Americans. 
Low-to-moderate ethanol intake is hypothetically associated with cognitive decline through 
cerebrovascular and cardiovascular pathways, involving effects that play out over an extended period of 
time [324, 439]. Heavy ethanol intake on the other hand has detrimental short- and long-term effects on 
the brain [440, 441],  including direct neurotoxic effect [441], proinflammatory effects [441, 442], and 
indirect impact via cerebrovascular disease [327]  and vitamin deficiency [443]. 
Cross-sectional studies finding on the relationship between ethanol intake and cognitive function 
have been mixed, with several suggesting a protective effect of moderate ethanol intake on cognitive 
function [444-446] . However, cross-sectional studies findings are inconclusive due to major concerns of 
reverse causation and their susceptibility to selection bias and residual confounding.  A cross-sectional 
analysis of the association of ethanol intake with MRI-defined cerebral abnormalities conducted in the  
Atherosclerosis Risk in Community (ARIC) study reported no significant neuroprotective effect of low-
to-moderate ethanol intake on white matter grade in middle-aged adults [447].  
Prospective studies finding on the relationship between low-to-moderate ethanol intake and 
cognitive decline have been inconsistent [32, 93, 336-348], potentially due to their single measurement of 
ethanol intake [93, 336, 339-341, 344-347] and  short follow-up times (<5 years). Our study, by focusing 
on the association of long-term trajectories of ethanol intake with cognitive decline adds to literature 
because it is unclear whether long-term ethanol intake influences cognitive decline. 
Our observation that stable low-to-moderate drinking and mostly low-to-,moderate drinking 
during mid-life is not associated with lesser 15-year decline in general cognitive performance from mid-
to-late life compared to stable never drinking is consistent with the findings of a recent Whitehall ll 
Cohort Study of 10,308 white European participants ages 44-69 years, which examined the relationship 
between ethanol intake (3 repeated measurements) averaged across 10 years in mid-life  and subsequent 
10-year cognitive decline [348].  The authors found that moderate drinking was not associated with lesser 





association between stable heavy drinking with greater 15-year decline in global cognitive performance 
differed from the Whitehall II study, which found heavy drinking is associated with greater 10-year 
cognitive decline in men only. However, in our study, we found an association between mostly heavy 
drinking and greater 15-year cognitive change in digit symbol substitution test in European-Americans 
only. 
Several limitations of this study should be mentioned. Our study findings of a lack of association 
between ethanol intake and cognitive decline in general cognitive performance may be the result of error 
in the measurement of ethanol intake that may have attenuated the effect estimates; the use of a 
standardized instrument administered by trained personnel and the availability of repeat measurements 
mitigates this concern. Cohort attrition over the prolonged follow up could have biased an association 
toward the null, if differentially related to ethanol intake. No clear pattern of association of ethanol intake 
with attrition was observed, and sensitivity analysis indicated that missing data patterns were effectively 
corrected by MICE imputation.  The low prevalence of heavy drinking in our study population limited our 
ability to estimate the impact of heaving drinking on cognitive performance over time. Lastly, although 
community-based our results emerge from 4 geographically defined, closed cohorts and may not widely 
generalize to other populations.  
Strengths of this study include the large population-based probability sample of middle-aged 
African Americans and European-Americans, a prospective design with 15 years of follow-up with 
repeated measurements of ethanol intake and well-characterized cognitive function. Ethanol intake was 
assessed using an instrument with beverage-specific questions (thus reducing under-reporting) that 
differentiated never from former drinkers. Additionally, we had rich covariate data that allowed 
adjustment of lifestyle, genetic, and clinical risk factors.  
6. Conclusion 
The results from this study suggest that stable low-to-moderate drinking and stable heavy 
drinking in mid-life are not associated with cognitive decline from mid-to late-life among African-





demonstrating that moderate ethanol intake may not be protective of cognitive decline. Therefore, low-to-








7. Main Tables and Figures 
 
Table 22. Long-term ethanol intake at study baseline with observed counts and percentage by race and overall† 
 
  African-Americans European-Americans 
 
Overall 
  N (%) N (%) N (%) 
Long-term Ethanol 
Intake  Weekly Ethanol Intake 2169 (19.9) 8707 (80.1) 10876 (100.0) 
Stable never 0 g/wk. at each visit 472 (21.8) 1033 (11.9) 1505 (13.8) 
Stable low-to-
moderate ≤210 g/wk. for men and ≤105 g/wk. for women at each visit 178 (8.2) 3095 (35.5) 3273 (30.1) 
Stable heavy >210 g/wk. for men and >105 g/wk. for women at each visit 15 (0.7) 176 (2.0) 191 (1.8) 
Stable former Classified as former drinker at each visit; visits 1-4 191 (8.8) 664 (7.6) 855 (7.9) 
Mostly low-to-
moderate 
Majority of visits were low-to-moderate ethanol drinking 314 (14.5) 1091 (12.5) 1405 (12.9) 
Mostly heavy Majority of visits were heavy ethanol drinking 53 (2.4) 511 (5.9) 564 (5.2) 
Mostly former Majority of visits were former ethanol drinking 561 (25.9) 1687 (19.4) 2248 (20.7) 
Unclassified‡  385 (17.7) 450 (5.2) 835 (7.7) 
† Counts and percentage were calculated based on data prior to using multiple imputation by chains equation to impute missing weekly ethanol intake data for 
Atherosclerosis Risk in Communities (ARIC) Study visits 1-4. 
Abbreviation: g/wk., grams per week.  
‡Unclassified, study participants’ long-term ethanol intake could not be classified as stable never drinking, stable low-to-moderate drinking, stable heavy drinking, stable former 












Table 23. Baseline characteristics of Atherosclerosis Risk in Communities (ARIC) study African-American participants by 9-year ethanol drinking trajectories, 1987-1996 (N=2169) † 
  Stable Stable Stable Stable Mostly Mostly Mostly   
 Never Low-to-moderate Heavy Former 
Low-to 
moderate Heavy Former 
Unclassified 
‡ Overall 
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Characteristics 472 (21.8) 178 (8.2) N=15 (0.2) N=191 (8.8) 314 (14.5) 53 (2.4) 561 (25.9) 385 (17.7) 2169 (19.9) 
Age (years), mean (SD) 62.8 (5.6) 60.1 (5.5) 60.3 (5.0) 62.8 (5.7) 60.2 (5.2) 60 (4.6) 61.6 (5.8) 62.4 (5.7) 61.7 (5.7) 
          
Female, n (%) 411 (87.1) 72 (40.4) 6 (40.0) 97 (50.8) 159 (50.6) 21 (39.6) 355 (63.3) 304 (79.0) 1425 (65.7) 
Study center, n (%)          
    Forsyth County, NC 42 (8.9) 35 (19.7) 4 (26.7) 34 (17.8) 20 (6.4) 2 (3.8) 71 (12.7) 32 (8.3) 240 (11.1) 
    Jackson, MS 430 (91.1) 143 (80.3) 11 (73.3) 157 (82.2) 294 (93.6) 51 (96.2) 490 (87.3) 353 (91.7) 1929 (88.9) 
Education, n (%)          
  <   high school   156 (33.1) 27 (15.2) 4 (26.7) 86 (45.0) 75 (23.9) 18 (34.0) 191 (34.0) 152 (39.5) 709 (32.7) 
  High school or vocational school 159 (33.7) 45 (25.3) 6 (40.0) 51 (26.7) 87 (27.7) 17 (32.1) 167 (29.8) 115 (29.9) 647 (29.8) 
   College or higher  157 (33.3) 106 (59.6) 5 (33.3) 54 (28.3) 152 (48.4) 18 (34.0) 203 (36.2) 118 (30.6) 813 (37.5) 
Smoking, n (%)          
    Never Smokers 379 (80.3) 65 (36.5) 1 (6.7) 46 (24.1) 103 (32.8) 10 (18.9) 203 (36.2) 220 (57.1) 1027 (47.3) 
    Former Smokers 67 (14.2) 66 (37.1) 4 (26.7) 114 (59.7) 126 (40.1) 12 (22.6) 268 (47.8) 125 (32.5) 782 (36.1) 
    Current Smokers 26 (5.5) 47 (26.4) 10 (66.7) 31 (16.2) 85 (27.1) 31 (58.5) 90 (16.0) 40 (10.4) 360 (16.6) 
Body Mass Index (kg/m2), mean (SD) 31.6 (6.4) 28.8 (5.4) 26.4 (5.7) 31 (6.5) 29.7 (5.3) 27.4 (5.9) 30.7 (6.3) 31.5 (6.9) 30.7 (6.3) 
Diabetes, n (%) 302 (20.1) 330 (10.1) 20 (10.5) 193 (22.6) 209 (14.9) 52 (9.2) 436 (19.4) 195 (23.4) 550 (25.4) 
Hypertension, n (%) 288 (61.0) 91 (51.1) 10 (66.7) 113 (59.2) 150 (47.8) 31 (58.5) 314 (56.0) 245 (63.6) 1242 (57.3) 
History of Stroke, n (%) 16 (3.4) 4 (2.2) 1 (6.7) 9 (4.7) 10 (3.2) 2 (3.8) 24 (4.3) 8 (2.1) 74 (3.4) 
Diet score, mean (SD) 21.2 (5.3) 21.4 (4.7) 19 (5.8) 20.5 (5.4) 20.6 (6.3) 19.2 (6.7) 19.4 (6.2) 19.4 (6.9) 20.2 (6.0) 
Physical activity (met-min/week), 
mean (SD) 7.1 (10.9) 12.2 (14.4) 9.2 (20.5) 9.2 (14.6) 10 (13.3) 9.4 (12.4) 8.3 (12.0) 7.2 (10.4) 8.5 (12.3) 
APOEε4 allele present, n (%)  195 (41.3) 66 (37.1) 5 (33.3) 79 (41.4) 122 (38.9) 23 (43.4) 220 (39.2) 150 (39) 860 (39.6) 
Ethanol Intake, median (25th-75th 
percentile)          
    Frequency  12 (5-19) 97 (78-157) 8 (4-23) 8.5 (2-31) 52 (32-69) 2 (0-10) 0 (0-1) 1 (0-11) 
    Grams/week  162.3 (58.3-258.9) 
1367.5 (1029.6-
1979.6)  64.0 (0-345.2) 
691.1 (451.8-
953.1) 28.3 (0-115.1) 0 (0-26.2) 54.2 (0-263.2) 
    Averaged ethanol intake (g/wk.) 
(visits 1-4)  41 (14.6-64.7) 341.9 (257.4-494.9)  25.1 (0-101.3) 
186.2 (118.8-
252.4) 19.6 (0-66) 0 (0-19.1) 25.9 (0-85.1) 
History of excessive drinking *, n (%)  13 (7.3) 7 (46.7) 34 (17.8) 30 (9.6) 13 (24.5) 45 (8.0) 3 (0.8) 145 (6.7) 
Cognitive test scores, mean (SD)          
    Global cognition factor z-score 
-0.74 
(0.71) 
-0.41 (0.79) -0.68 (0.90) -0.86 (0.67) -0.59 (0.77) -0.57 (0.92) -0.70 (0.77) -0.89 (0.68) 
0.72 (0.75) 
    DWRT 6.2 (1.6) 6.3 (1.6) 5.7 (1.5) 6.0 (1.5) 6.1 (1.8) 6.1 (1.8) 6.0 (1.7) 5.9 (1.7) 6.1 (1.7) 
    DSST 30.2 (12.8) 36.2 (13.8) 32.2 (13.3) 28.8 (11.9) 33.5 (12.9) 34.8 (15.9) 31.6 (13.6) 27.8 (13.0) 31.1 (13.3) 
    WFT 28.6 (12.8) 33.2 (14.6) 31.4 (12) 27.1 (13.1) 30.3 (13.5) 29.3 (14.3) 28.6 (13) 25.9 (12.3) 28.6 (13.2) 
† Counts and percentage were calculated based on data prior to imputation for missing ethanol intake data for Atherosclerosis Risk in Communities (ARIC) Study visits 1-4. 
Abbreviations: ‡ Unclassified, participants’ ethanol intake pattern across visits 1-4 could not be classified due to missing ethanol intake. Missing ethanol data were later imputed, and participants’ ethanol intake were 
determined; SD, standard deviation; n, number of participants; %, percent; NC, North Carolina, MS, Mississippi; GED, general educational development; kg/m2, grams per meter squared; met-min/week, metabolic 
equivalent of task per week; APOEε4, apolipoprotein epsilon 4 allele; g/wk., grams per week; self-reported at visit 3. “Was there ever a time in your life when you consumed 5 or more drinks of any kind of alcoholic 







Table 24. Baseline characteristics of Atherosclerosis Risk in Communities (ARIC) study European-American participants by 9-year ethanol drinking trajectories, 1987-1996 (N=8707) † 
          
  Stable              Stable                      Stable                Stable       Mostly Mostly Mostly Unclassified‡ Overall 
 Never Low-to-moderate Heavy Former 
Low-to-
moderate 
Heavy Former   
 N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) N (%) 
Characteristics 1033 (11.9) 3095 (35.5) 176 (2.0) 664 (7.6) 1091 (12.5) 511 (5.9) 1687 (19.4) 450 (5.2) 8707 (80.1) 
Age (years), mean (SD) 64.2 (5.5) 62.4 (5.6) 62.9 (5.7) 64 (5.5) 62.8 (5.6) 62.6 (5.4) 63.5 (5.8) 64.1 (5.5) 63.1 (5.6) 
Female, n (%) 791 (76.6) 1517 (49.0) 77 (43.8) 256 (38.6) 547 (50.1) 250 (48.9) 927 (54.9) 305 (67.8) 4792 (53.5) 
Study center, n (%)          
    Forsyth County, NC 486 (47.0) 657 (21.2) 50 (28.4) 180 (27.1) 267 (24.5) 127 (24.9) 595 (35.3) 156 (34.7) 2518 (28.9) 
    Minneapolis, MN 94 (9.1) 1619 (52.3) 72 (40.9) 192 (28.9) 383 (35.1) 252 (49.3) 482 (28.6) 68 (15.1) 3162 (36.3) 
    Washington County, MD 453 (43.9) 819 (26.5) 54 (30.7) 292 (44.0) 441 (40.4) 132 (25.8) 610 (36.2) 226 (50.2) 3027 (34.8) 
Education, n (%)          
  Less than high school   233 (22.6) 178 (5.8) 18 (10.2) 175 (26.4) 156 (14.3) 45 (8.8) 301 (17.8) 120 (26.7) 1226 (14.1) 
  High school, GED, or vocational 
school 
546 (52.9) 1325 (42.8) 77 (43.8) 290 (43.7) 498 (45.6) 209 (40.9) 851 (50.4) 223 (49.6) 4019 (46.2) 
  College, graduate, or professional 
school  
254 (24.6) 1592 (51.4) 81 (46.0) 199 (30.0) 437 (40.1) 257 (50.3) 535 (31.7) 107 (23.8) 3462 (39.8) 
Smoking, n (%)          
    Never Smokers 827 (80.1) 1140 (36.8) 25 (14.2) 154 (23.2) 336 (30.8) 91 (17.8) 662 (39.2) 275 (61.1) 3510 (40.3) 
    Former Smokers 146 (14.1) 1603 (51.8) 98 (55.7) 410 (61.7) 592 (54.3) 283 (55.4) 752 (44.6) 102 (22.7) 3986 (45.8) 
    Current Smokers 60 (5.8) 352 (11.4) 53 (30.1) 100 (15.1) 163 (14.9) 137 (26.8) 273 (16.2) 73 (16.2) 1211 (13.9) 
Body Mass Index (kg/m2), mean 
(SD) 
28.4 (5.6) 28.1 (4.9) 27.2 (4.6) 29.1 (5.5) 28.3 (5.4) 26.9 (4.6) 28.5 (5.3) 29.1 (5.8) 28.3 (5.2) 
Diabetes, n (%) 169 (16.4) 300 (9.7) 18 (10.2) 142 (21.4) 143 (13.1) 43 (8.4) 289 (17.1) 83 (18.4) 1187 (13.6) 
Hypertension, n (%) 377 (36.5) 910 (29.4) 56 (31.8) 233 (35.1) 374 (34.3) 133 (26.0) 571 (33.8) 178 (39.6) 2832 (32.5) 
History of Stroke n (%) 22 (2.1) 58 (1.9) 6 (3.4) 19 (2.9) 30 (2.7) 8 (1.6) 61 (3.6) 10 (2.2) 214 (2.5) 
Diet score, mean (SD) 20.5 (5.0) 21.4 (5.0) 20.4 (5.2) 20.5 (5.1) 20.3 (5.9) 20.8 (5.4) 20.4 (5.5) 20.5 (5.8) 20.8 (5.3) 
Physical activity (met-min/week), 
mean (SD) 
8.9 (10.6) 14.3 (14.2) 12.2 (12.9) 10.9 (12.9) 13.2 (14.1) 14 (14.4) 10.6 (12.0) 9.6 (11.8) 12.2 (13.3) 
APOEε4 allele present, n (%)   261 (25.3) 860 (27.8) 45 (25.6) 174 (26.2) 285 (26.1) 138 (27.0) 439 (26.0) 117 (26.0) 2319 (26.6) 
Ethanol Intake, median (25th-75th 
percentile)     
   
  
    Frequency  8 (2-17) 89.5 (58-113) 6 (1-22) 11 (1-36) 47 (31-66) 1 (0-6) 0 (0-0) 4 (0-19) 
    Grams/week   97.1 (25.9-218.9) 1214.5 (765.2-1582.2)  92.4 (0-430.8) 627.8 (421-884.4) 0 (0-66.9) 0 (0-0) 82.3 (0-296.3) 
    Averaged ethanol intake (g/wk.) 
(visits 1-4) 
 24.3 (6.5-54.8) 303.6 (191.3-395.5)  38.9 (0-119.3) 162.3 (108.9-231) 0 (0-28.8) 0 (0-0) 24.3 (0-
80.2) 
History of excessive drinking *, n (%)  95 (3.1) 57 (32.4) 164 (24.7) 112 (10.3) 77 (15.1) 101 (6.0)  0 (0.0) 606 (7.0) 
Cognitive test scores, mean (SD)          
    Global cognition factor z-score 0.02 (0.68) 0.30 (0.67) 0.14 (0.69) -0.20 (0.74) 0.13 (0.74) 0.25 (0.69) 0.02 (0.69) -0.11 (0.73) 0.12 (0.71) 
    DWRT 6.7 (1.5) 6.8 (1.5) 6.8 (1.6) 6.4 (1.5) 6.7 (1.5) 6.8 (1.5) 6.6 (1.6) 6.4 (1.5) 6.7 (1.5) 
    DSST 45.5 (11.0) 49.7 (10.7) 46.4 (10.6) 41.8 (11.3) 46.9 (11.5) 48.2 (10.6) 45.3 (11.1) 43.9 (11.4) 46.9 (11.2) 
    WFT 32.1 (11.1) 36.8 (11.6) 37.7 (11.8) 32.1 (11.8) 35.8 (12.2) 37.4 (12.4) 33.4 (11.7) 31 (11.5) 34.9 (11.9) 
† Counts and percentage were calculated based on data prior to imputation for missing ethanol intake data for Atherosclerosis Risk in Communities (ARIC) Study visits 1-4. 
Abbreviations: ‡ Unclassified, participants’ ethanol intake pattern across visits 1-4 could not be classified due to missing ethanol intake. Missing ethanol data were later imputed and participants’ ethanol intake were 
determined; SD, standard deviation; n, number of participants; %, percent; NC, North Carolina; MN, Minnesota; MD, Maryland; GED, general educational development; kg/m2, grams per meter squared; met-min/week, 
metabolic equivalent of task per week; APOEε4, apolipoprotein epsilon 4 allele; g/wk., grams per week; *, self-reported at visit 3. “Was there ever a time in your life when you consumed 5 or more drinks of any kind 








Table 25. Adjusted mean difference in 15-year change in cognitive performance by long-term ethanol intake category for Atherosclerosis Risk in Communities (ARIC) 
study African-American participants 
    Baseline Cognitive Score 15-Year Decline Difference*     
Test/Long-Term Drinking Category N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† P for Difference 
Global Factor Score z-score  2342 -0.73 (0.75)         
    Stable never drinking 529 -0.76 (0.71) -0.64 (-1.05, -0.24) Reference Reference 0.862 
    Stable low-to-moderate drinking 197 -0.42 (0.78) -0.61 (-1.03, -0.20) 0.03 (-0.13, 0.19) -5%  
    Stable heavy drinking 19 -0.69 (0.90) -0.57 (-1.14, 0.00) 0.08 (-0.34, 0.50) -12%  
    Stable former drinking 225 -0.90 (0.67) -0.67 (-1.08, -0.25) -0.02 (-0.18, 0.14) 3%  
    Mostly low-to-moderate drinking 335 -0.67 (0.76) -0.62 (-1.03, -0.21) 0.02 (-0.11, 0.16) -4%  
    Mostly heavy drinking 60 -0.59 (0.91) -0.49 (-0.95, -0.03) 0.15 (-0.10, 0.41) -24%  
    Mostly former drinking 673 -0.73 (0.76) -0.60 (-1.00, -0.19) 0.05 (-0.07,0.16) -7%   
Delayed Word Recall z-score 2340 -0.37 (1.11)         
    Stable never drinking 528 -0.27 (1.09) -1.00 (-1.82, -0.18) Reference Reference 0.425 
    Stable low-to-moderate drinking 196 -0.20 (1.05) -0.93 (-1.76, -0.10) 0.08 (-0.23, 0.39) -8%  
    Stable heavy drinking 19 -0.48 (1.08) -0.82 (-1.89, 0.24) 0.18 (-0.69, 1.05) -18%  
    Stable former drinking 225 -0.46 (1.05) -1.11 (-1.96, -0.26) -0.11 (-0.41, 0.19) 11%  
    Mostly low-to-moderate drinking 335 -0.43 (1.23) -0.80 (-1.64, 0.03) 0.20 (-0.07, 0.46) -20%  
    Mostly heavy drinking 59 -0.33 (1.05) -0.79 (-1.71, 0.12) 0.21 (-0.31, 0.73) -21%  
    Mostly former drinking 673 -0.38 (1.07) -0.85 (-1.65, -0.04) 0.16 (-0.07, 0.38) -16%   
Word Fluency z-score  2334 -0.39 (1.06)         
    Stable never drinking 528 -0.40 (1.02) -0.44 (-0.89, 0.02) Reference Reference 0.634 
    Stable low-to-moderate drinking 196 -0.02 (1.14) -0.41 (-0.86, 0.05) 0.03 (-0.14, 0.20) -6%  
    Stable heavy drinking 19 -0.12 (0.99) -0.37 (-0.98, 0.24) 0.06 (-0.40, 0.53) -15%  
    Stable former drinking 223 -0.56 (1.08) -0.39 (-0.86, 0.08) 0.05 (-0.12, 0.21) -10%  
    Mostly low-to-moderate drinking 331 -0.30 (1.09) -0.31 (-0.78, 0.17) 0.13 (-0.01, 0.28) -30%  
    Mostly heavy drinking 59 -0.31 (1.15) -0.27 (-0.80, 0.25) 0.16 (-0.12, 0.45) -37%  
    Mostly former drinking 672 -0.40 (1.04) -0.37 (-0.83, 0.09) 0.07 (-0.05, 0.19) -15%   
 Digit Symbol Substitution z-score 2325 -0.97 (0.94) -0.45 (-0.90, 0.01)       
    Stable never drinking 526 -1.04 (0.91) -0.39 (-0.84, 0.06) Reference Reference 0.954 
    Stable low-to-moderate drinking 196 -0.58 (0.94) -0.44 (-0.88, 0.01) -0.05 (-0.22, 0.12) 12%  
    Stable heavy drinking 18 -0.83 (0.90) -0.43 (-1.03, 0.18) -0.04 (-0.48, 0.40) 10%  
    Stable former drinking 221 -1.16 (0.84) -0.48 (-0.93, -0.02) -0.09 (-0.24, 0.06) 23%  
    Mostly low-to-moderate drinking 331 -0.88 (0.94) -0.45 (-0.90, 0.00) -0.06 (-0.20, 0.08) 16%  
    Mostly heavy drinking 59 -0.72 (1.11) -0.41 (-0.90, 0.09) -0.02 (-0.29, 0.25) 5%  
    Mostly former drinking 668 -0.95 (0.95) -0.42 (-0.86, 0.02) -0.03 (-0.15, 0.08) 8%   
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4; 1996-1998) z-score. Negative values correspond to 
greater decline compared to the reference (stable never drinker). All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the 
variance of a function of the within and between completed data set variances. CI, confidence interval. Adjusted for age, age squared, sex, race-center, education attainment, 
diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. † Percent, positive 
values represent % greater decline relative to the referent group. P for difference, p-value for t-test of equality of mean difference in 15-year change in cognitive performance 






Table 26. Adjusted mean difference in 15-year change in cognitive performance by long-term ethanol intake category for Atherosclerosis Risk in Communities (ARIC) 
study European-American participants 
    Baseline Cognitive Score 15-Year Decline Difference*     
Test/Long-Term Drinking Category N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† P for difference 
Global Factor Score z-score  8709 0.12 (0.72)         
    Stable never drinking 1046 0.02 (0.68) -0.86 (-1.10, -0.62) Reference Reference 0.275 
    Stable low-to-moderate drinking 3136 0.30 (0.67) -0.84 (-1.08, -0.60) 0.02 (-0.05, 0.08) -2%  
    Stable heavy drinking 185 0.13 (0.69) -0.89 (-1.18, -0.60) -0.03 (-0.18, 0.11) 4%  
    Stable former drinking 686 -0.21 (0.74) -0.78 (-1.03, -0.54) 0.07 (-0.02, 0.16) -8%  
    Mostly low-to-moderate drinking 1068 0.12 (0.73) -0.84 (-1.08, -0.59) 0.02 (-0.06, 0.10) -2%  
    Mostly heavy drinking 493 0.23 (0.70) -0.90 (-1.15, -0.66) -0.05 (-0.15, 0.05) 5%  
    Mostly former drinking 1602 0.02 (0.70) -0.83 (-1.07, -0.58) 0.03 (-0.04, 0.10) -4%   
Delayed Word Recall z-score 8706 0.06 (1.00)         
    Stable never drinking 1047 0.08 (1.01) -1.38 (-1.94, -0.82) Reference Reference 0.435 
    Stable low-to-moderate drinking 3136 0.14 (0.96) -1.37 (-1.93, -0.81) 0.01 (-0.12, 0.13) -1%  
    Stable heavy drinking 184 0.14 (1.02) -1.58 (-2.16, -1.00) -0.20 (-0.49, 0.09) 15%  
    Stable former drinking 687 -0.13 (1.01) -1.46 (-2.05, -0.87) -0.08 (-0.26, 0.11) 5%  
    Mostly low-to-moderate drinking 1067 0.04 (1.01) -1.41 (-1.98, -0.84) -0.02 (-0.18, 0.13) 2%  
    Mostly heavy drinking 492 0.13 (1.01) -1.52 (-2.12, -0.93) -0.14 (-0.34, 0.05) 10%  
    Mostly former drinking 1602 0.02 (1.04) -1.39 (-1.95, -0.82) 0.00 (-0.16, 0.15) 0.30%   
Word Fluency z-score  8702 0.14 (0.95)         
    Stable never drinking 1047 -0.08 (0.89) -0.47 (-0.79, -0.15) Reference  0.361 
    Stable low-to-moderate drinking 3135 0.29 (0.93) -0.45 (-0.76, -0.14) 0.02 (-0.05, 0.09) -5%  
    Stable heavy drinking 185 0.34 (0.95) -0.55 (-0.88, -0.22) -0.08 (-0.23, 0.07) 17%  
    Stable former drinking 685 -0.10 (0.96) -0.50 (-0.82, -0.17) -0.03 (-0.12, 0.07) 6%  
    Mostly low-to-moderate drinking 1068 0.19 (0.98) -0.50 (-0.82, -0.18) -0.04 (-0.12, 0.05) 7%  
    Mostly heavy drinking 492 0.34 (0.98) -0.51 (-0.83, -0.19) -0.04 (-0.15, 0.06) 9%  
    Mostly former drinking 1599 0.03 (0.95) -0.49 (-0.8, -0.17) -0.02 (-0.10, 0.06) 4%   
 Digit Symbol Substitution z-score 8691 0.17 (0.79)         
    Stable never drinking 1045 0.07 (0.78) -0.78 (-1.06, -0.51) Reference Reference 0.114 
    Stable low-to-moderate drinking 3134 0.36 (0.75) -0.84 (-1.11, -0.56) -0.05 (-0.12, 0.01) 7%  
    Stable heavy drinking 184 0.14 (0.74) -0.86 (-1.15, -0.58) -0.08 (-0.22, 0.05) 10%  
    Stable former drinking 683 -0.20 (0.80) -0.77 (-1.05, -0.49) 0.02 (-0.08, 0.11) -2%  
    Mostly low-to-moderate drinking 1066 0.15 (0.80) -0.83 (-1.1, -0.56) -0.05 (-0.13, 0.03) 6%  
    Mostly heavy drinking 492 0.25 (0.76) -0.89 (-1.18, -0.61) -0.11 (-0.21, -0.01) 14%  
    Mostly former drinking 1597 0.05 (0.79) -0.80 (-1.07, -0.53) -0.02 (-0.09, 0.05) 2%   
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4; 1996-1998) z-score. Negative values correspond to 
greater decline compared to the reference (stable never drinker).  All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the 
variance of a function of the within and between completed data set variances. CI, confidence interval. Adjusted for age, age squared, sex, race-center, education 
attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. † 
Percent, positive values represent % greater decline relative to the referent group. P for difference, p-value for t-test of equality of mean difference in 15-year change in 






Table 27. Adjusted mean difference in 15-year change in cognitive performance by quartiles of cumulative average ethanol intake for 
Atherosclerosis Risk in Communities (ARIC) study African-American participants 
    Baseline Cognitive Score 15-Year Decline Difference*     
Test/Quartile‡ N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† P for trend 
Global Factor Score z-score 2342 -0.73 (0.75)         
   Quartile 1 300 -0.55 (0.75) -0.66 (-1.23, -0.09) Reference Reference 0.791 
   Quartile 2 271 -0.56 (0.79) -0.69 (-1.26, -0.11) -0.02 (-0.17, 0.13) 3%  
   Quartile 3 263 -0.66 (0.82) -0.67 (-1.24, -0.10) 0.00 (-0.15, 0.14) 1%  
   Quartile 4 279 -0.77 (0.79) -0.67 (-1.24, -0.10) -0.01 (-0.17, 0.15) 1%  
   P for difference      0.992 
Delayed Word Recall z-score 2340 -0.37 (1.11)         
   Quartile 1 301 -0.30 (1.08) -0.78 (-1.85, 0.28) Reference Reference 0.828 
   Quartile 2 270 -0.27 (1.11) -0.75 (-1.81, 0.32) 0.04 (-0.25, 0.32) -4%  
   Quartile 3 261 -0.38 (1.08) -0.86 (-1.90, 0.19) -0.07 (-0.38, 0.23) 9%  
   Quartile 4 279 -0.49 (1.21) -0.84 (-1.88, 0.20) -0.06 (-0.39, 0.27) 7%  
   P for difference      0.885 
Word Fluency z-score 2334 -0.39 (1.06)         
   Quartile 1 300 -0.15 (1.05) -0.64 (-1.23, -0.05) Reference Reference 0.712 
   Quartile 2 269 -0.24 (1.06) -0.62 (-1.2, -0.05) 0.02 (-0.13, 0.17) -2%  
   Quartile 3 259 -0.32 (1.14) -0.62( -1.21, -0.03) 0.02 (-0.14, 0.18) -3%  
   Quartile 4 279 -0.41 (1.08) -0.66 (-1.23, -0.09) -0.02 (-0.19, 0.15) 3%  
   P for difference      0.96 
Digit Symbol Substitution z-score 2325 -0.97 (0.94)         
   Quartile 1 299 -0.74 (0.91) -0.60 (-1.2, 0.00) Reference Reference 0.866 
   Quartile 2 267 -0.72 (0.94) -0.62 (-1.22, -0.03) -0.02 (-0.17, 0.13) 4%  
   Quartile 3 266 -0.90 (1.03) -0.58 (-1.17, 0.00) 0.02 (-0.14, 0.18) -3%  
   Quartile 4 273 -1.00 (0.97) -0.61 (-1.19, -0.03) -0.01 (-0.17, 0.16) 1%  
   P for difference      0.963 
‡ Global Factor Score z-score: Quartile 1: 0g/wk., Quartile 2: 2.7-26.4 g/wk., Quartile 3:  26.4-86.2 g/wk., and Quartile 4: 86.3-1559.4 g/wk.; Delayed Word Recall z-score: Quartile 1:  0 
g/wk., Quartile 2: 2.7-26.4 g/wk., Quartile 3: 26.4-85.8 g/wk., and Quartile 4: 86.1-1526.1 g/wk.; Word Fluency z-score: Quartile 1: 0 g/wk., Quartile 2: 2.7-26.4 g/wk., Quartile 3: 26.4-
85.8 g/wk., and Quartile 4: 86.0-1565.1 g/wk.; and Digit Symbol Substitution z-score: Quartile 1: 0 g/wk., Quartile 2: 2.7-26.4 g/wk., Quartile 3:  26.4-87.3 g/wk., and Quartile 4:  87.9-
1566.9 g/wk. 
All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the variance of a function of the within and between completed data set variances. 
CI, confidence interval. 
Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of stroke and the Apo 
lipoprotein E ε4 (APOE ε4) allele. 
† Percent, positive values represent % greater decline relative to the referent group. 
P for trend, p-value for trend obtained from a linear regression model with average ethanol intake across 9-years modeled as an ordinal variable.  P for difference-, p-value for t-test of 






Table 28. Adjusted mean difference in 15-year change in cognitive performance by quartiles of cumulative average ethanol intake for 
Atherosclerosis Risk in Communities (ARIC) study European-American participants 
    Baseline Cognitive Score 15-Year Decline Difference
*     
Test/Quartile‡ N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† P for trend 
Global Factor Score z-score 8709 0.12 (0.72)         
   Quartile 1 1706 0.21 (0.70) -0.84 (-1.10, -0.57) Reference Reference 0.831 
   Quartile 2 1520 0.25 (0.69) -0.84 (-1.10, -0.58) 0.00 (-0.06, 0.05) 1%  
   Quartile 3 1609 0.21 (0.70) -0.83 (-1.09, -0.57) 0.00 (-0.06, 0.06) -0.30%  
   Quartile 4 1612 0.09 (0.71) -0.87 (-1.13, -0.60) -0.03 (-0.09, 0.03) 4%  
   P for difference      0.637 
Delayed Word Recall z-score 8706 0.06 (1.00)         
   Quartile 1 1704 0.15 (0.96) -1.46 (-2.05, -0.86) Reference Reference 0.394 
   Quartile 2 1518 0.12 (0.99) -1.44 (-2.02, -0.86) 0.02 (-0.10, 0.14) -1%  
   Quartile 3 1611 0.08 (0.98) -1.40 (-1.99, -0.81) 0.06 (-0.06, 0.18) -4%  
   Quartile 4 1612 0.00 (1.03) -1.50 (-2.09, -0.92) -0.05 (-0.17, 0.08) 3%  
   P for difference      0.342 
Word Fluency z-score 8702 0.14 (0.95)         
   Quartile 1 1704 0.14 (0.91) -0.53 (-0.85, -0.21) Reference Reference 0.531 
   Quartile 2 1517 0.25 (0.93) -0.52 (-0.84, -0.20) 0.01 (-0.06, 0.08) -2%  
   Quartile 3 1611 0.24 (0.97) -0.52 (-0.83, -0.20) 0.02 (-0.05, 0.08) -3%  
   Quartile 4 1610 0.23 (1.00) -0.56 (-0.88, -0.23) -0.02 (-0.09, 0.04) 5%  
   P for difference      0.641 
Digit Symbol Substitution z-score 8691 0.17 (0.79)         
   Quartile 1 1702 0.27 (0.78) -0.80 (-1.07, -0.52) Reference Reference 0.892 
   Quartile 2 1524 0.30 (0.77) -0.80 (-1.08, -0.53) -0.01 (-0.06, 0.05) 1%  
   Quartile 3 1603 0.27 (0.77) -0.79 (-1.06, -0.51) 0.01 (-0.04, 0.06) -1%  
   Quartile 4 1607 0.10 (0.77) -0.82 (-1.10, -0.54) -0.02 (-0.09, 0.04) 3%  
   P for difference      0.701 
‡ Global Factor Score z-score: Quartile 1: 0 g/wk., Quartile 2:  2.7-24.0 g/wk., Quartile 3:  24.3-80.2 g/wk., and Quartile 4: 80.3-1071.5 g/wk.; Delayed Word Recall z-score: Quartile 1:  0 
g/wk., Quartile 2:  2.7-24.0 g/wk., Quartile 3: 24.0-80.2 g/wk., and Quartile 4: 80.2-1072.8 g/wk.; Word Fluency z-score: Quartile 1: 0 g/wk., Quartile 2: 2.7-24.0 g/wk., Quartile 3: 24.0-80.2 
g/wk., and Quartile 4: 80.3-1071.5 g/wk.; and Digit Symbol Substitution z-score: Quartile 1:  0 g/wk., Quartile 2: 2.7-24.3 g/wk., Quartile 3: 24.3-80.1 g/wk., and Quartile 4:  80.2-1072.8 
g/wk..  
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4;1996-1998) z-score. Negative values correspond to greater decline 
compared to the reference (lowest quartile).  
All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the variance of a function of the within and between completed data set variances. 
CI, confidence interval. 
Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of stroke and the Apo 
lipoprotein E ε4 (APOE ε4) allele. 
† Percent, positive values represent % greater decline relative to the referent group. 
P for trend, p-value for trend obtained from a linear regression model with average ethanol intake across 9-years modeled as an ordinal variable.  P for difference-, p-value for t-test of 






Table 29. Adjusted mean difference in 15-year change in cognitive performance by visit 4 ethanol intake status for Atherosclerosis Risk 
in Communities (ARIC) study African-American participants 
    Baseline Cognitive Score 15-Year Decline Difference*     
Test/Drinking status at visit 4 N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† P for difference 
Global Factor Score z-score 2342 -0.73 (0.75)         
      Never drinking 817 -0.85(0.71) -0.53 (-0.91, -0.15) Reference Reference 0.697 
      Low-to-moderate drinking 531 -0.55(0.77) -0.52 (-0.90, -0.14) 0.01 (-0.10, 0.13) -2%  
      Heavy drinking 78 -0.62(0.91) -0.40 (-0.82, 0.03) 0.13 (-0.09, 0.35) -25%  
      Former drinking 915 -0.75(0.74) -0.52 (-0.90, -0.14) 0.01 (-0.09, 0.11) -1%   
Delayed Word Recall z-score 2340 -0.37 (1.11)         
      Never drinking 816 -0.39(1.12) -0.95 (-1.72, -0.18) Reference Reference 0.814 
      Low-to-moderate drinking 530 -0.31(1.16) -0.86 (-1.63, -0.09) 0.09 (-0.12, 0.31) -10%  
      Heavy drinking 78 -0.38(1.13) -0.79 (-1.62, 0.04) 0.16 (-0.30, 0.62) -17%  
      Former drinking 916 -0.38(1.06) -0.89 (-1.65, -0.12) 0.06 (-0.13, 0.26) -6%   
Word Fluency z-score 2334 -0.39 (1.06)         
     Never drinking 814 -0.53(1.02) -0.40 (-0.83, 0.03) Reference Reference 0.609 
     Low-to-moderate drinking 529 -0.16(1.1) -0.34 (-0.77, 0.10) 0.06 (-0.06 ,0.18) -16%  
     Heavy drinking 77 -0.28(1.13) -0.27 (-0.75, 0.22) 0.13 (-0.12, 0.38) -33%  
     Former drinking 914 -0.41(1.05) -0.38 (-0.80, 0.05) 0.02 (-0.08, 0.13) -6%   
Digit Symbol Substitution z-score 2325 -0.97 (0.94)         
     Never drinking 812 -1.13(0.91) -0.26 (-0.69, 0.17) Reference Reference 0.614 
     Low-to-moderate drinking 528 -0.74(0.94) -0.32 (-0.74, 0.11) -0.06 (-0.17, 0.06) 21%  
     Heavy drinking 77 -0.75(1.06) -0.27 (-0.74, 0.20) -0.01 (-0.23, 0.22) 3%  
     Former drinking 908 -0.98(0.92) -0.32 (-0.74, 0.10) -0.06 (-0.15, 0.03) 22%   
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4;1996-1998) z-score. Negative values correspond to 
greater decline compared to the reference (never drinker).  
All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the variance of a function of the within and between completed 
data set variances. 
CI, confidence interval 
Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of 
stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. 
† Percent, positive values represent % greater decline relative to the referent group. 









Table 30. Adjusted mean difference in 15-year change in cognitive performance by visit 4 ethanol intake status for Atherosclerosis 
Risk in Communities (ARIC) study European-American participants 
    Baseline Cognitive Score 15-Year Decline Difference
*     
Test/Drinking status at visit 4 N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† P for difference 
Global Factor Score z-score 8709 0.12 (0.72)         
      Never drinking 1450 -0.02 (0.70) -0.84 (-1.07, -0.61) Reference Reference 0.072 
      Low-to-moderate drinking 4247 0.25 (0.69) -0.83 (-1.06, -0.59) 0.01 (-0.04, 0.07) -1%  
      Heavy drinking 629 0.23 (0.69) -0.90 (-1.14, -0.65) -0.06 (-0.15, 0.03) 7%  
      Former drinking 2383 -0.05 (0.72) -0.80 (-1.04, -0.57) 0.04 (-0.02, 0.10) -4%   
 Delayed Word Recall z-score 8706 0.06 (1.00)         
    Never drinking 1450 0.01 (1.01) -1.37 (-1.91, -0.83) Reference 
 
0.177 
    Low-to-moderate drinking 4246 0.12 (0.98) -1.36 (-1.89, -0.83) 0.02 (-0.09, 0.13) -1%  
    Heavy drinking 627 0.15 (1.01) -1.53 (-2.08, -0.98) -0.16 (-0.34, 0.03) 11%  
    Former drinking 2383 -0.02 (1.03) -1.38 (-1.91, -0.84) 0.00 (-0.13, 0.12) 0.40%   
 Word Fluency z-score 8702 0.14 (0.95)         
    Never drinking 1450 -0.11 (0.90) -0.43 (-0.74, -0.12) Reference Reference 0.323 
    Low-to-moderate drinking 4245 0.27 (0.95) -0.43 (-0.73, -0.13) 0.00 (-0.07, 0.06) 1%  
    Heavy drinking 628 0.36 (0.96) -0.50 (-0.80, -0.20) -0.07 (-0.17, 0.02) 17%  
    Former drinking 2379 -0.01 (0.95) -0.45 (-0.75, -0.15) -0.03 (-0.09, 0.04) 6%   
Digit Symbol Substitution z-score 8691 0.17 (0.79)         
    Never drinking 1447 0.03 (0.78) -0.77 (-1.04, -0.50) Reference Reference 0.026 
    Low-to-moderate drinking 4242 0.30 (0.77) -0.81 (-1.07, -0.55) -0.04 (-0.10, 0.02) 5%  
    Heavy drinking 627 0.24 (0.75) -0.87 (-1.15, -0.6) -0.10 (-0.19, -0.02) 13%  
    Former drinking 2375 -0.02 (0.80) -0.77 (-1.04, -0.51) 0.00 (-0.06, 0.06) 0%   
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4;1996-1998) z-score. Negative values 
correspond to greater decline compared to the reference (never drinker).  
All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the variance of a function of the within and between completed 
data set variances. 
CI, confidence interval. 
Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history 
of stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. 
† Percent, positive values represent % greater decline relative to the referent group. 


















Figure 10. Estimated mean difference in the 15-year change in cognitive performance by long-term trajectories of ethanol intake in mid-life relative 
to those who reported stable never drinking 
All models were adjusted for sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), 
diabetes, history of stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. All estimates were averages from 25 rounds of multiple imputation 
combined using Rubin’s rule and the variance of a function of the within and between completed data set variances. Abbreviations: SNVR, stable 
never drinker; SLTM, stable low-to-moderate drinker; SHVY, stable heavy drinker; SFMR, stable former drinker; MLTM, mostly low-to-moderate 
drinker; MHVY, mostly heavy drinker; MFMR, mostly former drinker; DWRT, delayed word recall test; DSST, digit symbol substitution test; and 
WFT, word fluency test. Sample sizes: African-Americans (global cognition, n=2342; DWRT, n=2340; WFT, n=2334; and DSST, n=2325) and 










Background: Previous reports of the relationship between ethanol intake and cognitive decline 
have been inconsistent, yet possible interaction between ethanol intake and genetic susceptibility on the 
risk of cognitive decline has often not been considered.  
Objective:  To investigate whether unweighted genetic risk scores (GRSs) based on ethanol 
intake-associated single nucleotide polymorphisms (SNPs) modify the relationship between weekly 
ethanol intake in mid-life and 15-year rate of decline in general cognitive performance from mid-to-late 
life among African-American and European-American adults.  
Methods: A total of 9,183 participants (n=1,733 African-Americans and n=7,450 European-
Americans) of the Atherosclerosis Risk in Communities (ARIC) study completed an interviewer-
administered questionnaire on habitual ethanol intake and neurocognitive assessments at 1996 and 2013. 
Twenty ethanol intake-associated SNPs  for African-Americans and 11 for European-Americans served to 
create unweighted GRSs, uGRS20 and  uGRS11, respectively.  Multivariable linear regression was used to 
assess modification of the ethanol intake-cognitive decline association by uGRS20 and uGRS11. Multiple 
imputation by chained equations (MICE) were used to account for attrition.  
Results: Ethanol intake (log grams per week) in mid-life was not associated with 15-year decline 
in general cognitive performance from mid-to-late life (African-American: β for log-ethanol intake (log 
grams per week)= -0.011 ( (95% CI: -0.052,0.031), European-Americans: -0.010 (-0.021,0.002)). The  
uGRS20 and uGRS11 did not modify the association of ethanol intake in mid-life with 15-year change in 
general cognitive performance from mid-to-late life among African-Americans (P= 0.811) and European-
Americans (P= 0.847), respectively.  
Conclusions: Ethanol intake in mid-life is not associated with cognitive decline from mid-to-late. 
There is no indication that an association between ethanol intake and cognitive depends on genetic 






Reports from prospective studies on the relationship between ethanol intake and cognitive decline 
have been inconsistent [32, 93, 336-348]. While heavy ethanol intake is associated with greater cognitive 
decline [348], low-to-moderate ethanol intake has been associated with less cognitive decline [336, 339, 
340, 342-344, 346, 347] or  no cognitive decline [93, 345, 348]. Inconsistent findings may be attributable 
to potential effect modifiers that were not taken into account.  A limited number of studies have 
investigated the effects of ethanol in African-Americans populations even though the prevalence, 
incidence, and cumulative risk of Alzheimer’s Dementia (AD) is documented to be higher in African-
Americans than in European-Americans [343, 347]. Furthermore, few studies investigated the effects of 
mid-life ethanol intake with late-life cognition [341, 348].  
Genome-wide association studies (GWAS) have shown that ethanol intake is influenced by 
hundreds of common genetic variants [383]. Recently, the GWAS & Sequencing Consortium of Alcohol 
and Nicotine Use (GSCAN) study of 941,280 participants of European ancestry, identified 100 single 
nucleotide polymorphisms (SNPS) in 82 genetic loci to be independently associated with number of drink 
per week [400]. Little is known about the effect of these genetic variants in other populations such as 
African-Americans. It is well known that SNPs identified in European descent individuals do not transfer 
well to African ancestry populations, especially given the differences in linkage disequilibrium (LD) 
across ancestral populations. To date, only one study has investigated the modification of the ethanol 
intake-cognitive decline relationship by genetic variants identified by GWAS to be associated with 
ethanol intake [381]. This study was conducted in a primarily white European ancestry sample. The 
purpose of this investigation is to determine if ethanol intake-associated loci modify the association 
between  ethanol intake in mid-life and 15-year cognitive decline from mid-to-late life in American-









The Atherosclerosis Risk in Communities (ARIC) study is a community-based, prospective 
cohort study established in 1987, designed primarily to investigate the etiology of atherosclerosis and its 
clinical sequelae. From 1986 through 1990, 15,792 adults aged 45 to 64 years were recruited through 
probability sampling from 4 U.S. communities: Washington County, Maryland; Forsyth County, North 
Carolina; the suburbs of Minneapolis, Minnesota; and Jackson, Mississippi. Participants were seen at 4 
study visits approximately 3 years apart from 1987-1989 through 1996-1998, and a fifth examination visit 
in 2011-2013 (Figure 11). All study participants provided written informed consent, and study protocols 
were approved by the relevant institutional review boards.  
The baseline for the present analysis was visit 4, which allows for the investigation of the 
association of ethanol intake in mid-life and subsequent 15-year cognitive decline from mid-to-late life, 
and assessment of modification of this association by genetic variants that are associated with weekly 
ethanol intake (Figure 11).  Of the 9,576 African-American and European-American participants for 
whom we had genetic data at visit 4, we excluded participants who were missing general cognitive 
function measures  at study baseline (n=354), and those with missing covariates (n=39), giving a final 
sample size of 9,183 participants at study baseline. 
Exposures 
Assessment of Ethanol Intake 
Ethanol intake was assessed at all visits by means of an interviewer-administered questionnaire 
(Figure 11) [448].  Participants were asked if they currently or formerly drank alcoholic beverages. 
Current drinkers were asked how often they usually drank wine, beer, or hard liquor. The amount of 
ethanol consumed (in grams per week) was calculated assuming the following ethanol content: 4oz of 
wine = 10.8 grams; 12 oz. of beer = 13.2 grams; and 1.5 oz. of distilled spirits = 15.1 grams. Ethanol 
intake was recorded as 0 g/wk. for current drinkers having less than one drink per week. Total ethanol 





Assessment of Cognitive Function 
Cognitive function was assessed at visit 4 (1996-1998; ages 54-73) and visit 5 (as part of the 
ARIC-NCS) (2011-2013; ages 70-89 years) using 3 standardized cognitive tests to assess different 
domains of cognition: verbal learning and short-term memory, executive function and processing speed, 
and executive function and expressive language (Figure 11). 
Verbal learning and recent memory were assessed by the delayed word recall test (DWRT). 
Participants were asked to learn 10 nouns, and after a five-minute delay were given 60 seconds to recall 
the words. The  DWRT score is the number of words recalled  (0-10) [201]. Executive function and 
processing speed were assessed by the digit symbol substitution test (DSST). Participants were given 90 
seconds to  fill in blank squares with symbols corresponding to digits from 1 to 9 using a key that matches 
digits to symbols [199]. Executive function and expressive language were assessed by the word fluency 
test (WFT) , during which participants generate as many words starting with the letters F, A, and S as 
possible within 60 seconds, with one trial per letter [385]. The WFT score is the total number of 
acceptable words generated for the three letters [205]. All three tests were administered by trained 
examiners using standardized protocols in a quiet room. Recordings were reviewed for quality control. 
Using data from these tests in a factor analysis, factor scores for general cognitive performance 
were derived [387]. Briefly, the factor analysis is a structured approach for identifying common 
covariation between specific indicators, in this case the cognitive tests, to reduce measurement error when 
combining data across multiple cognitive tests. The interpretations of factor scores are similar to that for z 
scores because they were scaled to have a mean of 0 and standard deviation of 1 at ARIC visit 2 when the 
participant's cognitive function was first tested [387].  
 Covariates 
Age, sex, and educational attainment (< high school, high school, >high school), and smoking 
status (current, former, never) were assessed at visit 4 via self-report from the home interviews. Time 
spent in moderate to vigorous physical activity in MET-minutes/week was measured at  visits 1 and 3 





(Applied Biosystems, Foster City, California) [393, 394]. Body mass index (BMI) was calculated as 
weight (kg) divided by height squared (m2). Diabetes (yes, no) was defined as self-reported history of a 
physician’s diagnosis of diabetes, fasting blood glucose level of ≥126 mg/dL, or non-fasting blood 
glucose level of ≥200 mg/dL, or diabetes medication use in the past 2 weeks.  Stroke was defined by a 
self-reported history at visit one or an adjudicated event between visits 1 and 4 [396]. Dietary factors were 
assessed using an interviewer-administered 66-item FFQ measuring usual intake of foods over the past 
year. We calculated the Healthy Food Score, adapted from Steffen et al. described elsewhere [391, 392].  
SNP selection  
Genotyping 
ARIC study participants were imputed separately by race using IMPUTE2 [397] with the 1000 
Genomes Project phase 1 (March 2012) reference panel. Quality control excluded individuals based on 
single nucleotide polymorphism (SNP) mismatch, high discordance with previous TaqMan assay 
genotypes, genetic outlier status, and relatedness. SNPs with IMPUTE info score < 0.8 or minor allele 
frequency (MAF) < 0.05 were excluded. Only autosomal variants (on chromosomes 1–22) were 
considered [398]. Principal components analysis was used to estimate population substructure with 
EIGENSTRAT [399]. 
Investigation of previously reported GSCAN regions 
The GWAS & Sequencing Consortium of Alcohol and Nicotine Use (GSCAN) meta-analyses of  
941,280 participants of European ancestry from 34 studies, including the ARIC study, identified 100 
single nucleotide polymorphisms (SNPS) in 82 genetic loci to be independently associated with number 
of drinks per week (Appendix Table 1) [400]. In the ARIC 1000 Genome imputed dataset, 99 of the 100 
SNPs were available for ARIC European-American participants (Appendix Table 1), and 74 SNPs were 
available for ARIC African-American participants (Appendix Table 1).  
Replication of index variants  
Among ARIC European-American participants, we assessed the association between the 99 





SNPs, 11 SNPs direction of effect were consistent with the effect reported by GSCAN and were 
nominally significantly associated (P-value <0.05) with at least one measurement of weekly ethanol 
intake assessed across ARIC 1-4 (Appendix Table 4).  
Among ARIC African-American participants, we assessed the association between the 74 
GSCAN SNPs and weekly ethanol intake assessed at study baseline (Appendix Table 3).  We identified 
one SNP (rs12795042 (LOC646522)) that was nominally significantly associated with weekly ethanol 
intake at study baseline; however, the direction of effect for SNP s12795042 effect was not consistent the 
effect reported by GSCAN (Appendix Table 3). Consequently, this SNP was not included in our study. 
Identification of population appropriate tag SNPs 
To characterize the best tag SNP in ARIC African-American participants, we conducted fine-
mapping in the 1 MB region (± 500 kb windows surrounding each of the 99 GSCAN SNPs (index SNPs). 
Within each region, we identified the most strongly associated SNP with weekly ethanol intake at study 
baseline and in linkage disequilibrium (LD) (r2>0.2) with the index SNP. We identified a total of 92 
mostly strongly associated SNPs (Appendix Table 5). Of the 92 SNPs, 20 SNPs direction of effect were 
consistent with their index SNPs and were nominally significantly associated with at least one 
measurement of  weekly ethanol intake assessed across ARIC 1-4 (Appendix Table 6). Conditional 
analyses were performed and determined that 20 SNPs are independent of their GSCAN index SNPs 
(Appendix Table 7). These 20 SNPs were used to address Specific Aim 2 among ARIC African-American 
participants (Appendix Table 6). 
Genetic Risk Score 
 To study the cumulative effect of multiple gene loci, an unweighted genetic risk score (GRS)  for 
ethanol intake was computed for each study participant. Race-specific unweighted GRS were calculated 
by summing the number of ethanol intake risk alleles for the 20 SNPs for African-American participants 
(uGRS20), and 11 SNPs for European-American participants (uGRS11).  We defined a risk allele as the 
allele that is associated with a unit increase in log-ethanol intake level.  By construction, a higher GRS 







Missing data due to attrition were imputed by multiple imputation using chained equations 
(MICE)[401]. Missing ethanol intake and cognitive data across ARIC visits were imputed based on the 
observed values of key covariates for a given individual, as well as the relations observed in the data for 
other participants. To account for the uncertainty of the imputation and ensure correct standard error 
estimation [402], 25  datasets were imputed. Validation of the MICE approach for cognitive outcome in 
ARIC has been previously reported and it has been determined that MICE produced unbiased imputed 
values [403]. For this study, validation using observed data demonstrated MICE produces unbiased 
imputation of global cognition factor z-scores (Appendix Figure 1). 
 Statistical Modeling 
Our study outcome, fifteen-year cognitive performance change was calculated by subtracting visit 
4 cognitive performance z-score from visit 5 neurocognitive exam z-score. 
 To evaluate if the association between ethanol intake during mid-life and cognitive decline from 
mid-to-late life is modified by predisposition to ethanol intake, multivariable linear regression models 
were used and included the unweighted GRS, log-ethanol measured at study baseline, an interaction term 
between the unweighted GRS and log-ethanol intake, and covariates: age, age squared, sex, race-center, 
education attainment, smoking status, body mass index (BMI), diabetes, history of stroke, diet score, 
physical activity and APOE ε4 status. All models were race-stratified and further adjustments were made 
for principal components to account for population stratification.  
Statistical tests were 2-sided, and the test for statistically significant interaction was set a priori at 
P<0.10. However, adjustment for multiple testing using the Bonferroni method was performed for the 
interaction analyses based on single SNPs (African-Americans: P<0.005, European-Americans, P<0.009). 
Multiple Imputation were performed with  Stata15 (StataCorp, College Station, TX, USA) [423], 





results from each imputed data set were summarized using Rubin’s rule [424] into an overall estimate 
accounting for both within and between imputation variances. 
4. Results 
Description of Baseline Characteristics 
The mean age of participants at study baseline was 63 years (52-75 years), 56% were female, and 
19% were African-American (Table 31). Compared to European-Americans, African-Americans were 
less educated, had a higher proportion of current smokers (17.0% vs 14.2%), higher prevalence of 
diabetes (25.8% vs. 13.4%) and stroke (3.9% vs. 2.7%), and lower levels of physical activity (8.2 (11.9) 
vs.12.3 (13.5)). In addition, African-Americans had lower levels of weekly ethanol intake (15.9 (56.6) vs. 
38.3 (86.0)), lower prevalence of excessive drinking (6.5% vs. 7.2%), and lower general cognitive 
performance factor scores compared to European-American participants .  
The frequency distributions of uGRS20 and uGRS11 were approximately normally distributed (Figure 
12).  The mean for  uGRS20 was 12.1 (SD=2.7) for African-Americans, and the mean for  uGRS11 was 5.8 
(2.1) for European-American participants. Among African-American participants,  uGRS20 was associated 
with decreased ethanol intake at study baseline (β= -0.032, P=0.019) (Appendix Table 8) and explained 
approximately 0.30% of the variation in ethanol intake at study baseline. Among European-American 
participants, uGRS11 was associated with increased ethanol intake at study baseline (β=0.023, P=0.041) 
(Appendix Table 9) and  explained approximately 0.06% of the variation in  ethanol intake at study 
baseline. 
Association of log-ethanol intake and 15-year cognitive decline 
 The association between log-ethanol intake in mid-life and 15-year change in general cognitive 
performance from mid-to-late life is presented in Table 32. The multivariable linear regression models do 
not support an association between log-ethanol intake and 15-year change in general cognitive 
performance (African-American: β for log ethanol intake (log grams per week)= -0.011 (95% CI: -






Interaction between log-ethanol intake and 15-year cognitive decline                                                          
Results from the multivariable linear regression models suggest no interaction of uGRS20 with log-
ethanol intake in mid-life on 15-year change in general cognitive performance from mid-to-late life 
among African-American participants (P=0.811) (Table 33).  No interaction was observed of uGRS11 and 
log-ethanol intake in mid-life on 15-year change in general cognitive performance from mid-to-late life 
among European-American participants (P=0.847) (Table 33). 
Furthermore, after adjustment for multiple testing, no significant interaction was observed for any of 
the individual SNPs in relations to 15-year change in general cognitive performance among African-
American (Appendix Table 16) and European-American participants (Appendix Table 17). 
5. Discussion 
 
This study investigated the association between ethanol intake in mid-life and 15-year change in 
general cognitive performance from mid-to-late life, and possible effect modification by genetic 
predisposition to ethanol intake. We found no evidence that ethanol intake in mid-life is associated with 
lesser 15-year cognitive decline from mid-to-late life. In addition, we found no evidence that the 
association between ethanol intake at mid-life and 15-year change in general cognitive performance from 
mid-to-late life  is modified by an unweighted genetic risk score of ethanol intake-associated SNPs, or by 
any individual SNPs that is associated with ethanol intake among African-American and European-
American participants. 
The mechanisms underlying the association of ethanol intake and cognitive decline are complex. 
Low-to-moderate ethanol intake is hypothetically associated with cognitive decline through 
cerebrovascular and cardiovascular pathways, involving effects that play out over an extended period of 
time [324, 439]. Heavy ethanol intake on the other hand has detrimental short- and long-term effects on 
the brain [440, 441],  including direct neurotoxic effect [441], proinflammatory effects [441, 442], and 





 Results from cross-sectional studies on the relationship between ethanol intake and cognitive 
function have been mixed, with several suggesting a protective effect of moderate ethanol intake on 
cognitive function [444-446]. To be considered, cross-sectional studies are open to bias due to reverse 
causation and are susceptible to selection bias and residual confounding[449].  A cross-sectional analysis 
of the association of ethanol intake with MRI-defined cerebral abnormalities conducted in the 
Atherosclerosis Risk in Community (ARIC) study reported no significant neuroprotective effect of low-
to-moderate ethanol intake on white matter grade in men and women in middle-aged adults [447].  
 Findings on the relationship between ethanol intake and cognitive decline reported by prospective 
studies also have been inconsistent [32, 93, 336-348]. Our results add to the knowledge base by 
overcoming some of the limitations of previous studies, which includes short follow-up times (<5 years), 
homogeneous study populations (primarily white Europeans), and an analytic approach that does not 
appropriately consider effect modifiers and attrition.   
Our observation of a lack of association of ethanol intake in mid-life with 15-year cognitive 
decline from mid-to late life is consistent with the results reported by the Lothian Birth Cohort 1936 
Study of 1,079 white European participants, which examined the association between ethanol intake in 
late-life and lifetime cognitive change in cognitive ability, and possible effect modification by a four-SNP 
score  indexing alcohol dehydrogenase activity (ADH7 rs284779, ADH1B rs4147536, ADH1A rs975833 
and ADH1A rs2866151) [381].In contrast to our study results, a significant interaction between ethanol 
intake in late-life and a four-SNP score influenced lifetime change in cognitive ability in the Lothian 
Birth Cohort 1936 study (interaction beta parameter estimate= -1.13, p=0.007).  Unlike our study that 
investigated ethanol intake during mid-life, the Lothian Birth Cohort 1936  study examined ethanol intake 
measured in late-life, a period that may not reflect the most critical exposure window for disease risk and 
that may be influenced by other medical conditions developing in later life [450]. Adding uncertainty, 
cognitive function was measured ages at ~11 years and ~70 years in the Lothian Birth Cohort 1936 study. 





Previous studies provide evidence that genetic risk scores (GRS) derived from European-based 
GWAS are biased towards Europeans and are less accurate and predictive when applied to 
racially/ethnically diverse populations [451]. As a result, race-specific GRSs were created to measure an 
individual’s predisposition to ethanol intake among ARIC African-American and European-American 
participants. However, our GRS have not been validated in other populations and likely overestimate the 
effect of these variants in the population. Validation of the GRS developed in ARIC African-American 
participant is needed in a separate dataset to prove that the GRS did not overfit this study’s data and 
produced inflated results [452]. Moreover, we acknowledge that genotyping arrays considered herein are 
European biased. Nonetheless, it is well-established that GRSs are statistically powerful for detection of 
gene-environment (GxE) interactions in comparison to the common univariate single-variant 
approaches[453, 454].  
Limitations and Strengths 
Several limitations of this study should be mentioned. The lack of association between ethanol 
intake in mid-life and cognitive decline in general cognitive performance from mid-to-late life observed 
in our study may be the result of measurement variability, such as in the assessment of ethanol intake, 
which could have attenuated the effect estimates. The use of a standardized instrument administered by 
trained personnel and the availability of repeat measurements mitigates this concern. Cohort attrition over 
the prolonged follow up could have biased an association toward the null, if differentially related to 
ethanol intake [455]. No clear pattern of association of ethanol intake with attrition was observed, and 
sensitivity analysis indicated that missing data patterns were effectively corrected by MICE imputation.  
The low prevalence of heavy drinking in our study population limited our ability to estimate the impact of 
heaving drinking on cognitive performance over time. The unweighted GRS for African-American 
(0.30%) and European-American (0.06%) participants only explain a modest proportion of the total 
variation in weekly ethanol intake. Given the modest sample size, this study may be insufficiently 





European-American participants. Lastly, although community-based our results emerge from 4 
geographically defined, closed cohorts and may not widely generalize to other populations.  
Strengths of this study include the large population-based probability sample of middle-aged 
African Americans and European-Americans, a prospective design with 15 years of follow-up with 
repeated measurements of ethanol intake and well-characterized cognitive function. Ethanol intake was 
assessed using an instrument with beverage-specific questions (thus reducing under-reporting) that 
differentiated never from former drinkers. The rich covariate data that allowed adjustment of lifestyle, 
genetic, and clinical risk factors is a further strength. The potential of population stratification was 
addressed by controlling for principal components all analyses.  
6. Conclusion 
This results from this study suggest that ethanol intake in mid-life is not associated with cognitive 
decline from mid-to late-life among African-American and European-American adults. Furthermore, this 
study suggests the association of ethanol intake with cognitive decline is not influenced by genetic 















7. Main Tables and Figures 
 
 


















Table 31. Population characteristics, by race ethnicity, Atherosclerosis Risk in Communities 





Americans Total  
Characteristics (N=1733) (N=7450) (N=9183) 
Age (years), mean (SD) 61.8 (5.7) 63.1 (5.6) 62.8 (5.7) 
Female, n (%) 5105 (55.6) 1125 (64.9) 3980 (53.4) 
Study center, n (%)    
    Forsyth County, NC 182 (10.5) 2109 (28.3) 2291 (24.9) 
    Jackson, MS 1551 (89.5  1551 (16.9) 
    Minneapolis, MN  2842 (38.1) 2842 (30.9) 
    Washington County, MD    
Education, n (%)  2499 (33.5) 2499 (27.2) 
  Less than high school   506 (29.2) 3390 (45.5) 3896 (42.4) 
  High school, GED, or vocational school 590 (34.0) 1012 (13.6) 1602 (17.4) 
  College, graduate, or professional school  637 (36.8) 3048 (40.9) 3685 (40.1) 
Smoking, n (%)    
    Never Smokers 797 (46.0) 2953 (39.6) 3750 (40.8) 
    Former Smokers 642 (37.0) 3436 (46.1) 4078 (44.4) 
    Current Smokers 294 (17.0) 1061 (14.2) 1355 (14.8) 
Body Mass Index (kg/m2), mean (SD) 30.8 (6.4) 28.3 (5.3) 28.8 (5.6) 
Diabetes, n (%) 447 (25.8) 1001 (13.4) 1448 (15.8) 
Hypertension, n (%) 1005 (58.0) 2435 (32.7) 3440 (37.5) 
History of Stroke, n (%) 67 (3.9) 203 (2.7) 310 (3.2) 
Diet score, mean (SD) 20.2 (6.0) 20.8 (5.3) 20.7 (5.5) 
Physical activity (met-min/week), mean (SD) 8.2 (11.9) 12.3 (13.5) 11.6 (13.3) 
APOEε4 allele present, n (%)  675 (38.9) 1987 (26.7) 2662 (29.0) 
Ethanol Intake (Grams/Week), mean (SD) 15.9 (56.6) 38.3 (86.0) 34.0 (81.7) 
History of excessive drinking *, n (%) 113 (6.5) 533 (7.2) 646 (7.0) 
General cognitive function factor score, mean 
(SD) -0.73 (0.74) 0.13 (0.71) 
-0.04 
(0.79) 
† Counts and percentage were calculated based on data prior to imputation for missing ethanol intake data for 
Atherosclerosis Risk in Communities (ARIC) Study visits 1-4. 
Abbreviations: SD, standard deviation; n, number of participants; %, percent; NC, North Carolina, MS, 
Mississippi; GED, general educational development; kg/m2, grams per meter squared; met-min/week, 
metabolic equivalent of task per week; APOEε4, apolipoprotein epsilon 4 allele; g/wk., grams per week; self-
reported at visit 3. “Was there ever a time in your life when you consumed 5 or more drinks of any kind of 











Figure 12. Distribution of the unweighted genetic risk score for Atherosclerosis Risk in Communities (ARIC) 






















Table 32. Linear regression model results for the association of log ethanol intake at study baseline with 
15-cognitive change from ARIC visits 4 and 5, by race  
Race/Ethnicity N Beta (95% CI) SE P-value 
African-Americans 1733 -0.011 (-0.052,0.031) 0.021 0.619 
European-Americans 7450 -0.010 (-0.021,0.002) 0.006 0.089 
All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the variance 
of a function of the within and between completed data set variances. 



























Table 33. Linear regression results for the interaction of the unweighted genetic risk score (GRS) x log-
ethanol intake interaction in relation to 15-year cognitive change in general cognitive performance, by 
race* 
Race/Ethnicity  βE PE  βGRS PGRS  βGRSXE PGRSXE 
African-Americans 0.008 0.901 -0.007 0.432 -0.001 0.811 
European-Americans -0.010 0.457 -0.001 0.822 -0.0004 0.847 
* Unweighted genetic risk score (GRS) was created by summing together the number of ethanol intake ‐increasing 
alleles for 20 single nucleotide polymorphism (SNPs) among African-Americans and 11 SNPs among European-
Americans that are associated with weekly ethanol intake  
All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the variance of 
a function of the within and between completed data set variances. 
Abbreviations:  βE, estimate for log-ethanol intake with corresponding p-value (PE) ; βGRS, estimate for the unweighted 
GRS with corresponding p-value (PGRS);  βGRSXE, estimate for the interaction term between the unweighted GRS and 
log-ethanol intake with corresponding p-value (PGRSXE) 
Adjusted for age, sex, race-center, education attainment, smoking status, body mass index (BMI), diabetes, history of 


















CHAPTER VI: CONCLUSIONS 
6.1. Recapitulations of Specific Aims 
Cognitive impairment is a growing public health problem in the U.S. due to a rapidly aging and 
increasingly diverse population [1]. To reduce associated disability and morbidity [2], caretakers’ burden 
[3-7], and high health care costs [8], it is important to identify and intervene upon modifiable factors that 
may prevent or reduce the risk of cognitive impairment. One such factor is ethanol use, which has a high 
prevalence of use (70%) and misuse (14%)  in the U.S. [9]. The relationship between ethanol intake and 
cognitive decline has been studied extensively, but findings have been inconsistent. While heavy ethanol 
intake is associated with greater cognitive decline [348], low-to-moderate ethanol intake has been 
associated with less cognitive decline [336, 339, 340, 342-344, 346, 347] or  no cognitive decline [93, 
345, 348].  Limitations of previous studies include 1) single measurement of ethanol intake  [93, 336, 
339-341, 344-347] that does not capture changes in  individuals’ drinking habits over time [432, 433], 
which may affect their risk of developing disease [434, 435]; 2) the assessment of ethanol intake late in 
life, a period that may not reflect the most critical exposure window for disease risk and that may be 
influenced by other medical conditions developing in later life; and 3) not taking potential confounders 
and effect modifiers into account. In addition, few studies have been conducted in diverse populations 
despite their disproportionate burden of Alzheimer’s disease and other forms of cognitive impairment.  
Therefore, the goal of this doctoral research was to provide clear antecedent-consequent estimates 
of the ethanol intake-cognitive decline association by studying the relationship of long-term patterns of 
ethanol intake in mid-life and cognitive decline from mid-to-late life, and to inform mechanisms by which 
ethanol affects cognition by exploring possible effect modification of this association by ethanol intake-
associated genetic variants. To achieve this goal, we: 1) Characterized the temporal trajectories of ethanol 





term trajectories of ethanol intake in mid-life were associated with 15-year rate of decline in cognition 
from mid-to-late life among African-American and European-American adults; and 2) evaluated the 
evidence for the effect modification of the ethanol intake-cognitive decline relationship by ethanol intake 
associated SNPs in African-American and European-American men and women from mid-to-late life. 
We addressed our study aims using data from the Atherosclerosis Risk in Communities (ARIC) 
study, a large population-based probability sample of middle-aged African-Americans and European-
Americans recruited from 4 U.S. communities in 1987-1989 and followed through 2013. Participants had 
repeated assessment of ethanol intake by an interviewer-administered questionnaire [169] and assessment 
of cognitive function at two time points using 3 cognitive tests that assessed different domains of 
cognition.  In addition, participants were well-characterized on lifestyle and clinical risk factors. Genetic 
data was available for the majority of participants.  
6.2. Main Findings 
The final analytic sample for Specific Aim 1 included 10,876 (n=2,169 African-Americans, 
n=8,707 European-Americans) participants of the ARIC study who completed repeated assessments of 
ethanol intake using an interviewer-administered questionnaire across a 9-year interval (1987-1998) and 
two neurocognitive examinations at 1996 and 2013. We found no evidence that stable low-to-moderate 
drinking and mostly low-to-moderate alcohol consumption in mid-life was associated with l5-year 
cognitive decline from mid-to-late life compared to stable never drinking, after adjustment for attrition. In 
addition, we found no evidence that stable heavy drinking, mostly heavy drinking, stable former drinking, 
and mostly former drinking were associated with greater 15-year cognitive decline from mid-to-late life, 
after adjustment for attrition. In contrast, the 15-year change in digit symbol substitution test (a test of 
executive function and processing speed) for mostly heavy drinkers was slightly higher than that of stable 
never drinkers, equivalent to a 14% greater decline.  No association was found for ethanol intake 
averaged across 9 years during mid-life and 15-year cognitive decline from mid-to-late life. Further, we 
did not observe an association of ethanol intake at baseline with 15-year cognitive decline, except for 





year rate of change for heavy drinkers was slightly higher than never drinkers at study baseline, 
equivalent to a 13% greater decline. We observed similar declines in cognitive performance for stable 
drinking categories and drinking categories measured at study baseline in African-Americans and 
European-Americans. Overall, a slightly lower rate of decline was observed among African-Americans. 
The final analytic sample for Specific Aim 2 included 9,183 participants (n=1,733 African-
Americans and n=7,450 European-Americans) who had genetic data available.  At study baseline, we 
observed lower levels of weekly ethanol intake, lower prevalence of excessive drinking, and lower 
general cognitive performance factor score among African-Americans compared to European-American 
participants. We found no evidence that ethanol intake in mid-life is associated with lesser 15-year 
cognitive decline from mid-to-late life. In addition, we found no evidence that the association between 
ethanol intake at mid-life and 15-year change in general cognitive performance from mid-to-late life  is 
modified by an unweighted genetic risk scores of ethanol intake-associated SNPs or by any individual 
SNPs that is associated with ethanol intake among African-American and European-American 
participants. 
6.2.1. Strengths 
Our study is the second prospective study to examine the association between ethanol intake and 
cognitive decline using repeated measurements of ethanol intake. It is the only study to examine the 
association of long-term patterns of ethanol in mid-life and cognitive decline from mid-to-late life in 
African-American and European-American populations. Strengths of this study include the large 
population-based bi-racial probability sample of middle-aged African-Americans and European-
Americans, a prospective design with 15 years of follow-up with repeated measurements of ethanol intake 
and well-characterized cognitive function in 3 cognitive domains. Ethanol intake was assessed using an 
instrument with beverage-specific questions that differentiated never from former drinkers. Additionally, 
we had rich covariate data that allowed adjustment of lifestyle, genetic, and clinical risk factors.  
We were also able to address an additional limitation of previous studies, namely accounting for 





Our study was only the second study to evaluate for effect modification of the association of ethanol 
intake and cognitive decline by ethanol intake-associated genetic variants, although it is the first study to 
evaluate for effect modification using mid-life ethanol intake as exposure and the first to be conducted in 
an African-American population.  As our understanding of the molecular mechanisms that regulate and 
metabolize ethanol continues to grow, studies like ours will grow in importance. Further strengths of this 
study include the measurement of ethanol intake by an interviewer-administered questionnaire, repeated 
measurements of cognitive decline which allowed the study of changes in cognitive function from mid-to-
late life, and detailed assessments of lifestyle, genetic, and clinical risk factors.  Additional strengths of 
this study include the availability of quality-controlled genetic variants in most study participants, and the 
ability to address the potential of population stratification by controlling for principal components in all 
analyses. 
6.2.2. Limitations 
Several limitations should also be highlighted. The observation of a lack of association between 
ethanol intake in mid-life and cognitive decline in general cognitive performance from mid-to-late life 
could be the result of error in the measurement of ethanol intake, that may have attenuated the effect 
estimates; however, the use of a standardized instrument administered by trained personnel and the 
availability of repeat measurements mitigates this concern. Cohort attrition over the prolonged follow up 
could have biased an association toward the null, if non-differentially related to ethanol intake [455]. No 
clear pattern of association of ethanol intake with attrition was observed, and sensitivity analysis indicated 
that missing data patterns were effectively corrected by MICE imputation.  The low prevalence of heavy 
drinking in our study population limited our ability to estimate the impact of heaving drinking on 
cognitive performance over time. In addition, although the genetic risk scores were based on information 
from well-established ethanol intake associated SNPs, these variants only explain a limited proportion of 
the total variation in weekly ethanol intake (African-Americans=0.30%, European-Americans=0.06%).  
Lastly, although community-based our results emerge from 4 geographically defined, closed cohorts and 





6.3. Overall Conclusions 
The results from this study suggest that stable low-to-moderate drinking and stable heavy drinking in 
mid-life are not associated with cognitive decline from mid-to late-life among African-American and 
European-American adults. Slightly higher 15-year rate of cognitive decline was observed for stable 
heavy drinkers than stable never drinkers. Our findings are consistent with previous reports indicating that 
moderate ethanol intake likely is not be protective of cognitive decline. Our results support the American 
Heart Association (AHA) recommendation that adults who consume alcohol should do so at moderate 
level (≤2 drinks per day for men; ≤1 for women) while cautioning non-drinkers not to start drinking 
alcohol in order to reduce their risk of cardiovascular and certain types of cancer [456]. 
 Our study also suggests that the association of ethanol intake with cognitive decline does not depend 
on genetic variants that influence alcohol metabolism, among African-American as well as European-
American adults. This finding is inconsistent with a previous report of evidence of effect modification. 
Therefore, larger, longitudinal studies in populations of diverse ancestry are needed to improve our 








APPENDIX A: SNPS IDENTIFIED BY THE GWAS SEQUENCING CONSORTIUM OF ALCOHOL AND NICOTINE USE (GSCAN) 
TO BE GENOME-WIDE SIGNIFICANTLY ASSOCIATED WITH DRINKS PER WEEK IN A META-ANALYIS OF 941, 280 
INDIVIDUALS OF EUROPEAN-AMERICAN ANCESTRY FROM 34 STUDIES 
Appendix Table 1. SNPs identified by the GWAS & Sequencing Consortium of Alcohol and Nicotine Use (GSCAN) to be genome-wide significantly† associated with 
drinks per week in a meta-analysis of 941, 280 individuals of EA ancestry from 34 studies [407] 
Locus Gene rsID Chr Position EA OT EAF Beta SE P-value 
Available 
in ARIC 
1:4048453-5048453 Intergenic rs705687 1 4548453 G A 0.785 -0.011 0.002 8.20E-10 AA, EUR 
1:33337334-34337334 PHC2 rs58107686 1 33837334 A C 0.328 -0.010 0.002 7.80E-10 AA, EUR 
1:65907700-66907700 PDE4B rs12088813 1 66407700 C A 0.267 -0.009 0.002 1.60E-08 AA, EUR 
1:70991890-71991890 PTGER3 rs5024204 1 71491890 T A 0.278 0.010 0.002 2.60E-09 AA, EUR 
1:96481736-97481736 Intergenic rs184083806 1 96981736 C T 0.007 -0.048 0.009 3.40E-08 EUR 
1:164619792-165619792 Intergenic rs10753661 1 165119792 A G 0.684 -0.009 0.002 3.80E-08 AA, EUR 
1:173348808-175396299 ZBTB37 rs28680958 1 173848808 A G 0.217 -0.011 0.002 5.10E-10 AA, EUR 
1:205219532-206219532 Intergenic rs823114 1 205719532 A G 0.553 0.009 0.001 2.30E-09 AA, EUR 
2:-69025-930975 Intergenic rs77165542 2 430975 T C 0.035 -0.026 0.004 5.60E-11 EUR 
2:27230940-28746841 GCKR rs1260326 2 27730940 C T 0.601 0.021 0.001 8.10E-45 AA, EUR 
2:27230940-28746841 GPN1 rs2178197 2 27860551 G A 0.569 -0.009 0.001 2.50E-09 AA, EUR 
2:43771496-45655276 LINC01833 rs13383034 2 45155276 T C 0.329 0.015 0.002 6.30E-22 AA, EUR 
2:43771496-45655276 LINC01833 rs1004787 2 45159091 A G 0.551 0.008 0.001 8.40E-09 AA, EUR 
2:62478981-64081507 WDPCP rs13032049 2 63581507 G A 0.283 0.010 0.002 3.00E-10 AA, EUR 
2:73834462-74834462 Utr3:TET3 rs828867 2 74334462 A G 0.545 0.009 0.001 2.20E-09 AA, EUR 
2:97168945-98775354 ACTR1B rs11692435 2 98275354 A G 0.085 0.017 0.003 2.50E-11 EUR 
2:143725215-144725215 ARHGAP15 rs13024996 2 144225215 A C 0.364 -0.011 0.002 5.70E-13 AA, EUR 
2:147456293-148456293 Intergenic rs72859280 2 147956293 T G 0.036 0.023 0.004 4.40E-09 EUR 
2:224975560-225975560 Intergenic rs56337305 2 225475560 C T 0.383 -0.010 0.001 1.60E-10 AA, EUR 
3:70468431-71468431 Intergenic rs13094887 3 70968431 T A 0.301 -0.010 0.002 8.60E-11 AA, EUR 
3:84408785-85957240 CADM2 rs62250685 3 85457240 G A 0.614 -0.014 0.002 1.10E-21 AA, EUR 
3:84408785-85957240 CADM2 rs74664784 3 85475292 C T 0.359 -0.013 0.002 1.60E-14 AA, EUR 
3:93494255-94494255 Intergenic rs13066454 3 93994255 T C 0.398 -0.009 0.001 4.10E-09 AA, EUR 






Appendix Table 1. SNPs identified by the GWAS & Sequencing Consortium of Alcohol and Nicotine Use (GSCAN) to be genome-wide significantly† associated with 
drinks per week in a meta-analysis of 941, 280 individuals of EA ancestry from 34 studies [407] 
Locus Gene rsID Chr Position EA OT EAF Beta SE P-value 
Available 
in ARIC 
3:140767295-141767295 ZBTB38 rs2011092 3 141124607 C T 0.339 -0.009 0.002 7.40E-09 AA, EUR 
3:140767295-141767295 RASA2 rs60654199 3 141267295 A C 0.063 -0.017 0.003 2.90E-08 AA, EUR 
3:157687811-158687811 RSRC1 rs6787172 3 158187811 G T 0.554 -0.008 0.001 4.30E-08 AA, EUR 
4:2946091-3946091 HGFAC rs3748034 4 3446091 T G 0.143 -0.012 0.002 1.70E-08 EUR 
4:38914993-39914993 Intergenic rs7682824 4 39406254 T C 0.548 0.008 0.002 2.80E-08 AA, EUR 
4:38914993-39914993 KLB rs11940694 4 39414993 G A 0.597 0.026 0.001 3.00E-68 AA, EUR 
4:38914993-39914993 KLB rs35538052 4 39418965 A G 0.379 -0.009 0.002 1.40E-08 AA, EUR 
4:41651306-42651306 BEND4 rs4501255 4 42151306 G C 0.235 0.011 0.002 4.80E-10 AA, EUR 
4:96764066-101983024 Intergenic rs12499107 4 99678691 G A 0.131 0.013 0.002 4.50E-09 EUR 
4:96764066-101983024 Intergenic rs144198753 4 99713350 T C 0.016 -0.042 0.006 1.40E-12 EUR 
4:96764066-101983024 ADH5 rs1154414 4 100000136 C T 0.141 0.018 0.002 3.70E-17 EUR 
4:96764066-101983024 ADH1B rs1229984 4 100239319 C T 0.963 0.151 0.004 0.00E+00 EUR 
4:96764066-101983024 Intergenic rs10028756 4 100254520 A G 0.129 -0.019 0.002 1.20E-17 EUR 
4:96764066-101983024 ADH1C rs561222871 4 100260679 T C 0.047 -0.039 0.004 6.60E-27 AA, EUR 
4:96764066-101983024 ADH1C rs36052336 4 100273594 G A 0.061 -0.018 0.003 1.20E-09 EUR 
4:96764066-101983024 Intergenic rs2165670 4 100286085 A G 0.106 0.023 0.002 1.70E-22 EUR 
4:96764066-101983024 
Synonymous:C4
orf17 rs17029090 4 100443853 G A 0.020 -0.049 0.005 4.80E-21 AA, EUR 
4:96764066-101983024 C4orf17 rs79139602 4 100444363 T A 0.021 0.060 0.005 1.80E-32 AA, EUR 
4:96764066-101983024 Intergenic rs4699791 4 101243023 A G 0.096 0.019 0.002 6.60E-14 AA, EUR 
4:102688709-103688709 SLC39A8 rs13107325 4 103188709 T C 0.072 -0.028 0.003 1.50E-22 EUR 
4:143148579-144148579 INPP4B rs4690727 4 143648579 G C 0.718 0.011 0.002 2.40E-11 AA, EUR 
4:152468372-153468372 Intergenic rs10004020 4 152968372 A G 0.720 0.009 0.002 2.40E-08 AA, EUR 
4:170586393-171586393 Intergenic rs12651313 4 171086393 G C 0.443 -0.009 0.001 3.80E-09 AA, EUR 
5:86827886-88354395 LINC00461 rs4916723 5 87854395 C A 0.416 -0.010 0.001 1.70E-11 AA, EUR 
5:143912335-144912335 Intergenic rs12655091 5 144412335 A G 0.530 -0.008 0.001 1.30E-08 AA, EUR 
5:155402003-156402003 SGCD rs55872084 5 155902003 T G 0.235 0.010 0.002 6.30E-09 EUR 
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Locus Gene rsID Chr Position EA OT EAF Beta SE P-value 
Available 
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7:68574768-70283020 AUTS2 rs10085696 7 69783020 G A 0.186 -0.011 0.002 1.10E-09 AA, EUR 
7:72542443-73542443 Intergenic rs6460047 7 73042443 C T 0.208 0.012 0.002 9.70E-11 AA, EUR 
7:98477515-99477515 ARPC1B rs10236149 7 98977515 G A 0.123 -0.013 0.002 1.20E-09 AA, EUR 
7:103340115-104340115 ORC5 rs35034355 7 103840115 A G 0.521 -0.008 0.001 2.90E-08 AA, EUR 
7:152989744-153989744 Intergenic rs6951574 7 153489744 C T 0.458 0.013 0.001 1.60E-19 AA, EUR 
8:20449917-21449917 Intergenic rs13250583 8 20949917 T C 0.213 -0.010 0.002 4.70E-08 AA, EUR 
8:64027399-65027399 Intergenic rs1217091 8 64527399 C T 0.812 0.012 0.002 7.10E-11 AA, EUR 
8:126000031-127000031 Intergenic rs28601761 8 126500031 G C 0.420 0.009 0.001 7.20E-10 AA, EUR 
9:108255622-109845993 Intergenic rs55932213 9 108755622 G A 0.736 0.009 0.002 9.60E-09 AA, EUR 
9:108255622-109845993 Intergenic rs10978550 9 109345993 C T 0.206 -0.012 0.002 7.20E-11 EUR 
10:110007806-111007806 Intergenic rs7074871 10 110507806 A G 0.255 -0.009 0.002 1.90E-08 AA, EUR 
10:124593880-125593880 Intergenic rs17665139 10 125093880 T C 0.149 -0.012 0.002 1.60E-08 EUR 
11:8142218-9142218 TRIM66 rs7950166 11 8642218 T C 0.637 -0.010 0.002 9.90E-11 AA, EUR 
11:27143725-28143725 
BDNF-
AS|LINC00678 rs11030084 11 27643725 T C 0.184 -0.011 0.002 1.70E-08 EUR 
11:46897353-48410823 SPI1 rs56030824 11 47397353 A G 0.322 -0.012 0.002 1.20E-13 AA, EUR 
11:112924042-113924042 Intergenic rs10750025 11 113424042 T C 0.686 0.010 0.002 4.90E-11 AA, EUR 
11:112924042-113924042 Intergenic rs1713676 11 113660576 G A 0.522 -0.008 0.001 4.30E-08 AA, EUR 
11:115575001-116575001 Intergenic rs4938230 11 116075001 A C 0.842 0.013 0.002 1.50E-10 AA, EUR 
11:121044285-122044285 Intergenic rs682011 11 121544285 C T 0.559 0.008 0.001 2.20E-08 AA, EUR 
11:133158168-134158168 LOC646522 rs12795042 11 133658168 C A 0.623 -0.008 0.002 3.30E-08 AA, EUR 
12:51395882-52395882 SLC4A8 rs10876188 12 51895882 T C 0.457 -0.008 0.001 4.80E-08 AA, EUR 
12:54174235-55174235 Intergenic rs3809162 12 54674235 G A 0.397 0.009 0.001 1.20E-09 AA, EUR 
12:81101464-82875393 ACSS3 rs10506274 12 81601464 T G 0.484 -0.009 0.001 5.80E-10 AA, EUR 
12:91670791-92670791 Intergenic rs4842786 12 92170791 A G 0.584 -0.009 0.001 2.70E-09 AA, EUR 
13:26624360-27624360 Intergenic rs500321 13 27124360 T A 0.736 -0.010 0.002 4.90E-09 AA, EUR 
14:56774519-57774519 OTX2 rs1123285 14 57274519 G C 0.335 -0.009 0.002 8.10E-09 AA, EUR 
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Locus Gene rsID Chr Position EA OT EAF Beta SE P-value 
Available 
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14:94344947-95344947 SERPINA1 rs28929474 14 94844947 T C 0.018 -0.037 0.005 1.30E-11 EUR 
14:104110138-105110138 KIF26A rs11625650 14 104610138 A G 0.233 -0.010 0.002 2.90E-08 EUR 
15:74527880-75527880 Intergenic rs2472297 15 75027880 T C 0.249 0.011 0.002 3.10E-10 EUR 
15:86296012-87296012 AGBL1 rs12907323 15 86796012 G A 0.411 0.008 0.001 9.90E-09 AA, EUR 
16:19513793-20513793 Intergenic rs2764771 16 20013793 A G 0.307 0.010 0.002 4.00E-10 AA, EUR 
16:24310681-25310681 TNRC6A rs17177078 16 24810681 T C 0.063 -0.022 0.003 1.30E-13 EUR 
16:28254684-29254684 Intergenic rs378421 16 28754684 A G 0.404 -0.011 0.001 4.80E-14 AA, EUR 
16:29392184-30974856 SEZ6L2 rs113443718 16 29892184 A G 0.305 -0.010 0.002 1.20E-10 AA, EUR 
16:64372590-65372590 Intergenic rs62044525 16 64872590 G C 0.184 -0.012 0.002 1.00E-10 EUR 
16:68631281-69631281 Intergenic rs7185555 16 69131281 C G 0.153 -0.011 0.002 4.20E-08 AA, EUR 
16:71279310-72838507 LINC01572 rs79616692 16 72338507 C G 0.108 0.016 0.002 4.10E-12 AA, EUR 
16:73412588-74412588 Intergenic rs1104608 16 73912588 C G 0.425 -0.011 0.001 1.10E-13 EUR 
17:1709888-2709888 SRR rs4548913 17 2209888 A G 0.632 -0.008 0.002 3.10E-08 AA, EUR 
17:6962969-7962969 
TNFSF13|TNFS
F13 rs3803800 17 7462969 G A 0.786 0.011 0.002 1.50E-10 AA, EUR 
17:29215500-30215500 Intergenic rs2854334 17 29715500 G A 0.615 0.009 0.001 7.50E-10 AA, EUR 
17:43159975-45273783 KANSL1 . 17 44246624 A C 0.215 -0.022 0.003 1.60E-17 AA, EUR 
17:78024597-79024597 RPTOR rs10438820 17 78524597 T C 0.702 0.009 0.002 1.80E-08 AA, EUR 
18:52552169-53552169 TCF4 rs9950000 18 53052169 T C 0.395 -0.009 0.001 9.40E-10 AA, EUR 
18:54580437-55580437 Intergenic rs4092465 18 55080437 G A 0.635 -0.008 0.002 4.40E-08 AA, EUR 
19:48714274-49714274 Intergenic rs281379 19 49214274 A G 0.508 0.014 0.001 4.90E-21 AA, EUR 
20:24535711-25535711 ACSS1 rs4815364 20 25035711 A G 0.616 0.009 0.001 1.00E-08 AA, EUR 
22:41446519-42446519 Intergenic rs9607814 22 41946519 A C 0.200 -0.010 0.002 4.30E-08 AA, EUR 
†, p-value threshold <5.0x10-8. Abbreviations: SNP, single nucleotide polymorphisms;  GWAS, genome-wide association studies; Chr, chromosome;  SE, standard error; 







APPENDIX B: ASSOCIATION OF GCAN SNPS WITH WEEKLY ETHANOL INTAKE AT STUDY BASELINE AMONG ARIC 
EUROPEAN-AMERICAN PARTICIPANTS 
Appendix Table 2. Association of GSCAN SNPS (N=99) with weekly ethanol intake  at study baseline (visit 4)  among ARIC European-American Participants. 
    ARIC    GSCAN    
rsID Gene Chr Position EA OA EAF Beta SE P-value EA OA EAF Beta SE P-value 
rs705687 Intergenic 1 4548453 G A 0.789 -0.016 0.040 0.695 G A 0.785 -0.011 0.002 8.15E-10 
rs58107686 PHC2 1 33837334 A C 0.340 -0.036 0.035 0.303 A C 0.328 -0.010 0.002 7.79E-10 
rs12088813 PDE4B 1 66407700 C A 0.273 -0.060 0.037 0.111 C A 0.267 -0.009 0.002 1.58E-08 
rs5024204 PTGER3 1 71491890 T A 0.279 0.011 0.037 0.759 T A 0.278 0.010 0.002 2.55E-09 
rs184083806 Intergenic 1 96981736 C T 0.008 -0.063 0.187 0.738 C T 0.007 -0.048 0.009 3.42E-08 
rs10753661 Intergenic 1 165119792 A G 0.696 0.002 0.036 0.962 A G 0.684 -0.009 0.002 3.76E-08 
rs28680958 ZBTB37 1 171086393 A G 0.217 -0.023 0.040 0.571 A G 0.217 -0.011 0.002 5.13E-10 
rs823114 Intergenic 1 173848808 A G 0.547 -0.007 0.033 0.837 A G 0.553 0.009 0.001 2.31E-09 
rs77165542 Intergenic 2 430975 T C 0.023 0.080 0.111 0.468 T C 0.035 -0.026 0.004 5.63E-11 
rs1260326 GCKR 2 27730940 C T 0.594 -0.047 0.034 0.172 C T 0.601 0.021 0.001 8.05E-45 
rs2178197 GPN1 2 27860551 G A 0.575 -0.033 0.034 0.322 G A 0.569 -0.009 0.001 2.45E-09 
rs13383034 LINC01833 2 45155276 T C 0.318 -0.050 0.036 0.158 T C 0.329 0.015 0.002 6.31E-22 
rs1004787 LINC01833 2 45159091 A G 0.553 -0.002 0.033 0.958 A G 0.551 0.008 0.001 8.40E-09 
rs13032049 WDPCP 2 63581507 G A 0.284 0.044 0.037 0.235 G A 0.283 0.010 0.002 3.00E-10 
rs828867 Utr3:TET3 2 74334462 A G 0.552 0.018 0.033 0.583 A G 0.545 0.009 0.001 2.15E-09 
rs11692435 ACTR1B 2 98275354 A G 0.081 0.017 0.061 0.785 A G 0.085 0.017 0.003 2.53E-11 
rs13024996 ARHGAP15 2 144225215 A C 0.368 -0.056 0.035 0.103 A C 0.364 -0.011 0.002 5.72E-13 
rs72859280 Intergenic 2 147956293 T G 0.033 0.059 0.092 0.522 T G 0.036 0.023 0.004 4.44E-09 
rs56337305 Intergenic 2 205719532 C T 0.385 -0.020 0.034 0.563 C T 0.383 -0.010 0.001 1.63E-10 
rs13094887 Intergenic 3 70968431 T A 0.299 -0.036 0.036 0.324 T A 0.301 -0.010 0.002 8.57E-11 
rs62250685 CADM2 3 85457240 G A 0.625 -0.064 0.034 0.063 G A 0.614 -0.014 0.002 1.05E-21 
rs74664784 CADM2 3 85475292 C T 0.613 -0.061 0.034 0.074 C T 0.359 -0.013 0.002 1.58E-14 
rs13066454 Intergenic 3 93994255 T C 0.397 -0.041 0.034 0.230 T C 0.398 -0.009 0.001 4.13E-09 
rs9838144 CPNE4 3 131576287 C G 0.209 -0.036 0.041 0.375 C G 0.209 -0.010 0.002 2.65E-08 
rs2011092 ZBTB38 3 141124607 C T 0.342 -0.024 0.035 0.487 C T 0.339 -0.009 0.002 7.35E-09 
rs60654199 RASA2 3 141267295 A C 0.065 0.026 0.067 0.700 A C 0.063 -0.017 0.003 2.85E-08 
rs6787172 RSRC1 3 158187811 G T 0.558 -0.039 0.033 0.243 G T 0.554 -0.008 0.001 4.27E-08 
rs3748034 HGFAC 4 3446091     0.047 0.031 T G 0.143 -0.012 0.002 1.67E-08 






Appendix Table 2. Association of GSCAN SNPS (N=99) with weekly ethanol intake  at study baseline (visit 4)  among ARIC European-American Participants. 
    ARIC    GSCAN    
rsID Gene Chr Position EA OA EAF Beta SE P-value EA OA EAF Beta SE P-value 
rs11940694 KLB 4 39414993 G A 0.585 0.031 0.034 0.351 G A 0.597 0.026 0.001 3.03E-68 
rs35538052 KLB 4 39418965 A G 0.399 -0.021 0.034 0.544 A G 0.379 -0.009 0.002 1.39E-08 
rs4501255 BEND4 4 42151306 G C 0.229 0.049 0.039 0.213 G C 0.235 0.011 0.002 4.83E-10 
rs12499107 Intergenic 4 99678691 G A 0.128 -0.023 0.050 0.654 G A 0.131 0.013 0.002 4.45E-09 
rs144198753 Intergenic 4 99713350 T C 0.011 -0.227 0.158 0.150 T C 0.016 -0.042 0.006 1.35E-12 
rs1154414 ADH5 4 100000136 C T 0.141 -0.050 0.048 0.297 C T 0.141 0.018 0.002 3.74E-17 
rs1229984 ADH1B 4 100239319 C T 0.965 0.234 0.091 0.010 C T 0.963 0.151 0.004 0.00E+00 
rs10028756 Intergenic 4 100254520 A G 0.128 -0.080 0.051 0.116 A G 0.129 -0.019 0.002 1.16E-17 
rs561222871 ADH1C 4 100260679 T C 0.067 -0.095 0.068 0.161 T C 0.047 -0.039 0.004 6.56E-27 
rs36052336 ADH1C 4 100273594 G A 0.056 -0.067 0.072 0.356 G A 0.061 -0.018 0.003 1.23E-09 
rs2165670 Intergenic 4 100286085 A G 0.104 0.035 0.055 0.518 A G 0.106 0.023 0.002 1.67E-22 
rs17029090 
Synonymous:
C4orf17 4 100443853 G A 0.020 0.023 0.120 0.846 G A 0.020 -0.049 0.005 4.75E-21 
rs79139602 C4orf17 4 100444363 T A 0.022 0.038 0.115 0.745 T A 0.021 0.060 0.005 1.80E-32 
rs4699791 Intergenic 4 101243023 A G 0.096 -0.031 0.057 0.582 A G 0.096 0.019 0.002 6.58E-14 
rs13107325 SLC39A8 4 103188709 T C 0.081 -0.007 0.061 0.914 T C 0.072 -0.028 0.003 1.53E-22 
rs4690727 INPP4B 4 143648579 G C 0.729 0.008 0.038 0.822 G C 0.718 0.011 0.002 2.43E-11 
rs10004020 Intergenic 4 152968372 A G 0.729 0.022 0.037 0.556 A G 0.720 0.009 0.002 2.43E-08 
rs12651313 Intergenic 4 166803321 G C 0.441 -0.063 0.033 0.060 G C 0.443 -0.009 0.001 3.79E-09 
rs4916723 LINC00461 5 87854395 C A 0.421 -0.009 0.034 0.780 C A 0.416 -0.010 0.001 1.72E-11 
rs12655091 Intergenic 5 144412335 A G 0.528 -0.030 0.033 0.368 A G 0.530 -0.008 0.001 1.25E-08 
rs55872084 SGCD 5 155902003 T G 0.232 0.104 0.039 0.009 T G 0.235 0.010 0.002 6.32E-09 
rs10085696 AUTS2 7 69783020 G A 0.181 -0.031 0.043 0.479 G A 0.186 -0.011 0.002 1.12E-09 
rs6460047 Intergenic 7 73042443 C T 0.207 0.063 0.041 0.121 C T 0.208 0.012 0.002 9.69E-11 
rs10236149 ARPC1B 7 98977515 G A 0.125 -0.008 0.050 0.878 G A 0.123 -0.013 0.002 1.18E-09 
rs35034355 ORC5 7 103840115 A G 0.524 -0.042 0.033 0.208 A G 0.521 -0.008 0.001 2.87E-08 
rs6951574 Intergenic 7 153489744 C T 0.468 0.035 0.033 0.295 C T 0.458 0.013 0.001 1.58E-19 
rs13250583 Intergenic 8 20949917 T C 0.207 0.026 0.041 0.522 T C 0.213 -0.010 0.002 4.70E-08 
rs1217091 Intergenic 8 64527399 C T 0.803 -0.032 0.042 0.449 C T 0.812 0.012 0.002 7.05E-11 
rs28601761 Intergenic 8 126500031 G C 0.427 0.062 0.034 0.064 G C 0.420 0.009 0.001 7.17E-10 
rs55932213 Intergenic 9 108755622 G A 0.731 0.015 0.038 0.692 G A 0.736 0.009 0.002 9.55E-09 
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    ARIC    GSCAN    
rsID Gene Chr Position EA OA EAF Beta SE P-value EA OA EAF Beta SE P-value 
rs7074871 Intergenic 10 110507806 A G 0.255 -0.036 0.038 0.342 A G 0.255 -0.009 0.002 1.86E-08 
rs17665139 Intergenic 10 125093880 T C 0.154 -0.011 0.046 0.807 T C 0.149 -0.012 0.002 1.59E-08 




78 11 27643725 T C 0.190 0.002 0.042 0.963 T C 0.184 -0.011 0.002 1.72E-08 
rs56030824 SPI1 11 47397353 A G 0.334 -0.006 0.036 0.876 A G 0.322 -0.012 0.002 1.15E-13 
rs10750025 Intergenic 11 113424042 T C 0.691 0.053 0.036 0.147 T C 0.686 0.010 0.002 4.89E-11 
rs1713676 Intergenic 11 113660576 G A 0.529 -0.080 0.033 0.017 G A 0.522 -0.008 0.001 4.29E-08 
rs4938230 Intergenic 11 116075001 A C 0.844 -0.023 0.046 0.615 A C 0.842 0.013 0.002 1.48E-10 
rs682011 Intergenic 11 121544285 C T 0.555 -0.028 0.034 0.412 C T 0.559 0.008 0.001 2.22E-08 
rs12795042 LOC646522 11 133658168 C A 0.623 0.020 0.034 0.571 C A 0.623 -0.008 0.002 3.25E-08 
rs10876188 SLC4A8 12 51895882 T C 0.444 -0.021 0.033 0.523 T C 0.457 -0.008 0.001 4.84E-08 
rs3809162 Intergenic 12 54674235 G A 0.394 0.014 0.034 0.677 G A 0.397 0.009 0.001 1.19E-09 
rs10506274 ACSS3 12 81601464 T G 0.486 -0.007 0.033 0.835 T G 0.484 -0.009 0.001 5.78E-10 
rs4842786 Intergenic 12 92170791 A G 0.582 -0.043 0.034 0.202 A G 0.584 -0.009 0.001 2.73E-09 
rs500321 Intergenic 13 27124360 T A 0.742 -0.013 0.038 0.739 T A 0.736 -0.010 0.002 4.92E-09 
rs1123285 OTX2 14 57274519 G C 0.338 -0.046 0.035 0.186 G C 0.335 -0.009 0.002 8.14E-09 
rs2180870 ARID4A 14 58782779 C T 0.138 -0.047 0.048 0.330 C T 0.135 -0.012 0.002 1.12E-08 
rs28929474 SERPINA1 14 94844947 T C 0.019 0.003 0.122 0.981 T C 0.018 -0.037 0.005 1.34E-11 
rs11625650 KIF26A 14 104610138 A G 0.064 0.079 0.068 0.247 A G 0.233 -0.010 0.002 2.89E-08 
rs2472297 Intergenic 15 75027880 T C 0.253 -0.011 0.038 0.773 T C 0.249 0.011 0.002 3.10E-10 
rs12907323 AGBL1 15 86796012 G A 0.410 -0.029 0.034 0.386 G A 0.411 0.008 0.001 9.93E-09 
rs2764771 Intergenic 16 20013793 A G 0.301 0.057 0.036 0.118 A G 0.307 0.010 0.002 4.02E-10 
rs17177078 TNRC6A 16 24810681 T C 0.069 0.001 0.066 0.992 T C 0.063 -0.022 0.003 1.27E-13 
rs378421 Intergenic 16 28754684 A G 0.409 -0.012 0.034 0.717 A G 0.404 -0.011 0.001 4.83E-14 
rs113443718 SEZ6L2 16 29892184 A G 0.288 -0.021 0.037 0.566 A G 0.305 -0.010 0.002 1.19E-10 
rs62044525 Intergenic 16 64872590 G C 0.184 0.001 0.043 0.990 G C 0.184 -0.012 0.002 1.03E-10 
rs7185555 Intergenic 16 69131281 C G 0.141 -0.045 0.048 0.348 C G 0.153 -0.011 0.002 4.24E-08 
rs79616692 LINC01572 16 72338507 C G 0.108 -0.079 0.053 0.137 C G 0.108 0.016 0.002 4.11E-12 
rs1104608 Intergenic 16 73912588 C G 0.428 -0.003 0.034 0.928 C G 0.425 -0.011 0.001 1.05E-13 






Appendix Table 2. Association of GSCAN SNPS (N=99) with weekly ethanol intake  at study baseline (visit 4)  among ARIC European-American Participants. 
    ARIC    GSCAN    




FSF13 17 7462969 G A 0.793 0.021 0.041 0.606 G A 0.786 0.011 0.002 1.50E-10 
rs2854334 Intergenic 17 29715500 G A 0.611 -0.030 0.034 0.382 G A 0.615 0.009 0.001 7.51E-10 
. KANSL1 17 44246624 A C 0.211 0.031 0.040 0.439 A C 0.215 -0.022 0.003 1.62E-17 
rs10438820 RPTOR 17 78524597 T C 0.699 0.011 0.036 0.756 T C 0.702 0.009 0.002 1.76E-08 
rs9950000 TCF4 18 53052169 T C 0.401 -0.014 0.034 0.675 T C 0.395 -0.009 0.001 9.38E-10 
rs4092465 Intergenic 18 55080437 G A 0.625 -0.023 0.034 0.503 G A 0.635 -0.008 0.002 4.39E-08 
rs281379 Intergenic 19 49214274 A G 0.486 0.058 0.033 0.080 A G 0.508 0.014 0.001 4.91E-21 
rs4815364 ACSS1 20 25035711 A G 0.619 0.050 0.034 0.144 A G 0.616 0.009 0.001 1.02E-08 
rs9607814 Intergenic 22 41946519 A C 0.200 0.071 0.041 0.083 A C 0.200 -0.010 0.002 4.31E-08 
Abbreviations: SNP, Single Nucleotide Polymorphisms; ARIC, Atherosclerosis Risk in Communities (ARIC) Study; Chr, Chromosome;  EA, effect allele, OA, other 








APPENDIX C: ASSOCIATION OF GSCAN SNPS WITH WEEKLY ETHANOL INTAKE AT STUDY BASELINE (VISIT 4) AMONG 
ARIC AFRICAN-AMERICAN PARTICIPANTS 
Appendix Table 3. Association of GSCAN SNPS (N=74) with weekly ethanol intake  at study baseline (visit 4)  among ARIC African-American participants 
      ARIC      GSCAN    
rsID Gene Chr Position EA OA EAF Beta SE P-value EA 
O
A EAF Beta SE P-value 
rs705687 Intergenic 1 4548453 G A 0.849 0.055 0.066 0.404 G A 0.785 -0.011 0.002 8.15E-10 
rs58107686 PHC2 1 33837334 A C 0.137 -0.003 0.069 0.969 A C 0.328 -0.010 0.002 7.79E-10 
rs12088813 PDE4B 1 66407700 C A 0.084 0.131 0.085 0.122 C A 0.267 -0.009 0.002 1.58E-08 
rs5024204 PTGER3 1 71491890 T A 0.242 -0.016 0.056 0.775 T A 0.278 0.010 0.002 2.55E-09 
rs10753661 Intergenic 1 165119792 A G 0.882 0.024 0.075 0.753 A G 0.684 -0.009 0.002 3.76E-08 
rs28680958 ZBTB37 1 173848808 A G 0.406 -0.024 0.048 0.620 A G 0.217 -0.011 0.002 5.13E-10 
rs823114 Intergenic 1 205719532 A G 0.236 -0.084 0.057 0.145 A G 0.553 0.009 0.001 2.31E-09 
rs1260326 GCKR 2 27730940 C T 0.858 -0.012 0.068 0.854 C T 0.601 0.021 0.001 8.05E-45 
rs2178197 GPN1 2 27860551 G A 0.604 0.007 0.048 0.887 G A 0.569 -0.009 0.001 2.45E-09 
rs13383034 LINC01833 2 45155276 T C 0.206 0.105 0.059 0.073 T C 0.329 0.015 0.002 6.31E-22 
rs1004787 LINC01833 2 45159091 A G 0.849 0.107 0.068 0.117 A G 0.551 0.008 0.001 8.4E-09 
rs13032049 WDPCP 2 63581507 G A 0.056 -0.009 0.106 0.933 G A 0.283 0.010 0.002 3E-10 
rs828867 Utr3TET3 2 74334462 A G 0.230 -0.110 0.057 0.054 A G 0.545 0.009 0.001 2.15E-09 
rs13024996 ARHGAP15 2 144225215 A C 0.122 0.080 0.075 0.289 A C 0.364 -0.011 0.002 5.72E-13 
rs56337305 Intergenic 2 225475560 C T 0.300 0.073 0.051 0.157 C T 0.383 -0.010 0.001 1.63E-10 
rs13094887 Intergenic 3 70968431 T A 0.267 0.062 0.054 0.247 T A 0.301 -0.010 0.002 8.57E-11 
rs62250685 CADM2 3 85457240 G A 0.152 -0.063 0.071 0.378 G A 0.614 -0.014 0.002 1.05E-21 
rs74664784 CADM2 3 85475292 C T 0.367 -0.070 0.049 0.157 C T 0.359 -0.013 0.002 1.58E-14 
rs13066454 Intergenic 3 93994255 T C 0.083 -0.055 0.090 0.539 T C 0.398 -0.009 0.001 4.13E-09 
rs2011092 ZBTB38 3 141124607 C T 0.129 0.045 0.071 0.523 C T 0.339 -0.009 0.002 7.35E-09 
rs60654199 RASA2 3 141267295 A C 0.221 0.016 0.058 0.778 A C 0.063 -0.017 0.003 2.85E-08 
rs6787172 Intergenic 3 158187811 T A 0.739 -0.021 0.053 0.688 T A 0.301 -0.010 0.002 8.57E-11 






Appendix Table 3. Association of GSCAN SNPS (N=74) with weekly ethanol intake  at study baseline (visit 4)  among ARIC African-American participants 
      ARIC      GSCAN    
rsID Gene Chr Position EA OA EAF Beta SE P-value EA 
O
A EAF Beta SE P-value 
rs11940694 KLB 4 39414993 G A 0.576 0.091 0.047 0.057 G A 0.597 0.026 0.001 3.03E-68 
rs35538052 KLB 4 39418965 A G 0.098 -0.040 0.081 0.623 A G 0.379 -0.009 0.002 1.39E-08 
rs4501255 BEND4 4 42151306 G C 0.683 0.057 0.052 0.274 G C 0.235 0.011 0.002 4.83E-10 
rs561222871 ADH1C 4 100260679 T C 0.059 -0.012 0.100 0.905 T C 0.047 -0.039 0.004 6.56E-27 
rs17029090 C4orf17 4 100443853 G A   0.055 0.959 G A 0.020 -0.049 0.005 4.75E-21 
rs79139602 C4orf17 4 100444363 T A 0.183 -0.040 0.061 0.515 T A 0.021 0.060 0.005 1.8E-32 
rs4699791 Intergenic 4 101243023 A G 0.101 -0.003 0.078 0.971 A G 0.096 0.019 0.002 6.58E-14 
rs4690727 INPP4B 4 143648579 G C 0.834 0.045 0.063 0.480 G C 0.718 0.011 0.002 2.43E-11 
rs10004020 Intergenic 4 152968372 A G 0.726 0.094 0.052 0.070 A G 0.720 0.009 0.002 2.43E-08 
rs12651313 Intergenic 4 171086393 A G 0.683 -0.088 0.051 0.085 A G 0.530 -0.008 0.001 1.25E-08 
rs4916723 LINC00461 5 87854395 C A 0.171 -0.005 0.063 0.932 C A 0.416 -0.010 0.001 1.72E-11 
rs12655091 Intergenic 5 144412335 G C 0.765 0.041 0.057 0.467 G C 0.443 -0.009 0.001 3.79E-09 
rs10085696 AUTS2 7 69783020 G A 0.219 -0.015 0.057 0.795 G A 0.186 -0.011 0.002 1.12E-09 
rs6460047 Intergenic 7 73042443 C T 0.291 0.018 0.052 0.729 C T 0.208 0.012 0.002 9.69E-11 
rs10236149 ARPC1B 7 98977515 G A 0.815 0.020 0.066 0.766 G A 0.123 -0.013 0.002 1.18E-09 
rs35034355 ORC5 7 103840115 A G 0.160 -0.025 0.065 0.706 A G 0.521 -0.008 0.001 2.87E-08 
rs6951574 Intergenic 7 153489744 C T 0.399 -0.007 0.048 0.877 C T 0.458 0.013 0.001 1.58E-19 
rs13250583 Intergenic 8 20949917 T C 0.088 -0.118 0.083 0.152 T C 0.213 -0.010 0.002 4.7E-08 
rs1217091 Intergenic 8 64527399 C T 0.774 0.027 0.056 0.625 C T 0.812 0.012 0.002 7.05E-11 
rs28601761 Intergenic 8 126500031 G C 0.307 -0.033 0.052 0.525 G C 0.420 0.009 0.001 7.17E-10 
rs55932213 Intergenic 9 108755622 G A 0.237 0.038 0.055 0.498 G A 0.736 0.009 0.002 9.55E-09 
rs7074871 Intergenic 10 110507806 A G 0.268 -0.041 0.053 0.439 A G 0.255 -0.009 0.002 1.86E-08 
rs7950166 TRIM66 11 8642218 T C 0.504 -0.074 0.048 0.121 T C 0.637 -0.010 0.002 9.89E-11 
rs56030824 SPI1 11 47397353 A G 0.117 0.039 0.077 0.610 A G 0.322 -0.012 0.002 1.15E-13 






Appendix Table 3. Association of GSCAN SNPS (N=74) with weekly ethanol intake  at study baseline (visit 4)  among ARIC African-American participants 
      ARIC      GSCAN    
rsID Gene Chr Position EA OA EAF Beta SE P-value EA 
O
A EAF Beta SE P-value 
rs1713676 Intergenic 11 113660576 G A 0.202 0.001 0.060 0.993 G A 0.522 -0.008 0.001 4.29E-08 
rs4938230 Intergenic 11 116075001 A C 0.817 0.038 0.060 0.529 A C 0.842 0.013 0.002 1.48E-10 
rs682011 Intergenic 11 121544285 C T 0.742 -0.082 0.053 0.119 C T 0.559 0.008 0.001 2.22E-08 
rs12795042 LOC646522 11 133658168 C A 0.746 0.169 0.054 0.002 C A 0.623 -0.008 0.002 3.25E-08 
rs10876188 SLC4A8 12 51895882 T C 0.325 0.017 0.050 0.741 T C 0.457 -0.008 0.001 4.84E-08 
rs3809162 Intergenic 12 54674235 G A 0.770 0.055 0.057 0.338 G A 0.397 0.009 0.001 1.19E-09 
rs10506274 ACSS3 12 81601464 T G 0.199 -0.052 0.059 0.382 T G 0.484 -0.009 0.001 5.78E-10 
rs4842786 Intergenic 12 92170791 A G 0.843 0.054 0.066 0.412 A G 0.584 -0.009 0.001 2.73E-09 
rs500321 Intergenic 13 27124360 T A 0.848 0.010 0.066 0.879 T A 0.736 -0.010 0.002 4.92E-09 
rs1123285 OTX2 14 57274519 G C 0.453 0.004 0.047 0.934 G C 0.335 -0.009 0.002 8.14E-09 
rs2180870 ARID4A 14 58782779 C T 0.269 0.054 0.053 0.308 C T 0.135 -0.012 0.002 1.12E-08 
rs12907323 AGBL1 15 86796012 G A 0.555 -0.079 0.048 0.101 G A 0.411 0.008 0.001 9.93E-09 
rs2764771 Intergenic 16 20013793 A G 0.494 0.035 0.048 0.459 A G 0.307 0.010 0.002 4.02E-10 
rs378421 Intergenic 16 28754684 A G 0.293 -0.015 0.052 0.773 A G 0.404 -0.011 0.001 4.83E-14 
rs113443718 SEZ6L2 16 29892184 A G 0.071 0.005 0.095 0.959 A G 0.305 -0.010 0.002 1.19E-10 
rs7185555 Intergenic 16 69131281 C G 0.243 0.010 0.055 0.853 C G 0.153 -0.011 0.002 4.24E-08 
rs1104608 Intergenic 16 73912588 C G 0.621 0.015 0.049 0.766 C G 0.425 -0.011 0.001 1.05E-13 




NFSF13 17 7462969 G A 0.369 0.027 0.049 0.584 G A 0.786 0.011 0.002 1.5E-10 
rs2854334 Intergenic 17 29715500 G A 0.148 0.091 0.068 0.182 G A 0.615 0.009 0.001 7.51E-10 
rs10438820 RPTOR 17 78524597 T C 0.487 0.065 0.048 0.172 T C 0.702 0.009 0.002 1.76E-08 
rs9950000 TCF4 18 53052169 T C 0.768 0.019 0.058 0.744 T C 0.395 -0.009 0.001 9.38E-10 
rs4092465 Intergenic 18 55080437 G A 0.138 -0.013 0.069 0.848 G A 0.635 -0.008 0.002 4.39E-08 






Appendix Table 3. Association of GSCAN SNPS (N=74) with weekly ethanol intake  at study baseline (visit 4)  among ARIC African-American participants 
      ARIC      GSCAN    
rsID Gene Chr Position EA OA EAF Beta SE P-value EA 
O
A EAF Beta SE P-value 
rs4815364 ACSS1 20 25035711 A G 0.370 0.000 0.049 0.999 A G 0.616 0.009 0.001 1.02E-08 
rs9607814 Intergenic 22 41946519 A C 0.115 -0.096 0.072 0.186 A C 0.200 -0.010 0.002 4.31E-08 
Abbreviations: SNP, Single Nucleotide Polymorphisms; ARIC, Atherosclerosis Risk in Communities (ARIC) Study; Chr, Chromosome; EA, effect allele, OA, 




















APPENDIX D: FINAL GENETIC INSTRUMENTS FOR UNWEIGHTED GENETIC RISK SCORE FOR ARIC EUROPEAN-
AMERICAN PARTICIPANTS 
Appendix Table 4. ARIC European-American participants 1000 G SNPs that are nominally significant and directionally consistent with GSCAN SNPs across visits 1-4 - 
Final genetic instruments for unweighted genetic risk score (uGRS11) 
            ARIC           GSCAN     













A EAF Beta SE P 
rs1123285 OTX2 14 57274519 G C 0.338 -0.090 0.040 0.015 -0.090 V2 G C 0.335 -0.009 0.002 8.14E-09 
              -0.070 0.040 0.039 -0.070 V3           
rs1229984 ADH1B 4 100239319 C T 0.965 0.340 0.090 0.000 0.340 V1 C T 0.963 0.151 0.004 0.00E+00 
       0.240 0.090 0.010 0.240 V2       
       0.220 0.090 0.017 0.220 V3       
              0.260 0.090 0.005 0.260 V4             
rs12651313 Intergenic 4 171086393 G C 0.441 -0.080 0.030 0.017 -0.080 V2 G C 0.443 -0.009 0.001 3.79E-09 
              -0.080 0.030 0.018 -0.080 V3             
rs1713676 Intergenic 11 113660576 G A 0.529 -0.070 0.030 0.043 -0.070 V1 G A 0.522 -0.008 0.001 4.29E-08 
       -0.080 0.030 0.017 -0.080 V2       
              -0.080 0.030 0.020 -0.080 V4             
rs2165670   100286085 A G 0.104 0.120 0.060 0.033 0.120 V3 A G 0.106 0.023 0.002 1.67E-22 
rs55872084 Intergenic 5 155902003 T G 0.232 0.110 0.040 0.008 0.110 V1 T G 0.235 0.010 0.002 6.32E-09 
              0.110 0.040 0.005 0.110 V4             
rs62250685 CADM2 3 85457240 G A 0.625 -0.080 0.030 0.028 -0.080 V2 G A 0.614 -0.014 0.002 1.05E-21 
              -0.110 0.030 0.002 -0.110 V3             
rs7185555 Intergenic 16 69131281 C G 0.141 -0.110 0.050 0.026 -0.110 V1 C G 0.153 -0.011 0.002 4.24E-08 
rs72859280 Intergenic 2 147956293 T G 0.033 0.190 0.090 0.048 0.190 V1 T G 0.036 0.023 0.004 4.44E-09 
rs74664784 CADM2 3 85475292 C T 0.613 -0.070 0.030 0.032 -0.070 V2 C T 0.359 -0.013 0.002 1.58E-14 
              -0.100 0.030 0.004 -0.100 V3             
rs7950166 TRIM66 11 8642218 T C 0.635 -0.080 0.030 0.019 -0.080 V3 T C 0.637 -0.010 0.002 9.89E-11 
Abbreviations: SNP, Single Nucleotide Polymorphisms; ARIC, Atherosclerosis Risk in Communities (ARIC) Study; Chr, Chromosome;  SE, Standard Error; P, P-value; VE, 
variance explained; EA, effect allele, OA, other allele; EAF, effect allele frequency; V1, visit 1; V2, visit 2; V3, visit 3; V4, visit4; GSCAN, GWAS & Sequencing 






APPENDIX E: AFRICAN-AMERICAN 1000 GENOME SNPS MOST STRONGLY ASSOCIATED WITH ETHANOL INTAKE AT 
STUDY BASELINE AND IN LD WITH GSCAN INDEX SNP 
Appendix Table 5. ARIC African-American 1000 Genome SNPs† most strongly associated with  weekly ethanol intake  at study baseline (visit 4) and are in LD with their 
GSCAN index SNP 
   ARIC      GSCAN     








A EAF Beta SE P LD 
rs10915562 1 4630379 A G 0.235 -0.137 0.056 0.014 rs705687 4548453 G A 0.785 -0.011 0.002 1.00E-09 0.315 
rs6703350 1 33732772 T G 0.241 -0.111 0.055 0.046 rs58107686 33837334 A C 0.328 -0.010 0.002 1.00E-09 0.306 
rs1354060 1 66511404 G A 0.431 0.115 0.047 0.015 rs12088813 66407700 C A 0.267 -0.009 0.002 1.60E-08 0.283 
rs3932455 1 71511990 A C 0.124 -0.220 0.072 0.002 rs5024204 71491890 T A 0.278 0.010 0.002 3.00E-09 0.408 
rs12084359 1 165139653 A G 0.239 -0.129 0.055 0.020 rs10753661 165119792 A G 0.684 -0.009 0.002 3.80E-08 0.202 
rs10912751 1 174232130 G T 0.352 0.097 0.050 0.050 rs28680958 173848808 A G 0.217 -0.011 0.002 1.00E-09 0.207 
rs6673687 1 205670369 T A 0.359 -0.112 0.049 0.023 rs823114 205719532 A G 0.553 0.009 0.001 2.00E-09 0.725 
rs780096 2 27741072 C G 0.432 0.095 0.047 0.041 rs1260326 27730940 C T 0.601 0.021 0.001 8.05E-45 0.730 
rs1317580 2 27961344 C G 0.199 -0.162 0.058 0.006 rs2178197 27860551 G A 0.569 -0.009 0.001 2.00E-09 0.315 
rs11692742 2 45112453 A G 0.315 0.120 0.050 0.017 rs13383034 45155276 T C 0.329 0.015 0.002 0.00E+00 0.458 
rs494904 2 45141180 C T 0.470 0.111 0.047 0.018 rs1004787 45159091 A G 0.551 0.008 0.001 8.00E-09 0.361 
rs17348120 2 63434271 A T 0.137 -0.226 0.070 0.001 rs13032049 63581507 G A 0.283 0.010 0.002 0.00E+00 0.331 
rs828867 2 74334462 A G 0.230 -0.110 0.057 0.054 rs828867 74334462 A G 0.545 0.009 0.001 2.00E-09 1.000 
rs2544471 2 98241213 T G 0.420 -0.072 0.049 0.143 rs11692435 98275354 A G 0.085 0.017 0.003 0.00E+00 0.386 
rs35608804 2 144271545 T C 0.482 -0.066 0.047 0.158 rs13024996 144225215 A C 0.364 -0.011 0.002 0.00E+00 0.399 
rs17720710 2 148091377 C T 0.060 0.054 0.101 0.590 rs72859280 147956293 T G 0.036 0.023 0.004 4.00E-09 0.202 
rs1908252 2 225484736 A G 0.478 0.089 0.048 0.064 rs56337305 225475560 C T 0.383 -0.010 0.001 0.00E+00 0.331 
rs6790743 3 70957896 C A 0.489 0.101 0.048 0.036 rs13094887 70968431 T A 0.301 -0.010 0.002 0.00E+00 0.765 
rs7355953 3 85792137 C T 0.058 -0.229 0.103 0.027 rs62250685 85457240 G A 0.614 -0.014 0.002 0.00E+00 0.286 
rs7355953 3 85792137 C T 0.058 -0.229 0.103 0.027 rs74664784 85475292 C T 0.359 -0.013 0.002 0.00E+00 0.262 
rs13062355 3 93688511 A G 0.288 0.090 0.052 0.084 rs13066454 93994255 T C 0.398 -0.009 0.001 4.00E-09 0.337 
rs1913287 3 131469850 A G 0.427 0.081 0.049 0.097 rs9838144 131576287 C G 0.209 -0.010 0.002 2.70E-08 0.254 
rs7613516 3 141079309 T G 0.121 -0.210 0.077 0.006 rs2011092 141124607 C T 0.339 -0.009 0.002 7.00E-09 0.387 






Appendix Table 5. ARIC African-American 1000 Genome SNPs† most strongly associated with  weekly ethanol intake  at study baseline (visit 4) and are in LD with their 
GSCAN index SNP 
   ARIC      GSCAN     








A EAF Beta SE P LD 
rs12634907 3 158226886 G A 0.181 0.110 0.061 0.075 rs6787172 158187811 G T 0.554 -0.008 0.001 4.30E-08 0.358 
rs13108218 4 3443931 A G 0.483 -0.060 0.048 0.212 rs3748034 3446091 T G 0.143 -0.012 0.002 1.70E-08 0.255 
rs4974995 4 39218123 C T 0.176 0.138 0.063 0.029 rs11940694 39414993 G A 0.597 0.026 0.001 3.03E-68 0.220 
rs4974995 4 39218123 C T 0.176 0.138 0.063 0.029 rs11940694 39414993 G A 0.597 0.026 0.001 3.03E-68 0.220 
rs7682824 4 39406254 C T 0.209 0.027 0.058 0.645 rs7682824 39406254 T C 0.548 0.008 0.002 2.80E-08 1.000 
rs11940694 4 39414993 A G 0.424 -0.091 0.047 0.057 rs35538052 39418965 A G 0.379 -0.009 0.002 1.40E-08 0.864 
rs79754951 4 42160026 A T 0.273 0.126 0.053 0.017 rs4501255 42151306 G C 0.235 0.011 0.002 0.00E+00 0.598 
rs62325466 4 99625032 T G 0.057 -0.177 0.101 0.080 rs12499107 99678691 G A 0.131 0.013 0.002 4.00E-09 0.316 
rs7692974 4 100051161 A C 0.306 0.191 0.051 0.000 rs561222871 100260679 T C 0.047 -0.039 0.004 6.56E-27 0.228 
rs10008281 4 100142302 A C 0.293 0.154 0.052 0.003 rs1154414 100000136 C T 0.141 0.018 0.002 0.00E+00 0.436 
rs10008281 4 100142302 A C 0.293 0.154 0.052 0.003 rs10028756 100254520 A G 0.129 -0.019 0.002 0.00E+00 0.204 
rs1693457 4 100236762 C T 0.240 0.150 0.056 0.007 rs2165670 100286085 A G 0.106 0.023 0.002 0.00E+00 0.316 
rs58440244 4 100378680 A G 0.270 -0.123 0.053 0.021 rs17029090 100443853 G A 0.020 -0.049 0.005 0.00E+00 0.694 
rs58440244 4 100378680 A G 0.270 -0.123 0.053 0.021 rs79139602 100444363 T A 0.021 0.060 0.005 1.80E-32 0.694 
rs113930074 4 100529342 A G 0.052 -0.167 0.105 0.113 rs36052336 100273594 G A 0.061 -0.018 0.003 1.00E-09 0.228 
rs3077043 4 101361211 A C 0.101 -0.160 0.077 0.038 rs4699791 101243023 A G 0.096 0.019 0.002 0.00E+00 0.544 
rs238449 4 103112813 A C 0.348 -0.123 0.050 0.014 rs13107325 103188709 T C 0.072 -0.028 0.003 0.00E+00 0.215 
rs6831562 4 143716975 T C 0.467 0.104 0.047 0.026 rs4690727 143648579 G C 0.718 0.011 0.002 0.00E+00 0.868 
rs78757076 4 153010001 T C 0.242 -0.106 0.056 0.059 rs10004020 152968372 A G 0.720 0.009 0.002 2.40E-08 0.205 
rs578402 4 171047179 G A 0.257 0.120 0.055 0.028 rs12651313 171086393 G C 0.443 -0.009 0.001 4.00E-09 0.269 
rs7706932 5 87775691 T C 0.249 -0.078 0.055 0.159 rs4916723 87854395 C A 0.416 -0.010 0.001 0.00E+00 0.472 
rs271085 5 144543593 A G 0.304 0.118 0.051 0.020 rs12655091 144412335 A G 0.530 -0.008 0.001 1.20E-08 0.358 
rs56235470 5 155945315 A G 0.110 -0.153 0.075 0.043 rs55872084 155902003 T G 0.235 0.010 0.002 6.00E-09 0.296 
rs11959347 5 166815244 T C 0.491 0.165 0.048 0.001 rs11739827 166803321 T G 0.451 -0.008 0.001 1.20E-08 0.370 
rs11768390 7 69742936 G A 0.457 -0.108 0.048 0.025 rs10085696 69783020 G A 0.186 -0.011 0.002 1.00E-09 0.613 






Appendix Table 5. ARIC African-American 1000 Genome SNPs† most strongly associated with  weekly ethanol intake  at study baseline (visit 4) and are in LD with their 
GSCAN index SNP 
   ARIC      GSCAN     








A EAF Beta SE P LD 
rs13438288 7 98916414 G T 0.129 0.147 0.071 0.039 rs10236149 98977515 G A 0.123 -0.013 0.002 1.00E-09 0.283 
rs2385142 7 103869191 G A 0.111 -0.185 0.075 0.014 rs35034355 103840115 A G 0.521 -0.008 0.001 2.90E-08 0.222 
rs199626887 7 153404124 T G 0.281 -0.073 0.052 0.163 rs6951574 153489744 C T 0.458 0.013 0.001 0.00E+00 0.277 
rs10283354 8 21016340 C T 0.096 -0.212 0.079 0.008 rs13250583 20949917 T C 0.213 -0.010 0.002 4.70E-08 0.501 
rs1234627 8 64574537 A T 0.383 -0.100 0.051 0.049 rs1217091 64527399 C T 0.812 0.012 0.002 0.00E+00 0.547 
rs2980860 8 126485337 G A 0.338 0.089 0.050 0.078 rs28601761 126500031 G C 0.420 0.009 0.001 1.00E-09 0.725 
rs10978391 9 108803650 G C 0.165 0.157 0.063 0.013 rs55932213 108755622 G A 0.736 0.009 0.002 1.00E-08 0.293 
rs4743016 9 109377233 G T 0.382 0.108 0.048 0.025 rs10978550 109345993 C T 0.206 -0.012 0.002 0.00E+00 0.310 
rs67127636 10 110474056 G A 0.122 -0.199 0.073 0.006 rs7074871 110507806 A G 0.255 -0.009 0.002 1.90E-08 0.574 
rs35217446 10 124954612 A C 0.064 -0.199 0.097 0.041 rs17665139 125093880 T C 0.149 -0.012 0.002 1.60E-08 0.231 
rs10840100 11 8669437 A G 0.472 0.103 0.048 0.031 rs7950166 8642218 T C 0.637 -0.010 0.002 0.00E+00 0.943 
rs11030024 11 27508681 C T 0.450 0.110 0.047 0.020 rs11030084 27643725 T C 0.184 -0.011 0.002 1.70E-08 0.424 
rs1685404 11 47243665 C G 0.245 -0.115 0.054 0.033 rs56030824 47397353 A G 0.322 -0.012 0.002 0.00E+00 0.344 
rs2514218 11 113392994 T C 0.158 -0.193 0.064 0.003 rs10750025 113424042 T C 0.686 0.010 0.002 0.00E+00 0.665 
rs1022084 11 113508425 G A 0.496 0.118 0.047 0.013 rs1713676 113660576 G A 0.522 -0.008 0.001 4.30E-08 0.278 
rs7940127 11 116102388 T C 0.289 -0.124 0.052 0.018 rs4938230 116075001 A C 0.842 0.013 0.002 0.00E+00 0.845 
rs532585 11 121542675 C T 0.253 0.095 0.053 0.075 rs682011 121544285 C T 0.559 0.008 0.001 2.20E-08 0.992 
rs12795042 11 133658168 A C 0.254 -0.169 0.054 0.002 rs12795042 133658168 C A 0.623 -0.008 0.002 3.30E-08 1.000 
rs4578438 12 51939749 T C 0.268 -0.099 0.053 0.063 rs10876188 51895882 T C 0.457 -0.008 0.001 4.80E-08 0.245 
rs6580980 12 54692061 A G 0.068 -0.241 0.096 0.012 rs3809162 54674235 G A 0.397 0.009 0.001 1.00E-09 0.308 
rs10862233 12 81483052 C T 0.132 -0.139 0.073 0.056 rs10506274 81601464 T G 0.484 -0.009 0.001 1.00E-09 0.329 
rs12828474 12 92226816 A G 0.171 0.161 0.063 0.011 rs4842786 92170791 A G 0.584 -0.009 0.001 3.00E-09 0.326 
rs525956 13 27101573 A T 0.229 0.080 0.056 0.157 rs500321 27124360 T A 0.736 -0.010 0.002 5.00E-09 0.899 
rs1483107 14 57318956 A G 0.281 -0.084 0.054 0.119 rs1123285 57274519 G C 0.335 -0.009 0.002 8.00E-09 0.289 
rs1190979 14 58805862 C A 0.276 0.108 0.052 0.038 rs2180870 58782779 C T 0.135 -0.012 0.002 1.10E-08 0.923 






Appendix Table 5. ARIC African-American 1000 Genome SNPs† most strongly associated with  weekly ethanol intake  at study baseline (visit 4) and are in LD with their 
GSCAN index SNP 
   ARIC      GSCAN     








A EAF Beta SE P LD 
rs12910841 15 74725822 T C 0.096 0.136 0.083 0.101 rs2472297 75027880 T C 0.249 0.011 0.002 0.00E+00 0.308 
rs6496321 15 86858420 T G 0.154 0.217 0.065 0.001 rs12907323 86796012 G A 0.411 0.008 0.001 1.00E-08 0.211 
rs4780836 16 19985393 C A 0.355 0.119 0.049 0.015 rs2764771 20013793 A G 0.307 0.010 0.002 0.00E+00 0.536 
rs8054332 16 24861927 T C 0.411 -0.107 0.049 0.029 rs17177078 24810681 T C 0.063 -0.022 0.003 0.00E+00 0.392 
rs12919058 16 28927818 A C 0.476 -0.105 0.047 0.027 rs378421 28754684 A G 0.404 -0.011 0.001 0.00E+00 0.628 
rs3815822 16 29872361 G A 0.463 -0.076 0.047 0.110 rs113443718 29892184 A G 0.305 -0.010 0.002 0.00E+00 0.326 
rs62040427 16 64839701 T C 0.306 -0.112 0.051 0.029 rs62044525 64872590 G C 0.184 -0.012 0.002 0.00E+00 0.888 
rs9929584 16 69489576 T C 0.462 -0.077 0.047 0.102 rs7185555 69131281 C G 0.153 -0.011 0.002 4.20E-08 0.219 
rs62058280 16 72285039 C A 0.051 -0.167 0.107 0.119 rs79616692 72338507 C G 0.108 0.016 0.002 0.00E+00 0.400 
rs1492559 16 73868230 G T 0.343 -0.049 0.049 0.320 rs1104608 73912588 C G 0.425 -0.011 0.001 0.00E+00 0.254 
rs17761864 17 2171637 A C 0.127 0.228 0.071 0.001 rs4548913 2209888 A G 0.632 -0.008 0.002 3.10E-08 0.265 
rs4578723 17 7437845 C T 0.281 0.101 0.053 0.059 rs3803800 7462969 G A 0.786 0.011 0.002 0.00E+00 0.257 
rs178840 17 29737612 G A 0.267 0.118 0.053 0.027 rs2854334 29715500 G A 0.615 0.009 0.001 1.00E-09 0.205 
rs78011262 17 43837917 C T 0.152 -0.211 0.065 0.001 . 44246624 A C 0.215 -0.022 0.003 0.00E+00 0.623 
rs6565473 17 78643206 T C 0.408 0.187 0.048 0.000 rs10438820 78524597 T C 0.702 0.009 0.002 1.80E-08 0.288 
rs7231748 18 53109035 G A 0.403 0.107 0.048 0.025 rs9950000 53052169 T C 0.395 -0.009 0.001 1.00E-09 0.421 
rs221876 18 55066438 C G 0.467 0.051 0.047 0.281 rs4092465 55080437 G A 0.635 -0.008 0.002 4.40E-08 0.245 
rs281392 19 49164952 G A 0.411 0.098 0.048 0.043 rs281379 49214274 A G 0.508 0.014 0.001 0.00E+00 0.286 
rs6083730 20 25027526 G A 0.152 -0.115 0.066 0.082 rs4815364 25035711 A G 0.616 0.009 0.001 1.00E-08 0.771 
rs139568 22 42210985 T C 0.296 0.134 0.051 0.009 rs9607814 41946519 A C 0.200 -0.010 0.002 4.30E-08 0.397 
†Single Nucleotide Polymorphisms (SNP)s were identified by fine-mapping in ± 500 kb windows surrounding each of the 99 index SNPs that were independently associated 
with drinks per week in those of European ancestry 
Abbreviations: SNP, Single Nucleotide Polymorphisms; ARIC, Atherosclerosis Risk in Communities (ARIC) Study; Chr, Chromosome; EA, effect allele, OA, other allele; 
EAF, effect allele frequency; SE, Standard Error; P, P-value; GSCAN, GWAS & Sequencing Consortium of Alcohol and Nicotine Use; LD, Linkage Disequilibrium. 
Linear regression models adjusted for age, sex, race-center, education attainment, smoking status, body mass index (BMI), diabetes, history of stroke, diet score, physical 







APPENDIX F: FINAL GENETIC INSTRUMENTS FOR UNWEIGHTED GENETIC RISK SCORE FOR ARIC AFRICAN-
AMERICAN PARTICIPANTS 
Appendix Table 6. ARIC African-American participants 1000 G SNPs that are nominally significant and directionally consistent with GSCAN SNPs across visits 1-4  - Final 
genetic instruments for unweighted genetic risk score (uGRS20) 
   ARIC       GSCAN     
rsID Chr Position EA 
O








A EAF Beta SE P LD 
rs6673687 1 205670369 T A 0.359 -0.140 0.060 0.019 0.28 V1 rs823114 A G 0.553 0.009 0.001 2.00E-09 0.725 
      -0.130 0.060 0.021 0.30 V2          
      -0.150 0.060 0.020 0.29 V3          
            -0.120 0.050 0.020 0.27 V4                 
rs35608804 2 144271545 T C 0.482 -0.140 0.050 0.010 0.24 V2 rs13024996 A C 0.364 -0.011 0.002 0.00E+00 0.399 
rs7355953 3 85792137 C T 0.058 -0.380 0.130 0.003 0.28 V1 rs62250685 G A 0.614 -0.014 0.002 0.00E+00 0.286 
      -0.210 0.110 0.047 0.13 V4          
rs11940694 4 39414993 A G 0.424 -0.120 0.060 0.041 0.15 V1 rs35538052 A G 0.379 -0.009 0.002 1.40E-08 0.864 
      -0.140 0.060 0.019 0.22 V3          
rs10008281 4 100142302 A C 0.293 0.160 0.060 0.011 0.30 V1 rs1154414 C T 0.141 0.018 0.002 0.00E+00 0.436 
      0.130 0.050 0.017 0.26 V4          
rs58440244 4 100378680 A G 0.270 -0.140 0.070 0.035 0.18 V1 rs17029090 G A 0.020 -0.049 0.005 0.00E+00 0.694 
      -0.110 0.060 0.046 0.15 V4          
rs78757076 4 153010001 T C 0.242 -0.160 0.070 0.018 0.17 V1 rs10004020 A G 0.720 0.009 0.002 2.40E-08 0.205 
rs271085 5 144543593 A G 0.304 0.170 0.060 0.005 0.26 V1 rs12655091 A G 0.530 -0.008 0.001 1.20E-08 0.358 
      0.110 0.050 0.029 0.15 V4          
rs11768390 7 69742936 G A 0.457 -0.140 0.060 0.010 0.28 V2 rs10085696 G A 0.186 -0.011 0.002 1.00E-09 0.613 
      -0.120 0.050 0.014 0.26 V4          
rs10283354 8 21016340 C T 0.096 -0.290 0.100 0.003 0.29 V1 rs13250583 T C 0.213 -0.010 0.002 4.70E-08 0.501 
      -0.250 0.090 0.007 0.25 V2          
      -0.220 0.080 0.007 0.24 V4          
rs10840100 11 8669437 A G 0.472 0.140 0.060 0.013 0.31 V2 rs7950166 T C 0.637 -0.010 0.002 0.00E+00 0.943 
      0.150 0.060 0.019 0.30 V3          
rs1685404 11 47243665 C G 0.245 -0.180 0.070 0.007 0.36 V1 rs56030824 A G 0.322 -0.012 0.002 0.00E+00 0.344 
      -0.160 0.060 0.012 0.31 V2          






Appendix Table 6. ARIC African-American participants 1000 G SNPs that are nominally significant and directionally consistent with GSCAN SNPs across visits 1-4  - Final 
genetic instruments for unweighted genetic risk score (uGRS20) 
   ARIC       GSCAN     
rsID Chr Position EA 
O








A EAF Beta SE P LD 
rs2514218 11 113392994 T C 0.158 -0.260 0.080 0.001 0.61 V1 rs10750025 T C 0.686 0.010 0.002 0.00E+00 0.665 
      -0.180 0.070 0.006 0.43 V4          
rs1022084 11 113508425 G A 0.496 0.120 0.060 0.026 0.32 V2 rs1713676 G A 0.522 -0.008 0.001 4.30E-08 0.278 
      0.100 0.050 0.047 0.26 V4          
rs7940127 11 116102388 T C 0.289 -0.140 0.060 0.025 0.28 V1 rs4938230 A C 0.842 0.013 0.002 0.00E+00 0.845 
      -0.110 0.050 0.034 0.28 V4          
rs12910841 15 74725822 T C 0.096 0.320 0.110 0.003 0.10 V2 rs2472297 T C 0.249 0.011 0.002 0.00E+00 0.308 
      0.170 0.090 0.044 0.11 V4          
rs6496321 15 86858420 T G 0.154 0.200 0.080 0.012 0.24 V1 rs12907323 G A 0.411 0.008 0.001 1.00E-08 0.211 
      0.220 0.070 0.001 0.40 V4          
rs4780836 16 19985393 C A 0.355 0.140 0.060 0.010 0.29 V2 rs2764771 A G 0.307 0.010 0.002 0.00E+00 0.536 
rs62040427 16 64839701 T C 0.306 -0.140 0.060 0.028 0.40 V1 rs62044525 G C 0.184 -0.012 0.002 0.00E+00 0.888 
      -0.130 0.050 0.014 0.44 V4          
rs9929584 16 69489576 T C 0.462 -0.150 0.050 0.006 0.30 V2 rs7185555 C G 0.153 -0.011 0.002 4.20E-08 0.219 
Abbreviations: SNP, Single Nucleotide Polymorphisms; ARIC, Atherosclerosis Risk in Communities (ARIC) Study; Chr, Chromosome;  SE, Standard Error; P, P-value; EA, 













APPENDIX G: CONDITIONAL ANALYSES RESULTS FOR GENETIC VARIANTS ASSOCIATED WITH ETHANOL INTAKE AT 
ARIC VISITS 1-4 AMONG AFRICAN-AMERICAN PARTICIPANTS 
 
   Appendix Table 7. Conditional analyses results variants associated with ethanol intake at ARIC visits 1-4 among African-Americans 
 
                  Unconditioned Conditioned on GSCAN  
Trait rsID Chr Position Gene EA OA EAF 
GSCAN 
Reference 
SNP Beta SE P Beta SE P 
Ethanol Intake 
at visit 1 rs6673687 1 205670369 Intergenic T A 0.359 rs823114 -0.140 0.060 0.019 -0.120 0.060 0.051 
 rs7355953 3 85792137 CADM2 C T 0.058 rs74664784 -0.381 0.128 0.003 -0.410 0.130 0.001 
 rs11940694 4 39414993 KLB A G 0.424 rs35538052 -0.119 0.058 0.041 -0.130 0.060 0.034 
 rs58440244 4 100378680 C4orf17 A G 0.270 rs17029090 -0.139 0.066 0.035 -0.150 0.070 0.032 
 rs78757076 4 153010001 Intergenic T C 0.242 rs10004020 -0.162 0.069 0.018 -0.160 0.070 0.020 
 rs271085 5 144543593 Intergenic A G 0.304 rs12655091 0.175 0.062 0.005 0.170 0.060 0.006 
 rs10283354 8 21016340 Intergenic C T 0.096 rs13250583 -0.295 0.098 0.003 -0.350 0.110 0.002 
 rs1685404 11 47243665 SPI1 C G 0.245 rs56030824 -0.180 0.067 0.007 -0.200 0.070 0.003 
 rs2514218 11 113392994 Intergenic T C 0.158 rs10750025 -0.255 0.079 0.001 -0.260 0.090 0.006 
 rs7940127 11 116102388 Intergenic T C 0.289 rs4938230 -0.144 0.064 0.025 -0.250 0.090 0.004 
 rs6496321 15 86858420 AGBL1 T G 0.154 rs12907323 0.201 0.080 0.012 0.200 0.080 0.012 
Ethanol Intake 
at visit 2 rs6673687 1 205670369 Intergenic T A 0.359 rs823114 -0.130 0.057 0.021 -0.120 0.060 0.046 
 rs35608804 2 144271545 ARHGAP15 T C 0.482 rs13024996 -0.139 0.054 0.010 -0.160 0.060 0.007 
 rs11768390 7 69742936 AUTS2 G A 0.457 rs10085696 -0.143 0.055 0.010 -0.190 0.060 0.003 
 rs10283354 8 21016340 Intergenic C T 0.096 rs13250583 -0.248 0.092 0.007 -0.170 0.100 0.110 
 rs10840100 11 8669437 TRIM66 A G 0.472 rs7950166 0.137 0.055 0.013 0.350 0.180 0.045 
 rs1685404 11 47243665 SPI1 C G 0.245 rs56030824 -0.158 0.063 0.012 -0.160 0.060 0.013 
 rs1022084 11 113508425 Intergenic G A 0.496 rs1713676 0.123 0.055 0.026 0.130 0.060 0.025 
 rs4780836 16 19985393 Intergenic C A 0.355 rs2764771 0.144 0.056 0.010 0.150 0.060 0.014 
 rs9929584 16 69489576 Intergenic T C 0.462 rs7185555 -0.150 0.055 0.006 -0.150 0.060 0.005 
Ethanol Intake 
at visit 3 rs6673687 1 205670369 Intergenic T A 0.359 rs823114 -0.148 0.063 0.020 -0.140 0.070 0.028 
 rs11940694 4 39414993 KLB A G 0.424 rs35538052 -0.143 0.061 0.019 -0.150 0.060 0.015 
 rs10840100 11 8669437 TRIM66 A G 0.472 rs7950166 0.147 0.063 0.019 0.650 0.200 0.001 
 rs1685404 11 47243665 SPI1 C G 0.245 rs56030824 -0.147 0.071 0.037 -0.170 0.070 0.018 
Ethanol Intake 
at visit 4 rs6673687 1 205670369 Intergenic T A 0.359 rs823114 -0.117 0.050 0.020 -0.110 0.050 0.037 
 rs7355953 3 85792137 CADM2 C T 0.058 rs74664784 -0.214 0.108 0.047 -0.230 0.110 0.031 
 rs58440244 4 100378680 C4orf17 A G 0.270 rs17029090 -0.110 0.055 0.046 -0.130 0.060 0.033 







                  Unconditioned Conditioned on GSCAN  
Trait rsID Chr Position Gene EA OA EAF 
GSCAN 
Reference 
SNP Beta SE P Beta SE P 
 rs11768390 7 69742936 AUTS2 G A 0.457 rs10085696 -0.122 0.049 0.014 -0.160 0.060 0.006 
 rs10283354 8 21016340 Intergenic C T 0.096 rs13250583 -0.221 0.082 0.007 -0.210 0.090 0.022 
 rs2514218 11 113392994 Intergenic T C 0.158 rs10750025 -0.184 0.066 0.006 -0.250 0.080 0.002 
 rs1022084 11 113508425 Intergenic G A 0.496 rs1713676 0.098 0.049 0.047 0.100 0.050 0.042 
 rs7940127 11 116102388 Intergenic T C 0.289 rs4938230 -0.115 0.054 0.034 -0.160 0.070 0.024 
  rs6496321 15 86858420 AGBL1 T G 0.154 rs12907323 0.216 0.067 0.001 0.210 0.070 0.003 
Abbreviations: SNP, Single Nucleotide Polymorphisms; ARIC, Atherosclerosis Risk in Communities (ARIC) Study; Chr, Chromosome;  SE, Standard Error; P, P-







APPENDIX H: ASSOCIATION BETWEEN UNWEIGHTED GENETIC RISK SCORE AND ETHANOL INTAKE AT ARIC VISIT 1-4 
AMONG AFRICAN-AMERICAN PARTICIPANTS 
Appendix Table 8. Association between unweighted genetic risk score (uGRS20) and weekly ethanol 
intake at ARIC visits 1-4 among African-American participants 
Weekly Ethanol Intake Beta SE P-value 
Percent of variance 
explained (%)   
At visit 1 -0.045 0.016 0.006 0.41  
At visit 2 -0.047 0.015 0.002 0.52  
At visit 3 -0.037 0.017 0.029 0.28  
At visit 4 -0.032 0.013 0.019 0.30  


















APPENDIX I: ASSOCIATION BETWEEN UNWEIGHTED GENETIC RISK SCORE AND ETHANOL INTAKE AT ARIC VISITS 1-4 
AMONG EUROPEAN-AMERICAN PARTICIPANTS 
Appendix Table 9. Association between unweighted genetic risk score (uGRS11) and weekly ethanol 
intake at ARIC visits 1-4 among European-American participants 
Weekly Ethanol Intake Beta SE P-value 
Percent of variance 
explained (%)   
At visit 1 0.014 0.012 0.246 0.02  
At visit 2 0.019 0.011 0.092 0.04  
At visit 3 0.024 0.012 0.036 0.06  
At visit 4 0.023 0.011 0.041 0.06  


















APPENDIX J: VALIDATION OF MULTIPLE IMPUTED GLOBAL Z FACTOR SCORES USING EXISTING DATA 
 
 
Appendix Figure 1. Validation of multiple imputed global Z score using existing data 
Note: Multiple imputation was done using chained equations, and 25 imputations were obtained and 
averaged for display in plot.  
20% validation sample (N=1,247) to simulate missing completely at random (MCAR) data. All 
participants had a 0.2 probability of being selected. If selected, participants’ Z scores at visit 5 were set 





































APPENDIX K: ADJUSTED MEAN DIFFERENCE IN 15-YEAR CHANGE IN COGNITIVE PERFORMANCE BY LONG-TERM 
ETHANOL INTAKE CATEGORY FOR AFRICAN-AMERICAN PARTICIPANTS 
 
Appendix Table 10. Adjusted mean difference in 15-year change in cognitive performance by long-term ethanol intake category for ARIC African-American 
participants* 
 
 Baseline Cognitive 
Score 15-Year Decline Difference*  
 
Test/Long-Term Drinking Category N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† Poverall 
Global Factor Score z-score  2169 -0.72 (0.75)     
    Stable never drinking 472 -0.74 (0.71) -1.36 (-1.77, -0.95) Reference Reference 0.314 
    Stable low-to-moderate drinking 178 -0.41 (0.79) -1.27 (-1.69, -0.86) 0.08 (-0.06, 0.23) -6%  
    Stable heavy drinking 15 -0.68 (0.90) -0.89 (-1.46, -0.33)                 0.46 (0.05, 0.88) -34%  
    Stable former drinking 191 -0.86 (0.67) -1.26 (-1.68, -0.85) 0.10 (-0.05, 0.25) -7%  
    Mostly low-to-moderate drinking 314 -0.59 (0.77) -1.26 (-1.67, -0.84) 0.10 (-0.02, 0.22) -8%  
    Mostly heavy drinking 53 -0.57 (0.92) -1.26 (-1.71, -0.81) 0.10 (-0.13, 0.33) -7%  
    Mostly former drinking 561 -0.70 (0.77) -1.26 (-1.67, -0.86) 0.10 (-0.01, 0.20) -7%  
Delayed Word Recall z-score 2169 -0.35 (1.11)     
    Stable never drinking 472 -0.25 (1.08) -1.99 (-2.92, -1.06) Reference Reference 0.132 
    Stable low-to-moderate drinking 178 -0.20 (1.06) -1.89 (-2.83, -0.95) 0.10 (-0.22, 0.42) -5%  
    Stable heavy drinking 15 -0.62 (1.02) -0.85 (-2.13,0.43) 1.14 (0.19, 2.08) -57%  
    Stable former drinking 191 -0.39 (1.01) -1.96 (-2.90, -1.02) 0.03 (-0.31, 0.36) -1.30%  
    Mostly low-to-moderate drinking 314 -0.33 (1.21) -1.78 (-2.72, -0.84) 0.21 (-0.06, 0.49) -11%  
    Mostly heavy drinking 53 -0.33 (1.17) -2.01 (-3.04, -0.99) -0.02 (-0.55, 0.50) 1%  
    Mostly former drinking 561 -0.40 (1.12) -1.75 (-2.67, -0.84) 0.24 (-0.01, 0.48) -12%  
Word Fluency z-score  2169 -0.36 (1.06)     
    Stable never drinking 472 -0.37 (1.03) -0.55 (-1.06, -0.04) Reference Reference 0.063 
    Stable low-to-moderate drinking 178 0.00 (1.17) -0.53 (-1.04, -0.01) 0.03 (-0.15, 0.20) -5%  
    Stable heavy drinking 15 -0.14 (0.96) -0.21 (-0.90, 0.49) 0.35 (-0.16, 0.86) -62%  
    Stable former drinking 191 -0.49 (1.05) -0.32 (-0.84, 0.2) 0.23 (0.05, 0.42) -42%  
    Mostly low-to-moderate drinking 314 -0.23 (1.08) -0.35 (-0.87, 0.16) 0.20 (0.05, 0.35) -36%  
    Mostly heavy drinking 53 -0.31 (1.14) -0.46 (-1.02, 0.10) 0.10 (-0.19, 0.38) -17%  
    Mostly former drinking 561 -0.37 (1.04) -0.44 (-0.95, 0.06) 0.11 (-0.02, 0.24) -19%  
 Digit Symbol Substitution z-score 2169 -0.95 (0.94)     
    Stable never drinking 2169 -0.95 (0.94) -0.96 (-1.41, -0.51) Reference Reference 0.847 
    Stable low-to-moderate drinking 472 -1.02 (0.90) -0.99 (-1.44, -0.54) -0.03 (-0.18, 0.12) 3%  
    Stable heavy drinking 178 -0.60 (0.97) -0.87 (-1.5, -0.25) 0.08 (-0.37, 0.54) -9%  
    Stable former drinking 15 -0.87 (0.94) -0.95 (-1.41, -0.5) 0.00 (-0.16, 0.16) -0.3%  
    Mostly low-to-moderate drinking 191 -1.12 (0.84) -0.95 (-1.4, -0.5) 0.01 (-0.12, 0.14) -0.9%  
    Mostly heavy drinking 314 -0.79 (0.91) -1.13 (-1.63, -0.64) -0.18 (-0.43, 0.08) 18%  
    Mostly former drinking 53 -0.69 (1.12) -0.99 (-1.43, -0.55) -0.03 (-0.14, 0.09) 3%  
* Difference. modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4;1996-1998) z-score. Negative values correspond to greater decline 
compared to the reference (stable never drinker). * Complete case analysis. Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, 
smoking status, body mass-index (BMI), diabetes, history of stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. † CI, confidence interval; percent, positive values represent % greater 






APPENDIX L: ADJUSTED MEAN DIFFERENCE IN 15-YEAR CHANGE IN COGNITIVE PERFORMANCE BY LONG-TERM 
ETHANOL INTAKE CATEGORY FOR EUROPEAN-AMERICAN PARTICIPANTS 
 
               Appendix Table 11. Adjusted mean difference in 15-year change in cognitive performance by long-term ethanol intake category for ARIC for European-American 
               participants* 
  Baseline Cognitive Score 15-Year Decline Difference*   
Test/Long-Term Drinking Category N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† Poverall 
Global Factor Score z-score  8707 0.12 (0.71)     
    Stable never drinking 1033 0.02 (0.68) -1.16 (-1.42, -0.91) Reference Reference 0.301 
    Stable low-to-moderate drinking 3095 0.30 (0.67) -1.14 (-1.39, -0.88) 0.03 (-0.03, 0.09) -2%  
    Stable heavy drinking 176 0.14 (0.69) -1.23 (-1.51, -0.95) -0.07 (-0.20, 0.07) 6%  
    Stable former drinking 664 -0.20 (0.74) -1.14 (-1.4, -0.88) 0.02(-0.07, 0.10) -2%  
    Mostly low-to-moderate drinking 1091 0.13 (0.74) -1.19 (-1.44, -0.93) -0.02 (-0.09, 0.05) 2%  
    Mostly heavy drinking 511 0.25 (0.69) -1.20 (-1.46, -0.94) -0.04 (-0.12, 0.05) 3%  
    Mostly former drinking 1687 0.02 (0.69) -1.17 (-1.42, -0.91) 0.00 (-0.07, 0.06) 0.3%  
Delayed Word Recall z-score  8707 0.06 (1.01)     
    Stable never drinking 1033 0.08(1.02) -1.74 (-2.29, -1.18) Reference Reference 0.032 
    Stable low-to-moderate drinking 3095 0.14 (0.97) -1.71 (-2.26, -1.16) 0.02 (-0.10 ,0.15) -1%  
    Stable heavy drinking 176 0.13 (1.05) -2.02 (-2.63, -1.42) -0.29 (-0.58, 0.01) 17%  
    Stable former drinking 664 -0.13 (1.01) -1.90 (-2.46, -1.34) -0.17 (-0.35, 0.01) 10%  
    Mostly low-to-moderate drinking 1091 0.04 (1.01) -1.78 (-2.33, -1.23) -0.04 (-0.19, 0.11) 2%  
    Mostly heavy drinking 511 0.14 (1.01) -1.85 (-2.42, -1.29) -0.12 (-0.30, 0.07) 7%  
    Mostly former drinking 1687 0.01 (1.04) -1.82 (-2.37, -1.28) -0.09 (-0.22, 0.05) 5%  
Word Fluency z-score  8707 0.13 (0.95)     
    Stable never drinking 1033 -0.09 (0.89) -0.51 (-0.82, -0.20) Reference Reference 0.249 
    Stable low-to-moderate drinking 3095 0.29 (0.93) -0.50 (-0.81, -0.19) 0.01 (-0.06, 0.08) -2%  
    Stable heavy drinking 176 0.36 (0.95) -0.61 (-0.96, -0.27) -0.10 (-0.27, 0.07) 20%  
    Stable former drinking 664 -0.08 (0.95) -0.55 (-0.87, -0.23) -0.04 (-0.14, 0.06) 8%  
    Mostly low-to-moderate drinking 1091 0.21 (0.98) -0.57 (-0.88, -0.25) -0.06 (-0.14, 0.03) 11%  
    Mostly heavy drinking 511 0.33 (0.99) -0.56 (-0.88, -0.24) -0.05 (-0.16, 0.06) 10%  
    Mostly former drinking 1687 0.02 (0.94) -0.54 (-0.85, -0.23) -0.03 (-0.10, 0.05) 5%  
Digit Symbol Substitution z-score  8707 0.16 (0.79)     
    Stable never drinking 1033 0.06 (0.77) -0.98 (-1.21, -0.74) Reference Reference 0.228 
    Stable low-to-moderate drinking 3095 0.35 (0.75) -1.03 (-1.26, -0.79) -0.05 (-0.11, 0.00) 5%  
    Stable heavy drinking 176 0.13 (0.74) -1.07 (-1.33, -0.80) -0.09 (-0.22, 0.04) 9%  
    Stable former drinking 664 -0.20 (0.80) -1.00 (-1.25, -0.76) -0.03 (-0.11, 0.05) 3%  
    Mostly low-to-moderate drinking 1091 0.16 (0.81) -1.05 (-1.29, -0.81) -0.07 (-0.14, -0.01) 7%  
    Mostly heavy drinking 511 0.25 (0.75) -1.08 (-1.32, -0.83) -0.10 (-0.18, -0.02) 10%  
    Mostly former drinking 1687 0.05 (0.78) -1.02 (-1.26, -0.79) -0.05 (-0.11, 0.01) 5%  
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4; 1996-1998) z-score. Negative values 
correspond to greater decline compared to the reference (stable never drinker). * Complete case analysis. Adjusted for age, age squared, sex, race-center, 
education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of stroke and the Apo lipoprotein E ε4 






APPENDIX M: ADJUSTED MEAN DIFFERENCE IN 15-YEAR CHANGE IN COGNITIVE PERFORMANCE BY QUARTILES OF 
CUMULATIVE AVERAGE ETHANOL INTAKE FOR ATHERSOCLEROSIS RISK IN COMMUNITIES (ARIC) FOR AFRICAN-
AMERICAN PARTICIPANTS 
 
Appendix Table 12. Adjusted Mean difference in 15-year change in cognitive performance by quartiles of cumulative average ethanol intake for 
Atherosclerosis Risk in Communities (ARIC) for African-American participants* 
  Baseline Cognitive Score 15-Year Decline Difference*   
Test/Quartile‡ N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† Poverall 
Global Factor Score z-score 2169 -0.72 (0.75)     
    Quartile 1 286 -0.54 (0.75) -1.18 (-1.77, -0.58) Reference Reference 0.812 
    Quartile 2 223 -0.50 (0.79) -1.17 (-1.77, -0.58) 0.00 (-0.13, 0.14) -0.4%  
    Quartile 3 254 -0.68 (0.83) -1.12 (-1.71, -0.53) 0.05 (-0.09, 0.20) -4%  
    Quartile 4 254 -0.72 (0.79) -1.19 (-1.77, -0.61) -0.01 (-0.17, 0.14) 1%  
Delayed Word Recall z-score 2169 -0.35 (1.11)     
    Quartile 1 286 -0.28 (1.10) -0.98 (-2.3,0.33) Reference Reference 0.644 
    Quartile 2 223 -0.24 (1.11) -0.86 (-2.17,0.45) 0.13 (-0.17, 0.43) -13%  
    Quartile 3 254 -0.38 (1.09) -0.95 (-2.25,0.34) 0.03 (-0.29, 0.35) -3%  
    Quartile 4 254 -0.46 (1.20) -1.07 (-2.35,0.21) -0.08 (-0.43, 0.27) 8%  
Word Fluency z-score 2169 -0.36 (1.06)     
    Quartile 1 286 -0.15 (1.06) -0.73 (-1.46,0.00) Reference Reference 0.904 
    Quartile 2 223 -0.16 (1.06) -0.76 (-1.48, -0.03) -0.03 (-0.20, 0.14) 4%  
    Quartile 3 254 -0.34 (1.14) -0.69 (-1.41, 0.02) 0.04 (-0.14, 0.21) -5%  
    Quartile 4 254 -0.36 (1.08) -0.74 (-1.45, -0.03) -0.01 (-0.20, 0.18) 1%  
Digit Symbol Substitution z-score 2169 -0.95 (0.94)     
    Quartile 1 286 -0.73 (0.91) -0.90 (-1.57, -0.24) Reference Reference 0.567 
    Quartile 2 223 -0.66 (0.91) -0.87 (-1.53, -0.21) 0.03 (-0.11, 0.18) -4%  
    Quartile 3 254 -0.91 (1.04) -0.84 (-1.49, -0.19) 0.06 (-0.09, 0.22) -7%  
    Quartile 4 254 -0.94 (0.97) -0.95 (-1.60, -0.30) -0.05 (-0.21, 0.12) 5%  
‡ Global Factor Score z-score:  Quartile 1: 0 g/wk., Quartile 2: 2.7-25.9g/wk., Quartile 3: 26.4-85.1g/wk., and Quartile 4: 85.5-2106.9g/wk.; Delayed Word Recall z-
score: Quartile 1: 0 g/wk., Quartile 2: 2.7-25.9 g/wk., Quartile 3: 26.4-85.1 g/wk., and Quartile 4: 85.5-2106.9 g/wk.; Word Fluency z-score: Quartile 1: 0 g/wk., 
Quartile 2: 2.7-25.9 g/wk., Quartile 3: 26.4-85.1 g/wk., and Quartile 4: 85.5-2106.9 g/wk.; and Digit Symbol Substitution z-score: Quartile 1: 0 g/wk., Quartile 2: 2.7-
25.9 g/wk., Quartile 3: 26.4-85.1 g/wk., and Quartile 4: 85.5-2106.9 g/wk. 
* Difference. modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4;1996-1998) z-score. Negative values 
correspond to greater decline compared to the reference (stable never drinker).  
* Complete case analysis 
Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of 
stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. 







APPENDIX N: ADJUSTED MEAN DIFFERENCE IN 15-YEAR CHANGE IN COGNITIVE PERFORMANCE BY QUARTILES OF 
CUMULATIVE AVERAGE ETHANOL FOR EUROPEAN-AMERICAN PARTICIPANTS 
 
Appendix Table 13. Adjusted Mean difference in 15-year change in cognitive performance by quartiles of cumulative average ethanol intake for 
Atherosclerosis Risk in Communities (ARIC) for European-American participants* 
 
 Baseline Cognitive 
Score 15-Year Decline Difference*  
 
Test/Quartile‡ N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† Poverall 
Global Factor Score z-score 8707 0.12 (0.71)     
   Quartile 1 1712 0.20 (0.70) -1.18 (-1.47, -0.89) Reference Reference 0.089 
   Quartile 2 1512 0.26 (0.69) -1.20 (-1.49, -0.91) -0.02 (-0.07, 0.03) 2%  
   Quartile 3 1610 0.22 (0.70) -1.22 (-1.51, -0.93) -0.04 (-0.09, 0.01) 3%  
   Quartile 4 1611 0.09 (0.70) -1.25 (-1.54, -0.96) -0.07 (-0.13, -0.01) 6%  
Delayed Word Recall z-score 8707 0.06 (1.01)     
   Quartile 1 1712 0.14 (0.97) -1.84 (-2.46, -1.21) Reference Reference 0.292 
   Quartile 2 1512 0.12 (1.00) -1.84 (-2.47, -1.21) 0.00 (-0.11, 0.11) 0.2%  
   Quartile 3 1610 0.08 (0.99) -1.81 (-2.43, -1.19) 0.02 (-0.09, 0.14) -1%  
   Quartile 4 1611 0.00 (1.03) -1.92 (-2.55, -1.30) -0.09 (-0.21, 0.04) 5%  
Word Fluency z-score 8707 0.13 (0.95)     
   Quartile 1 1712 0.14 (0.91) -0.64 (-0.99, -0.28) Reference Reference 0.406 
   Quartile 2 1512 0.24 (0.94) -0.66 (-1.02, -0.30) -0.02 (-0.08, 0.04) 3%  
   Quartile 3 1610 0.24 (0.97) -0.69 (-1.05, -0.34) -0.05 (-0.12, 0.01) 8%  
   Quartile 4 1611 0.23 (0.99) -0.68 (-1.03, -0.32) -0.04 (-0.11, 0.03) 6%  
Digit Symbol Substitution z-score 8707 0.16 (0.79)     
   Quartile 1 1712 0.26 (0.78) -1.06 (-1.34, -0.79) Reference Reference 0.384 
   Quartile 2 1512 0.31 (0.77) -1.09 (-1.36, -0.82) -0.03 (-0.07, 0.02) 2%  
   Quartile 3 1610 0.26 (0.78) -1.08 (-1.35, -0.81) -0.02 (-0.07, 0.03) 1%  
   Quartile 4 1611 0.10 (0.77) -1.11 (-1.38, -0.84) -0.05 (-0.10, 0.01) 4%  
‡ Global Factor Score z-score:  Quartile 1: 0 g/wk., Quartile 2: 2.7-24.3 g/wk., Quartile 3: 24.3-80.1 g/wk., and Quartile 4: 80.2-1071.5 g/wk.; Delayed Word Recall z-
score: Quartile 1: 0 g/wk., Quartile 2: 2.7-24.3 g/wk., Quartile 3: 24.3-80.1 g/wk., and Quartile 4: 80.2-1071.5 g/wk.; Word Fluency z-score: Quartile 1: 0 g/wk., Quartile 
2: 2.7-24.3 g/wk., Quartile 3: 24.3-80.1 g/wk., and Quartile 4: 80.2-1071.5 g/wk.; and Digit Symbol Substitution z-score: Quartile 1: 0 g/wk., Quartile 2: 2.7-24.3 g/wk., 
Quartile 3: 24.3-80.1 g/wk., and Quartile 4: 80.2-1071.5 g/wk. 
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4;1996-1998) z-score. Negative values correspond to 
greater decline compared to the reference (stable never drinker).  
* Complete case analysis 
Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of 
stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. 






APPENDIX O: ADJUSTED MEAN DIFERENCE IN 15-YEAR CHANGE IN COGNITIVE PERFORMANCE BY VISIT 4 ETHANOL 
INTAKE STATUS FOR AFRICAN-AMERICAN PARTICIPANTS 
 
Appendix Table 14. Adjusted Mean difference in 15-year change in cognitive performance by visit 4 ethanol intake status for Atherosclerosis Risk in 
Communities (ARIC) for African-American participants* 
  Baseline Cognitive Score 15-Year Decline Difference*   
Test/Drinking status at visit 4 N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† Poverall 
Global Factor Score z-score 2169 -0.72 (0.75)     
      Never drinking 753 -0.83 (0.70) -1.21 (-1.59, -0.83) Reference Reference 0.052 
      Low-to-moderate drinking 498 -0.54 (0.78) -1.09 (-1.47, -0.71) 0.12 (0.02, 0.22) -10%  
      Heavy drinking 68 -0.59 (0.91) -1.03 (-1.45, -0.61) 0.18 (-0.03, 0.39) -15%  
      Former drinking 848 -0.73 (0.75) -1.11 (-1.48, -0.74) 0.10 (0.01, 0.19) -8%  
Delayed Word Recall z-score 2169 -0.35 (1.11)     
      Never drinking 753 -0.37 (1.11) -1.88 (-2.73, -1.03) Reference Reference 0.478 
      Low-to-moderate drinking 498 -0.30 (1.17) -1.76 (-2.61, -0.90) 0.12 (-0.10,0.34) -6%  
      Heavy drinking 68 -0.39 (1.13) -1.71 (-2.65, -0.77) 0.17 (-0.30, 0.64) -9%  
      Former drinking 848 -0.37 (1.08) -1.72 (-2.56, -0.88) 0.16 (-0.04, 0.36) -8%  
Word Fluency z-score 2169 -0.36 (1.06)     
     Never drinking 753 -0.49 (1.02) -0.61 (-1.08, -0.14) Reference Reference 0.084 
     Low-to-moderate drinking 498 -0.14 (1.11) -0.47 (-0.95, 0.00) 0.13 (0.01, 0.26) -22%  
     Heavy drinking 68 -0.28 (1.1) -0.45 (-0.97, 0.07) 0.16 (-0.10, 0.41) -26%  
     Former drinking 848 -0.39 (1.03) -0.48 (-0.95, -0.01) 0.13 (0.02, 0.24) -21%  
Digit Symbol Substitution z-score 2169 -0.95 (0.94)     
     Never drinking 753 -1.11 (0.91) -0.80 (-1.22, -0.38) Reference Reference 0.529 
     Low-to-moderate drinking 498 -0.74 (0.94) -0.78 (-1.2, -0.36) 0.02 (-0.09, 0.12) -2%  
     Heavy drinking 68 -0.73 (1.08) -0.92 (-1.39, -0.46) -0.12 (-0.34, 0.10) 15%  
     Former drinking 848 -0.96 (0.92 -0.83 (-1.25, -0.42) -0.03 (-0.12, 0.07) 4%  
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4; 1996-1998) z-score. Negative 
values correspond to greater decline compared to the reference (stable never drinker).  
* Complete case analysis 
Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), 
diabetes, history of stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. 









APPENDIX P: ADJUSTED MEAN DIFFERENCE IN 15-YEAR CHANGE IN COGNITIVE PERFORMANCE BY VISIT 4 ETHANOL 
INTAKE STATUS FOR EUROPEAN-AMERICAN PARTICIPANTS  
Appendix Table 15. Adjusted Mean difference in 15-year change in cognitive performance by visit 4 ethanol intake status for Atherosclerosis Risk in 
Communities (ARIC) for European-American participants* 
  Baseline Cognitive Score 15-Year Decline Difference*   
Test/Drinking status at visit 4 N Mean (SD) Estimate (95% CI) Estimate (95% CI) Percent† Poverall 
Global Factor Score z-score 8707 0.12 (0.71)     
    Never drinking 1450 -0.02 (0.69) -1.16 (-1.41, -0.92) Reference Reference 0.249 
    Low-to-moderate drinking 4254 0.25 (0.69) -1.17 (-1.41, -0.92) 0.00 (-0.05, 0.05) 0.3%  
    Heavy drinking 629 0.23 (0.69) -1.23 (-1.49, -0.98) -0.07 (-0.15, 0.01) 6%  
    Former drinking 2373 -0.04 (0.71) -1.18 (-1.42, -0.93) -0.01 (-0.07, 0.04) 1%  
 Delayed Word Recall z-score 8707 0.06 (1.01)     
    Never drinking 1450 0.01 (1.01) -1.77 (-2.30, -1.24) Reference Reference 0.007 
    Low-to-moderate drinking 4254 0.11 (0.98) -1.77 (-2.30, -1.24) 0.00 (-0.11, 0.11) 0%  
    Heavy drinking 629 0.14 (1.03) -1.96 (-2.50, -1.41) -0.19 (-0.36, -0.02) 11%  
    Former drinking 2373 -0.03 (1.04) -1.88 (-2.41, -1.36) -0.11 (-0.23, 0.00) 6%  
 Word Fluency z-score 8707 0.13 (0.95)     
    Never drinking 1450 -0.11 (0.9) -0.44 (-0.74, -0.14) Reference Reference 0.348 
    Low-to-moderate drinking 4254 0.27 (0.95) -0.46 (-0.76, -0.16) -0.02 (-0.08, 0.04) 4%  
    Heavy drinking 629 0.35 (0.96) -0.51 (-0.82, -0.21) -0.08 (-0.17, 0.02) 18%  
    Former drinking 2373 -0.01 (0.94) -0.48 (-0.78, -0.18) -0.04 (-0.11, 0.03) 9%  
Digit Symbol Substitution z-score 8707 0.16 (0.79)     
    Never drinking 1450 0.03 (0.78) -0.97 (-1.20, -0.74) Reference Reference 0.016 
    Low-to-moderate drinking 4254 0.30 (0.77) -1.03 (-1.26, -0.80) -0.06 (-0.11, -0.01) 6%  
    Heavy drinking 629 0.23 (0.75) -1.08 (-1.32, -0.85) -0.11 (-0.18, -0.04) 11%  
    Former drinking 2373 -0.02 (0.79) -1.02 (-1.25, -0.79) -0.05 (-0.10, 0.00) 5%  
* Difference modeled as the follow-up neurocognitive exam (visit 5; 2011-2013) z-score minus study baseline (visit 4; 1996-1998) z-score. Negative values correspond to 
greater decline compared to the reference (stable never drinker).  
* Complete case analysis 
Adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical activity, smoking status, body mass-index (BMI), diabetes, history of 
stroke and the Apo lipoprotein E ε4 (APOE ε4) allele. 









APPENDIX Q: PLOT OF ADJUSTED MEAN DIFFERENCE IN 15-YEAR CHANGE IN COGNITIVE PERFORMANCE BY VISIT 4 
ETHANOL INTAKE STATUS BY RACE/ETHNICITY  
 
 
Appendix Figure 2. Estimated mean difference in the 15-year change in cognitive performance by average ethanol 
intake across 9-years in mid-life relative to quartile 1 
All models were adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical 
activity, smoking status, body mass-index (BMI), diabetes, history of stroke and the Apo lipoprotein E ε4 (APOE 
ε4) allele. All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the 
variance of a function of the within and between completed data set variances. Abbreviations: DWRT, delayed word 
recall test; DSST, digit symbol substitution test; and WFT, word fluency test. Sample sizes: African-Americans 
(global cognition, n=2362; DWRT, n=2,380; WFT, n=2,375; and DSST, n=2367) and European-Americans (global 






APPENDIX R: PLOT OF ADJUSTED MEAN DIFFERENCE IN 15-YEAR CHANGE IN COGNITIVE PERFORMANCE BY VISIT 4 
ETHANOL INTAKE STATUS BY RACE/ETHNICITY  
 
 
Appendix Figure 3. Estimated mean difference in the 15-year change in cognitive performance by ethanol intake at 
study baseline relative to those who reported never drinking 
All models were adjusted for age, age squared, sex, race-center, education attainment, diet quality score, physical 
activity, smoking status, body mass-index (BMI), diabetes, history of stroke and the Apo lipoprotein E ε4 (APOE 
ε4) allele. All estimates were averages from 25 rounds of multiple imputation combined using Rubin’s rule and the 
variance of a function of the within and between completed data set variances. Abbreviations: DWRT, delayed word 
recall test; DSST, digit symbol substitution test; and WFT, word fluency test. Sample sizes: African-Americans 
(global cognition, n=2360; DWRT, n=2378; WFT, n=2373; and DSST, n=2365) and European-Americans (global 





APPENDIX S: SINGLE SNPS INTERACTION RESULTS FOR AFRICAN-AMERICANS 
Appendix Table 16. Linear regression results for the interaction of ethanol intake-associated 
genetic variants and  log-ethanol intake in relation to 15-year cognitive change in general 
cognitive performance for African-Americans 
SNP   βE PE  βG PG  βGXE PGXE 
rs10008281 0.003 0.891 0.006 0.869 -0.013 0.558 
rs1022084 -0.038 0.143 -0.013 0.701 0.029 0.129 
rs10283354 -0.006 0.715 -0.065 0.237 -0.006 0.860 
rs10840100 -0.014 0.555 -0.007 0.831 0.009 0.647 
rs11768390 -0.016 0.476 -0.045 0.183 0.011 0.557 
rs11940694 0.007 0.738 0.026 0.430 -0.015 0.426 
rs12910841 -0.013 0.444 -0.017 0.776 0.033 0.285 
rs1685404 -0.010 0.592 -0.040 0.283 0.010 0.685 
rs2514218 0.000 0.991 0.010 0.815 -0.024 0.396 
rs271085 0.005 0.801 0.032 0.381 -0.017 0.417 
rs35608804 -0.005 0.822 0.001 0.970 0.000 0.998 
rs4780836 -0.007 0.745 0.023 0.496 0.002 0.931 
rs58440244 -0.004 0.836 0.022 0.542 -0.003 0.907 
rs62040427 0.001 0.954 -0.001 0.983 -0.014 0.523 
rs6496321 -0.006 0.727 -0.022 0.631 0.003 0.893 
rs6673687 -0.007 0.724 -0.011 0.743 0.002 0.910 
rs7355953 -0.004 0.795 -0.060 0.393 -0.024 0.624 
rs78757076 0.004 0.813 -0.012 0.763 -0.023 0.310 
rs7940127 0.001 0.939 -0.004 0.904 -0.014 0.528 
rs9929584 -0.012 0.587 -0.033 0.310 0.007 0.710 
Abbreviations: ARIC, Atherosclerosis Risk in Communities (ARIC) Study; SNP, Single nucleotide 
polymorphism;   βE, estimate for log-ethanol intake with corresponding p-value (PE) ; βG, estimate for the 
SNP with corresponding p-value (PG);  βGXE, Estimate for the interaction term between the SNP and log-
ethanol intake with corresponding p-value (PGXE). 
Adjusted for age, sex, race-center, education attainment, smoking status, body mass index (BMI), 


















APPENDIX T: SINGLE SNPS INTERACTION RESULTS FOR EUROPEAN-AMERICANS 
Appendix Table 17. Linear regression results for the interaction of ethanol intake-
associated genetic variants and  log-ethanol intake in relation to 15-year cognitive 
change in general cognitive performance for European-Americans 
SNP  βE PE  βG PG  βGXE PGXE 
rs1123285 -0.011 0.088 -0.001 0.952 -0.001 0.850 
rs1229984 -0.013 0.011 -0.036 0.443 0.002 0.927 
rs12651313 -0.015 0.034 -0.024 0.134 0.003 0.584 
rs1713676 -0.011 0.150 0.007 0.674 -0.002 0.766 
rs2165670 -0.015 0.006 -0.033 0.233 0.011 0.270 
rs55872084 -0.012 0.053 -0.010 0.607 -0.001 0.839 
rs62250685 -0.014 0.034 0.009 0.572 0.002 0.754 
rs7185555 -0.011 0.046 0.013 0.592 -0.006 0.490 
rs72859280 -0.012 0.020 0.008 0.867 -0.010 0.585 
rs74664784 -0.012 0.059 0.014 0.392 0.000 0.994 
rs7950166 -0.008 0.279 0.001 0.937 -0.006 0.340 
Abbreviations: SNP, Single nucleotide polymorphism;   βE, estimate for log-ethanol intake with 
corresponding p-value (PE) ; βG, estimate for the SNP with corresponding p-value (PG);  βGXE, 
Estimate for the interaction term between the SNP and log-ethanol intake with corresponding p-
value (PGXE). 
Adjusted for age, sex, race-center, education attainment, smoking status, body mass index 





























1. Ortman, J.M., V.A. Velkoff, and H. Hogan, An Aging Nation: The Older Population in the 
United States. 2014, U.S.C. Bureau (Ed.)  Washington, DC. 
2. Murray, C.J., C. Atkinson, K. Bhalla, G. Birbeck, R. Burstein, D. Chou, R. Dellavalle, G. Danaei, 
M. Ezzati, A. Fahimi, D. Flaxman, Foreman, S. Gabriel, E. Gakidou, N. Kassebaum, S. 
Khatibzadeh, S. Lim, S.E. Lipshultz, S. London, Lopez, M.F. MacIntyre, A.H. Mokdad, A. 
Moran, A.E. Moran, D. Mozaffarian, T. Murphy, M. Naghavi, C. Pope, T. Roberts, J. Salomon, 
D.C. Schwebel, S. Shahraz, D.A. Sleet, Murray, J. Abraham, M.K. Ali, C. Atkinson, D.H. 
Bartels, K. Bhalla, G. Birbeck, R. Burstein, H. Chen, M.H. Criqui, Dahodwala, Jarlais, E.L. Ding, 
E.R. Dorsey, B.E. Ebel, M. Ezzati, Fahami, S. Flaxman, A.D. Flaxman, D. Gonzalez-Medina, B. 
Grant, H. Hagan, H. Hoffman, N. Kassebaum, S. Khatibzadeh, J.L. Leasher, J. Lin, S.E. 
Lipshultz, R. Lozano, Y. Lu, L. Mallinger, M.M. McDermott, R. Micha, T.R. Miller, A.A. 
Mokdad, A.H. Mokdad, D. Mozaffarian, M. Naghavi, K.M. Narayan, S.B. Omer, P.M. Pelizzari, 
D. Phillips, D. Ranganathan, F.P. Rivara, T. Roberts, U. Sampson, E. Sanman, A. Sapkota, D.C. 
Schwebel, S. Sharaz, R. Shivakoti, G.M. Singh, D. Singh, M. Tavakkoli, J.A. Towbin, J.D. 
Wilkinson, A. Zabetian, Murray, J. Abraham, M.K. Ali, M. Alvardo, C. Atkinson, L.M. Baddour, 
E.J. Benjamin, K. Bhalla, G. Birbeck, I. Bolliger, R. Burstein, E. Carnahan, D. Chou, S.S. Chugh, 
A. Cohen, K.E. Colson, L.T. Cooper, W. Couser, M.H. Criqui, K.C. Dabhadkar, R.P. Dellavalle, 
Jarlais, D. Dicker, E.R. Dorsey, H. Duber, B.E. Ebel, R.E. Engell, M. Ezzati, D.T. Felson, M.M. 
Finucane, S. Flaxman, A.D. Flaxman, T. Fleming, Foreman, M.H. Forouzanfar, G. Freedman, 
M.K. Freeman, E. Gakidou, R.F. Gillum, D. Gonzalez-Medina, R. Gosselin, H.R. Gutierrez, H. 
Hagan, R. Havmoeller, H. Hoffman, K.H. Jacobsen, S.L. James, R. Jasrasaria, S. Jayarman, N. 
Johns, N. Kassebaum, S. Khatibzadeh, Q. Lan, J.L. Leasher, S. Lim, S.E. Lipshultz, S. London, 
Lopez, R. Lozano, Y. Lu, L. Mallinger, M. Meltzer, G.A. Mensah, C. Michaud, T.R. Miller, C. 
Mock, T.E. Moffitt, A.A. Mokdad, A.H. Mokdad, A. Moran, M. Naghavi, K.M. Narayan, R.G. 
Nelson, C. Olives, S.B. Omer, K. Ortblad, B. Ostro, P.M. Pelizzari, D. Phillips, M. Raju, H. 
Razavi, B. Ritz, T. Roberts, R.L. Sacco, J. Salomon, U. Sampson, D.C. Schwebel, S. Shahraz, K. 
Shibuya, D. Silberberg, J.A. Singh, K. Steenland, J.A. Taylor, G.D. Thurston, M.S. Vavilala, T. 
Vos, G.R. Wagner, M.A. Weinstock, M.G. Weisskopf, S. Wulf and Murray, The state of US 
health, 1990-2010: burden of diseases, injuries, and risk factors. Jama, 2013. 310(6): p. 591-608. 
3. Sorensen, S., P. Duberstein, D. Gill, and M. Pinquart, Dementia care: mental health effects, 
intervention strategies, and clinical implications. Lancet Neurol, 2006. 5(11): p. 961-73. 
4. Pinquart, M. and S. Sorensen, Associations of stressors and uplifts of caregiving with caregiver 
burden and depressive mood: a meta-analysis. J Gerontol B Psychol Sci Soc Sci, 2003. 58(2): p. 
P112-28. 
5. Vitaliano, P.P., J. Zhang, and J.M. Scanlan, Is caregiving hazardous to one's physical health? A 
meta-analysis. Psychol Bull, 2003. 129(6): p. 946-72. 
6. Schulz, R. and S.R. Beach, Caregiving as a risk factor for mortality: the Caregiver Health Effects 
Study. Jama, 1999. 282(23): p. 2215-9. 
7. Kiecolt-Glaser, J.K., R. Glaser, S. Gravenstein, W.B. Malarkey, and J. Sheridan, Chronic stress 
alters the immune response to influenza virus vaccine in older adults. Proc Natl Acad Sci U S A, 





8. Hurd, M.D., P. Martorell, and K.M. Langa, Monetary costs of dementia in the United States. N 
Engl J Med, 2013. 369(5): p. 489-90. 
9. Substance Abuse and Mental Health Services Administration (SAMHSA). 2015 National Survey 
on Drug Use and Health (NSDUH). Table 2.41B—Alcohol Use in Lifetime, Past Year, and Past 
Month among Persons Aged 12 or Older, by Demographic Characteristics: Percentages, 2014 
and 2015. 
10. Beydoun, M.A., H.A. Beydoun, A.A. Gamaldo, A. Teel, A.B. Zonderman, and Y. Wang, 
Epidemiologic studies of modifiable factors associated with cognition and dementia: systematic 
review and meta-analysis. BMC Public Health, 2014. 14: p. 643. 
11. Committee on the Public Health Dimensions of Cognitive, Aging Board on Health Sciences 
Policy,  Institute of Medicine, The National Academies Collection: Reports funded by National 
Institutes of Health, in Cognitive Aging: Progress in Understanding and Opportunities for 
Action, D.G. Blazer, K. Yaffe, and C.T. Liverman, Editors. 2015, National Academies Press (US) 
Copyright 2015 by the National Academy of Sciences. All rights reserved.: Washington (DC). 
12. Salthouse, T.A., When does age-related cognitive decline begin? Neurobiol Aging, 2009. 30(4): 
p. 507-14. 
13. Christensen, H. and J. O'Brien, Age-related cognitive decline and its relationship to dementia. In 
O'Brien J, Ames D, Burns A, eds. Dementia, 2000: p. 15-28. 
14. Schaie, K., The optimization of cognitive functioning in old age: predictions based on cohort-
sequential and longitudinal data. In Baltes PB, Baltes MM, eds. Successful ageing. 1990, 
Cambridge: European Science Foundation and Cambridge University Press. 
15. Lezak , M., D. Howieson, E. Bigler, and D. Tranel, Neuropsychological Assessment. 5 ed. 2012, 
New York: Oxford University Press. 
16. Salthouse, T., Consequences of age-related cognitive declines. Annu Rev Psychol, 2012. 63: p. 
201-26. 
17. Gow, J., Gilhooly, M., Risk factors for dementia and cognitive decline. Glasgow: NHS Health 
Scotland, 2003. 
18. HM, F., The clinical significance of normal cognitive decline in later life. In Fillit HM, Butler 
RN, eds. Cognitive decline: strategies for prevention. 1997, London: Greenwich Medical Media. 
19. DR, R., Brain Aging: Models, Methods, and Mechanisms. 2007, Boca Raton (FL): CRC 
Press/Taylor & Francis. 
20. Craik FIM, J.J., Human memory. In: Craik FIM, Salthouse TA, editors. The Handbook of Aging 
and Cognition. Erlbaum; Hillsdale, NJ. 1992. 
21. Silver, M.H., E. Jilinskaia, and T.T. Perls, Cognitive functional status of age-confirmed 






22. Schaie, K.W., Variability in cognitive function in the elderly: implications for societal 
participation. Basic Life Sci, 1988. 43: p. 191-211. 
23. Deary, I.J., J. Corley, A.J. Gow, S.E. Harris, L.M. Houlihan, R.E. Marioni, L. Penke, S.B. 
Rafnsson, and J.M. Starr, Age-associated cognitive decline. Br Med Bull, 2009. 92: p. 135-52. 
24. Zelinski, E.M. and S.T. Stewart, Individual differences in 16-year memory changes. Psychol 
Aging, 1998. 13(4): p. 622-30. 
25. Comijs, H.C., M.G. Dik, D.J. Deeg, and C. Jonker, The course of cognitive decline in older 
persons: results from the longitudinal aging study amsterdam. Dement Geriatr Cogn Disord, 
2004. 17(3): p. 136-42. 
26. Sachs-Ericsson, N. and D.G. Blazer, Racial differences in cognitive decline in a sample of 
community-dwelling older adults: the mediating role of education and literacy. Am J Geriatr 
Psychiatry, 2005. 13(11): p. 968-75. 
27. Schaie, K.W., The Seattle Longitudinal Study: a thirty-five-year inquiry of adult intellectual 
development. Z Gerontol, 1993. 26(3): p. 129-37. 
28. Zsembik, B.A. and M.K. Peek, Race differences in cognitive functioning among older adults. J 
Gerontol B Psychol Sci Soc Sci, 2001. 56(5): p. S266-74. 
29. Sloan, F.A. and J. Wang, Disparities among older adults in measures of cognitive function by 
race or ethnicity. J Gerontol B Psychol Sci Soc Sci, 2005. 60(5): p. P242-50. 
30. Brewster, P.W.H., R.J. Melrose, M.J. Marquine, J.K. Johnson, A. Napoles, A. MacKay-Brandt, S. 
Farias, B. Reed, and D. Mungas, Life Experience and Demographic Influences on Cognitive 
Function in Older Adults. Neuropsychology, 2014. 28(6): p. 846-858. 
31. Sachs-Ericsson, N. and D.G. Blazer, Racial differences in cognitive decline in a sample of 
community-dwelling older adults - The mediating role of education and literacy. American 
Journal of Geriatric Psychiatry, 2005. 13(11): p. 968-975. 
32. Yaffe, K., A.J. Fiocco, K. Lindquist, E. Vittinghoff, E.M. Simonsick, A.B. Newman, S. 
Satterfield, C. Rosano, S.M. Rubin, H.N. Ayonayon, and T.B. Harris, Predictors of maintaining 
cognitive function in older adults: the Health ABC study. Neurology, 2009. 72(23): p. 2029-35. 
33. Lee, H.B., A.K. Richardson, B.S. Black, A.D. Shore, J.D. Kasper, and P.V. Rabins, Race and 
cognitive decline among community-dwelling elders with mild cognitive impairment: Findings 
from the Memory and Medical Care Study. Aging & Mental Health, 2012. 16(3): p. 372-377. 
34. Atkinson, H.H., M. Cesari, S.B. Kritchevsky, B. Penninx, L.P. Fried, J.M. Guralnik, and J.D. 
Williamson, Predictors of combined cognitive and physical decline. Journal of the American 
Geriatrics Society, 2005. 53(7): p. 1197-1202. 
35. Masel, M.C. and M.K. Peek, Ethnic Differences in Cognitive Function Over Time. Annals of 





36. Karlamangla, A.S., D. Miller-Martinez, C.S. Aneshensel, T.E. Seeman, R.G. Wight, and J. 
Chodosh, Trajectories of Cognitive Function in Late Life in the United States: Demographic and 
Socioeconomic Predictors. American Journal of Epidemiology, 2009. 170(3): p. 331-342. 
37. Barnes, L.L., R.S. Wilson, Y. Li, D.W. Gilley, D.A. Bennett, and D.A. Evans, Change in 
cognitive function in Alzheimer's disease in African-American and white persons. 
Neuroepidemiology, 2006. 26(1): p. 16-22. 
38. Alley, D., K. Suthers, and E. Crimmins, Education and Cognitive Decline in Older Americans: 
Results From the AHEAD Sample. Research on aging, 2007. 29(1): p. 73-94. 
39. 2014 Alzheimer's disease facts and figures. Alzheimers Dement, 2014. 10(2): p. e47-92. 
40. Stott, D., Cognitive decline in ageing. Asian J Gerontol Geriatr, 2006. 1: p. 21-25. 
41. R Sujata, S.D., Dementia and cognitive decline: A review of the evidence. 2014. 
42. Gauthier, S., B. Reisberg, M. Zaudig, R.C. Petersen, K. Ritchie, K. Broich, S. Belleville, H. 
Brodaty, D. Bennett, H. Chertkow, J.L. Cummings, M. de Leon, H. Feldman, M. Ganguli, H. 
Hampel, P. Scheltens, M.C. Tierney, P. Whitehouse, and B. Winblad, Mild cognitive impairment. 
Lancet, 2006. 367(9518): p. 1262-70. 
43. Albert, M.S., S.T. DeKosky, D. Dickson, B. Dubois, H.H. Feldman, N.C. Fox, A. Gamst, D.M. 
Holtzman, W.J. Jagust, R.C. Petersen, P.J. Snyder, M.C. Carrillo, B. Thies, and C.H. Phelps, The 
diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the 
National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for 
Alzheimer's disease. Alzheimers Dement, 2011. 7(3): p. 270-9. 
44. Knopman, D.S., R.F. Gottesman, A.R. Sharrett, L.M. Wruck, B.G. Windham, L. Coker, A.L. 
Schneider, S. Hengrui, A. Alonso, J. Coresh, M.S. Albert, and T.H. Mosley, Jr., Mild Cognitive 
Impairment and Dementia Prevalence: The Atherosclerosis Risk in Communities Neurocognitive 
Study (ARIC-NCS). Alzheimers Dement (Amst), 2016. 2: p. 1-11. 
45. Roberts, R. and D.S. Knopman, Classification and epidemiology of MCI. Clin Geriatr Med, 2013. 
29(4): p. 753-72. 
46. Petersen, R.C., R.O. Roberts, D.S. Knopman, B.F. Boeve, Y.E. Geda, R.J. Ivnik, G.E. Smith, and 
C.R. Jack, Jr., Mild cognitive impairment: ten years later. Arch Neurol, 2009. 66(12): p. 1447-55. 
47. Luck, T., M. Luppa, S. Briel, and S.G. Riedel-Heller, Incidence of mild cognitive impairment: a 
systematic review. Dement Geriatr Cogn Disord, 2010. 29(2): p. 164-75. 
48. Plassman, B.L., K.M. Langa, R.J. McCammon, G.G. Fisher, G.G. Potter, J.R. Burke, D.C. 
Steffens, N.L. Foster, B. Giordani, F.W. Unverzagt, K.A. Welsh-Bohmer, S.G. Heeringa, D.R. 
Weir, and R.B. Wallace, Incidence of dementia and cognitive impairment, not dementia in the 
United States. Ann Neurol, 2011. 70(3): p. 418-26. 
49. Bennett, D.A., R.S. Wilson, J.A. Schneider, D.A. Evans, L.A. Beckett, N.T. Aggarwal, L.L. 
Barnes, J.H. Fox, and J. Bach, Natural history of mild cognitive impairment in older persons. 





50. Hunderfund, A.L., R.O. Roberts, T.C. Slusser, C.L. Leibson, Y.E. Geda, R.J. Ivnik, E.G. 
Tangalos, and R.C. Petersen, Mortality in amnestic mild cognitive impairment: a prospective 
community study. Neurology, 2006. 67(10): p. 1764-8. 
51. Mitchell, A.J. and M. Shiri-Feshki, Rate of progression of mild cognitive impairment to 
dementia--meta-analysis of 41 robust inception cohort studies. Acta Psychiatr Scand, 2009. 
119(4): p. 252-65. 
52. Farias, S.T., D. Mungas, B.R. Reed, D. Harvey, and C. DeCarli, Progression of mild cognitive 
impairment to dementia in clinic- vs community-based cohorts. Arch Neurol, 2009. 66(9): p. 
1151-7. 
53. Palmer, K., A.K. Berger, R. Monastero, B. Winblad, L. Backman, and L. Fratiglioni, Predictors 
of progression from mild cognitive impairment to Alzheimer disease. Neurology, 2007. 68(19): p. 
1596-602. 
54. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth 
Edition (DSM-5), American Psychiatric Association, Arlington 2013. 
55. McKhann, G.M., D.S. Knopman, H. Chertkow, B.T. Hyman, C.R. Jack, Jr., C.H. Kawas, W.E. 
Klunk, W.J. Koroshetz, J.J. Manly, R. Mayeux, R.C. Mohs, J.C. Morris, M.N. Rossor, P. 
Scheltens, M.C. Carrillo, B. Thies, S. Weintraub, and C.H. Phelps, The diagnosis of dementia due 
to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's 
Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement, 
2011. 7(3): p. 263-9. 
56. Roman, G.C., T.K. Tatemichi, T. Erkinjuntti, J.L. Cummings, J.C. Masdeu, J.H. Garcia, L. 
Amaducci, J.M. Orgogozo, A. Brun, A. Hofman, and et al., Vascular dementia: diagnostic 
criteria for research studies. Report of the NINDS-AIREN International Workshop. Neurology, 
1993. 43(2): p. 250-60. 
57. McKeith, I.G., D.W. Dickson, J. Lowe, M. Emre, J.T. O'Brien, H. Feldman, J. Cummings, J.E. 
Duda, C. Lippa, E.K. Perry, D. Aarsland, H. Arai, C.G. Ballard, B. Boeve, D.J. Burn, D. Costa, T. 
Del Ser, B. Dubois, D. Galasko, S. Gauthier, C.G. Goetz, E. Gomez-Tortosa, G. Halliday, L.A. 
Hansen, J. Hardy, T. Iwatsubo, R.N. Kalaria, D. Kaufer, R.A. Kenny, A. Korczyn, K. Kosaka, 
V.M. Lee, A. Lees, I. Litvan, E. Londos, O.L. Lopez, S. Minoshima, Y. Mizuno, J.A. Molina, 
E.B. Mukaetova-Ladinska, F. Pasquier, R.H. Perry, J.B. Schulz, J.Q. Trojanowski, and M. 
Yamada, Diagnosis and management of dementia with Lewy bodies: third report of the DLB 
Consortium. Neurology, 2005. 65(12): p. 1863-72. 
58. Neary, D., J.S. Snowden, L. Gustafson, U. Passant, D. Stuss, S. Black, M. Freedman, A. Kertesz, 
P.H. Robert, M. Albert, K. Boone, B.L. Miller, J. Cummings, and D.F. Benson, Frontotemporal 
lobar degeneration: a consensus on clinical diagnostic criteria. Neurology, 1998. 51(6): p. 1546-
54. 
59. 2015 Alzheimer's disease facts and figures. Alzheimers Dement, 2015. 11(3): p. 332-84. 
60. M Prince, M.G., M Prina, Alzheimer's Disease International. Policy Brief for Heads of 






61.  National Center for Health Statistics. Deaths: Final Data for 2013.National Vital Statistics 
Report. 2015, Hyattsville, Md. 
62. Plassman, B.L., J.W. Williams, Jr., J.R. Burke, T. Holsinger, and S. Benjamin, Systematic review: 
factors associated with risk for and possible prevention of cognitive decline in later life. Ann 
Intern Med, 2010. 153(3): p. 182-93. 
63. Baumgart, M., H.M. Snyder, M.C. Carrillo, S. Fazio, H. Kim, and H. Johns, Summary of the 
evidence on modifiable risk factors for cognitive decline and dementia: A population-based 
perspective. Alzheimers Dement, 2015. 11(6): p. 718-26. 
64. Yamada, M., R.D. Landes, Y. Mimori, Y. Nagano, and H. Sasaki, Trajectories of cognitive 
function in dementia-free subjects: Radiation Effects Research Foundation Adult Health Study. J 
Neurol Sci, 2015. 351(1-2): p. 115-9. 
65. Gur, R.E. and R.C. Gur, Gender differences in aging: cognition, emotions, and neuroimaging 
studies. Dialogues in Clinical Neuroscience, 2002. 4(2): p. 197-210. 
66. Saykin, A.J., R.C. Gur, R.E. Gur, D.L. Shtasel, K.A. Flannery, L.H. Mozley, B.L. Malamut, B. 
Watson, and P.D. Mozley, Normative neuropsychological test performance: effects of age, 
education, gender and ethnicity. Appl Neuropsychol, 1995. 2(2): p. 79-88. 
67. Josefsson, M., X. de Luna, S. Pudas, L.G. Nilsson, and L. Nyberg, Genetic and lifestyle 
predictors of 15-year longitudinal change in episodic memory. J Am Geriatr Soc, 2012. 60(12): p. 
2308-12. 
68. Barnes, L.L., R.S. Wilson, J.A. Schneider, J.L. Bienias, D.A. Evans, and D.A. Bennett, Gender, 
cognitive decline, and risk of AD in older persons. Neurology, 2003. 60(11): p. 1777-81. 
69. Jacqmin-Gadda, H., C. Fabrigoule, D. Commenges, and J.F. Dartigues, A 5-year longitudinal 
study of the Mini-Mental State Examination in normal aging. Am J Epidemiol, 1997. 145(6): p. 
498-506. 
70. Weber, D., V. Skirbekk, I. Freund, and A. Herlitz, The changing face of cognitive gender 
differences in Europe. Proc Natl Acad Sci U S A, 2014. 111(32): p. 11673-8. 
71. Manly, J.J., P. Touradji, M.X. Tang, and Y. Stern, Literacy and memory decline among ethnically 
diverse elders. J Clin Exp Neuropsychol, 2003. 25(5): p. 680-90. 
72. Cummings, S.M., J.A. Neff, and B.A. Husaini, Functional impairment as a predictor of 
depressive symptomatology: the role of race, religiosity, and social support. Health Soc Work, 
2003. 28(1): p. 23-32. 
73. Cullum, S., F.A. Huppert, M. McGee, T. Dening, A. Ahmed, E.S. Paykel, and C. Brayne, Decline 
across different domains of cognitive function in normal ageing: results of a longitudinal 
population-based study using CAMCOG. Int J Geriatr Psychiatry, 2000. 15(9): p. 853-62. 
74. Bosma, H., M.P. van Boxtel, R.W. Ponds, P.J. Houx, A. Burdorf, and J. Jolles, Mental work 
demands protect against cognitive impairment: MAAS prospective cohort study. Exp Aging Res, 





75. Lenehan, M.E., M.J. Summers, N.L. Saunders, J.J. Summers, and J.C. Vickers, Relationship 
between education and age-related cognitive decline: a review of recent research. 
Psychogeriatrics, 2014. 
76. Schmand, B., J.H. Smit, M.I. Geerlings, and J. Lindeboom, The effects of intelligence and 
education on the development of dementia. A test of the brain reserve hypothesis. Psychol Med, 
1997. 27(6): p. 1337-44. 
77. Albert, M.S., How does education affect cognitive function? Ann Epidemiol, 1995. 5(1): p. 76-8. 
78. Seeman, T.E., D.M. Miller-Martinez, S. Stein Merkin, M.E. Lachman, P.A. Tun, and A.S. 
Karlamangla, Histories of social engagement and adult cognition: midlife in the U.S. study. J 
Gerontol B Psychol Sci Soc Sci, 2011. 66 Suppl 1: p. i141-52. 
79. Crooks, V.C., J. Lubben, D.B. Petitti, D. Little, and V. Chiu, Social network, cognitive function, 
and dementia incidence among elderly women. Am J Public Health, 2008. 98(7): p. 1221-7. 
80. Scarmeas, N., G. Levy, M.X. Tang, J. Manly, and Y. Stern, Influence of leisure activity on the 
incidence of Alzheimer's disease. Neurology, 2001. 57(12): p. 2236-42. 
81. Holtzman, R.E., G.W. Rebok, J.S. Saczynski, A.C. Kouzis, K. Wilcox Doyle, and W.W. Eaton, 
Social network characteristics and cognition in middle-aged and older adults. J Gerontol B 
Psychol Sci Soc Sci, 2004. 59(6): p. P278-84. 
82. Barnes, L.L., C.F. Mendes de Leon, R.S. Wilson, J.L. Bienias, and D.A. Evans, Social resources 
and cognitive decline in a population of older African Americans and whites. Neurology, 2004. 
63(12): p. 2322-6. 
83. Karp, A., S. Paillard-Borg, H.X. Wang, M. Silverstein, B. Winblad, and L. Fratiglioni, Mental, 
physical and social components in leisure activities equally contribute to decrease dementia risk. 
Dement Geriatr Cogn Disord, 2006. 21(2): p. 65-73. 
84. Stine-Morrow, E.A., J.M. Parisi, D.G. Morrow, and D.C. Park, The effects of an engaged lifestyle 
on cognitive vitality: a field experiment. Psychol Aging, 2008. 23(4): p. 778-86. 
85. Ertel, K.A., M.M. Glymour, and L.F. Berkman, Effects of social integration on preserving 
memory function in a nationally representative US elderly population. Am J Public Health, 2008. 
98(7): p. 1215-20. 
86. Noice, T., H. Noice, and A.F. Kramer, Participatory arts for older adults: a review of benefits 
and challenges. Gerontologist, 2014. 54(5): p. 741-53. 
87. James, B.D., R.S. Wilson, L.L. Barnes, and D.A. Bennett, Late-life social activity and cognitive 
decline in old age. J Int Neuropsychol Soc, 2011. 17(6): p. 998-1005. 
88. Yeh, S.-C.J. and Y.-Y. Liu, Influence of social support on cognitive function in the elderly. BMC 
Health Services Research, 2003. 3: p. 9-9. 
89. Berkman, L.F., Which influences cognitive function: living alone or being alone? Lancet, 2000. 





90. Christensen, H., A. Korten, A.F. Jorm, A.S. Henderson, R. Scott, and A.J. Mackinnon, Activity 
levels and cognitive functioning in an elderly community sample. Age Ageing, 1996. 25(1): p. 72-
80. 
91. Brown, C.L., L.E. Gibbons, R.F. Kennison, A. Robitaille, M. Lindwall, M.B. Mitchell, S.D. 
Shirk, A. Atri, C.R. Cimino, A. Benitez, S.W. Macdonald, E.M. Zelinski, S.L. Willis, K.W. 
Schaie, B. Johansson, R.A. Dixon, D.M. Mungas, S.M. Hofer, and A.M. Piccinin, Social activity 
and cognitive functioning over time: a coordinated analysis of four longitudinal studies. J Aging 
Res, 2012. 2012: p. 287438. 
92. Peters, R., N. Beckett, M. Geneva, M. Tzekova, F.H. Lu, R. Poulter, N. Gainsborough, B. 
Williams, M.C. de Vernejoul, A. Fletcher, and C. Bulpitt, Sociodemographic and lifestyle risk 
factors for incident dementia and cognitive decline in the HYVET. Age Ageing, 2009. 38(5): p. 
521-7. 
93. Herbert, L.E., P.A. Scherr, L.A. Beckett, M.S. Albert, B. Rosner, J.O. Taylor, and D.A. Evans, 
Relation of smoking and low-to-moderate alcohol consumption to change in cognitive function: a 
longitudinal study in a defined community of older persons. Am J Epidemiol, 1993. 137(8): p. 
881-91. 
94. Chen, W.T., P.N. Wang, S.J. Wang, J.L. Fuh, K.N. Lin, and H.C. Liu, Smoking and cognitive 
performance in the community elderly: a longitudinal study. J Geriatr Psychiatry Neurol, 2003. 
16(1): p. 18-22. 
95. van Dijk, E.J., N.D. Prins, H.A. Vrooman, A. Hofman, P.J. Koudstaal, and M.M. Breteler, 
Progression of cerebral small vessel disease in relation to risk factors and cognitive 
consequences: Rotterdam Scan study. Stroke, 2008. 39(10): p. 2712-9. 
96. Ott, A., K. Andersen, M.E. Dewey, L. Letenneur, C. Brayne, J.R. Copeland, J.F. Dartigues, P. 
Kragh-Sorensen, A. Lobo, J.M. Martinez-Lage, T. Stijnen, A. Hofman, and L.J. Launer, Effect of 
smoking on global cognitive function in nondemented elderly. Neurology, 2004. 62(6): p. 920-4. 
97. Nooyens, A.C., B.M. van Gelder, and W.M. Verschuren, Smoking and cognitive decline among 
middle-aged men and women: the Doetinchem Cohort Study. Am J Public Health, 2008. 98(12): 
p. 2244-50. 
98. Collins, N., N. Sachs-Ericsson, K.J. Preacher, K.M. Sheffield, and K. Markides, Smoking 
increases risk for cognitive decline among community-dwelling older Mexican Americans. Am J 
Geriatr Psychiatry, 2009. 17(11): p. 934-42. 
99. Kalmijn, S., M.P. van Boxtel, M.W. Verschuren, J. Jolles, and L.J. Launer, Cigarette smoking 
and alcohol consumption in relation to cognitive performance in middle age. Am J Epidemiol, 
2002. 156(10): p. 936-44. 
100. Sabia, S., A. Elbaz, A. Dugravot, J. Head, M. Shipley, G. Hagger-Johnson, M. Kivimaki, and A. 
Singh-Manoux, Impact of smoking on cognitive decline in early old age: the Whitehall II cohort 
study. Arch Gen Psychiatry, 2012. 69(6): p. 627-35. 
101. Richards, M., M.J. Jarvis, N. Thompson, and M.E. Wadsworth, Cigarette smoking and cognitive 
decline in midlife: evidence from a prospective birth cohort study. Am J Public Health, 2003. 





102. Reitz, C., J. Luchsinger, M.X. Tang, and R. Mayeux, Effect of smoking and time on cognitive 
function in the elderly without dementia. Neurology, 2005. 65(6): p. 870-5. 
103. Rogers, R.L., J.S. Meyer, and K.F. Mortel, After reaching retirement age physical activity 
sustains cerebral perfusion and cognition. J Am Geriatr Soc, 1990. 38(2): p. 123-8. 
104. Spirduso, W.W., Physical fitness, aging, and psychomotor speed: a review. J Gerontol, 1980. 
35(6): p. 850-65. 
105. Dustman, R.E., R.O. Ruhling, E.M. Russell, D.E. Shearer, H.W. Bonekat, J.W. Shigeoka, J.S. 
Wood, and D.C. Bradford, Aerobic exercise training and improved neuropsychological function 
of older individuals. Neurobiol Aging, 1984. 5(1): p. 35-42. 
106. Cotman, C.W. and C. Engesser-Cesar, Exercise enhances and protects brain function. Exerc 
Sport Sci Rev, 2002. 30(2): p. 75-9. 
107. Gomez-Pinilla, F., L. Dao, and V. So, Physical exercise induces FGF-2 and its mRNA in the 
hippocampus. Brain Res, 1997. 764(1-2): p. 1-8. 
108. Angevaren, M., G. Aufdemkampe, H.J. Verhaar, A. Aleman, and L. Vanhees, Physical activity 
and enhanced fitness to improve cognitive function in older people without known cognitive 
impairment. Cochrane Database Syst Rev, 2008(3): p. Cd005381. 
109. Barnes, D.E., W. Santos-Modesitt, G. Poelke, A.F. Kramer, C. Castro, L.E. Middleton, and K. 
Yaffe, The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance 
cognitive function in older adults. JAMA Intern Med, 2013. 173(9): p. 797-804. 
110. Paterson, D.H. and D.E. Warburton, Physical activity and functional limitations in older adults: a 
systematic review related to Canada's Physical Activity Guidelines. Int J Behav Nutr Phys Act, 
2010. 7: p. 38. 
111. Sofi, F., D. Valecchi, D. Bacci, R. Abbate, G.F. Gensini, A. Casini, and C. Macchi, Physical 
activity and risk of cognitive decline: a meta-analysis of prospective studies. J Intern Med, 2011. 
269(1): p. 107-17. 
112. Lautenschlager, N.T., K.L. Cox, L. Flicker, J.K. Foster, F.M. van Bockxmeer, J. Xiao, K.R. 
Greenop, and O.P. Almeida, Effect of physical activity on cognitive function in older adults at 
risk for Alzheimer disease: a randomized trial. Jama, 2008. 300(9): p. 1027-37. 
113. Colcombe, S. and A.F. Kramer, Fitness effects on the cognitive function of older adults: a meta-
analytic study. Psychol Sci, 2003. 14(2): p. 125-30. 
114. Robinson, J.G., N. Ijioma, and W. Harris, Omega-3 fatty acids and cognitive function in women. 
Women's health (London, England), 2010. 6(1): p. 119-134. 
115. Corder, E.H., A.M. Saunders, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, G.W. Small, A.D. 
Roses, J.L. Haines, and M.A. Pericak-Vance, Gene dose of apolipoprotein E type 4 allele and the 





116. Slooter, A.J., M. Cruts, S. Kalmijn, A. Hofman, M.M. Breteler, C. Van Broeckhoven, and C.M. 
van Duijn, Risk estimates of dementia by apolipoprotein E genotypes from a population-based 
incidence study: the Rotterdam Study. Arch Neurol, 1998. 55(7): p. 964-8. 
117. Corder, E.H., A.M. Saunders, N.J. Risch, W.J. Strittmatter, D.E. Schmechel, P.C. Gaskell, Jr., 
J.B. Rimmler, P.A. Locke, P.M. Conneally, K.E. Schmader, and et al., Protective effect of 
apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat Genet, 1994. 7(2): p. 180-4. 
118. Mahley, R.W. and S.C. Rall, Jr., Apolipoprotein E: far more than a lipid transport protein. Annu 
Rev Genomics Hum Genet, 2000. 1: p. 507-37. 
119. Blair, C.K., A.R. Folsom, D.S. Knopman, M.S. Bray, T.H. Mosley, and E. Boerwinkle, APOE 
genotype and cognitive decline in a middle-aged cohort. Neurology, 2005. 64(2): p. 268-76. 
120. Bretsky, P., J.M. Guralnik, L. Launer, M. Albert, and T.E. Seeman, The role of APOE-epsilon4 in 
longitudinal cognitive decline: MacArthur Studies of Successful Aging. Neurology, 2003. 60(7): 
p. 1077-81. 
121. Caselli, R.J., A.C. Dueck, D. Osborne, M.N. Sabbagh, D.J. Connor, G.L. Ahern, L.C. Baxter, 
S.Z. Rapcsak, J. Shi, B.K. Woodruff, D.E. Locke, C.H. Snyder, G.E. Alexander, R. Rademakers, 
and E.M. Reiman, Longitudinal modeling of age-related memory decline and the APOE epsilon4 
effect. N Engl J Med, 2009. 361(3): p. 255-63. 
122. Deary, I.J., M.C. Whiteman, A. Pattie, J.M. Starr, C. Hayward, A.F. Wright, A. Carothers, and 
L.J. Whalley, Cognitive change and the APOE epsilon 4 allele. Nature, 2002. 418(6901): p. 932. 
123. Fillenbaum, G.G., L.R. Landerman, D.G. Blazer, A.M. Saunders, T.B. Harris, and L.J. Launer, 
The relationship of APOE genotype to cognitive functioning in older African-American and 
Caucasian community residents. J Am Geriatr Soc, 2001. 49(9): p. 1148-55. 
124. Luciano, M., A.J. Gow, S.E. Harris, C. Hayward, M. Allerhand, J.M. Starr, P.M. Visscher, and 
I.J. Deary, Cognitive ability at age 11 and 70 years, information processing speed, and APOE 
variation: the Lothian Birth Cohort 1936 study. Psychol Aging, 2009. 24(1): p. 129-38. 
125. Packard, C.J., R.G. Westendorp, D.J. Stott, M.J. Caslake, H.M. Murray, J. Shepherd, G.J. Blauw, 
M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. 
Jukema, A.M. Kamper, P.W. Macfarlane, J. Jolles, I.J. Perry, B.J. Sweeney, and C. Twomey, 
Association between apolipoprotein E4 and cognitive decline in elderly adults. J Am Geriatr Soc, 
2007. 55(11): p. 1777-85. 
126. Yaffe, K., T. Blackwell, A.M. Kanaya, N. Davidowitz, E. Barrett-Connor, and K. Krueger, 
Diabetes, impaired fasting glucose, and development of cognitive impairment in older women. 
Neurology, 2004. 63(4): p. 658-63. 
127. Gregg, E.W., K. Yaffe, J.A. Cauley, D.B. Rolka, T.L. Blackwell, K.M. Narayan, and S.R. 
Cummings, Is diabetes associated with cognitive impairment and cognitive decline among older 
women? Study of Osteoporotic Fractures Research Group. Arch Intern Med, 2000. 160(2): p. 
174-80. 
128. Arvanitakis, Z., R.S. Wilson, J.L. Bienias, D.A. Evans, and D.A. Bennett, Diabetes mellitus and 





129. Kanaya, A.M., E. Barrett-Connor, G. Gildengorin, and K. Yaffe, Change in cognitive function by 
glucose tolerance status in older adults: a 4-year prospective study of the Rancho Bernardo study 
cohort. Arch Intern Med, 2004. 164(12): p. 1327-33. 
130. Verdelho, A., S. Madureira, J.M. Ferro, A.M. Basile, H. Chabriat, T. Erkinjuntti, F. Fazekas, M. 
Hennerici, J. O'Brien, L. Pantoni, E. Salvadori, P. Scheltens, M.C. Visser, L.O. Wahlund, G. 
Waldemar, A. Wallin, and D. Inzitari, Differential impact of cerebral white matter changes, 
diabetes, hypertension and stroke on cognitive performance among non-disabled elderly. The 
LADIS study. J Neurol Neurosurg Psychiatry, 2007. 78(12): p. 1325-30. 
131. Rawlings, A.M., A.R. Sharrett, A.L. Schneider, J. Coresh, M. Albert, D. Couper, M. Griswold, 
R.F. Gottesman, L.E. Wagenknecht, B.G. Windham, and E. Selvin, Diabetes in midlife and 
cognitive change over 20 years: a cohort study. Ann Intern Med, 2014. 161(11): p. 785-93. 
132. Cukierman, T., H.C. Gerstein, and J.D. Williamson, Cognitive decline and dementia in diabetes--
systematic overview of prospective observational studies. Diabetologia, 2005. 48(12): p. 2460-9. 
133. Biessels, G.J., M.W. Strachan, F.L. Visseren, L.J. Kappelle, and R.A. Whitmer, Dementia and 
cognitive decline in type 2 diabetes and prediabetic stages: towards targeted interventions. 
Lancet Diabetes Endocrinol, 2014. 2(3): p. 246-55. 
134. Elias, M.F., A.L. Goodell, and G.A. Dore, Hypertension and cognitive functioning: a perspective 
in historical context. Hypertension, 2012. 60(2): p. 260-8. 
135. Gottesman, R.F., A.L. Schneider, M. Albert, A. Alonso, K. Bandeen-Roche, L. Coker, J. Coresh, 
D. Knopman, M.C. Power, A. Rawlings, A.R. Sharrett, L.M. Wruck, and T.H. Mosley, Midlife 
hypertension and 20-year cognitive change: the atherosclerosis risk in communities 
neurocognitive study. JAMA Neurol, 2014. 71(10): p. 1218-27. 
136. Kohler, S., M.A. Baars, P. Spauwen, S. Schievink, F.R. Verhey, and M.J. van Boxtel, Temporal 
evolution of cognitive changes in incident hypertension: prospective cohort study across the adult 
age span. Hypertension, 2014. 63(2): p. 245-51. 
137. Debette, S., S. Seshadri, A. Beiser, R. Au, J.J. Himali, C. Palumbo, P.A. Wolf, and C. DeCarli, 
Midlife vascular risk factor exposure accelerates structural brain aging and cognitive decline. 
Neurology, 2011. 77(5): p. 461-8. 
138. Glynn, R.J., L.A. Beckett, L.E. Hebert, M.C. Morris, P.A. Scherr, and D.A. Evans, Current and 
remote blood pressure and cognitive decline. Jama, 1999. 281(5): p. 438-45. 
139. Knopman, D.S., T.H. Mosley, D.J. Catellier, and L.H. Coker, Fourteen-year longitudinal study of 
vascular risk factors, APOE genotype, and cognition: the ARIC MRI Study. Alzheimers Dement, 
2009. 5(3): p. 207-14. 
140. Kaffashian, S., A. Dugravot, A. Elbaz, M.J. Shipley, S. Sabia, M. Kivimaki, and A. Singh-
Manoux, Predicting cognitive decline: a dementia risk score vs. the Framingham vascular risk 







141. Bangen, K.J., A. Beiser, L. Delano-Wood, D.A. Nation, M. Lamar, D.J. Libon, M.W. Bondi, S. 
Seshadri, P.A. Wolf, and R. Au, APOE genotype modifies the relationship between midlife 
vascular risk factors and later cognitive decline. J Stroke Cerebrovasc Dis, 2013. 22(8): p. 1361-
9. 
142. Qiu, C., B. Winblad, and L. Fratiglioni, The age-dependent relation of blood pressure to 
cognitive function and dementia. Lancet Neurol, 2005. 4(8): p. 487-99. 
143. Gąsecki, D., M. Kwarciany, W. Nyka, and K. Narkiewicz, Hypertension, Brain Damage and 
Cognitive Decline. Current Hypertension Reports, 2013. 15(6): p. 547-558. 
144. Etgen, T., D. Sander, H. Bickel, and H. Forstl, Mild cognitive impairment and dementia: the 
importance of modifiable risk factors. Dtsch Arztebl Int, 2011. 108(44): p. 743-50. 
145. Ledesma, M.D., M.G. Martin, and C.G. Dotti, Lipid changes in the aged brain: effect on synaptic 
function and neuronal survival. Prog Lipid Res, 2012. 51(1): p. 23-35. 
146. Reynolds, C.A., M. Gatz, J.A. Prince, S. Berg, and N.L. Pedersen, Serum lipid levels and 
cognitive change in late life. J Am Geriatr Soc, 2010. 58(3): p. 501-9. 
147. van Vliet, P., Cholesterol and late-life cognitive decline. J Alzheimers Dis, 2012. 30 Suppl 2: p. 
S147-62. 
148. Sellbom, K.S. and J. Gunstad, Cognitive function and decline in obesity. J Alzheimers Dis, 2012. 
30 Suppl 2: p. S89-95. 
149. Holden, K.F., K. Lindquist, F.A. Tylavsky, C. Rosano, T.B. Harris, and K. Yaffe, Serum leptin 
level and cognition in the elderly: Findings from the Health ABC Study. Neurobiol Aging, 2009. 
30(9): p. 1483-9. 
150. Zeki Al Hazzouri, A., K.L. Stone, M.N. Haan, and K. Yaffe, Leptin, mild cognitive impairment, 
and dementia among elderly women. J Gerontol A Biol Sci Med Sci, 2013. 68(2): p. 175-80. 
151. Gustafson, D.R., Adiposity and cognitive decline: underlying mechanisms. J Alzheimers Dis, 
2012. 30 Suppl 2: p. S97-112. 
152. Anstey, K.J., N. Cherbuin, M. Budge, and J. Young, Body mass index in midlife and late-life as a 
risk factor for dementia: a meta-analysis of prospective studies. Obes Rev, 2011. 12(5): p. e426-
37. 
153. Levine, D.A., A.T. Galecki, K.M. Langa, F.W. Unverzagt, M.U. Kabeto, B. Giordani, and V.G. 
Wadley, Trajectory of Cognitive Decline after Incident Stroke. JAMA, 2015. 314(1): p. 41-51. 
154. Tatemichi, T.K., D.W. Desmond, Y. Stern, M. Paik, M. Sano, and E. Bagiella, Cognitive 
impairment after stroke: frequency, patterns, and relationship to functional abilities. J Neurol 
Neurosurg Psychiatry, 1994. 57(2): p. 202-7. 
155. Snowdon, D.A., L.H. Greiner, J.A. Mortimer, K.P. Riley, P.A. Greiner, and W.R. Markesbery, 
Brain infarction and the clinical expression of Alzheimer disease. The Nun Study. Jama, 1997. 





156. Garcia-Alloza, M., J. Gregory, K.V. Kuchibhotla, S. Fine, Y. Wei, C. Ayata, M.P. Frosch, S.M. 
Greenberg, and B.J. Bacskai, Cerebrovascular lesions induce transient beta-amyloid deposition. 
Brain, 2011. 134(Pt 12): p. 3697-707. 
157. Whitehead, S.N., G. Cheng, V.C. Hachinski, and D.F. Cechetto, Progressive increase in infarct 
size, neuroinflammation, and cognitive deficits in the presence of high levels of amyloid. Stroke, 
2007. 38(12): p. 3245-50. 
158. Wilson, R.S., A.W. Capuano, P.A. Boyle, G.M. Hoganson, L.P. Hizel, R.C. Shah, S. Nag, J.A. 
Schneider, S.E. Arnold, and D.A. Bennett, Clinical-pathologic study of depressive symptoms and 
cognitive decline in old age. Neurology, 2014. 83(8): p. 702-9. 
159. Kohler, S., M.P. van Boxtel, J. van Os, A.J. Thomas, J.T. O'Brien, J. Jolles, F.R. Verhey, and J. 
Allardyce, Depressive symptoms and cognitive decline in community-dwelling older adults. J Am 
Geriatr Soc, 2010. 58(5): p. 873-9. 
160. Wilson, R.S., L.L. Barnes, C.F. Mendes de Leon, N.T. Aggarwal, J.S. Schneider, J. Bach, J. Pilat, 
L.A. Beckett, S.E. Arnold, D.A. Evans, and D.A. Bennett, Depressive symptoms, cognitive 
decline, and risk of AD in older persons. Neurology, 2002. 59(3): p. 364-70. 
161. Lemmens, P., R.A. Knibbe, and F. Tan, Weekly recall and dairy estimates of alcohol 
consumption in a general population survey. J Stud Alcohol, 1988. 49(2): p. 131-5. 
162. Midanik, L., The validity of self-reported alcohol consumption and alcohol problems: a literature 
review. Br J Addict, 1982. 77(4): p. 357-82. 
163. Rehm, J., Measuring quantity, frequency, and volume of drinking. Alcohol Clin Exp Res, 1998. 
22(2 Suppl): p. 4s-14s. 
164. Simpura, J. and K. Poikolainen, Accuracy of retrospective measurement of individual alcohol 
consumption in men; a reinterview after 18 years. J Stud Alcohol, 1983. 44(5): p. 911-7. 
165. M. B.  Sobell, L.C.S., Self-report issues in alcohol abuse: State of the art and future directions. 
Behavioral Assessment, 1990. 12: p. 91–106. 
166. Harris, T.R., R.W. Wilsnack, and A.D. Klassen, Reliability of retrospective self-reports of alcohol 
consumption among women: data from a U.S. national sample. J Stud Alcohol, 1994. 55(3): p. 
309-14. 
167. Aday, L.A., Designing and conducting health surveys: A comprehensive guide. 1996: San 
Francisco: Jossey-Bass. 
168. Groves, R.M., Survey errors and survey costs. 1989, New York: NY: Wiley. 
169. Willett, W.C., L. Sampson, M.L. Browne, M.J. Stampfer, B. Rosner, C.H. Hennekens, and F.E. 
Speizer, The use of a self-administered questionnaire to assess diet four years in the past. Am J 
Epidemiol, 1988. 127(1): p. 188-99. 
170. Gibson, R., Validity in dietary assessment methods. Principles of Nutritional Assessment. 2nd ed. 





171. Cade, J.E., V.J. Burley, D.L. Warm, R.L. Thompson, and B.M. Margetts, Food-frequency 
questionnaires: a review of their design, validation and utilisation. Nutr Res Rev, 2004. 17(1): p. 
5-22. 
172. FE Thompson, T.B., Dietary assessment resource manual. J Nutr Educ Behav, 1994: p. 124(11 
Suppl): 2245S-2317S. 
173. Adamson, A.J., J. Collerton, K. Davies, E. Foster, C. Jagger, E. Stamp, J.C. Mathers, and T. 
Kirkwood, Nutrition in advanced age: dietary assessment in the Newcastle 85+ study. Eur J Clin 
Nutr, 2009. 63 Suppl 1: p. S6-18. 
174. R. Straus, S.D.B., Drinking in College. 1953: New Haven, CT: Yale University Press. 
175. Dawson, D.A., Methodological issues in measuring alcohol use. Alcohol Res Health, 2003. 
27(1): p. 18-29. 
176. Room, R., Measuring alcohol consumption in the United States: Methods and rationales. In: 
Kozlowski, L.T.; Annis, H.M.; Cappell, H.D.; Glaser, F.B.; Goodstadt, M.S.; Israel, Y.; Kalant, 
H.; Sellers, E.M.; and Vingilis, E.R., eds. Research Advances in Alcohol and Drug Problems. 
Vol. 10. 1990: New York: Plenum Press. 
177. Sobell L.C., S.M.B., Timeline Followback: A technique for assessing self-reported alcohol 
consumption. In: Litten, R.Z., and Allen, J.P., eds. Measuring Alcohol Consumption: 
Psychosocial and Biological Methods. 1992: Totowa, NJ: Humana Press. 
178. Poikolainen, K. and P. Karkkainen, Diary gives more accurate information about alcohol 
consumption than questionnaire. Drug Alcohol Depend, 1983. 11(2): p. 209-16. 
179. Greenfield, T.K., Quantity per occasion and consequences of drinking: a reconsideration and 
recommendation. Int J Addict, 1986. 21(9-10): p. 1059-79. 
180. D. J Armor, J.M.P., Measurement of alcohol consumption. In: Pattison E. M., Kaufman E., 
editors. Encyclopedic Handbook of Alcoholism. 1982: New York: Gardner Press. 
181. Rehm, J., T.K. Greenfield, G. Walsh, X. Xie, L. Robson, and E. Single, Assessment methods for 
alcohol consumption, prevalence of high risk drinking and harm: a sensitivity analysis. Int J 
Epidemiol, 1999. 28(2): p. 219-24. 
182. Midanik, L.T., Comparing usual quantity/frequency and graduated frequency scales to assess 
yearly alcohol consumption: results from the 1990 US National Alcohol Survey. Addiction, 1994. 
89(4): p. 407-12. 
183. Kuhlhorn, E. and H. Leifman, Alcohol surveys with high and low coverage rate: a comparative 
analysis of survey strategies in the alcohol field. J Stud Alcohol, 1993. 54(5): p. 542-54. 
184. Del Boca, F.K. and J. Darkes, The validity of self-reports of alcohol consumption: state of the 
science and challenges for research. Addiction, 2003. 98 Suppl 2: p. 1-12. 
185. Poikolainen, K., I. Podkletnova, and H. Alho, Accuracy of quantity-frequency and graduated 
frequency questionnaires in measuring alcohol intake: comparison with daily diary and 





186. Graham, K., A. Demers, J. Rehm, and G. Gmel, Problems with the graduated frequency 
approach to measuring alcohol consumption: results from a pilot study in Toronto, Canada. 
Alcohol Alcohol, 2004. 39(5): p. 455-62. 
187. Murman, D.L., The Impact of Age on Cognition. Seminars in Hearing, 2015. 36(3): p. 111-121. 
188. Diamond, A., Executive functions. Annu Rev Psychol, 2013. 64: p. 135-68. 
189. IOM (Institute of Medicine). Health literacy and numeracy: Workshop summary. 2014: 
Washington, DC: The National Academies Press. 
190. Salthouse, T.A., The aging of working memory. Neuropsychology, 1994. 8(4): p. 535-543. 
191. Salthouse, T.A., Effects of age and skill in typing. J Exp Psychol Gen, 1984. 113(3): p. 345-71. 
192. Salthouse, T.A., What and when of cognitive aging. Current Directions in Psychological Science, 
2004. 13(4): p. 140-144. 
193. Zacks, R.T., L. Hasher, and K.Z. H. Li, Human Memory. In The handbook of aging and 
cognition. 2nd ed, ed. T.A.S. F.I. Craik. 2000, Mahwah, NJ: Erlbaum. 
194. Bell-McGinty, S., K. Podell, M. Franzen, A.D. Baird, and M.J. Williams, Standard measures of 
executive function in predicting instrumental activities of daily living in older adults. Int J Geriatr 
Psychiatry, 2002. 17(9): p. 828-34. 
195. Zanto, T.P., and Gazzaley, A., Attention and aging. In The handbook of aging and cognition 
2014, Oxford: Oxford University Press. 
196. Kramer, A.F., Madden, D.J., Attention. In The handbook of aging and cognition. 3rd ed. 2008, 
New York Psychology Press. 
197. Mick, P., I. Kawachi, and F.R. Lin, The association between hearing loss and social isolation in 
older adults. Otolaryngol Head Neck Surg, 2014. 150(3): p. 378-84. 
198. Seidman, L.J., Neuropsychological testing, in Harvard Mental Health Lette. 1998. p. 4-6. 
199. M. D. Lezak, D.B.H., and D. W. Loring, Neuropsychological Assessment. 4 ed. 2004, New York, 
NY, USA: Oxford University Press. 
200. Proust-Lima, C., H. Amieva, J.-F. Dartigues, and H. Jacqmin-Gadda, Sensitivity of four 
psychometric tests to measure cognitive changes in brain aging-population-based studies. 
American Journal of Epidemiology, 2007. 165(3): p. 344-350. 
201. Knopman, D.S. and S. Ryberg, A verbal memory test with high predictive accuracy for dementia 
of the Alzheimer type. Arch Neurol, 1989. 46(2): p. 141-5. 
202. Geffen, G.M., L. Geffen, K. Bishop, and L. Manning, Extended Delayed Recall of Avlt Word 
Lists: Effects of Age and Sex on Adult Performance. Australian Journal of Psychology, 1997. 
49(2): p. 78-84. 
203. Spreen O, B.A., Neurosensory Center Comprehensive Examination for Aphasia (NCCEA) 





204. Benton, A.L., P.J. Eslinger, and A.R. Damasio, Normative observations on neuropsychological 
test performances in old age. J Clin Neuropsychol, 1981. 3(1): p. 33-42. 
205. A.L Benton, K.H., Multilingual Aphasia Examination. Manual of instructions (2nd ed), AJA 
Associates, Iowa City 1989. 
206. DesRosiers, G. and D.J. Kavanagh, Cognitive assessment in closed head injury : stability, validity 
and parallel forms for two neuropsychological measures of recovery. International Journal of 
Clinical Neuropsychology, 1987. 9(4): p. 162-173. 
207. Benton AL, H.K., Multilingual Aphasia Examination (2nd ed.), in Iowa City, IA: AJA Associates. 
1989. 
208. Folstein, M.F., S.E. Folstein, and P.R. McHugh, "Mini-mental state". A practical method for 
grading the cognitive state of patients for the clinician. J Psychiatr Res, 1975. 12(3): p. 189-98. 
209. Lezak, M.D., D.B. Howieson, and D.W. Loring, Neuropsychological Assessment 4th ed. 2004, 
New York: NY: Oxford University Press. 
210. Tombaugh, T.N. and N.J. McIntyre, The mini-mental state examination: a comprehensive review. 
J Am Geriatr Soc, 1992. 40(9): p. 922-35. 
211. O'Connor, D.W., P.A. Pollitt, J.B. Hyde, J.L. Fellows, N.D. Miller, C.P. Brook, and B.B. Reiss, 
The reliability and validity of the Mini-Mental State in a British community survey. J Psychiatr 
Res, 1989. 23(1): p. 87-96. 
212. Bondi M. W., S.D.P., & Kaszniak A. W., The neuropsychology of dementia In Grant I. & Adams 
K. M. (Eds.), Neuropsychological assessment of neuropsychiatric disorders. 1996: New York: 
Oxford University Press. 
213. Galasko, D., L.A. Hansen, R. Katzman, W. Wiederholt, E. Masliah, R. Terry, L.R. Hill, P. Lessin, 
and L.J. Thal, Clinical-neuropathological correlations in Alzheimer's disease and related 
dementias. Arch Neurol, 1994. 51(9): p. 888-95. 
214. Kang Y., N.D.L., & Hahn S. H., A validity study on the Korean version of Mini-Mental State 
Examination in dementia patients. Journal of Korean Neurological Association, 1997. 15: p. 300–
307. 
215. Nys, G.M., M.J. van Zandvoort, P.L. de Kort, B.P. Jansen, L.J. Kappelle, and E.H. de Haan, 
Restrictions of the Mini-Mental State Examination in acute stroke. Arch Clin Neuropsychol, 
2005. 20(5): p. 623-9. 
216. Seidman, L.J., The Mini-Mental State Examination: Strengths and Weaknesses of a Clinical 
Instrument. Harvard Mental Health Letter, 1998. 14(11): p. 4-5. 
217. Franco-Marina, F., J.J. Garcia-Gonzalez, F. Wagner-Echeagaray, J. Gallo, O. Ugalde, S. Sanchez-
Garcia, C. Espinel-Bermudez, T. Juarez-Cedillo, M.A. Rodriguez, and C. Garcia-Pena, The Mini-
mental State Examination revisited: ceiling and floor effects after score adjustment for 





218. Teng, E.L. and H.C. Chui, The Modified Mini-Mental State (3MS) examination. J Clin Psychiatry, 
1987. 48(8): p. 314-8. 
219. Bravo, G. and R. Hebert, Reliability of the Modified Mini-Mental State Examination in the 
context of a two-phase community prevalence study. Neuroepidemiology, 1997. 16(3): p. 141-8. 
220. McDowell, I., B. Kristjansson, G.B. Hill, and R. Hebert, Community screening for dementia: the 
Mini Mental State Exam (MMSE) and Modified Mini-Mental State Exam (3MS) compared. J Clin 
Epidemiol, 1997. 50(4): p. 377-83. 
221. T.N Tombaugh, I.M., B Kristjansson, A.M Hubley, Mini-Mental State Examination (MMSE) and 
the Modified MMSE (3MS): a psychometric comparison and normative data. Psychological 
Assessment, 1996. 8: p. 48–59. 
222. Nadler, J.D., N.R. Relkin, M.S. Cohen, R.A. Hodder, J. Reingold, and F. Plum, Mental status 
testing in the elderly nursing home population. J Geriatr Psychiatry Neurol, 1995. 8(3): p. 177-83. 
223. Grace, J., J.D. Nadler, D.A. White, T.J. Guilmette, A.J. Giuliano, A.U. Monsch, and M.G. Snow, 
Folstein vs modified Mini-Mental State Examination in geriatric stroke. Stability, validity, and 
screening utility. Arch Neurol, 1995. 52(5): p. 477-84. 
224. E.L Teng, H.C.C., A Gong, Comparisons between the Mini-Mental State Exam (MMSE) and its 
modified version—the 3MS test.  K Hasegawa, A Homma (Eds.), Psychogeriatrics: biomedical 
and social advances, Excerpta Medica, . 1990, Tokyo. 
225. Brandt J, S.M., Folstein MF, The Telephone Interview for Cognitive Status. Neuropsychiatry, 
Neuropsychol, Behavioral Neurol, 1988. 1: p. 111–17. 
226. K.A. Welsh, J.C.S.B., K.M. Mgruder-Habib, Detection of dementia in the elderly using telephone 
screening of cognitive status. Neuropsychiatry Neuropsychol. Behav. Neurol, 1993. 6: p. 103–
110. 
227. Desmond, D.W., T.K. Tatemichi, and L. Hanzawa, The Telephone Interview for Cognitive Status 
(TICS): Reliability and validity in a stroke sample. International Journal of Geriatric Psychiatry, 
1994. 9(10): p. 803-807. 
228. Breitner, J.C. and K.A. Welsh, Diagnosis and management of memory loss and cognitive 
disorders among elderly persons. Psychiatr Serv, 1995. 46(1): p. 29-35. 
229. Lines, C.R., K.A. McCarroll, R.B. Lipton, and G.A. Block, Telephone screening for amnestic 
mild cognitive impairment. Neurology, 2003. 60(2): p. 261-6. 
230. Hogervorst, E., S. Bandelow, J. Hart, Jr., and V.W. Henderson, Telephone word-list recall tested 
in the rural aging and memory study: two parallel versions for the TICS-M. Int J Geriatr 
Psychiatry, 2004. 19(9): p. 875-80. 
231. Gallo, J.J. and J.C. Breitner, Alzheimer's disease in the NAS-NRC Registry of aging twin veterans, 
IV. Performance characteristics of a two-stage telephone screening procedure for Alzheimer's 





232. Beeri, M.S., P. Werner, M. Davidson, J. Schmidler, and J. Silverman, Validation of the modified 
telephone interview for cognitive status (TICS-m) in Hebrew. Int J Geriatr Psychiatry, 2003. 
18(5): p. 381-6. 
233. Graves, A.B., E.B. Larson, S.D. Edland, J.D. Bowen, W.C. McCormick, S.M. McCurry, M.M. 
Rice, A. Wenzlow, and J.M. Uomoto, Prevalence of dementia and its subtypes in the Japanese 
American population of King County, Washington state. The Kame Project. Am J Epidemiol, 
1996. 144(8): p. 760-71. 
234. White, L., H. Petrovitch, G.W. Ross, K.H. Masaki, R.D. Abbott, E.L. Teng, B.L. Rodriguez, P.L. 
Blanchette, R.J. Havlik, G. Wergowske, D. Chiu, D.J. Foley, C. Murdaugh, and J.D. Curb, 
Prevalence of dementia in older Japanese-American men in Hawaii: The Honolulu-Asia Aging 
Study. Jama, 1996. 276(12): p. 955-60. 
235. Yamada, M., H. Sasaki, Y. Mimori, F. Kasagi, S. Sudoh, J. Ikeda, Y. Hosoda, S. Nakamura, and 
K. Kodama, Prevalence and risks of dementia in the Japanese population: RERF's adult health 
study Hiroshima subjects. Radiation Effects Research Foundation. J Am Geriatr Soc, 1999. 
47(2): p. 189-95. 
236. Liu, H.C., P. Chou, K.N. Lin, S.J. Wang, J.L. Fuh, H.C. Lin, C.Y. Liu, G.S. Wu, E.B. Larson, 
L.R. White, and et al., Assessing cognitive abilities and dementia in a predominantly illiterate 
population of older individuals in Kinmen. Psychol Med, 1994. 24(3): p. 763-70. 
237. Liu, H.C., J.L. Fuh, S.J. Wang, C.Y. Liu, E.B. Larson, K.N. Lin, H.C. Wang, P. Chou, Z.A. Wu, 
C.H. Lin, P.N. Wang, and E.L. Teng, Prevalence and subtypes of dementia in a rural Chinese 
population. Alzheimer Dis Assoc Disord, 1998. 12(3): p. 127-34. 
238. Hasegawa, K., The clinical assessment of dementia in the aged: A dementia screening scale for 
psychogeriatric patients. In M. Bergener, U. Lehr, E. Lang, & R. SchmitzScherzer (Eds.), Aging 
in the eighties and beyond. 1983, New York: Springer. 
239. Teng, E.L., K. Hasegawa, A. Homma, Y. Imai, E. Larson, A. Graves, K. Sugimoto, T. 
Yamaguchi, H. Sasaki, D. Chiu, and et al., The Cognitive Abilities Screening Instrument (CASI): 
a practical test for cross-cultural epidemiological studies of dementia. Int Psychogeriatr, 1994. 
6(1): p. 45-58; discussion 62. 
240. Norberg, A., A.W. Jones, R.G. Hahn, and J.L. Gabrielsson, Role of variability in explaining 
ethanol pharmacokinetics: research and forensic applications. Clin Pharmacokinet, 2003. 42(1): 
p. 1-31. 
241. Wilkinson, P.K., A.J. Sedman, E. Sakmar, D.R. Kay, and J.G. Wagner, Pharmacokinetics of 
ethanol after oral administration in the fasting state. J Pharmacokinet Biopharm, 1977. 5(3): p. 
207-24. 
242. Holford, N.H., Clinical pharmacokinetics of ethanol. Clin Pharmacokinet, 1987. 13(5): p. 273-92. 
243. O'Neill, B., A.F. Williams, and K.M. Dubowski, Variability in blood alcohol concentrations. 
Implications for estimating individual results. J Stud Alcohol, 1983. 44(2): p. 222-30. 
244. Dubowski, K.M., Absorption, distribution and elimination of alcohol: highway safety aspects. J 





245. Sedman, A.J., P.K. Wilkinson, E. Sakmar, D.J. Weidler, and J.G. Wagner, Food effects on 
absorption and metabolism of alcohol. J Stud Alcohol, 1976. 37(9): p. 1197-214. 
246. Edenberg, H.J., The genetics of alcohol metabolism: role of alcohol dehydrogenase and aldehyde 
dehydrogenase variants. Alcohol Res Health, 2007. 30(1): p. 5-13. 
247. Alcoholism, N.I.o.A.A.a., Alcohol Alert: Alcohol Metabolism. 1997, the Institute: Bethesda, MD. 
248. Agrawal, A. and L.J. Bierut, Identifying genetic variation for alcohol dependence. Alcohol Res, 
2012. 34(3): p. 274-81. 
249. Quertemont, E., Genetic polymorphism in ethanol metabolism: acetaldehyde contribution to 
alcohol abuse and alcoholism. Mol Psychiatry, 2004. 9(6): p. 570-81. 
250. Li, T.K., S.J. Yin, D.W. Crabb, S. O'Connor, and V.A. Ramchandani, Genetic and environmental 
influences on alcohol metabolism in humans. Alcohol Clin Exp Res, 2001. 25(1): p. 136-44. 
251. Agarwal, D.P., Genetic polymorphisms of alcohol metabolizing enzymes. Pathol Biol (Paris), 
2001. 49(9): p. 703-9. 
252. Vestal, R.E., E.A. McGuire, J.D. Tobin, R. Andres, A.H. Norris, and E. Mezey, Aging and 
ethanol metabolism. Clin Pharmacol Ther, 1977. 21(3): p. 343-54. 
253. Jones, A.W. and A. Neri, Age-related differences in blood ethanol parameters and subjective 
feelings of intoxication in healthy men. Alcohol Alcohol, 1985. 20(1): p. 45-52. 
254. Thomasson, H.R., J.D. Beard, and T.K. Li, ADH2 gene polymorphisms are determinants of 
alcohol pharmacokinetics. Alcohol Clin Exp Res, 1995. 19(6): p. 1494-9. 
255. Kwo, P.Y., V.A. Ramchandani, S. O'Connor, D. Amann, L.G. Carr, K. Sandrasegaran, K.K. 
Kopecky, and T.K. Li, Gender differences in alcohol metabolism: relationship to liver volume 
and effect of adjusting for body mass. Gastroenterology, 1998. 115(6): p. 1552-7. 
256. Mizoi, Y., K. Yamamoto, Y. Ueno, T. Fukunaga, and S. Harada, Involvement of genetic 
polymorphism of alcohol and aldehyde dehydrogenases in individual variation of alcohol 
metabolism. Alcohol Alcohol, 1994. 29(6): p. 707-10. 
257. Wall, T.L., C. Garcia-Andrade, H.R. Thomasson, M. Cole, and C.L. Ehlers, Alcohol elimination 
in Native American Mission Indians: an investigation of interindividual variation. Alcohol Clin 
Exp Res, 1996. 20(7): p. 1159-64. 
258. Wall, T.L., C.M. Peterson, K.P. Peterson, M.L. Johnson, H.R. Thomasson, M. Cole, and C.L. 
Ehlers, Alcohol metabolism in Asian-American men with genetic polymorphisms of aldehyde 
dehydrogenase. Ann Intern Med, 1997. 127(5): p. 376-9. 
259. Peng, G.S., J.H. Yin, M.F. Wang, J.T. Lee, Y.D. Hsu, and S.J. Yin, Alcohol sensitivity in 
Taiwanese men with different alcohol and aldehyde dehydrogenase genotypes. J Formos Med 
Assoc, 2002. 101(11): p. 769-74. 
260. Ramchandani, V.A., P.Y. Kwo, and T.K. Li, Effect of food and food composition on alcohol 





261. Peng, G.S. and S.J. Yin, Effect of the allelic variants of aldehyde dehydrogenase ALDH2*2 and 
alcohol dehydrogenase ADH1B*2 on blood acetaldehyde concentrations. Hum Genomics, 2009. 
3(2): p. 121-7. 
262. Duester, G., J. Farres, M.R. Felder, R.S. Holmes, J.O. Hoog, X. Pares, B.V. Plapp, S.J. Yin, and 
H. Jornvall, Recommended nomenclature for the vertebrate alcohol dehydrogenase gene family. 
Biochem Pharmacol, 1999. 58(3): p. 389-95. 
263. Chen, Y.C., R.B. Lu, G.S. Peng, M.F. Wang, H.K. Wang, H.C. Ko, Y.C. Chang, J.J. Lu, T.K. Li, 
and S.J. Yin, Alcohol metabolism and cardiovascular response in an alcoholic patient 
homozygous for the ALDH2*2 variant gene allele. Alcohol Clin Exp Res, 1999. 23(12): p. 1853-
60. 
264. TD Hurley, H.E., T-K Li Pharmacogenomics: The Search for Individualized Therapies. 2002, 
Weinheim, Germany: Wiley-VCH. 
265. Lee, S.L., G.Y. Chau, C.T. Yao, C.W. Wu, and S.J. Yin, Functional assessment of human alcohol 
dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin 
Exp Res, 2006. 30(7): p. 1132-42. 
266. Edenberg, H.J., Regulation of the mammalian alcohol dehydrogenase genes. Prog Nucleic Acid 
Res Mol Biol, 2000. 64: p. 295-341. 
267. Vasiliou, V., A. Bairoch, K.F. Tipton, and D.W. Nebert, Eukaryotic aldehyde dehydrogenase 
(ALDH) genes: human polymorphisms, and recommended nomenclature based on divergent 
evolution and chromosomal mapping. Pharmacogenetics, 1999. 9(4): p. 421-34. 
268. Crabb, D.W., M. Matsumoto, D. Chang, and M. You, Overview of the role of alcohol 
dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related 
pathology. Proc Nutr Soc, 2004. 63(1): p. 49-63. 
269. Yoshida, A., A. Rzhetsky, L.C. Hsu, and C. Chang, Human aldehyde dehydrogenase gene family. 
Eur J Biochem, 1998. 251(3): p. 549-57. 
270. Lieber, C.S., Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)--a 
review. Alcohol Clin Exp Res, 1999. 23(6): p. 991-1007. 
271. Lieber, C.S., The discovery of the microsomal ethanol oxidizing system and its physiologic and 
pathologic role. Drug Metab Rev, 2004. 36(3-4): p. 511-29. 
272. Lieber, C.S., Microsomal ethanol-oxidizing system. Enzyme, 1987. 37(1-2): p. 45-56. 
273. Crabb, D.W., Ethanol oxidizing enzymes: roles in alcohol metabolism and alcoholic liver disease. 
Prog Liver Dis, 1995. 13: p. 151-72. 
274. Hurley, T.D. and H.J. Edenberg, Genes encoding enzymes involved in ethanol metabolism. 
Alcohol Res, 2012. 34(3): p. 339-44. 
275. Osier, M.V., A.J. Pakstis, D. Goldman, H.J. Edenberg, J.R. Kidd, and K.K. Kidd, A proline-
threonine substitution in codon 351 of ADH1C is common in Native Americans. Alcohol Clin Exp 





276. Ramchandani , V.W., RR., Alcohol,Nutrition, and Health Consequences, Nutrition and Health. 
2013, New York: Springer Science Business Media. 
277. O'Connor, S., S. Morzorati, J. Christian, and T.K. Li, Clamping breath alcohol concentration 
reduces experimental variance: application to the study of acute tolerance to alcohol and alcohol 
elimination rate. Alcohol Clin Exp Res, 1998. 22(1): p. 202-10. 
278. Goedde, H.W., D.P. Agarwal, G. Fritze, D. Meier-Tackmann, S. Singh, G. Beckmann, K. Bhatia, 
L.Z. Chen, B. Fang, R. Lisker, and et al., Distribution of ADH2 and ALDH2 genotypes in 
different populations. Hum Genet, 1992. 88(3): p. 344-6. 
279. Li, T.K., Pharmacogenetics of responses to alcohol and genes that influence alcohol drinking. J 
Stud Alcohol, 2000. 61(1): p. 5-12. 
280. Bosron, W.F. and T.K. Li, Genetic polymorphism of human liver alcohol and aldehyde 
dehydrogenases, and their relationship to alcohol metabolism and alcoholism. Hepatology, 1986. 
6(3): p. 502-10. 
281. Cederbaum, A.I., ALCOHOL METABOLISM. Clinics in liver disease, 2012. 16(4): p. 667-685. 
282. Chen, H.J., H. Tian, and H.J. Edenberg, Natural haplotypes in the regulatory sequences affect 
human alcohol dehydrogenase 1C (ADH1C) gene expression. Hum Mutat, 2005. 25(2): p. 150-5. 
283. Pochareddy, S. and H.J. Edenberg, Variation in the ADH1B proximal promoter affects 
expression. Chem Biol Interact, 2011. 191(1-3): p. 38-41. 
284. Pochareddy, S. and H.J. Edenberg, Identification of a FOXA-dependent enhancer of human 
alcohol dehydrogenase 4 (ADH4). Gene, 2010. 460(1-2): p. 1-7. 
285. Jackson, B., C. Brocker, D.C. Thompson, W. Black, K. Vasiliou, D.W. Nebert, and V. Vasiliou, 
Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics, 2011. 5(4): p. 
283-303. 
286. Yoshida, A., I.Y. Huang, and M. Ikawa, Molecular abnormality of an inactive aldehyde 
dehydrogenase variant commonly found in Orientals. Proc Natl Acad Sci U S A, 1984. 81(1): p. 
258-61. 
287. Hsu, L.C., R.E. Bendel, and A. Yoshida, Genomic structure of the human mitochondrial aldehyde 
dehydrogenase gene. Genomics, 1988. 2(1): p. 57-65. 
288. Crabb, D.W., H.J. Edenberg, W.F. Bosron, and T.K. Li, Genotypes for aldehyde dehydrogenase 
deficiency and alcohol sensitivity. The inactive ALDH2(2) allele is dominant. J Clin Invest, 1989. 
83(1): p. 314-6. 
289. Goedde, H.W., S. Singh, D.P. Agarwal, G. Fritze, K. Stapel, and Y.K. Paik, Genotyping of 
mitochondrial aldehyde dehydrogenase in blood samples using allele-specific oligonucleotides: 
comparison with phenotyping in hair roots. Human Genetics, 1989. 81(4): p. 305-307. 
290. Peng, G.S., Y.C. Chen, T.P. Tsao, M.F. Wang, and S.J. Yin, Pharmacokinetic and 
pharmacodynamic basis for partial protection against alcoholism in Asians, heterozygous for the 





291. Chen, Y.C., G.S. Peng, M.F. Wang, T.P. Tsao, and S.J. Yin, Polymorphism of ethanol-
metabolism genes and alcoholism: correlation of allelic variations with the pharmacokinetic and 
pharmacodynamic consequences. Chem Biol Interact, 2009. 178(1-3): p. 2-7. 
292. Neumark, Y.D., Y. Friedlander, R. Durst, E. Leitersdorf, D. Jaffe, V.A. Ramchandani, S. 
O'Connor, L.G. Carr, and T.K. Li, Alcohol dehydrogenase polymorphisms influence alcohol-
elimination rates in a male Jewish population. Alcohol Clin Exp Res, 2004. 28(1): p. 10-4. 
293. McCarthy, D.M., S.L. Pedersen, E.A. Lobos, R.D. Todd, and T.L. Wall, ADH1B*3 and Response 
to Alcohol in African Americans. Alcoholism, clinical and experimental research, 2010. 34(7): p. 
1274-1281. 
294. Wall, T.L., C. Garcia-Andrade, H.R. Thomasson, M. Cole, and C.L. Ehlers, Alcohol Elimination 
in Native American Mission Indians: An Investigation of Interindividual Variation. Alcoholism: 
Clinical and Experimental Research, 1996. 20(7): p. 1159-1164. 
295. Peng, G.-S., M.-F. Wang, C.-Y. Chen, S.-U. Luu, H.-C. Chou, T.-K. Li, and S.-J. Yin, 
Involvement of acetaldehyde for full protection against alcoholism by homozygosity of the variant 
allele of mitochondrial aldehyde dehydrogenase gene in Asians. Pharmacogenetics and 
Genomics, 1999. 9(4): p. 463-476. 
296. Enomoto, N., S. Takase, M. Yasuhara, and A. Takada, Acetaldehyde Metabolism in Different 
Aldehyde Dehydrogenase-2 Genotypes. Alcoholism: Clinical and Experimental Research, 1991. 
15(1): p. 141-144. 
297. Thomasson, H.R., D.W. Crabb, H.J. Edenberg, and T.-K. Li, Alcohol and aldehyde 
dehydrogenase polymorphisms and alcoholism. Behavior Genetics, 1993. 23(2): p. 131-136. 
298. Birley, A.J., M.R. James, P.A. Dickson, G.W. Montgomery, A.C. Heath, J.B. Whitfield, and N.G. 
Martin, Association of the gastric alcohol dehydrogenase gene ADH7 with variation in alcohol 
metabolism. Hum Mol Genet, 2008. 17(2): p. 179-89. 
299. Birley, A.J., M.R. James, P.A. Dickson, G.W. Montgomery, A.C. Heath, N.G. Martin, and J.B. 
Whitfield, ADH single nucleotide polymorphism associations with alcohol metabolism in vivo. 
Hum Mol Genet, 2009. 18(8): p. 1533-42. 
300. Verbaten, M.N., Chronic effects of low to moderate alcohol consumption on structural and 
functional properties of the brain: beneficial or not? Hum Psychopharmacol, 2009. 24(3): p. 199-
205. 
301. Neiman, J., Alcohol as a risk factor for brain damage: neurologic aspects. Alcohol Clin Exp Res, 
1998. 22(7 Suppl): p. 346s-351s. 
302. Clapp, P., S.V. Bhave, and P.L. Hoffman, How adaptation of the brain to alcohol leads to 
dependence: a pharmacological perspective. Alcohol Res Health, 2008. 31(4): p. 310-39. 






304. Robinson, J.K. and R.G. Mair, MK-801 prevents brain lesions and delayed-nonmatching-to-
sample deficits produced by pyrithiamine-induced encephalopathy in rats. Behav Neurosci, 1992. 
106(4): p. 623-33. 
305. Kopelman, M.D., A.D. Thomson, I. Guerrini, and E.J. Marshall, The Korsakoff syndrome: 
clinical aspects, psychology and treatment. Alcohol Alcohol, 2009. 44(2): p. 148-54. 
306. Anttila, T., E.L. Helkala, M. Viitanen, I. Kareholt, L. Fratiglioni, B. Winblad, H. Soininen, J. 
Tuomilehto, A. Nissinen, and M. Kivipelto, Alcohol drinking in middle age and subsequent risk 
of mild cognitive impairment and dementia in old age: a prospective population based study. 
Bmj, 2004. 329(7465): p. 539. 
307. Mahley, R.W. and S.C. Rall, Jr., Is epsilon4 the ancestral human apoE allele? Neurobiol Aging, 
1999. 20(4): p. 429-30. 
308. Bleich, S., D. Degner, W. Sperling, D. Bonsch, N. Thurauf, and J. Kornhuber, Homocysteine as a 
neurotoxin in chronic alcoholism. Prog Neuropsychopharmacol Biol Psychiatry, 2004. 28(3): p. 
453-64. 
309. Brust, J.C., Ethanol and cognition: indirect effects, neurotoxicity and neuroprotection: a review. 
Int J Environ Res Public Health, 2010. 7(4): p. 1540-57. 
310. Robinson, G., S. Narasimhan, M. Weatherall, and R. Beasley, Raised plasma homocysteine levels 
in alcoholism: increasing the risk of heart disease and dementia? N Z Med J, 2005. 118(1216): p. 
U1490. 
311. Wilhelm, J., K. Bayerlein, T. Hillemacher, U. Reulbach, H. Frieling, B. Kromolan, D. Degner, J. 
Kornhuber, and S. Bleich, Short-term cognition deficits during early alcohol withdrawal are 
associated with elevated plasma homocysteine levels in patients with alcoholism. J Neural 
Transm (Vienna), 2006. 113(3): p. 357-63. 
312. Crews, F.T., R. Bechara, L.A. Brown, D.M. Guidot, P. Mandrekar, S. Oak, L. Qin, G. Szabo, M. 
Wheeler, and J. Zou, Cytokines and alcohol. Alcohol Clin Exp Res, 2006. 30(4): p. 720-30. 
313. Kumar, S., P. Porcu, D.F. Werner, D.B. Matthews, J.L. Diaz-Granados, R.S. Helfand, and A.L. 
Morrow, The role of GABA(A) receptors in the acute and chronic effects of ethanol: a decade of 
progress. Psychopharmacology (Berl), 2009. 205(4): p. 529-64. 
314. Haddad, J.J., Alcoholism and neuro-immune-endocrine interactions: physiochemical aspects. 
Biochem Biophys Res Commun, 2004. 323(2): p. 361-71. 
315. Deitrich, R.A., T.V. Dunwiddie, R.A. Harris, and V.G. Erwin, Mechanism of action of ethanol: 
initial central nervous system actions. Pharmacol Rev, 1989. 41(4): p. 489-537. 
316. Stephens, R., J. Ling, T.M. Heffernan, N. Heather, and K. Jones, A review of the literature on the 
cognitive effects of alcohol hangover. Alcohol Alcohol, 2008. 43(2): p. 163-70. 
317. Newlin, D.B. and M.B. Pretorius, Sons of alcoholics report greater hangover symptoms than sons 





318. Read, J.P., J.E. Merrill, C.W. Kahler, and D.R. Strong, Predicting functional outcomes among 
college drinkers: reliability and predictive validity of the Young Adult Alcohol Consequences 
Questionnaire. Addict Behav, 2007. 32(11): p. 2597-610. 
319. Association, A.P., Task Force on DSM-IV. Diagnostic and Statistical Manual of Mental 
Disorders: DSM-IV-TR. 2000, Washington, DC: American Psychiatric Association. 
320. Brandt, J., N. Butters, C. Ryan, and R. Bayog, Cognitive loss and recovery in long-term alcohol 
abusers. Arch Gen Psychiatry, 1983. 40(4): p. 435-42. 
321. Grant, I., Alcohol and the brain: neuropsychological correlates. J Consult Clin Psychol, 1987. 
55(3): p. 310-24. 
322. White, A.M., What happened? Alcohol, memory blackouts, and the brain. Alcohol Res Health, 
2003. 27(2): p. 186-96. 
323. Lee, H., S. Roh, and D.J. Kim, Alcohol-induced blackout. Int J Environ Res Public Health, 2009. 
6(11): p. 2783-92. 
324. Collins, M.A., E.J. Neafsey, K.J. Mukamal, M.O. Gray, D.A. Parks, D.K. Das, and R.J. Korthuis, 
Alcohol in moderation, cardioprotection, and neuroprotection: epidemiological considerations 
and mechanistic studies. Alcohol Clin Exp Res, 2009. 33(2): p. 206-19. 
325. Cleophas, T.J., Wine, beer and spirits and the risk of myocardial infarction: a systematic review. 
Biomed Pharmacother, 1999. 53(9): p. 417-23. 
326. Corrao, G., L. Rubbiati, V. Bagnardi, A. Zambon, and K. Poikolainen, Alcohol and coronary 
heart disease: a meta-analysis. Addiction, 2000. 95(10): p. 1505-23. 
327. Reynolds, K., B. Lewis, J.D. Nolen, G.L. Kinney, B. Sathya, and J. He, Alcohol consumption and 
risk of stroke: a meta-analysis. Jama, 2003. 289(5): p. 579-88. 
328. Mukamal, K.J., M.K. Jensen, M. Gronbaek, M.J. Stampfer, J.E. Manson, T. Pischon, and E.B. 
Rimm, Drinking frequency, mediating biomarkers, and risk of myocardial infarction in women 
and men. Circulation, 2005. 112(10): p. 1406-13. 
329. Renaud, S.C. and J.C. Ruf, Effects of alcohol on platelet functions. Clin Chim Acta, 1996. 246(1-
2): p. 77-89. 
330. Aikens, M.L., H.E. Grenett, R.L. Benza, E.M. Tabengwa, G.C. Davis, and F.M. Booyse, Alcohol-
induced upregulation of plasminogen activators and fibrinolytic activity in cultured human 
endothelial cells. Alcohol Clin Exp Res, 1998. 22(2): p. 375-81. 
331. Sierksma, A., M.S. van der Gaag, C. Kluft, and H.F. Hendriks, Moderate alcohol consumption 
reduces plasma C-reactive protein and fibrinogen levels; a randomized, diet-controlled 
intervention study. Eur J Clin Nutr, 2002. 56(11): p. 1130-6. 
332. Tsai, S.K., L.M. Hung, Y.T. Fu, H. Cheng, M.W. Nien, H.Y. Liu, F.B. Zhang, and S.S. Huang, 
Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide 





333. Mokni, M., F. Limam, S. Elkahoui, M. Amri, and E. Aouani, Strong cardioprotective effect of 
resveratrol, a red wine polyphenol, on isolated rat hearts after ischemia/reperfusion injury. Arch 
Biochem Biophys, 2007. 457(1): p. 1-6. 
334. Juric, D., P. Wojciechowski, D.K. Das, and T. Netticadan, Prevention of concentric hypertrophy 
and diastolic impairment in aortic-banded rats treated with resveratrol. Am J Physiol Heart Circ 
Physiol, 2007. 292(5): p. H2138-43. 
335. Das, S., N. Khan, S. Mukherjee, D. Bagchi, N. Gurusamy, H. Swartz, and D.K. Das, Redox 
regulation of resveratrol-mediated switching of death signal into survival signal. Free Radic Biol 
Med, 2008. 44(1): p. 82-90. 
336. Dufouil, C., C. Tzourio, C. Brayne, C. Berr, P. Amouyel, and A. Alperovitch, Influence of 
apolipoprotein E genotype on the risk of cognitive deterioration in moderate drinkers and 
smokers. Epidemiology, 2000. 11(3): p. 280-4. 
337. Leroi, I., J.M. Sheppard, and C.G. Lyketsos, Cognitive function after 11.5 years of alcohol use: 
relation to alcohol use. Am J Epidemiol, 2002. 156(8): p. 747-52. 
338. Bond, G.E., R. Burr, S.M. McCurry, M.M. Rice, A.R. Borenstein, W.A. Kukull, L. Teri, J.D. 
Bowen, W.C. McCormick, and E.B. Larson, Alcohol, gender, and cognitive performance: a 
longitudinal study comparing older Japanese and non-Hispanic white Americans. J Aging 
Health, 2004. 16(5): p. 615-40. 
339. Espeland, M.A., L. Gu, K.H. Masaki, R.D. Langer, L.H. Coker, M.L. Stefanick, J. Ockene, and 
S.R. Rapp, Association between reported alcohol intake and cognition: results from the Women's 
Health Initiative Memory Study. Am J Epidemiol, 2005. 161(3): p. 228-38. 
340. Ganguli, M., J. Vander Bilt, J.A. Saxton, C. Shen, and H.H. Dodge, Alcohol consumption and 
cognitive function in late life: a longitudinal community study. Neurology, 2005. 65(8): p. 1210-7. 
341. Richards, M., R. Hardy, and M.E. Wadsworth, Alcohol consumption and midlife cognitive change 
in the British 1946 birth cohort study. Alcohol Alcohol, 2005. 40(2): p. 112-7. 
342. Stampfer, M.J., J.H. Kang, J. Chen, R. Cherry, and F. Grodstein, Effects of moderate alcohol 
consumption on cognitive function in women. N Engl J Med, 2005. 352(3): p. 245-53. 
343. Wright, C.B., M.S. Elkind, X. Luo, M.C. Paik, and R.L. Sacco, Reported alcohol consumption 
and cognitive decline: The northern Manhattan study. Neuroepidemiology, 2006. 27(4): p. 201-7. 
344. Stott, D.J., A. Falconer, G.D. Kerr, H.M. Murray, S. Trompet, R.G. Westendorp, B. Buckley, A.J. 
de Craen, N. Sattar, and I. Ford, Does low to moderate alcohol intake protect against cognitive 
decline in older people? J Am Geriatr Soc, 2008. 56(12): p. 2217-24. 
345. Lobo, E., C. Dufouil, G. Marcos, B. Quetglas, P. Saz, E. Guallar, and A. Lobo, Is there an 
association between low-to-moderate alcohol consumption and risk of cognitive decline? Am J 
Epidemiol, 2010. 172(6): p. 708-16. 
346. Zanjani, F., B.G. Downer, T.M. Kruger, S.L. Willis, and K.W. Schaie, Alcohol effects on 





347. Beydoun, M.A., A.A. Gamaldo, H.A. Beydoun, T. Tanaka, K.L. Tucker, S.A. Talegawkar, L. 
Ferrucci, and A.B. Zonderman, Caffeine and alcohol intakes and overall nutrient adequacy are 
associated with longitudinal cognitive performance among U.S. adults. J Nutr, 2014. 144(6): p. 
890-901. 
348. Sabia, S., A. Elbaz, A. Britton, S. Bell, A. Dugravot, M. Shipley, M. Kivimaki, and A. Singh-
Manoux, Alcohol consumption and cognitive decline in early old age. Neurology, 2014. 82(4): p. 
332-9. 
349. Schneider, A.L., A.R. Sharrett, M.D. Patel, A. Alonso, J. Coresh, T. Mosley, O. Selnes, E. Selvin, 
and R.F. Gottesman, Education and cognitive change over 15 years: the atherosclerosis risk in 
communities study. J Am Geriatr Soc, 2012. 60(10): p. 1847-53. 
350. Morris, M.C., D.A. Evans, L.E. Hebert, and J.L. Bienias, Methodological issues in the study of 
cognitive decline. Am J Epidemiol, 1999. 149(9): p. 789-93. 
351. Eriksson, C.J., T. Fukunaga, T. Sarkola, W.J. Chen, C.C. Chen, J.M. Ju, A.T. Cheng, H. 
Yamamoto, K. Kohlenberg-Muller, M. Kimura, M. Murayama, S. Matsushita, H. Kashima, S. 
Higuchi, L. Carr, D. Viljoen, L. Brooke, T. Stewart, T. Foroud, J. Su, T.K. Li, and J.B. Whitfield, 
Functional relevance of human adh polymorphism. Alcohol Clin Exp Res, 2001. 25(5 Suppl 
ISBRA): p. 157s-163s. 
352. Thomasson, H.R., D.W. Crabb, H.J. Edenberg, T.K. Li, H.G. Hwu, C.C. Chen, E.K. Yeh, and S.J. 
Yin, Low frequency of the ADH2*2 allele among Atayal natives of Taiwan with alcohol use 
disorders. Alcohol Clin Exp Res, 1994. 18(3): p. 640-3. 
353. Dick, D.M. and L.J. Bierut, The genetics of alcohol dependence. Current Psychiatry Reports. 
8(2): p. 151-157. 
354. Goodwin, D.W., F. Schulsinger, N. Moller, L. Hermansen, G. Winokur, and S.B. Guze, Drinking 
problems in adopted and nonadopted sons of alcoholics. Arch Gen Psychiatry, 1974. 31(2): p. 
164-9. 
355. Heath, A.C., K.K. Bucholz, P.A. Madden, S.H. Dinwiddie, W.S. Slutske, L.J. Bierut, D.J. 
Statham, M.P. Dunne, J.B. Whitfield, and N.G. Martin, Genetic and environmental contributions 
to alcohol dependence risk in a national twin sample: consistency of findings in women and men. 
Psychol Med, 1997. 27(6): p. 1381-96. 
356. Kendler, K.S., M.C. Neale, A.C. Heath, R.C. Kessler, and L.J. Eaves, A twin-family study of 
alcoholism in women. Am J Psychiatry, 1994. 151(5): p. 707-15. 
357. Prescott, C.A. and K.S. Kendler, Genetic and environmental contributions to alcohol abuse and 
dependence in a population-based sample of male twins. Am J Psychiatry, 1999. 156(1): p. 34-
40. 
358. Prescott, C.A., P.F. Sullivan, P.H. Kuo, B.T. Webb, J. Vittum, D.G. Patterson, D.L. Thiselton, 
J.M. Myers, M. Devitt, L.J. Halberstadt, V.P. Robinson, M.C. Neale, E.J. van den Oord, D. 
Walsh, B.P. Riley, and K.S. Kendler, Genomewide linkage study in the Irish affected sib pair 
study of alcohol dependence: evidence for a susceptibility region for symptoms of alcohol 





359. Schuckit, M.A., H.J. Edenberg, J. Kalmijn, L. Flury, T.L. Smith, T. Reich, L. Bierut, A. Goate, 
and T. Foroud, A genome-wide search for genes that relate to a low level of response to alcohol. 
Alcohol Clin Exp Res, 2001. 25(3): p. 323-9. 
360. Li, D., H. Zhao, and J. Gelernter, Strong association of the alcohol dehydrogenase 1B gene 
(ADH1B) with alcohol dependence and alcohol-induced medical diseases. Biol Psychiatry, 2011. 
70(6): p. 504-12. 
361. Kopun, M. and P. Propping, The kinetics of ethanol absorption and elimination in twins and 
supplementary repetitive experiments in singleton subjects. Eur J Clin Pharmacol, 1977. 11(5): p. 
337-44. 
362. Thomasson, H.R., H.J. Edenberg, D.W. Crabb, X.L. Mai, R.E. Jerome, T.K. Li, S.P. Wang, Y.T. 
Lin, R.B. Lu, and S.J. Yin, Alcohol and aldehyde dehydrogenase genotypes and alcoholism in 
Chinese men. Am J Hum Genet, 1991. 48(4): p. 677-81. 
363. Li, D., H. Zhao, and J. Gelernter, Strong protective effect of the aldehyde dehydrogenase gene 
(ALDH2) 504lys (*2) allele against alcoholism and alcohol-induced medical diseases in Asians. 
Hum Genet, 2012. 131(5): p. 725-37. 
364. Zuccolo, L., N. Fitz-Simon, R. Gray, S.M. Ring, K. Sayal, G.D. Smith, and S.J. Lewis, A non-
synonymous variant in ADH1B is strongly associated with prenatal alcohol use in a European 
sample of pregnant women. Hum Mol Genet, 2009. 18(22): p. 4457-66. 
365. Gelernter, J., H.R. Kranzler, R. Sherva, L. Almasy, R. Koesterer, A.H. Smith, R. Anton, U.W. 
Preuss, M. Ridinger, D. Rujescu, N. Wodarz, P. Zill, H. Zhao, and L.A. Farrer, Genome-wide 
association study of alcohol dependence:significant findings in African- and European-
Americans including novel risk loci. Mol Psychiatry, 2014. 19(1): p. 41-9. 
366. Yin, S.J., W.F. Bosron, L.J. Magnes, and T.K. Li, Human liver alcohol dehydrogenase: 
purification and kinetic characterization of the .beta.2.beta.2, .beta.2.beta.1, .alpha..beta.2, and 
.beta.2.gamma.1 "Oriental" isoenzymes. Biochemistry, 1984. 23(24): p. 5847-5853. 
367. Hurley, T.D., H.J. Edenberg, and W.F. Bosron, Expression and kinetic characterization of 
variants of human beta 1 beta 1 alcohol dehydrogenase containing substitutions at amino acid 
47. J Biol Chem, 1990. 265(27): p. 16366-72. 
368. Park, B.L., J.W. Kim, H.S. Cheong, L.H. Kim, B.C. Lee, C.H. Seo, T.C. Kang, Y.W. Nam, G.B. 
Kim, H.D. Shin, and I.G. Choi, Extended genetic effects of ADH cluster genes on the risk of 
alcohol dependence: from GWAS to replication. Hum Genet, 2013. 132(6): p. 657-68. 
369. Li, H., N. Mukherjee, U. Soundararajan, Z. Tarnok, C. Barta, S. Khaliq, A. Mohyuddin, S.L. 
Kajuna, S.Q. Mehdi, J.R. Kidd, and K.K. Kidd, Geographically separate increases in the 
frequency of the derived ADH1B*47His allele in eastern and western Asia. Am J Hum Genet, 







370. Treutlein, J., S. Cichon, M. Ridinger, N. Wodarz, M. Soyka, P. Zill, W. Maier, R. Moessner, W. 
Gaebel, N. Dahmen, C. Fehr, N. Scherbaum, M. Steffens, K.U. Ludwig, J. Frank, H.E. 
Wichmann, S. Schreiber, N. Dragano, W.H. Sommer, F. Leonardi-Essmann, A. Lourdusamy, P. 
Gebicke-Haerter, T.F. Wienker, P.F. Sullivan, M.M. Nothen, F. Kiefer, R. Spanagel, K. Mann, 
and M. Rietschel, Genome-wide association study of alcohol dependence. Arch Gen Psychiatry, 
2009. 66(7): p. 773-84. 
371. Bierut, L.J., A.M. Goate, N. Breslau, E.O. Johnson, S. Bertelsen, L. Fox, A. Agrawal, K.K. 
Bucholz, R. Grucza, V. Hesselbrock, J. Kramer, S. Kuperman, J. Nurnberger, B. Porjesz, N.L. 
Saccone, M. Schuckit, J. Tischfield, J.C. Wang, T. Foroud, J.P. Rice, and H.J. Edenberg, ADH1B 
is associated with alcohol dependence and alcohol consumption in populations of European and 
African ancestry. Mol Psychiatry, 2012. 17(4): p. 445-50. 
372. Way, M., A. McQuillin, J. Saini, K. Ruparelia, G.J. Lydall, I. Guerrini, D. Ball, I. Smith, G. 
Quadri, A.D. Thomson, K. Kasiakogia-Worlley, R. Cherian, P. Gunwardena, H. Rao, G. Kottalgi, 
S. Patel, A. Hillman, E. Douglas, S.Y. Qureshi, G. Reynolds, S. Jauhar, A. O'Kane, A. Dedman, 
S. Sharp, R. Kandaswamy, K. Dar, D. Curtis, M.Y. Morgan, and H.M. Gurling, Genetic variants 
in or near ADH1B and ADH1C affect susceptibility to alcohol dependence in a British and Irish 
population. Addict Biol, 2015. 20(3): p. 594-604. 
373. Ferrari, P., J.D. McKay, M. Jenab, P. Brennan, F. Canzian, U. Vogel, A. Tjonneland, K. Overvad, 
J.S. Tolstrup, M.C. Boutron-Ruault, F. Clavel-Chapelon, S. Morois, R. Kaaks, H. Boeing, M. 
Bergmann, A. Trichopoulou, M. Katsoulis, D. Trichopoulos, V. Krogh, S. Panico, C. Sacerdote, 
D. Palli, R. Tumino, P.H. Peeters, C.H. van Gils, B. Bueno-de-Mesquita, A. Vrieling, E. Lund, A. 
Hjartaker, A. Agudo, L.R. Suarez, L. Arriola, M.D. Chirlaque, E. Ardanaz, M.J. Sanchez, J. 
Manjer, B. Lindkvist, G. Hallmans, R. Palmqvist, N. Allen, T. Key, K.T. Khaw, N. Slimani, S. 
Rinaldi, I. Romieu, P. Boffetta, D. Romaguera, T. Norat, and E. Riboli, Alcohol dehydrogenase 
and aldehyde dehydrogenase gene polymorphisms, alcohol intake and the risk of colorectal 
cancer in the European Prospective Investigation into Cancer and Nutrition study. Eur J Clin 
Nutr, 2012. 66(12): p. 1303-8. 
374. Macgregor, S., P.A. Lind, K.K. Bucholz, N.K. Hansell, P.A. Madden, M.M. Richter, G.W. 
Montgomery, N.G. Martin, A.C. Heath, and J.B. Whitfield, Associations of ADH and ALDH2 
gene variation with self report alcohol reactions, consumption and dependence: an integrated 
analysis. Hum Mol Genet, 2009. 18(3): p. 580-93. 
375. Edenberg, H.J., X. Xuei, H.J. Chen, H. Tian, L.F. Wetherill, D.M. Dick, L. Almasy, L. Bierut, 
K.K. Bucholz, A. Goate, V. Hesselbrock, S. Kuperman, J. Nurnberger, B. Porjesz, J. Rice, M. 
Schuckit, J. Tischfield, H. Begleiter, and T. Foroud, Association of alcohol dehydrogenase genes 
with alcohol dependence: a comprehensive analysis. Hum Mol Genet, 2006. 15(9): p. 1539-49. 
376. Toth, R., S. Fiatal, B. Petrovski, M. McKee, and R. Adany, Combined effect of ADH1B 
RS1229984, RS2066702 and ADH1C RS1693482/ RS698 alleles on alcoholism and chronic liver 
diseases. Dis Markers, 2011. 31(5): p. 267-77. 
377. Li, D., H. Zhao, and J. Gelernter, Further clarification of the contribution of the ADH1C gene to 
vulnerability of alcoholism and selected liver diseases. Hum Genet, 2012. 131(8): p. 1361-74. 
378. Norden-Krichmar, T.M., I.R. Gizer, K.C. Wilhelmsen, N.J. Schork, and C.L. Ehlers, Protective 
variant associated with alcohol dependence in a Mexican American cohort. BMC Med Genet, 





379. Biernacka, J.M., J.R. Geske, T.D. Schneekloth, M.A. Frye, J.M. Cunningham, D.S. Choi, C.L. 
Tapp, B.R. Lewis, M.S. Drews, L.P. T, C.L. Colby, D.K. Hall-Flavin, L.L. Loukianova, J.A. 
Heit, D.A. Mrazek, and V.M. Karpyak, Replication of genome wide association studies of alcohol 
dependence: support for association with variation in ADH1C. PLoS One, 2013. 8(3): p. e58798. 
380. Luo, X., H.R. Kranzler, L. Zuo, B.Z. Yang, J. Lappalainen, and J. Gelernter, ADH4 gene 
variation is associated with alcohol and drug dependence: results from family controlled and 
population-structured association studies. Pharmacogenet Genomics, 2005. 15(11): p. 755-68. 
381. Ritchie, S.J., T.C. Bates, J. Corley, G. McNeill, G. Davies, D.C. Liewald, J.M. Starr, and I.J. 
Deary, Alcohol consumption and lifetime change in cognitive ability: a gene x environment 
interaction study. Age (Dordr), 2014. 36(3): p. 9638. 
382. Smith, G.D. and S. Ebrahim, Mendelian randomization: prospects, potentials, and limitations. Int 
J Epidemiol, 2004. 33(1): p. 30-42. 
383. Vu, K.N., C.M. Ballantyne, R.C. Hoogeveen, V. Nambi, K.A. Volcik, E. Boerwinkle, and A.C. 
Morrison, Causal Role of Alcohol Consumption in an Improved Lipid Profile: The 
Atherosclerosis Risk in Communities (ARIC) Study. PLoS ONE, 2016. 11(2): p. e0148765. 
384. U.S. Department of Health and Human Services and U.S. Department of Agriculture. 2015 – 
2020 Dietary Guidelines for Americans. 8th Edition. December 2015. . 
385. Lezar, M., Neuropsychological assessment. 2nd ed. 1983, New York, NY: Oxford University 
Press. 
386. Asparouhov, T. and B. Muthén, Plausible values for latent variables using Mplus. Technical 
Report. 2010. from http://www.statmodel.com/download/Plausible.pdf. 
387. Gross, A.L., M.C. Power, M.S. Albert, J.A. Deal, R.F. Gottesman, M. Griswold, L.M. Wruck, 
T.H. Mosley, J. Coresh, A.R. Sharrett, and K. Bandeen-Roche, Application of latent variable 
methods to the study of cognitive decline when tests change over time. Epidemiology (Cambridge, 
Mass.), 2015. 26(6): p. 878-887. 
388. Fillmore, K.M., J.M. Golding, K.L. Graves, S. Kniep, E.V. Leino, A. Romelsjo, C. Shoemaker, 
C.R. Ager, P. Allebeck, and H.P. Ferrer, Alcohol consumption and mortality. I. Characteristics of 
drinking groups. Addiction, 1998. 93(2): p. 183-203. 
389. Textor, J., J. Hardt, and S. Knuppel, DAGitty: a graphical tool for analyzing causal diagrams. 
Epidemiology, 2011. 22(5): p. 745. 
390. Baecke, J.A., J. Burema, and J.E. Frijters, A short questionnaire for the measurement of habitual 
physical activity in epidemiological studies. Am J Clin Nutr, 1982. 36(5): p. 936-42. 
391. Weng, L.C., L.M. Steffen, M. Szklo, J. Nettleton, L. Chambless, and A.R. Folsom, A diet pattern 
with more dairy and nuts, but less meat is related to lower risk of developing hypertension in 







392. Steffen, L.M., C.H. Kroenke, X. Yu, M.A. Pereira, M.L. Slattery, L. Van Horn, M.D. Gross, and 
D.R. Jacobs, Jr., Associations of plant food, dairy product, and meat intakes with 15-y incidence 
of elevated blood pressure in young black and white adults: the Coronary Artery Risk 
Development in Young Adults (CARDIA) Study. Am J Clin Nutr, 2005. 82(6): p. 1169-77; quiz 
1363-4. 
393. Gene Expression Analysis Using TaqMan1 Assays: Life Technologies.  [cited 2018 February 10]; 
Available from: http://www.lifetechnologies.com/us/en/home/life-science/pcr/real-time-pcr/real-
time-pcr-assays/taqman-geneexpression.html. 
394. Volcik, K.A., R.A. Barkley, R.G. Hutchinson, T.H. Mosley, G. Heiss, A.R. Sharrett, C.M. 
Ballantyne, and E. Boerwinkle, Apolipoprotein E Polymorphisms Predict Low Density 
Lipoprotein Cholesterol Levels and Carotid Artery Wall Thickness but Not Incident Coronary 
Heart Disease in 12,491 ARIC Study Participants. American Journal of Epidemiology, 2006. 
164(4): p. 342-348. 
395. Selvin, E., Y. Ning, M.W. Steffes, L.D. Bash, R. Klein, T.Y. Wong, B.C. Astor, A.R. Sharrett, 
F.L. Brancati, and J. Coresh, Glycated hemoglobin and the risk of kidney disease and retinopathy 
in adults with and without diabetes. Diabetes, 2011. 60(1): p. 298-305. 
396. Toole, J.F., D.S. Lefkowitz, L.E. Chambless, L. Wijnberg, C.C. Paton, and G. Heiss, Self-
reported transient ischemic attack and stroke symptoms: methods and baseline prevalence. The 
ARIC Study, 1987-1989. Am J Epidemiol, 1996. 144(9): p. 849-56. 
397. Howie, B.N., P. Donnelly, and J. Marchini, A flexible and accurate genotype imputation method 
for the next generation of genome-wide association studies. PLoS Genet, 2009. 5(6): p. 
e1000529. 
398. Loomis, S.J., M. Li, N.M. Maruthur, A.S. Baldridge, K.E. North, H. Mei, A. Morrison, A.P. 
Carson, J.S. Pankow, E. Boerwinkle, R. Scharpf, L.J. Rasmussen-Torvik, J. Coresh, P. Duggal, 
A. Kottgen, and E. Selvin, Genome-Wide Association Study of Serum Fructosamine and Glycated 
Albumin in Adults Without Diagnosed Diabetes: Results From the Atherosclerosis Risk in 
Communities Study. Diabetes, 2018. 67(8): p. 1684-1696. 
399. Price, A.L., N.J. Patterson, R.M. Plenge, M.E. Weinblatt, N.A. Shadick, and D. Reich, Principal 
components analysis corrects for stratification in genome-wide association studies. Nat Genet, 












400. Liu, M., Y. Jiang, R. Wedow, Y. Li, D.M. Brazel, F. Chen, G. Datta, J. Davila-Velderrain, D. 
McGuire, C. Tian, X. Zhan, M. Agee, B. Alipanahi, A. Auton, R.K. Bell, K. Bryc, S.L. Elson, P. 
Fontanillas, N.A. Furlotte, D.A. Hinds, B.S. Hromatka, K.E. Huber, A. Kleinman, N.K. 
Litterman, M.H. McIntyre, J.L. Mountain, C.A.M. Northover, J.F. Sathirapongsasuti, O.V. 
Sazonova, J.F. Shelton, S. Shringarpure, C. Tian, J.Y. Tung, V. Vacic, C.H. Wilson, S.J. Pitts, A. 
Mitchell, A.H. Skogholt, B.S. Winsvold, B. Sivertsen, E. Stordal, G. Morken, H. Kallestad, I. 
Heuch, J.-A. Zwart, K.K. Fjukstad, L.M. Pedersen, M.E. Gabrielsen, M.B. Johnsen, M. Skrove, 
M.S. Indredavik, O.K. Drange, O. Bjerkeset, S. Børte, S.Ø. Stensland, H. Choquet, A.R. 
Docherty, J.D. Faul, J.R. Foerster, L.G. Fritsche, M.E. Gabrielsen, S.D. Gordon, J. Haessler, J.-J. 
Hottenga, H. Huang, S.-K. Jang, P.R. Jansen, Y. Ling, R. Mägi, N. Matoba, G. McMahon, A. 
Mulas, V. Orrù, T. Palviainen, A. Pandit, G.W. Reginsson, A.H. Skogholt, J.A. Smith, A.E. 
Taylor, C. Turman, G. Willemsen, H. Young, K.A. Young, G.J.M. Zajac, W. Zhao, W. Zhou, G. 
Bjornsdottir, J.D. Boardman, M. Boehnke, D.I. Boomsma, C. Chen, F. Cucca, G.E. Davies, C.B. 
Eaton, M.A. Ehringer, T. Esko, E. Fiorillo, N.A. Gillespie, D.F. Gudbjartsson, T. Haller, K.M. 
Harris, A.C. Heath, J.K. Hewitt, I.B. Hickie, J.E. Hokanson, C.J. Hopfer, D.J. Hunter, W.G. 
Iacono, E.O. Johnson, Y. Kamatani, S.L.R. Kardia, M.C. Keller, M. Kellis, C. Kooperberg, P. 
Kraft, K.S. Krauter, M. Laakso, P.A. Lind, A. Loukola, S.M. Lutz, P.A.F. Madden, N.G. Martin, 
M. McGue, M.B. McQueen, S.E. Medland, A. Metspalu, K.L. Mohlke, J.B. Nielsen, Y. Okada, 
U. Peters, T.J.C. Polderman, D. Posthuma, A.P. Reiner, J.P. Rice, E. Rimm, R.J. Rose, V. 
Runarsdottir, M.C. Stallings, A. Stančáková, H. Stefansson, K.K. Thai, H.A. Tindle, T. 
Tyrfingsson, T.L. Wall, D.R. Weir, C. Weisner, J.B. Whitfield, B.S. Winsvold, J. Yin, L. 
Zuccolo, L.J. Bierut, K. Hveem, J.J. Lee, M.R. Munafò, N.L. Saccone, C.J. Willer, M.C. 
Cornelis, S.P. David, D.A. Hinds, E. Jorgenson, J. Kaprio, J.A. Stitzel, K. Stefansson, T.E. 
Thorgeirsson, G. Abecasis, D.J. Liu, S. Vrieze, T. andMe Research and H.A.-I. Psychiatry, 
Association studies of up to 1.2 million individuals yield new insights into the genetic etiology of 
tobacco and alcohol use. Nature Genetics, 2019. 51(2): p. 237-244. 
401. Azur, M.J., E.A. Stuart, C. Frangakis, and P.J. Leaf, Multiple imputation by chained equations: 
what is it and how does it work? Int J Methods Psychiatr Res, 2011. 20(1): p. 40-9. 
402. Little, R.J.A. and D.B. Rubin, Statistical analysis with missing data. 2nd ed. 2002: Hoboken: 
Wiley. 
403. Rawlings, A.M., Y. Sang, A.R. Sharrett, J. Coresh, M. Griswold, A.M. Kucharska-Newton, P. 
Palta, L.M. Wruck, A.L. Gross, J.A. Deal, M.C. Power, and K.J. Bandeen-Roche, Multiple 
imputation of cognitive performance as a repeatedly measured outcome. Eur J Epidemiol, 2017. 
32(1): p. 55-66. 
404. Michael C Donohue, S.D.E., longpower: Power and sample size calculators for longitudinal 
data. R package version 1.0-16. 2016. 
405. Austin, M.A., T.H. Beaty, and W.D. Dotson, Genetic Epidemiology: Methods and Applications. 
2013: CABI. 
406. Chakraborty, R. and K.M. Weiss, Admixture as a tool for finding linked genes and detecting that 
difference from allelic association between loci. Proc Natl Acad Sci U S A, 1988. 85(23): p. 
9119-23. 
407. Deng, H.W., Population admixture may appear to mask, change or reverse genetic effects of 





408. Wang, Y., R. Localio, and T.R. Rebbeck, Evaluating bias due to population stratification in case-
control association studies of admixed populations. Genet Epidemiol, 2004. 27(1): p. 14-20. 
409. Wacholder, S., N. Rothman, and N. Caporaso, Counterpoint: bias from population stratification 
is not a major threat to the validity of conclusions from epidemiological studies of common 
polymorphisms and cancer. Cancer Epidemiol Biomarkers Prev, 2002. 11(6): p. 513-20. 
410. Wang, Y., R. Localio, and T.R. Rebbeck, Evaluating bias due to population stratification in 
epidemiologic studies of gene-gene or gene-environment interactions. Cancer Epidemiol 
Biomarkers Prev, 2006. 15(1): p. 124-32. 
411. Marchini, J., L.R. Cardon, M.S. Phillips, and P. Donnelly, The effects of human population 
structure on large genetic association studies. Nat Genet, 2004. 36(5): p. 512-7. 
412. Reich, D.E. and D.B. Goldstein, Detecting association in a case-control study while correcting 
for population stratification. Genet Epidemiol, 2001. 20(1): p. 4-16. 
413. Patterson, N., A.L. Price, and D. Reich, Population structure and eigenanalysis. PLoS Genet, 
2006. 2(12): p. e190. 
414. Price, A.L., N.J. Patterson, R.M. Plenge, M.E. Weinblatt, N.A. Shadick, and D. Reich, Principal 
components analysis corrects for stratification in genome-wide association studies. Nat Genet, 
2006. 38(8): p. 904-9. 
415. Chen, H.S., X. Zhu, H. Zhao, and S. Zhang, Qualitative semi-parametric test for genetic 
associations in case-control designs under structured populations. Ann Hum Genet, 2003. 67(Pt 
3): p. 250-64. 
416. Burgess, S. and S.G. Thompson, Use of allele scores as instrumental variables for Mendelian 
randomization. Int J Epidemiol, 2013. 42(4): p. 1134-44. 
417. Smith, J.A., E.B. Ware, P. Middha, L. Beacher, and S.L.R. Kardia, Current Applications of 
Genetic Risk Scores to Cardiovascular Outcomes and Subclinical Phenotypes. Current 
Epidemiology Reports, 2015. 2(3): p. 180-190. 
418. Hivert, M.F., J.L. Vassy, and J.B. Meigs, Susceptibility to type 2 diabetes mellitus--from genes to 
prevention. Nat Rev Endocrinol, 2014. 10(4): p. 198-205. 
419. Rasmussen-Torvik, L.J., M. Li, W.H. Kao, D. Couper, E. Boerwinkle, S.J. Bielinski, A.R. 
Folsom, and J.S. Pankow, Association of a fasting glucose genetic risk score with subclinical 










420. Ehret, G.B., P.B. Munroe, K.M. Rice, M. Bochud, A.D. Johnson, D.I. Chasman, A.V. Smith, 
M.D. Tobin, G.C. Verwoert, S.J. Hwang, V. Pihur, P. Vollenweider, P.F. O'Reilly, N. Amin, J.L. 
Bragg-Gresham, A. Teumer, N.L. Glazer, L. Launer, J.H. Zhao, Y. Aulchenko, S. Heath, S. 
Sober, A. Parsa, J. Luan, P. Arora, A. Dehghan, F. Zhang, G. Lucas, A.A. Hicks, A.U. Jackson, 
J.F. Peden, T. Tanaka, S.H. Wild, I. Rudan, W. Igl, Y. Milaneschi, A.N. Parker, C. Fava, J.C. 
Chambers, E.R. Fox, M. Kumari, M.J. Go, P. van der Harst, W.H. Kao, M. Sjogren, D.G. Vinay, 
M. Alexander, Y. Tabara, S. Shaw-Hawkins, P.H. Whincup, Y. Liu, G. Shi, J. Kuusisto, B. Tayo, 
M. Seielstad, X. Sim, K.D. Nguyen, T. Lehtimaki, G. Matullo, Y. Wu, T.R. Gaunt, N.C. Onland-
Moret, M.N. Cooper, C.G. Platou, E. Org, R. Hardy, S. Dahgam, J. Palmen, V. Vitart, P.S. 
Braund, T. Kuznetsova, C.S. Uiterwaal, A. Adeyemo, W. Palmas, H. Campbell, B. Ludwig, M. 
Tomaszewski, I. Tzoulaki, N.D. Palmer, T. Aspelund, M. Garcia, Y.P. Chang, J.R. O'Connell, 
N.I. Steinle, D.E. Grobbee, D.E. Arking, S.L. Kardia, A.C. Morrison, D. Hernandez, S. Najjar, 
W.L. McArdle, D. Hadley, M.J. Brown, J.M. Connell, A.D. Hingorani, I.N. Day, D.A. Lawlor, 
J.P. Beilby, R.W. Lawrence, R. Clarke, J.C. Hopewell, H. Ongen, A.W. Dreisbach, Y. Li, J.H. 
Young, J.C. Bis, M. Kahonen, J. Viikari, L.S. Adair, N.R. Lee, M.H. Chen, M. Olden, C. Pattaro, 
J.A. Bolton, A. Kottgen, S. Bergmann, V. Mooser, N. Chaturvedi, T.M. Frayling, M. Islam, T.H. 
Jafar, J. Erdmann, S.R. Kulkarni, S.R. Bornstein, J. Grassler, L. Groop, B.F. Voight, J. Kettunen, 
P. Howard, A. Taylor, S. Guarrera, F. Ricceri, V. Emilsson, A. Plump, I. Barroso, K.T. Khaw, 
A.B. Weder, S.C. Hunt, Y.V. Sun, R.N. Bergman, F.S. Collins, L.L. Bonnycastle, L.J. Scott, 
H.M. Stringham, L. Peltonen, M. Perola, E. Vartiainen, S.M. Brand, J.A. Staessen, T.J. Wang, 
P.R. Burton, M. Soler Artigas, Y. Dong, H. Snieder, X. Wang, H. Zhu, K.K. Lohman, M.E. 
Rudock, S.R. Heckbert, N.L. Smith, K.L. Wiggins, A. Doumatey, D. Shriner, G. Veldre, M. 
Viigimaa, S. Kinra, D. Prabhakaran, V. Tripathy, C.D. Langefeld, A. Rosengren, D.S. Thelle, 
A.M. Corsi, A. Singleton, T. Forrester, G. Hilton, C.A. McKenzie, T. Salako, N. Iwai, Y. Kita, T. 
Ogihara, T. Ohkubo, T. Okamura, H. Ueshima, S. Umemura, S. Eyheramendy, T. Meitinger, H.E. 
Wichmann, Y.S. Cho, H.L. Kim, J.Y. Lee, J. Scott, J.S. Sehmi, W. Zhang, B. Hedblad, P. 
Nilsson, G.D. Smith, A. Wong, N. Narisu, A. Stancakova, L.J. Raffel, J. Yao, S. Kathiresan, C.J. 
O'Donnell, S.M. Schwartz, M.A. Ikram, W.T. Longstreth, Jr., T.H. Mosley, S. Seshadri, N.R. 
Shrine, L.V. Wain, M.A. Morken, A.J. Swift, J. Laitinen, I. Prokopenko, P. Zitting, J.A. Cooper, 
S.E. Humphries, J. Danesh, A. Rasheed, A. Goel, A. Hamsten, H. Watkins, S.J. Bakker, W.H. 
van Gilst, C.S. Janipalli, K.R. Mani, C.S. Yajnik, A. Hofman, F.U. Mattace-Raso, B.A. Oostra, 
A. Demirkan, A. Isaacs, F. Rivadeneira, E.G. Lakatta, M. Orru, A. Scuteri, M. Ala-Korpela, A.J. 
Kangas, L.P. Lyytikainen, P. Soininen, T. Tukiainen, P. Wurtz, R.T. Ong, M. Dorr, H.K. 
Kroemer, U. Volker, H. Volzke, P. Galan, S. Hercberg, M. Lathrop, D. Zelenika, P. Deloukas, M. 
Mangino, T.D. Spector, G. Zhai, J.F. Meschia, M.A. Nalls, P. Sharma, J. Terzic, M.V. Kumar, M. 
Denniff, E. Zukowska-Szczechowska, L.E. Wagenknecht, F.G. Fowkes, F.J. Charchar, P.E. 
Schwarz, C. Hayward, X. Guo, C. Rotimi, M.L. Bots, E. Brand, N.J. Samani, O. Polasek, P.J. 
Talmud, F. Nyberg, D. Kuh, M. Laan, K. Hveem, L.J. Palmer, Y.T. van der Schouw, J.P. Casas, 
K.L. Mohlke, P. Vineis, O. Raitakari, S.K. Ganesh, T.Y. Wong, E.S. Tai, R.S. Cooper, M. 
Laakso, D.C. Rao, T.B. Harris, R.W. Morris, A.F. Dominiczak, M. Kivimaki, M.G. Marmot, T. 
Miki, D. Saleheen, G.R. Chandak, J. Coresh, G. Navis, V. Salomaa, B.G. Han, X. Zhu, J.S. 
Kooner, O. Melander, P.M. Ridker, S. Bandinelli, U.B. Gyllensten, A.F. Wright, J.F. Wilson, L. 
Ferrucci, M. Farrall, J. Tuomilehto, P.P. Pramstaller, R. Elosua, N. Soranzo, E.J. Sijbrands, D. 
Altshuler, R.J. Loos, A.R. Shuldiner, C. Gieger, P. Meneton, A.G. Uitterlinden, N.J. Wareham, 
V. Gudnason, J.I. Rotter, R. Rettig, M. Uda, D.P. Strachan, J.C. Witteman, A.L. Hartikainen, J.S. 
Beckmann, E. Boerwinkle, R.S. Vasan, M. Boehnke, M.G. Larson, M.R. Jarvelin, B.M. Psaty, 
G.R. Abecasis, A. Chakravarti, P. Elliott, C.M. van Duijn, C. Newton-Cheh, D. Levy, M.J. 
Caulfield and T. Johnson, Genetic variants in novel pathways influence blood pressure and 





421. Voight, B.F., G.M. Peloso, M. Orho-Melander, R. Frikke-Schmidt, M. Barbalic, M.K. Jensen, G. 
Hindy, H. Holm, E.L. Ding, T. Johnson, H. Schunkert, N.J. Samani, R. Clarke, J.C. Hopewell, 
J.F. Thompson, M. Li, G. Thorleifsson, C. Newton-Cheh, K. Musunuru, J.P. Pirruccello, D. 
Saleheen, L. Chen, A. Stewart, A. Schillert, U. Thorsteinsdottir, G. Thorgeirsson, S. Anand, J.C. 
Engert, T. Morgan, J. Spertus, M. Stoll, K. Berger, N. Martinelli, D. Girelli, P.P. McKeown, C.C. 
Patterson, S.E. Epstein, J. Devaney, M.S. Burnett, V. Mooser, S. Ripatti, I. Surakka, M.S. 
Nieminen, J. Sinisalo, M.L. Lokki, M. Perola, A. Havulinna, U. de Faire, B. Gigante, E. 
Ingelsson, T. Zeller, P. Wild, P.I. de Bakker, O.H. Klungel, A.H. Maitland-van der Zee, B.J. 
Peters, A. de Boer, D.E. Grobbee, P.W. Kamphuisen, V.H. Deneer, C.C. Elbers, N.C. Onland-
Moret, M.H. Hofker, C. Wijmenga, W.M. Verschuren, J.M. Boer, Y.T. van der Schouw, A. 
Rasheed, P. Frossard, S. Demissie, C. Willer, R. Do, J.M. Ordovas, G.R. Abecasis, M. Boehnke, 
K.L. Mohlke, M.J. Daly, C. Guiducci, N.P. Burtt, A. Surti, E. Gonzalez, S. Purcell, S. Gabriel, J. 
Marrugat, J. Peden, J. Erdmann, P. Diemert, C. Willenborg, I.R. Konig, M. Fischer, C. 
Hengstenberg, A. Ziegler, I. Buysschaert, D. Lambrechts, F. Van de Werf, K.A. Fox, N.E. El 
Mokhtari, D. Rubin, J. Schrezenmeir, S. Schreiber, A. Schafer, J. Danesh, S. Blankenberg, R. 
Roberts, R. McPherson, H. Watkins, A.S. Hall, K. Overvad, E. Rimm, E. Boerwinkle, A. 
Tybjaerg-Hansen, L.A. Cupples, M.P. Reilly, O. Melander, P.M. Mannucci, D. Ardissino, D. 
Siscovick, R. Elosua, K. Stefansson, C.J. O'Donnell, V. Salomaa, D.J. Rader, L. Peltonen, S.M. 
Schwartz, D. Altshuler and S. Kathiresan, Plasma HDL cholesterol and risk of myocardial 
infarction: a mendelian randomisation study. Lancet, 2012. 380(9841): p. 572-80. 
422. Morrison, A.C., L.A. Bare, L.E. Chambless, S.G. Ellis, M. Malloy, J.P. Kane, J.S. Pankow, J.J. 
Devlin, J.T. Willerson, and E. Boerwinkle, Prediction of Coronary Heart Disease Risk using a 
Genetic Risk Score: The Atherosclerosis Risk in Communities Study. American Journal of 
Epidemiology, 2007. 166(1): p. 28-35. 
423. StataCorp. 2017. Stata Statistical Software: Release 15. College Station, TX: StataCorp LLC. 
424. Rubin, D.B., Multiple Imputation for Nonresponse in Surveys. 1987, Hoboken, NJ: John Wiley & 
Sons, Inc. 
425. Gauderman W, M.J. QUANTO 1.1: a computer program for power and sample size calculations 
for genetic-epidemiology studies.  [cited 2017 7/22]; Available from: http://hydra.usc.edu/gxe  
426. Dudbridge, F., Power and predictive accuracy of polygenic risk scores. PLoS Genet, 2013. 9(3): 
p. e1003348. 
427. Browne WJ MG, P.R., A Guide to Sample Size Calculations for Random Effect Models via 
Simulation and the MLPowSim Software Package. 2009: Bristol, United Kingdom: University of 
Bristol. 
428. Schwartz, B.S., T.A. Glass, K.I. Bolla, W.F. Stewart, G. Glass, M. Rasmussen, J. Bressler, W. 
Shi, and K. Bandeen-Roche, Disparities in cognitive functioning by race/ethnicity in the 
Baltimore Memory Study. Environ Health Perspect, 2004. 112(3): p. 314-20. 
429. Tang, M.X., P. Cross, H. Andrews, D.M. Jacobs, S. Small, K. Bell, C. Merchant, R. Lantigua, R. 
Costa, Y. Stern, and R. Mayeux, Incidence of AD in African-Americans, Caribbean Hispanics, 
and Caucasians in northern Manhattan. Neurology, 2001. 56(1): p. 49-56. 
430. Bowen, M.E., Childhood socioeconomic status and racial differences in disability: evidence from 





431. Kelley-Moore, J.A. and K.F. Ferraro, The black/white disability gap: persistent inequality in later 
life? J Gerontol B Psychol Sci Soc Sci, 2004. 59(1): p. S34-43. 
432. Britton, A., Y. Ben-Shlomo, M. Benzeval, D. Kuh, and S. Bell, Life course trajectories of alcohol 
consumption in the United Kingdom using longitudinal data from nine cohort studies. BMC Med, 
2015. 13: p. 47. 
433. Britton, A. and S. Bell, Reasons why people change their alcohol consumption in later life: 
findings from the Whitehall II Cohort Study. PLoS One, 2015. 10(3): p. e0119421. 
434. Britton, A., M.G. Marmot, and M.J. Shipley, How does variability in alcohol consumption over 
time affect the relationship with mortality and coronary heart disease? Addiction, 2010. 105(4): 
p. 639-45. 
435. Howe, C.J., P.M. Sander, M.W. Plankey, and S.R. Cole, Effects of time-varying exposures 
adjusting for time-varying confounders: the case of alcohol consumption and risk of incident 
human immunodeficiency virus infection. International Journal of Public Health, 2010. 55(3): p. 
227-228. 
436. Wood, A.M., I. White, S.G. Thompson, S. Lewington, and J. Danesh, Regression dilution 
methods for meta-analysis: assessing long-term variability in plasma fibrinogen among 27,247 
adults in 15 prospective studies. Int J Epidemiol, 2006. 35(6): p. 1570-8. 
437. Bell, S. and A. Britton, The Role of Alcohol Consumption in Regulating Circulating Levels of 
Adiponectin: A Prospective Cohort Study. J Clin Endocrinol Metab, 2015. 100(7): p. 2763-8. 
438. Greenfield, T.K. and W.C. Kerr, Commentary on Liang & Chikritzhs (2011): Quantifying the 
impacts of health problems on drinking and subsequent morbidity and mortality - life-course 
measures are essential. Addiction, 2011. 106(1): p. 82-3. 
439. Pinder, R.M. and M. Sandler, Alcohol, wine and mental health: focus on dementia and stroke. J 
Psychopharmacol, 2004. 18(4): p. 449-56. 
440. Zhu, W., N.D. Volkow, Y. Ma, J.S. Fowler, and G.J. Wang, Relationship between ethanol-
induced changes in brain regional metabolism and its motor, behavioural and cognitive effects. 
Alcohol Alcohol, 2004. 39(1): p. 53-8. 
441. Panza, F., V. Frisardi, D. Seripa, G. Logroscino, A. Santamato, B.P. Imbimbo, E. Scafato, A. 
Pilotto, and V. Solfrizzi, Alcohol consumption in mild cognitive impairment and dementia: 
harmful or neuroprotective? Int J Geriatr Psychiatry, 2012. 27(12): p. 1218-38. 
442. Imhof, A., M. Woodward, A. Doering, N. Helbecque, H. Loewel, P. Amouyel, G.D. Lowe, and 
W. Koenig, Overall alcohol intake, beer, wine, and systemic markers of inflammation in western 
Europe: results from three MONICA samples (Augsburg, Glasgow, Lille). Eur Heart J, 2004. 
25(23): p. 2092-100. 
443. Zahr, N.M., K.L. Kaufman, and C.G. Harper, Clinical and pathological features of alcohol-





444. Dufouil, C., P. Ducimetiere, and A. Alperovitch, Sex differences in the association between 
alcohol consumption and cognitive performance. EVA Study Group. Epidemiology of Vascular 
Aging. Am J Epidemiol, 1997. 146(5): p. 405-12. 
445. Elias, P.K., M.F. Elias, R.B. D'Agostino, H. Silbershatz, and P.A. Wolf, Alcohol consumption 
and cognitive performance in the Framingham Heart Study. Am J Epidemiol, 1999. 150(6): p. 
580-9. 
446. Lang, I., R.B. Wallace, F.A. Huppert, and D. Melzer, Moderate alcohol consumption in older 
adults is associated with better cognition and well-being than abstinence. Age Ageing, 2007. 
36(3): p. 256-61. 
447. Ding, J., M.L. Eigenbrodt, T.H. Mosley, Jr., R.G. Hutchinson, A.R. Folsom, T.B. Harris, and F.J. 
Nieto, Alcohol intake and cerebral abnormalities on magnetic resonance imaging in a 
community-based population of middle-aged adults: the Atherosclerosis Risk in Communities 
(ARIC) study. Stroke, 2004. 35(1): p. 16-21. 
448. Goncalves, A., B. Claggett, P.S. Jhund, W. Rosamond, A. Deswal, D. Aguilar, A.M. Shah, S. 
Cheng, and S.D. Solomon, Alcohol consumption and risk of heart failure: the Atherosclerosis 
Risk in Communities Study. Eur Heart J, 2015. 
449. Naimi, T.S., T. Stockwell, J. Zhao, Z. Xuan, F. Dangardt, R. Saitz, W. Liang, and T. Chikritzhs, 
Selection biases in observational studies affect associations between ‘moderate’ alcohol 
consumption and mortality. Addiction, 2017. 112(2): p. 207-214. 
450. Jones, S.B., L. Loehr, C.L. Avery, R.F. Gottesman, L. Wruck, E. Shahar, and W.D. Rosamond, 
Midlife Alcohol Consumption and the Risk of Stroke in the Atherosclerosis Risk in Communities 
Study. Stroke, 2015. 46(11): p. 3124-30. 
451. Martin, A.R., C.R. Gignoux, R.K. Walters, G.L. Wojcik, B.M. Neale, S. Gravel, M.J. Daly, C.D. 
Bustamante, and E.E. Kenny, Human Demographic History Impacts Genetic Risk Prediction 
across Diverse Populations. Am J Hum Genet, 2017. 100(4): p. 635-649. 
452. De La Vega, F.M. and C.D. Bustamante, Polygenic risk scores: a biased prediction? Genome 
Medicine, 2018. 10(1): p. 100. 
453. Hüls, A., U. Krämer, C. Carlsten, T. Schikowski, K. Ickstadt, and H. Schwender, Comparison of 
weighting approaches for genetic risk scores in gene-environment interaction studies. BMC 
Genetics, 2017. 18(1): p. 115. 
454. Aschard, H., A perspective on interaction effects in genetic association studies. Genet Epidemiol, 
2016. 40(8): p. 678-688. 
455. Copeland, K.T., H. Checkoway, A.J. McMichael, and R.H. Holbrook, Bias due to 







456. American Heart Association. Alcohol and Heart Health. 2015  [cited 2019 January 15]; Available 
from: 
http://www.heart.org/HEARTORG/GettingHealthy/NutritionCenter/HealthyEating/Alcohol-and-
Heart-Health_UCM_305173_Article.jsp. 
 
